PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
18216144-3	2008	Previous experiments in Oat1 knockout (-/-) mice revealed an almost complete loss of renal secretion of the prototypic organic anion p-aminohippurate (PAH) and a role of OAT1 in tubular secretion of furosemide (Eraly SA, Vallon V, Vaughn D, Gangoiti JA, Richter K, Nagle M, Monte JC, Rieg T, Truong DM, Long JM, Barshop BA, Kaler G, Nigam SK.	Furosemide	199-209	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	24-28
18216144-3	2008	Previous experiments in Oat1 knockout (-/-) mice revealed an almost complete loss of renal secretion of the prototypic organic anion p-aminohippurate (PAH) and a role of OAT1 in tubular secretion of furosemide (Eraly SA, Vallon V, Vaughn D, Gangoiti JA, Richter K, Nagle M, Monte JC, Rieg T, Truong DM, Long JM, Barshop BA, Kaler G, Nigam SK.	Furosemide	199-209	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	170-174
18216144-5	2008	In this study we found that both furosemide and bendroflumethiazide inhibited mOat1- and mOat3-mediated uptake of a labeled tracer in Xenopus oocytes injected with cRNA, consistent with their being substrates for mouse OAT1 and OAT3.	Furosemide	33-43	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	78-83
18216144-5	2008	In this study we found that both furosemide and bendroflumethiazide inhibited mOat1- and mOat3-mediated uptake of a labeled tracer in Xenopus oocytes injected with cRNA, consistent with their being substrates for mouse OAT1 and OAT3.	Furosemide	33-43	solute carrier family 22 (organic anion transporter), member 8	Mus musculus	89-94
18216144-5	2008	In this study we found that both furosemide and bendroflumethiazide inhibited mOat1- and mOat3-mediated uptake of a labeled tracer in Xenopus oocytes injected with cRNA, consistent with their being substrates for mouse OAT1 and OAT3.	Furosemide	33-43	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	219-223
18216144-5	2008	In this study we found that both furosemide and bendroflumethiazide inhibited mOat1- and mOat3-mediated uptake of a labeled tracer in Xenopus oocytes injected with cRNA, consistent with their being substrates for mouse OAT1 and OAT3.	Furosemide	33-43	solute carrier family 22 (organic anion transporter), member 8	Mus musculus	228-232
18216144-7	2008	Thus, whereas OAT1 (in contrast to OAT3) is the classic basolateral PAH transporter of the proximal tubule, both OAT1 and OAT3 contribute similarly to normal renal secretion of furosemide and bendroflumethiazide, and a lack of either one is not fully compensated by the other.	Furosemide	177-187	solute carrier family 22 (organic anion transporter), member 6	Mus musculus	113-117
18216144-7	2008	Thus, whereas OAT1 (in contrast to OAT3) is the classic basolateral PAH transporter of the proximal tubule, both OAT1 and OAT3 contribute similarly to normal renal secretion of furosemide and bendroflumethiazide, and a lack of either one is not fully compensated by the other.	Furosemide	177-187	solute carrier family 22 (organic anion transporter), member 8	Mus musculus	122-126
18078705-6	2008	Each compound elicited significant serum ALT increases after 24h (ALT U/L: APAP, 3036+/-1462; BB, 5308+/-2210; CCl4, 5089+/-1665; FS, 2301+/-1053), accompanied by centrilobular damage as assessed by histopathology.	Furosemide	130-132	glutamic pyruvic transaminase, soluble	Mus musculus	41-44
18179782-13	2008	Furosemide significantly elevated plasma renin activity and aldosterone concentration.	Furosemide	0-10	renin	Rattus norvegicus	41-46
18059056-0	2008	Interaction of glycyrrhetinic acid, furosemide and hydrochlorothiazide with bovine serum albumin and their displacement interactions: capillary electrophoresis and fluorescence quenching study.	Furosemide	36-46	albumin	Homo sapiens	83-96
18059056-3	2008	In this work, capillary electrophoresis-frontal analysis (CE-FA) was applied to study the binding of bovine serum albumin with GA and two diuretics: furosemide (FU) and hydrochlorothiazide (HZ).	Furosemide	149-159	albumin	Homo sapiens	108-121
18078705-15	2008	In summary, we have demonstrated that the hepatotoxins BB, CCl4 and FS can induce a small but significant increase in Nrf2 accumulation in hepatic nuclei.	Furosemide	68-70	nuclear factor, erythroid derived 2, like 2	Mus musculus	118-122
17719021-5	2007	cDNA-expressed and reconstituted Oat3 transported both GSH and p-aminohippurate (PAH) in exchange for 2-oxoglutarate (2-OG) and 2-OG and PAH in exchange for GSH, and PAH uptake was inhibited by both probenecid and furosemide, consistent with function of Oat3.	Furosemide	214-224	solute carrier family 22 member 8	Rattus norvegicus	33-37
18081357-6	2008	In the furosemide group, a significant increase in arterial angiotensin-II (AT-II) plasma levels was observed compared with the torasemide group (relative treatment effect over time between groups; p = 0.031).	Furosemide	7-17	angiotensinogen	Homo sapiens	60-74
18081357-6	2008	In the furosemide group, a significant increase in arterial angiotensin-II (AT-II) plasma levels was observed compared with the torasemide group (relative treatment effect over time between groups; p = 0.031).	Furosemide	7-17	angiotensinogen	Homo sapiens	76-81
18081357-7	2008	CONCLUSION: Torasemide increased cardiac output (relative treatment effect over the time), whereas treatment with furosemide significantly increased arterial AT-II plasma levels.	Furosemide	114-124	angiotensinogen	Homo sapiens	158-163
18081357-8	2008	A possible explanation for these findings might be activation of the renin-angiotensin system by furosemide.	Furosemide	97-107	renin	Homo sapiens	69-74
18081357-9	2008	However, the underlying pathomechanism remains to be established and evidence from an adequately powered trial is needed to determine if furosemide aggravates cardiac function by increasing AT-II plasma levels.	Furosemide	137-147	angiotensinogen	Homo sapiens	190-195
18178800-3	2008	To answer this question, CCD from furosemide-treated mice were perfused in vitro, and the subcellular distributions of pendrin and the H(+)-ATPase were quantified using immunogold cytochemistry and morphometric analysis.	Furosemide	34-44	solute carrier family 26, member 4	Mus musculus	119-126
18094726-4	2008	Expression of ClC-K1 is upregulated by dehydration and downregulated by the diuretic furosemide, whereas expression of ClC-K2 is upregulated by furosemide and downregulated by high salt levels.	Furosemide	85-95	chloride voltage-gated channel Ka	Homo sapiens	14-20
18094726-4	2008	Expression of ClC-K1 is upregulated by dehydration and downregulated by the diuretic furosemide, whereas expression of ClC-K2 is upregulated by furosemide and downregulated by high salt levels.	Furosemide	144-154	chloride voltage-gated channel Kb	Homo sapiens	119-125
18094240-10	2007	Application of the KCC2 blocker, furosemide, to control neurons mimicked E(GABA) shifts evident in granule cells post-STEP.	Furosemide	33-43	solute carrier family 12 member 5	Rattus norvegicus	19-23
17652376-6	2007	Our results showed that, in acute experiments, furosemide enhanced urinary calcium excretion, which was associated with a significant increase in mRNA levels of TRPV5, TRPV6, and calbindin-D28k but not calbindin-D9k as measured by real-time PCR (TRPV5 and TRPV6 are transient receptor potential vanilloid 5 and 6).	Furosemide	47-57	transient receptor potential cation channel, subfamily V, member 5	Mus musculus	161-166
17728380-8	2007	In A1AR-/-, furosemide did not further impair autoregulation at 5-25 s, but eliminated the third mechanism and enhanced MR.	Furosemide	12-22	adenosine A1 receptor	Mus musculus	3-7
17652376-6	2007	Our results showed that, in acute experiments, furosemide enhanced urinary calcium excretion, which was associated with a significant increase in mRNA levels of TRPV5, TRPV6, and calbindin-D28k but not calbindin-D9k as measured by real-time PCR (TRPV5 and TRPV6 are transient receptor potential vanilloid 5 and 6).	Furosemide	47-57	transient receptor potential cation channel, subfamily V, member 6	Mus musculus	168-173
17652376-6	2007	Our results showed that, in acute experiments, furosemide enhanced urinary calcium excretion, which was associated with a significant increase in mRNA levels of TRPV5, TRPV6, and calbindin-D28k but not calbindin-D9k as measured by real-time PCR (TRPV5 and TRPV6 are transient receptor potential vanilloid 5 and 6).	Furosemide	47-57	calbindin 1	Mus musculus	179-193
17652376-6	2007	Our results showed that, in acute experiments, furosemide enhanced urinary calcium excretion, which was associated with a significant increase in mRNA levels of TRPV5, TRPV6, and calbindin-D28k but not calbindin-D9k as measured by real-time PCR (TRPV5 and TRPV6 are transient receptor potential vanilloid 5 and 6).	Furosemide	47-57	transient receptor potential cation channel, subfamily V, member 5	Mus musculus	246-251
17652376-6	2007	Our results showed that, in acute experiments, furosemide enhanced urinary calcium excretion, which was associated with a significant increase in mRNA levels of TRPV5, TRPV6, and calbindin-D28k but not calbindin-D9k as measured by real-time PCR (TRPV5 and TRPV6 are transient receptor potential vanilloid 5 and 6).	Furosemide	47-57	transient receptor potential cation channel, subfamily V, member 6	Mus musculus	256-261
17652376-7	2007	Chronic furosemide administration induced three- to fourfold increases in urinary calcium excretion and elevated mRNA levels of TRPV5, TRPV6, calbindin-D28k, and calbindin-D9k without or with salt supplement.	Furosemide	8-18	transient receptor potential cation channel, subfamily V, member 5	Mus musculus	128-133
17652376-7	2007	Chronic furosemide administration induced three- to fourfold increases in urinary calcium excretion and elevated mRNA levels of TRPV5, TRPV6, calbindin-D28k, and calbindin-D9k without or with salt supplement.	Furosemide	8-18	transient receptor potential cation channel, subfamily V, member 6	Mus musculus	135-140
17652376-7	2007	Chronic furosemide administration induced three- to fourfold increases in urinary calcium excretion and elevated mRNA levels of TRPV5, TRPV6, calbindin-D28k, and calbindin-D9k without or with salt supplement.	Furosemide	8-18	calbindin 1	Mus musculus	142-156
17652376-7	2007	Chronic furosemide administration induced three- to fourfold increases in urinary calcium excretion and elevated mRNA levels of TRPV5, TRPV6, calbindin-D28k, and calbindin-D9k without or with salt supplement.	Furosemide	8-18	S100 calcium binding protein G	Mus musculus	162-175
17670898-4	2007	Western blot analysis of NKCC2 expression using two different antibodies revealed a band of approximately 160 kDa, and RT-PCR analysis demonstrated the presence of NKCC2 isoforms A and F, which was confirmed by DNA sequencing; transport of Cl(-) into raTAL cells was inhibited by furosemide.	Furosemide	280-290	solute carrier family 12 member 1	Rattus norvegicus	164-169
17804801-7	2007	NaCl supplementation of Pvalb(-/-) mice increased calciuria at baseline and after furosemide.	Furosemide	82-92	parvalbumin	Mus musculus	24-29
17596413-7	2007	Interruption of the Cl(-) extrusion by [(dihydroindenyl)oxy] alkanoic acid or furosemide gradually shifted E(GABA) in positive direction with increasing maturity, suggesting that KCC2 could be involved in maintaining low [Cl(-)]i after the postnatal day 7 thereby providing the hyperpolarizing Cl(-)-mediated inhibition in SBC.	Furosemide	78-88	solute carrier family 12 member 5	Homo sapiens	179-183
17556636-3	2007	To define the nature of the toxic metabolite, we examined the relationship between furosemide metabolism in CD-1 mice and Wistar rats.	Furosemide	83-93	CD1 antigen complex	Mus musculus	108-112
17515456-7	2007	Acute stimulation of renin release by furosemide, quinaprilat, captopril, or candesartan caused significant increases of plasma renin concentration in both beta1/beta2ADR(-/-) and WT mice, but again the absolute changes were greater in WT mice.	Furosemide	38-48	hemoglobin, beta adult major chain	Mus musculus	156-161
17555702-10	2007	Km of 14C-tetraethylammonium and 3H-estrone-3-sulfate uptake and hOAT3 inhibition by ibuprofen and furosemide were similar to conventional dish uptake studies.	Furosemide	99-109	solute carrier family 22 member 8	Homo sapiens	65-70
17494095-2	2007	In isolated perfused afferent arterioles preconstricted with angiotensin II or N(G)-nitro-L-arginine methyl ester, furosemide caused a dose-dependent increase of vascular diameter, but it was without effect in vessels from NKCC1-/- mice suggesting that inhibition of NKCC1 mediates dilatation in afferent arterioles.	Furosemide	115-125	solute carrier family 12, member 2	Mus musculus	223-228
17494095-2	2007	In isolated perfused afferent arterioles preconstricted with angiotensin II or N(G)-nitro-L-arginine methyl ester, furosemide caused a dose-dependent increase of vascular diameter, but it was without effect in vessels from NKCC1-/- mice suggesting that inhibition of NKCC1 mediates dilatation in afferent arterioles.	Furosemide	115-125	solute carrier family 12, member 2	Mus musculus	267-272
17494095-5	2007	Similarly, NKCC1-/- mice responded to furosemide with a 45.4% decrease of RBF and a 29% decrease of SBF.	Furosemide	38-48	solute carrier family 12, member 2	Mus musculus	11-16
17703139-9	2007	At 24 hours postdose, plasma renin activity was increased after furosemide or HCTZ administered alone or with tolvaptan, but it was unchanged after tolvaptan alone.	Furosemide	64-74	renin	Homo sapiens	29-34
17587708-2	2007	METHODS AND RESULTS: The first protocol was to examine if an infusion of human ANP (carperitide) changed serum levels of TRX (thioredoxin) during the treatment of patients with heart failure compared with conventional therapy using furosemide.	Furosemide	232-242	natriuretic peptide A	Homo sapiens	79-82
17587708-4	2007	In Protocol 1, 8 patients were treated with only an intravenous bolus of furosemide and 11 patients with only an intravenous infusion of carperitide for 24 h. Serum TRX levels significantly decreased at 4 h (p<0.03) and at 24 h (p<0.05) in the carperitide group, whereas they decreased slightly but were not significantly different in the furosemide group.	Furosemide	345-355	thioredoxin	Homo sapiens	165-168
17584643-0	2007	[Effects of furosemide, antisterone and hydrochlorothiazide on expression of kidney aquaporin-2 gene and urine aquaporin-2 excretion in rats].	Furosemide	12-22	aquaporin 2	Rattus norvegicus	84-95
17584643-1	2007	OBJECTIVE: To investigate effects of the furosemide, antisterone and hydrochlorothiazide on expression of kidney aquaporin-2 (AQP(2)) gene and urine aquaporin-2 excretion in rats.	Furosemide	41-51	aquaporin 2	Rattus norvegicus	113-124
17584643-1	2007	OBJECTIVE: To investigate effects of the furosemide, antisterone and hydrochlorothiazide on expression of kidney aquaporin-2 (AQP(2)) gene and urine aquaporin-2 excretion in rats.	Furosemide	41-51	aquaporin 2	Rattus norvegicus	126-132
17584643-9	2007	The kidney inner medullary AQP(2) mRNA, V(2)-R mRNA and AQP(2) protein expression of furosemide group increased in comparison with that of the control group (Plt;0.05).	Furosemide	85-95	aquaporin 2	Rattus norvegicus	27-33
17584643-9	2007	The kidney inner medullary AQP(2) mRNA, V(2)-R mRNA and AQP(2) protein expression of furosemide group increased in comparison with that of the control group (Plt;0.05).	Furosemide	85-95	aquaporin 2	Rattus norvegicus	56-62
17584643-12	2007	Hydrochlorothiazide reduces kidney AQP(2) mRNA and protein expression, while furosemide increased kidney AQP(2) gene expression.	Furosemide	77-87	aquaporin 2	Rattus norvegicus	105-111
19086502-10	2007	Captopril (3, 1, 0.3 microg mL(-1)) and Furosemide (5, 2.5, 1.25 microg mL(-1)) caused a dose dependent inhibition in TNF-alpha compared with control (329 +/- 23, 427 +/- 15, 519 +/- 19 and 343 +/- 19, 430 +/- 14, respectively vs. 562 +/- 24 pg mL(-1) p < 0.05).	Furosemide	40-50	tumor necrosis factor	Homo sapiens	118-127
19086502-11	2007	Furosemide caused a dose dependent decrease in IL-6 (421 +/- 31, 534 +/- 33 vs. 662 +/- 41 pg mL(-1) p < 0.05).	Furosemide	0-10	interleukin 6	Homo sapiens	47-51
17314201-5	2007	hOAT3-mediated sitagliptin uptake was inhibited by probenecid, ibuprofen, furosemide, fenofibric acid, quinapril, indapamide, and cimetidine with IC50 values of 5.6, 3.7, 1.7, 2.2, 6.2, 11, and 79 microM, respectively.	Furosemide	74-84	solute carrier family 22 member 8	Homo sapiens	0-5
17464433-9	2007	The important observations were a) the AT-1 antagonist alone suppressed intakes in offspring from mothers not treated with furosemide, b) both AT-1 and AT-2 antagonists suppressed intakes in offspring from furosemide-treated mothers, and c) combined administration of AT-1 and AT-2 antagonists greatly suppressed water intake in offspring from mothers not treated with furosemide.	Furosemide	206-216	angiotensin II receptor, type 1a	Rattus norvegicus	143-147
17464433-9	2007	The important observations were a) the AT-1 antagonist alone suppressed intakes in offspring from mothers not treated with furosemide, b) both AT-1 and AT-2 antagonists suppressed intakes in offspring from furosemide-treated mothers, and c) combined administration of AT-1 and AT-2 antagonists greatly suppressed water intake in offspring from mothers not treated with furosemide.	Furosemide	206-216	angiotensin II receptor, type 2	Rattus norvegicus	152-156
17464433-9	2007	The important observations were a) the AT-1 antagonist alone suppressed intakes in offspring from mothers not treated with furosemide, b) both AT-1 and AT-2 antagonists suppressed intakes in offspring from furosemide-treated mothers, and c) combined administration of AT-1 and AT-2 antagonists greatly suppressed water intake in offspring from mothers not treated with furosemide.	Furosemide	206-216	angiotensin II receptor, type 1a	Rattus norvegicus	143-147
17464433-9	2007	The important observations were a) the AT-1 antagonist alone suppressed intakes in offspring from mothers not treated with furosemide, b) both AT-1 and AT-2 antagonists suppressed intakes in offspring from furosemide-treated mothers, and c) combined administration of AT-1 and AT-2 antagonists greatly suppressed water intake in offspring from mothers not treated with furosemide.	Furosemide	206-216	angiotensin II receptor, type 1a	Rattus norvegicus	143-147
17464433-9	2007	The important observations were a) the AT-1 antagonist alone suppressed intakes in offspring from mothers not treated with furosemide, b) both AT-1 and AT-2 antagonists suppressed intakes in offspring from furosemide-treated mothers, and c) combined administration of AT-1 and AT-2 antagonists greatly suppressed water intake in offspring from mothers not treated with furosemide.	Furosemide	206-216	angiotensin II receptor, type 2	Rattus norvegicus	152-156
17464433-9	2007	The important observations were a) the AT-1 antagonist alone suppressed intakes in offspring from mothers not treated with furosemide, b) both AT-1 and AT-2 antagonists suppressed intakes in offspring from furosemide-treated mothers, and c) combined administration of AT-1 and AT-2 antagonists greatly suppressed water intake in offspring from mothers not treated with furosemide.	Furosemide	206-216	angiotensin II receptor, type 1a	Rattus norvegicus	143-147
17442791-9	2007	The furosemide-induced increase in urinary PGE(2) excretion that was seen in wild-type mice was attenuated in mPGES1-deficient mice.	Furosemide	4-14	prostaglandin E synthase	Mus musculus	110-116
17442791-10	2007	However, furosemide-associated diuresis was reduced only in male, not female, mPGES1-deficient mice.	Furosemide	9-19	prostaglandin E synthase	Mus musculus	78-84
17077386-5	2007	Thus further experiments employed mice given the high-NaCl diet and furosemide to upregulate renal pendrin expression.	Furosemide	68-78	solute carrier family 26, member 4	Mus musculus	99-106
17077386-8	2007	In contrast, in CCDs from furosemide-treated Slc26a4 null mice, Cl(-) secretion and a V(T) of approximately 0 were observed, neither of which changed with angiotensin II application.	Furosemide	26-36	solute carrier family 26, member 4	Mus musculus	45-52
17172466-4	2007	Inhibition of Bax translocation using furosemide, as well as Bax gene deletion, afforded significant protection against malonate-induced apoptosis.	Furosemide	38-48	BCL2 associated X, apoptosis regulator	Homo sapiens	14-17
16926446-11	2007	Treatment of neonatal animals with furosemide dramatically reduced expression of TonEBP, AR, and UT-A1.	Furosemide	35-45	nuclear factor of activated T cells 5	Mus musculus	81-87
16954339-7	2007	Urinary K(+) excretion was significantly smaller in TRPV4(-/-) than in TRPV4(+/+) mice when urine production was stimulated by a venous application of furosemide.	Furosemide	151-161	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	52-57
16954339-7	2007	Urinary K(+) excretion was significantly smaller in TRPV4(-/-) than in TRPV4(+/+) mice when urine production was stimulated by a venous application of furosemide.	Furosemide	151-161	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	71-76
16926446-11	2007	Treatment of neonatal animals with furosemide dramatically reduced expression of TonEBP, AR, and UT-A1.	Furosemide	35-45	aldo-keto reductase family 1, member B3 (aldose reductase)	Mus musculus	89-91
16926446-11	2007	Treatment of neonatal animals with furosemide dramatically reduced expression of TonEBP, AR, and UT-A1.	Furosemide	35-45	solute carrier family 14 (urea transporter), member 2	Mus musculus	97-102
16926446-12	2007	Furosemide also prevented the disappearance of NKCC2-expressing TALs in the papilla.	Furosemide	0-10	solute carrier family 12, member 1	Mus musculus	47-52
16926446-13	2007	The sequential expression of NKCC2, TonEBP, and its targets AR and UT-A and the reduced expression TonEBP and its targets in response to furosemide treatment support the hypothesis that local hypertonicity produced by the activity of NKCC2 activates TonEBP during development.	Furosemide	137-147	nuclear factor of activated T cells 5	Mus musculus	99-105
16926446-13	2007	The sequential expression of NKCC2, TonEBP, and its targets AR and UT-A and the reduced expression TonEBP and its targets in response to furosemide treatment support the hypothesis that local hypertonicity produced by the activity of NKCC2 activates TonEBP during development.	Furosemide	137-147	solute carrier family 12, member 1	Mus musculus	234-239
16926446-13	2007	The sequential expression of NKCC2, TonEBP, and its targets AR and UT-A and the reduced expression TonEBP and its targets in response to furosemide treatment support the hypothesis that local hypertonicity produced by the activity of NKCC2 activates TonEBP during development.	Furosemide	137-147	nuclear factor of activated T cells 5	Mus musculus	99-105
16965835-10	2007	Thus, an overnight infusion of ANG II is sufficient to mimic the robust expression of salt appetite as observed after furosemide and overnight sodium depletion.	Furosemide	118-128	angiotensinogen	Rattus norvegicus	31-37
17135398-0	2007	Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide.	Furosemide	106-116	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	0-41
17710582-9	2007	IL-10, TNF-alpha, and IL-6 production from preeclamptic placenta and PBMCs were inhibited by diazoxide and furosemide.	Furosemide	107-117	interleukin 10	Homo sapiens	0-5
17710582-9	2007	IL-10, TNF-alpha, and IL-6 production from preeclamptic placenta and PBMCs were inhibited by diazoxide and furosemide.	Furosemide	107-117	tumor necrosis factor	Homo sapiens	7-16
17710582-9	2007	IL-10, TNF-alpha, and IL-6 production from preeclamptic placenta and PBMCs were inhibited by diazoxide and furosemide.	Furosemide	107-117	interleukin 6	Homo sapiens	22-26
17135398-2	2007	Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Furosemide	66-76	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	126-167
17135398-2	2007	Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Furosemide	66-76	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	169-173
17135398-2	2007	Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Furosemide	66-76	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	179-211
17135398-2	2007	Significant ATP-dependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP).	Furosemide	66-76	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	213-217
17135398-4	2007	The functional importance of MRP4 and BCRP in the urinary excretion of HCT and furosemide was investigated using gene knockout mice.	Furosemide	79-89	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	29-33
17135398-4	2007	The functional importance of MRP4 and BCRP in the urinary excretion of HCT and furosemide was investigated using gene knockout mice.	Furosemide	79-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	38-42
17135398-7	2007	Our results suggest that Mrp4, together with other unknown transporters, accounts for the luminal efflux of HCT and furosemide from proximal tubular epithelial cells.	Furosemide	116-126	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	25-29
17497460-12	2007	Compared to the I/R group, furosemide significantly (p < 0.01) upregulated the phosphorylation of Akt.	Furosemide	27-37	AKT serine/threonine kinase 1	Rattus norvegicus	101-104
17483578-2	2007	Recent evidence suggests that acute furosemide decreases both dopamine uptake and striatal dopamine transporter density and increases enkephalin mRNA levels in the nucleus accumbens (Acb).	Furosemide	36-46	proenkephalin	Rattus norvegicus	134-144
17483578-8	2007	Additionally, in rats previously primed with furosemide to crave salt in a "need-free" manner, salt intake was augmented in the VTA and reduced in the AcbSh after infusion of [D-Ser(2),Leu(5),Thr(6)]-enkephalin.	Furosemide	45-55	proenkephalin	Rattus norvegicus	200-210
17052386-1	2006	Furosemide, a blocker of Na(+)/K(+)/2Cl(-) cotransporter (NKCC), is often used as a diuretic to improve edema, ascites, and pleural effusion of patients with cancers.	Furosemide	0-10	solute carrier family 12 member 1	Homo sapiens	25-56
17052386-1	2006	Furosemide, a blocker of Na(+)/K(+)/2Cl(-) cotransporter (NKCC), is often used as a diuretic to improve edema, ascites, and pleural effusion of patients with cancers.	Furosemide	0-10	solute carrier family 12 member 1	Homo sapiens	58-62
17052386-7	2006	Based on these observations, we indicate that furosemide diminishes cell growth by delaying the G(1)-S phase progression in poorly differentiated gastric adenocarcinoma cells, which show high expression and activity of NKCC, but not in moderately differentiated gastric adenocarcinoma cells with low expression and NKCC activity.	Furosemide	46-56	solute carrier family 12 member 1	Homo sapiens	219-223
17052386-7	2006	Based on these observations, we indicate that furosemide diminishes cell growth by delaying the G(1)-S phase progression in poorly differentiated gastric adenocarcinoma cells, which show high expression and activity of NKCC, but not in moderately differentiated gastric adenocarcinoma cells with low expression and NKCC activity.	Furosemide	46-56	solute carrier family 12 member 1	Homo sapiens	315-319
16985514-6	2006	This effect of furosemide was abolished with amiloride or benzamil blocking ENaC action.	Furosemide	15-25	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	76-80
16985514-8	2006	In contrast, in mice with a kidney-specific inactivation of the alpha subunit of ENaC in the CCD and MCD, but not in the CNT, furosemide alone and in combination with hydrochlorothiazide induced normal urinary acidification.	Furosemide	126-136	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	81-85
16985514-11	2006	Thus, functional expression of ENaC channels in the CNT is sufficient for furosemide-stimulated urinary acidification and identifies the CNT as a major segment in electrogenic urinary acidification.	Furosemide	74-84	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	31-35
17015841-10	2006	Further, the lower renal inner medullary interstitial NaCl concentration that occurs chronically in ClCK1-/- mice and acutely in normal mice given furosemide is associated with lower NTE mRNA and protein.	Furosemide	147-157	patatin-like phospholipase domain containing 6	Mus musculus	183-186
16905250-4	2006	Our results showed that inhibition of KCC2 with furosemide, as well as blockade of GABA(A)R with bicuculline, significantly enhanced circuit activity.	Furosemide	48-58	solute carrier family 12 member 5	Homo sapiens	38-42
16712968-3	2006	The present studies examined expression of the immediate early gene Fos in the nucleus accumbens (NAc) as a marker of neuronal activation following the induction and expression of furosemide-induced sodium appetite.	Furosemide	180-190	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	68-71
16581019-7	2006	Furthermore, the inhibition of KCC2 function with furosemide directly induced EPSP-spike (E-S) potentiation, an important component of LTP in hippocampus.	Furosemide	50-60	solute carrier family 12 member 5	Rattus norvegicus	31-35
16418303-8	2006	Renal clearance studies revealed that IROA normalized the increased natriuretic efficacy of furosemide found in CBL rats.	Furosemide	92-102	Cbl proto-oncogene	Rattus norvegicus	112-115
16418303-10	2006	Finally, Western blot analyses of outer medullary homogenates showed increased abundance of the furosemide-sensitive Na-K-2Cl (NKCC2) cotransporter.	Furosemide	96-106	solute carrier family 12 member 1	Rattus norvegicus	127-132
16571595-5	2006	Increasing angiotensin II concentration restored autoregulation and increased renal vascular resistance (RVR) in B60 kidneys; this facilitated autoregulation, and the increase in RVR was abolished by 100 microM furosemide.	Furosemide	211-221	angiotensinogen	Rattus norvegicus	11-25
17111813-4	2006	Furosemide and ouabain were applied to block the two channels in Castel mice line which can long-time maintain normal auditory function and then their auditory function was detected by ABR to authenticate the mode of potassium recycling in vivo and the relationship between cochlear potassium recycling and NKCC1(+/-) and alpha2 Na, K-ATPase.	Furosemide	0-10	solute carrier family 12, member 2	Mus musculus	307-312
16609147-5	2006	The loop diuretic furosemide 2-fold diluted and increased approximately 10-fold the volume of distal tubular fluid, while also causing the release of 20% of juxtaglomerular renin content.	Furosemide	18-28	renin	Homo sapiens	173-178
16675646-0	2006	Visual compatibility of furosemide with phenylephrine and vasopressin.	Furosemide	24-34	arginine vasopressin	Homo sapiens	58-69
16222701-1	2006	In this study, we demonstrated that the specific inhibitors of the Na+/K+/Cl- cotransporter (NKCC1), bumetanide and furosemide, inhibited extracellular regulated kinase (ERK) phosphorylation in Balb/c 3T3 fibroblasts, stimulated with a variety of mitogens.	Furosemide	116-126	mitogen-activated protein kinase 1	Homo sapiens	138-168
16303857-7	2006	The increase in PRC caused by an intraperitoneal injection of furosemide (40 mg/kg) was comparable in WT and A1AR-/- mice, and it was accompanied by similar transient increases in blood pressure, heart rate, and activity.	Furosemide	62-72	adenosine A1 receptor	Mus musculus	109-113
16628676-2	2006	The objective of this work was to study, in rats with acute extrahepatic cholestasis, the cortical renal expression of the organic anion transporter 1 (OAT1) and the organic anion transporter 3 (OAT3), in association with the pharmacokinetics and renal excretion of furosemide (FS).	Furosemide	278-280	solute carrier family 22 member 6	Rattus norvegicus	123-150
16628676-2	2006	The objective of this work was to study, in rats with acute extrahepatic cholestasis, the cortical renal expression of the organic anion transporter 1 (OAT1) and the organic anion transporter 3 (OAT3), in association with the pharmacokinetics and renal excretion of furosemide (FS).	Furosemide	278-280	solute carrier family 22 member 6	Rattus norvegicus	152-156
16628676-2	2006	The objective of this work was to study, in rats with acute extrahepatic cholestasis, the cortical renal expression of the organic anion transporter 1 (OAT1) and the organic anion transporter 3 (OAT3), in association with the pharmacokinetics and renal excretion of furosemide (FS).	Furosemide	278-280	solute carrier family 22 member 8	Rattus norvegicus	166-193
16628676-2	2006	The objective of this work was to study, in rats with acute extrahepatic cholestasis, the cortical renal expression of the organic anion transporter 1 (OAT1) and the organic anion transporter 3 (OAT3), in association with the pharmacokinetics and renal excretion of furosemide (FS).	Furosemide	278-280	solute carrier family 22 member 8	Rattus norvegicus	195-199
16628676-12	2006	In conclusion, acute obstructive jaundice is associated with an upregulation of OAT1 and OAT3, which might explain, at least in part, the increased systemic and renal elimination of FS.	Furosemide	182-184	solute carrier family 22 member 6	Rattus norvegicus	80-84
16628676-12	2006	In conclusion, acute obstructive jaundice is associated with an upregulation of OAT1 and OAT3, which might explain, at least in part, the increased systemic and renal elimination of FS.	Furosemide	182-184	solute carrier family 22 member 8	Rattus norvegicus	89-93
16612254-6	2006	RESULTS: Placental production of IL-10 was not affected by clonidine, but decreased significantly after incubation of the tissue with diazoxide, hydralazine or furosemide.	Furosemide	160-170	interleukin 10	Homo sapiens	33-38
16612254-8	2006	There was a stepwise reduction in production of TNF-alpha and IL-6 with increasing doses of diazoxide, hydralazine and furosemide by placentas and PBMCs from these women with normal pregnancies.	Furosemide	119-129	tumor necrosis factor	Homo sapiens	48-57
16612254-8	2006	There was a stepwise reduction in production of TNF-alpha and IL-6 with increasing doses of diazoxide, hydralazine and furosemide by placentas and PBMCs from these women with normal pregnancies.	Furosemide	119-129	interleukin 6	Homo sapiens	62-66
16612254-9	2006	CONCLUSION: Our data suggest that the antihypertensive drugs clonidine and hydralazine can stimulate production of the circulating anti-inflammatory cytokine IL-10, whereas furosemide and diazoxide inhibit the production of this cytokine and the proinflammatory cytokines TNF-alpha and IL-6 by placentas and PBMCs.	Furosemide	173-183	tumor necrosis factor	Homo sapiens	272-281
16612254-9	2006	CONCLUSION: Our data suggest that the antihypertensive drugs clonidine and hydralazine can stimulate production of the circulating anti-inflammatory cytokine IL-10, whereas furosemide and diazoxide inhibit the production of this cytokine and the proinflammatory cytokines TNF-alpha and IL-6 by placentas and PBMCs.	Furosemide	173-183	interleukin 6	Homo sapiens	286-290
16531376-4	2006	Furosemide was considered appropriate when the primary or secondary ED or hospital diagnoses included congestive heart failure (CHF) or pulmonary edema, or the BNP was > 400.	Furosemide	0-10	natriuretic peptide B	Homo sapiens	160-163
16222701-1	2006	In this study, we demonstrated that the specific inhibitors of the Na+/K+/Cl- cotransporter (NKCC1), bumetanide and furosemide, inhibited extracellular regulated kinase (ERK) phosphorylation in Balb/c 3T3 fibroblasts, stimulated with a variety of mitogens.	Furosemide	116-126	mitogen-activated protein kinase 1	Homo sapiens	170-173
16222701-5	2006	Several additional lines of evidence supported the above conclusion: (i) furosemide inhibits phosphorylation of MAPK kinase (MEK) induced by receptor tyrosine kinase (RTK) ligands, such as PDGF, FGF, and EGF.	Furosemide	73-83	mitogen-activated protein kinase kinase 7	Homo sapiens	125-128
16222701-5	2006	Several additional lines of evidence supported the above conclusion: (i) furosemide inhibits phosphorylation of MAPK kinase (MEK) induced by receptor tyrosine kinase (RTK) ligands, such as PDGF, FGF, and EGF.	Furosemide	73-83	ret proto-oncogene	Homo sapiens	141-165
16222701-5	2006	Several additional lines of evidence supported the above conclusion: (i) furosemide inhibits phosphorylation of MAPK kinase (MEK) induced by receptor tyrosine kinase (RTK) ligands, such as PDGF, FGF, and EGF.	Furosemide	73-83	ret proto-oncogene	Homo sapiens	167-170
16222701-5	2006	Several additional lines of evidence supported the above conclusion: (i) furosemide inhibits phosphorylation of MAPK kinase (MEK) induced by receptor tyrosine kinase (RTK) ligands, such as PDGF, FGF, and EGF.	Furosemide	73-83	epidermal growth factor	Homo sapiens	204-207
16222701-6	2006	(ii) Furosemide also inhibited ERK phosphorylation, induced by thrombin, a GPCR.	Furosemide	5-15	mitogen-activated protein kinase 1	Homo sapiens	31-34
16222701-6	2006	(ii) Furosemide also inhibited ERK phosphorylation, induced by thrombin, a GPCR.	Furosemide	5-15	coagulation factor II, thrombin	Homo sapiens	63-71
16222701-7	2006	(iii) Furosemide inhibited MEK and ERK phosphorylation even when ERK phosphorylation was induced by direct activation of protein kinase C (PKC) by TPA, which bypasses early steps of the mitogenic cascade.	Furosemide	6-16	mitogen-activated protein kinase kinase 7	Homo sapiens	27-30
16222701-7	2006	(iii) Furosemide inhibited MEK and ERK phosphorylation even when ERK phosphorylation was induced by direct activation of protein kinase C (PKC) by TPA, which bypasses early steps of the mitogenic cascade.	Furosemide	6-16	mitogen-activated protein kinase 1	Homo sapiens	35-38
16222701-7	2006	(iii) Furosemide inhibited MEK and ERK phosphorylation even when ERK phosphorylation was induced by direct activation of protein kinase C (PKC) by TPA, which bypasses early steps of the mitogenic cascade.	Furosemide	6-16	mitogen-activated protein kinase 1	Homo sapiens	65-68
15917300-9	2005	Treatment of the gland with furosemide, a blocker of the NKCC1 cotransporter, reduced the plateau phase of fluid flow by approximately 30%.	Furosemide	28-38	solute carrier family 12, member 2	Mus musculus	57-62
16464787-0	2006	Increased urinary aquaporin-2 excretion in response to furosemide in patients with chronic heart failure.	Furosemide	55-65	aquaporin 2	Homo sapiens	18-29
16464787-4	2006	We tested the hypothesis that U-AQP2 increases after a single intravenous dose of furosemide in CHF patients.	Furosemide	82-92	aquaporin 2	Homo sapiens	32-36
16464787-8	2006	RESULTS: Furosemide increased U-AQP2 (140 %), urine volume (280 %), C(H2O) (95 %) and FE(Na) by a factor of 15 (p<0.008 for all), and also AVP (51 %), PRC, Ang II (86 %) and Aldo (59 %) (p<0.021 for all).	Furosemide	9-19	aquaporin 2	Homo sapiens	32-36
16464787-8	2006	RESULTS: Furosemide increased U-AQP2 (140 %), urine volume (280 %), C(H2O) (95 %) and FE(Na) by a factor of 15 (p<0.008 for all), and also AVP (51 %), PRC, Ang II (86 %) and Aldo (59 %) (p<0.021 for all).	Furosemide	9-19	angiotensinogen	Homo sapiens	159-165
16464787-10	2006	CONCLUSIONS: In CHF, furosemide increased the vasopressin level, which stimulated water reabsorption via the APQ2 water channels.	Furosemide	21-31	arginine vasopressin	Homo sapiens	46-57
16715419-6	2006	The bleeding volume, homologous blood transfusion volume, furosemide dose, and corrected KCl volume were all significantly less in the hANP group.	Furosemide	58-68	natriuretic peptide A	Homo sapiens	135-139
16239278-7	2005	Furosemide (100 microm), a pharmacological compound known to block the activity of the neurone-specific K(+)-Cl- cotransporter, KCC2, reversed IPSC polarity and shifted E(IPSC) towards its theoretical value.	Furosemide	0-10	solute carrier family 12 member 5	Rattus norvegicus	128-132
16106034-1	2005	Acute administration of loop diuretics like furosemide leads to a stimulation of renin secretion, an effect thought to result from inhibition of Na-K-2Cl cotransporter (NKCC2)-mediated salt transport at the luminal surface of the macula densa (MD).	Furosemide	44-54	solute carrier family 12, member 1	Mus musculus	169-174
16452663-8	2006	Bumetanide and furosemide, which inhibit Cl- influx through the Na(+)-K(+)-Cl- cotransporter isoform-1 (NKCC-1) and efflux through the K(+)-Cl- cotransporter isoform-2, were unable to inhibit the first rise in [Cl-]i, yet entirely prevented the secondary rise in [Cl-]i during reoxygenation.	Furosemide	15-25	solute carrier family 12, member 2	Mus musculus	64-102
16452663-8	2006	Bumetanide and furosemide, which inhibit Cl- influx through the Na(+)-K(+)-Cl- cotransporter isoform-1 (NKCC-1) and efflux through the K(+)-Cl- cotransporter isoform-2, were unable to inhibit the first rise in [Cl-]i, yet entirely prevented the secondary rise in [Cl-]i during reoxygenation.	Furosemide	15-25	solute carrier family 12, member 2	Mus musculus	104-110
16412259-6	2005	The established cell line (NE-MD) showed a time-dependent increase in signals of the nNOS protein when they were incubated with 12 microM furosemide (an inhibitor of Na(+)-K(+)-2Cl(-) symporter) for 5 h. In conclusion, this newly developed macula densa cell line will be useful in studies of the TGF stem.	Furosemide	138-148	nitric oxide synthase 1, neuronal	Mus musculus	85-89
15917300-13	2005	Blocking NKCC1 with furosemide reduced the amount of shrinkage by approximately 50%.	Furosemide	20-30	solute carrier family 12, member 2	Mus musculus	9-14
15961422-11	2005	Together with the earlier evidence on the dependence of post-furosemide medullary hypoperfusion on angiotensin II, the study exposes its interaction with PG in the control of medullary circulation.	Furosemide	61-71	angiotensinogen	Rattus norvegicus	99-113
16157691-4	2005	In the current work, we provide additional insight in these regards by showing in mouse that the administration of either furosemide or an H(2)O-rich diet, which are predicted to alter NKCC2 expression in the TAL, exerts differential effects on mRNA levels for the variants, increasing those of A (furosemide) but decreasing those of F and AF (furosemide or H(2)O).	Furosemide	122-132	solute carrier family 12, member 1	Mus musculus	185-190
16157691-4	2005	In the current work, we provide additional insight in these regards by showing in mouse that the administration of either furosemide or an H(2)O-rich diet, which are predicted to alter NKCC2 expression in the TAL, exerts differential effects on mRNA levels for the variants, increasing those of A (furosemide) but decreasing those of F and AF (furosemide or H(2)O).	Furosemide	122-132	talipes	Mus musculus	209-212
16157691-4	2005	In the current work, we provide additional insight in these regards by showing in mouse that the administration of either furosemide or an H(2)O-rich diet, which are predicted to alter NKCC2 expression in the TAL, exerts differential effects on mRNA levels for the variants, increasing those of A (furosemide) but decreasing those of F and AF (furosemide or H(2)O).	Furosemide	298-308	solute carrier family 12, member 1	Mus musculus	185-190
16157691-4	2005	In the current work, we provide additional insight in these regards by showing in mouse that the administration of either furosemide or an H(2)O-rich diet, which are predicted to alter NKCC2 expression in the TAL, exerts differential effects on mRNA levels for the variants, increasing those of A (furosemide) but decreasing those of F and AF (furosemide or H(2)O).	Furosemide	298-308	solute carrier family 12, member 1	Mus musculus	185-190
16174750-5	2005	In Atp6v1b1(-/-) mice, the normal urinary acidification induced by a lumen-negative potential in response to furosemide infusion is abolished.	Furosemide	109-119	ATPase, H+ transporting, lysosomal V1 subunit B1	Mus musculus	3-11
15952020-5	2005	Compared with reported plasma concentration achieved during treatment, only furosemide would have the potential to inhibit TPMT also in vivo, whereas the IC50 values of the other agents are far above the corresponding plasma levels.	Furosemide	76-86	thiopurine S-methyltransferase	Homo sapiens	123-127
15937522-4	2005	Everolimus also attenuated the stimulation of renocortical COX-2 expression by furosemide (12 mg day(-1) for 7 days; s.c. via osmotic minipumps), by low salt intake (0.02% NaCl, wt wt(-1)) or by a combination of low salt intake with the AT(1)-receptor antagonist valsartan (30 mg kg(-1) day(-1); oral).	Furosemide	79-89	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	59-64
16011733-7	2005	In treated group: cardiac dimensions were reduced with left ventricular fractional shortening significantly increased in combination group (from 22.4 to 28%); captopril + furosemide animals had highest heart rate and lowest systolic and diastolic blood pressures; body and heart weight were reduced, but kidney weight was significantly increased with furosemide (1.7 g in control vs. 2 g in capto + furo); plasma renin activity and angiotensin 1 were greatly increased, and moderately stimulated in control.	Furosemide	171-181	renin	Rattus norvegicus	413-418
15967872-2	2005	Furosemide-induced diuresis and acute oral captopril stimulated the renal vein/contralateral renin ratios to 4.3:1 and 6.5:1 in patients 1 and 2, respectively.	Furosemide	0-10	renin	Homo sapiens	93-98
15976003-0	2005	Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome.	Furosemide	50-60	prostaglandin E receptor 4 (subtype EP4)	Mus musculus	34-37
15976003-10	2005	The furosemide-induced increase in plasma renin concentration was significantly decreased in EP4-/- mice and to a lesser degree also in IP-/- mice.	Furosemide	4-14	prostaglandin E receptor 4 (subtype EP4)	Mus musculus	93-96
15952020-6	2005	CONCLUSIONS: Our ex vivo study revealed that only furosemide has the potential to inhibit TPMT activity in patients with IBD.	Furosemide	50-60	thiopurine S-methyltransferase	Homo sapiens	90-94
15912074-0	2005	The effect of furosemide infusion on serum epidermal growth factor concentration after acute lung injury.	Furosemide	14-24	epidermal growth factor	Homo sapiens	43-66
15976003-11	2005	Pharmacologic inhibition of EP4 receptors in furosemide-treated WT mice with the specific antagonist ONO-AE3-208 mimicked the changes in renin mRNA expression, plasma renin concentration, diuresis, and sodium excretion seen in EP4-/- mice.	Furosemide	45-55	prostaglandin E receptor 4 (subtype EP4)	Mus musculus	28-31
15976003-11	2005	Pharmacologic inhibition of EP4 receptors in furosemide-treated WT mice with the specific antagonist ONO-AE3-208 mimicked the changes in renin mRNA expression, plasma renin concentration, diuresis, and sodium excretion seen in EP4-/- mice.	Furosemide	45-55	prostaglandin E receptor 4 (subtype EP4)	Mus musculus	227-230
15912074-4	2005	The current study was undertaken to clarify whether furosemide attenuates the inflammatory response by changing the epidermal growth factor level in patients with acute lung injury.	Furosemide	52-62	epidermal growth factor	Homo sapiens	116-139
15528393-8	2005	Sodium depletion with furosemide and low-sodium diet produced a strong sodium appetite and induced Fos-ir in SFO and MnPO.	Furosemide	22-32	FBJ osteosarcoma oncogene	Mus musculus	99-102
15656876-6	2005	Per 40 mg day(-1) of furosemide, urinary calcium was increased by 17% (P < 0.05) and plasma PTH levels were increased by 28% (P = 0.04).	Furosemide	21-31	parathyroid hormone	Homo sapiens	95-98
15977143-3	2005	DRS "F-0" was started after intravenous administration of diethylene-triamine- pentaacetic acid (DTPA) mixed with furosemide.	Furosemide	114-124	sushi repeat containing protein X-linked	Homo sapiens	0-3
15623552-7	2005	Treatment with furosemide, which decreases inner-medullary NaCl, reduces inner-medullary Pax2 mRNA and protein.	Furosemide	15-25	paired box 2	Mus musculus	89-93
16095054-17	2005	CONCLUSIONS: Furosemide treatment increased U-AQP2, AVP, and the activity of the renin-angiotensin-aldosterone system.	Furosemide	13-23	aquaporin 2	Homo sapiens	46-50
16095054-17	2005	CONCLUSIONS: Furosemide treatment increased U-AQP2, AVP, and the activity of the renin-angiotensin-aldosterone system.	Furosemide	13-23	renin	Homo sapiens	81-86
15564765-8	2004	The abundance of NKCC2 and NCC is increased by furosemide and hydrochlorothiazide, respectively.	Furosemide	47-57	solute carrier family 12 member 1	Homo sapiens	17-22
16095054-0	2005	Urinary excretion of aquaporin-2 after furosemide and felodipine in healthy humans.	Furosemide	39-49	aquaporin 2	Homo sapiens	21-32
16095054-5	2005	We sought to test the hypotheses that urinary excretion of aquaporin-2 (U-AQP2) increases after a single intravenous dose of furosemide, and that U-AQP2 decreases after a single oral dose of felodipine.	Furosemide	125-135	aquaporin 2	Homo sapiens	59-70
16095054-5	2005	We sought to test the hypotheses that urinary excretion of aquaporin-2 (U-AQP2) increases after a single intravenous dose of furosemide, and that U-AQP2 decreases after a single oral dose of felodipine.	Furosemide	125-135	aquaporin 2	Homo sapiens	74-78
16095054-10	2005	RESULTS: Furosemide treatment increased U-AQP2 (202%), urine volume (214%), and FENa by a factor of 11, (p < 0.001 for all), whereas CH2O and GFR were unchanged.	Furosemide	9-19	aquaporin 2	Homo sapiens	42-46
16095054-12	2005	Furosemide treatment increased AVP (18%), PRC (60%), ang II (100%), and aldo (98%) (p < 0.032); ANP was decreased by 29% (p < 0.001), whereas there was no change in BNP.	Furosemide	0-10	angiotensinogen	Homo sapiens	53-59
16095054-12	2005	Furosemide treatment increased AVP (18%), PRC (60%), ang II (100%), and aldo (98%) (p < 0.032); ANP was decreased by 29% (p < 0.001), whereas there was no change in BNP.	Furosemide	0-10	natriuretic peptide B	Homo sapiens	171-174
15564765-8	2004	The abundance of NKCC2 and NCC is increased by furosemide and hydrochlorothiazide, respectively.	Furosemide	47-57	solute carrier family 12 member 3	Homo sapiens	27-30
15564765-10	2004	In the proximal tubule, the abundance of OAT1 is increased by chronic treatment with furosemide or hydrochlorothiazide.	Furosemide	85-95	solute carrier family 22 member 6	Homo sapiens	41-45
15223304-5	2004	Furosemide, which inhibits the NKCC-1 and KCC2 cotransporters, and bumetanide, a more specific NKCC-1 inhibitor, enhanced ATP recovery when measured 3 h after OGD.	Furosemide	0-10	solute carrier family 12 member 2	Homo sapiens	31-37
15175220-3	2004	Using exogenously expressed KCC2 protein, we first examined the interaction of cations at the transport site of KCC2 by monitoring furosemide-sensitive (86)Rb(+) influx as a function of external Rb(+) concentration at different fixed external cation concentrations (Na(+), Li(+), K(+), Cs(+), and NH(4)(+)).	Furosemide	131-141	solute carrier family 12 member 5	Homo sapiens	112-116
15175220-10	2004	Consistent with KCC2-mediated NH(4)(+) transport, pH(i) recovery in KCC2-expressing cells could be inhibited by furosemide (200 microM) or removal of external [Cl(-)].	Furosemide	112-122	solute carrier family 12 member 5	Homo sapiens	16-20
15175220-10	2004	Consistent with KCC2-mediated NH(4)(+) transport, pH(i) recovery in KCC2-expressing cells could be inhibited by furosemide (200 microM) or removal of external [Cl(-)].	Furosemide	112-122	solute carrier family 12 member 5	Homo sapiens	68-72
15450096-4	2004	Here we demonstrate that isolated CA1 neurons of these mice showed furosemide-sensitivity of GABA-evoked currents, confirming the functional expression of alpha6 subunit.	Furosemide	67-77	carbonic anhydrase 1	Mus musculus	34-37
15364336-2	2004	BACKGROUND: Furosemide activates the renin-angiotensin-aldosterone system in patients with congestive heart failure (CHF).	Furosemide	12-22	renin	Homo sapiens	37-42
15175220-3	2004	Using exogenously expressed KCC2 protein, we first examined the interaction of cations at the transport site of KCC2 by monitoring furosemide-sensitive (86)Rb(+) influx as a function of external Rb(+) concentration at different fixed external cation concentrations (Na(+), Li(+), K(+), Cs(+), and NH(4)(+)).	Furosemide	131-141	solute carrier family 12 member 5	Homo sapiens	28-32
15283765-6	2004	(4) cBS is caused by mutations in the chloride channel ClC-Kb with similar clinical characteristics as seen under combination of thiazides and furosemide, (5) GS is caused by mutations in the thiazide-sensitive sodium-chloride cotransporter NCCT resembling the effect of long-term thiazide administration.	Furosemide	143-153	chloride voltage-gated channel Kb	Homo sapiens	55-61
15283765-7	2004	CONCLUSION: The combination of pharmacology and genetics suggests a new terminology for the above described SLTs: Furosemide-like-SLT for HPS caused by NKCC2-mutations, furosemide/amiloride-like-SLT for HPS caused by ROMK-mutations, furosemide/thiazide-like-SLT for HPS + SND, thiazide/furosemide-like-SLT for cBS, and thiazide-like-SLT for GS.	Furosemide	114-124	solute carrier family 12 member 1	Homo sapiens	152-157
15283765-7	2004	CONCLUSION: The combination of pharmacology and genetics suggests a new terminology for the above described SLTs: Furosemide-like-SLT for HPS caused by NKCC2-mutations, furosemide/amiloride-like-SLT for HPS caused by ROMK-mutations, furosemide/thiazide-like-SLT for HPS + SND, thiazide/furosemide-like-SLT for cBS, and thiazide-like-SLT for GS.	Furosemide	114-124	potassium inwardly rectifying channel subfamily J member 1	Homo sapiens	217-221
15223304-5	2004	Furosemide, which inhibits the NKCC-1 and KCC2 cotransporters, and bumetanide, a more specific NKCC-1 inhibitor, enhanced ATP recovery when measured 3 h after OGD.	Furosemide	0-10	solute carrier family 12 member 5	Homo sapiens	42-46
15223304-6	2004	Furosemide and bumetanide also attenuated area CA1 neuronal injury after OGD.	Furosemide	0-10	carbonic anhydrase 1	Homo sapiens	47-50
15180925-7	2004	Despite the abrogation of glomerular filtration, detected by inulin clearance measurements, renocortical COX-2 mRNA abundance was stimulated by furosemide treatment (3.2-fold) or low-salt diet (2.9-fold) to similar degrees compared with the intact contralateral kidney (2.7-fold for both treatments), whereas a high-salt diet did not significantly suppress COX-2 mRNA in the macula densa region of either kidney.	Furosemide	144-154	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	105-110
15314687-7	2004	Amiloride or furosemide reduced BP in CD ET-1 KO mice on a normal or high-Na diet and prevented excessive Na retention in salt-loaded CD ET-1 KO mice.	Furosemide	13-23	endothelin 1	Mus musculus	41-45
15180925-7	2004	Despite the abrogation of glomerular filtration, detected by inulin clearance measurements, renocortical COX-2 mRNA abundance was stimulated by furosemide treatment (3.2-fold) or low-salt diet (2.9-fold) to similar degrees compared with the intact contralateral kidney (2.7-fold for both treatments), whereas a high-salt diet did not significantly suppress COX-2 mRNA in the macula densa region of either kidney.	Furosemide	144-154	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	357-362
15180925-8	2004	Renin mRNA expression was regulated strictly in parallel in both kidneys, a low-salt diet or furosemide treatment stimulating and a high-salt diet suppressing it.	Furosemide	93-103	renin	Rattus norvegicus	0-5
14985360-9	2004	Inhibition of insulin-induced swelling by furosemide largely abolished activation of beta(1) integrin and phosphorylation of Src, but not of PKB.	Furosemide	42-52	insulin	Homo sapiens	14-21
15314687-7	2004	Amiloride or furosemide reduced BP in CD ET-1 KO mice on a normal or high-Na diet and prevented excessive Na retention in salt-loaded CD ET-1 KO mice.	Furosemide	13-23	endothelin 1	Mus musculus	137-141
15149320-7	2004	Basal as well as furosemide-induced stimulation of plasma renin activity (PRA) and of renal renin mRNA was further enhanced by CsA.	Furosemide	17-27	renin	Rattus norvegicus	58-63
15149320-7	2004	Basal as well as furosemide-induced stimulation of plasma renin activity (PRA) and of renal renin mRNA was further enhanced by CsA.	Furosemide	17-27	renin	Rattus norvegicus	92-97
15149320-8	2004	In contrast, rofecoxib attenuated the furosemide-induced rise of PRA and of renin mRNA, both in the absence and in the presence of CsA.	Furosemide	38-48	renin	Rattus norvegicus	76-81
15149320-11	2004	Since the furosemide-induced stimulation of the renin system is not attenuated by CsA but by COX-2 inhibition, we speculate that extrarenal COX-2-derived prostanoids may be involved in the stimulation of the renin system by CsA and by loop diuretics.	Furosemide	10-20	renin	Rattus norvegicus	48-53
15149320-11	2004	Since the furosemide-induced stimulation of the renin system is not attenuated by CsA but by COX-2 inhibition, we speculate that extrarenal COX-2-derived prostanoids may be involved in the stimulation of the renin system by CsA and by loop diuretics.	Furosemide	10-20	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	93-98
15149320-11	2004	Since the furosemide-induced stimulation of the renin system is not attenuated by CsA but by COX-2 inhibition, we speculate that extrarenal COX-2-derived prostanoids may be involved in the stimulation of the renin system by CsA and by loop diuretics.	Furosemide	10-20	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	140-145
15149320-11	2004	Since the furosemide-induced stimulation of the renin system is not attenuated by CsA but by COX-2 inhibition, we speculate that extrarenal COX-2-derived prostanoids may be involved in the stimulation of the renin system by CsA and by loop diuretics.	Furosemide	10-20	renin	Rattus norvegicus	208-213
14985360-9	2004	Inhibition of insulin-induced swelling by furosemide largely abolished activation of beta(1) integrin and phosphorylation of Src, but not of PKB.	Furosemide	42-52	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	125-128
15086907-2	2004	We showed previously that parathyroidectomy protected against the development of furosemide-induced nephrocalcinosis in young rats, indicating a possible role for parathyroid hormone (PTH) in its pathogenesis.	Furosemide	81-91	parathyroid hormone	Rattus norvegicus	163-182
15075186-8	2004	In furosemide-induced alkalotic rats, NBCn1 protein abundance was decreased in both the IM and inner stripe of outer medulla (ISOM) as determined by immunoblotting and immunohistochemistry.	Furosemide	3-13	solute carrier family 4 member 7	Rattus norvegicus	38-43
15089816-12	2004	Non-adherence with furosemide was less common among those who died and appeared to occur at different time points from non-adherence with ACE inhibitor treatment, which was slightly more common in all outcome groups.	Furosemide	19-29	angiotensin I converting enzyme	Homo sapiens	138-141
15023890-0	2004	Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.	Furosemide	78-88	natriuretic peptide B	Canis lupus familiaris	0-25
15023890-0	2004	Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.	Furosemide	52-62	natriuretic peptide B	Canis lupus familiaris	0-25
15039295-10	2004	Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence.	Furosemide	407-417	solute carrier family 22 member 6	Homo sapiens	34-39
15039295-10	2004	Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence.	Furosemide	407-417	solute carrier family 22 member 6	Homo sapiens	46-51
15039295-10	2004	Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence.	Furosemide	407-417	solute carrier family 22 member 6	Homo sapiens	46-51
15039295-10	2004	Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence.	Furosemide	407-417	solute carrier family 22 member 6	Homo sapiens	46-51
15039295-10	2004	Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence.	Furosemide	407-417	solute carrier family 22 member 6	Homo sapiens	46-51
15039295-10	2004	Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence.	Furosemide	407-417	solute carrier family 22 member 6	Homo sapiens	46-51
15039295-10	2004	Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence.	Furosemide	407-417	solute carrier family 22 member 6	Homo sapiens	46-51
15039295-10	2004	Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence.	Furosemide	407-417	solute carrier family 22 member 6	Homo sapiens	46-51
15039295-10	2004	Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence.	Furosemide	407-417	solute carrier family 22 member 6	Homo sapiens	46-51
15039295-10	2004	Further functional comparisons of hOAT1-1 and hOAT1-2 in fluorescein uptake studies exhibited almost identical affinities for fluorescein with Michaelis constants of 11.6 +/- 3.7 microM (hOAT1-1) and 11.9 +/- 6.4 microM (hOAT1-2), and similar sensitivities to inhibition by p-aminohippurate [IC(50): 16 microM (hOAT1-1), 10 microM (hOAT1-2)], urate [IC(50): 440 microM (hOAT1-1), 385 microM (hOAT1-2)], and furosemide (IC(50): 14 microM (hOAT1-1), 20 microM (hOAT1-2)], implying functional equivalence.	Furosemide	407-417	solute carrier family 22 member 6	Homo sapiens	46-51
15007654-3	2004	Contrastingly, we have shown earlier that the abundance of the major ion transporter of the TAL, the furosemide-sensitive Na-K-2Cl cotransporter (NKCC2) was increased when related to kidney function in the hypothyroid organism.	Furosemide	101-111	solute carrier family 12 member 1	Rattus norvegicus	146-151
15005740-0	2004	Investigation into the mechanisms by which nedocromil sodium, frusemide and bumetanide inhibit the histamine-induced itch and flare response in human skin in vivo.	Furosemide	62-71	itchy E3 ubiquitin protein ligase	Homo sapiens	117-121
15005740-8	2004	RESULTS: In study 1, nedocromil sodium, frusemide and bumetanide reduced itch scores by 36%, 48% and 34%, respectively, and flare areas by 17%, 26% and 15% respectively (all P<0.05).	Furosemide	40-49	itchy E3 ubiquitin protein ligase	Homo sapiens	73-77
15005740-12	2004	CONCLUSION: This study has provided evidence to support the hypothesis that nedocromil sodium, frusemide and bumetanide inhibit sensory nerve activation to reduce the itch and flare responses induced by histamine in human skin in vivo.	Furosemide	95-104	itchy E3 ubiquitin protein ligase	Homo sapiens	167-171
14684611-7	2004	Acute treatment with specific V1 or V2 receptor agonists resulted in specific increases in medullary COX-2, which was prevented by furosemide.	Furosemide	131-141	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	101-106
14610216-8	2004	hOAT1 and hOAT3, but not hOAT2 and hOAT4 mediated the uptake of furosemide.	Furosemide	64-74	solute carrier family 22 member 6	Homo sapiens	0-5
14610216-8	2004	hOAT1 and hOAT3, but not hOAT2 and hOAT4 mediated the uptake of furosemide.	Furosemide	64-74	solute carrier family 22 member 8	Homo sapiens	10-15
15023890-3	2004	The objective of this study was to test the hypothesis that exogenous BNP enhances the renal diuretic and natriuretic actions of furosemide (Fs) and retards the activation of aldosterone in a model of CHF.	Furosemide	129-139	natriuretic peptide B	Canis lupus familiaris	70-73
15023890-3	2004	The objective of this study was to test the hypothesis that exogenous BNP enhances the renal diuretic and natriuretic actions of furosemide (Fs) and retards the activation of aldosterone in a model of CHF.	Furosemide	141-143	natriuretic peptide B	Canis lupus familiaris	70-73
15023890-8	2004	Similarly, urinary sodium excretion was higher in the Fs+BNP group.	Furosemide	54-56	natriuretic peptide B	Canis lupus familiaris	57-60
14670634-1	2004	The present study investigates co-localization of AT(1A) receptor subtype and Fos protein in neuronal populations of the lamina terminalis (LT) that have been recruited during acute Na(+) and water depletion mediated by furosemide injections.	Furosemide	220-230	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	78-81
14670634-3	2004	As expected, furosemide treatment dramatically increased the density of Fos-immunoreactive neuronal population in all the regions of the LT compared to control (saline-injected animals).	Furosemide	13-23	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	72-75
14592462-9	2003	Purified Na+/K+ ATPase only presented ouabain-induced phosphoprotein, indicating that furosemide-induced phosphorylation is not related to this enzyme and appears to correspond to a new member of P-type ATPases associated with the second Na+ pump.	Furosemide	86-96	dynein axonemal heavy chain 8	Homo sapiens	16-22
14992282-7	2004	On the other hand, DIDS, furosemide, and bumetanide prevented CGC death induced by K5 and St.	Furosemide	25-35	keratin 5	Homo sapiens	83-92
15489025-3	2004	Additionally, we investigated if moxonidine into the LPBN would modify furosemide+captopril-induced c-fos expression in the forebrain.	Furosemide	71-81	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	100-105
12840061-6	2003	HEK/EP1 [Ca2+]i responses were observed mainly in preparations from rabbits on a low-salt diet and were completely inhibited by either a selective COX-2 inhibitor or an EP1 antagonist, and also by 100 microM luminal furosemide.	Furosemide	216-226	prostaglandin E receptor 1	Homo sapiens	4-7
12922924-6	2003	We tested the hypothesis that the selective adenosine A(1) receptor antagonist FK838 is orally active and causes diuresis and natriuresis, but maintains glomerular filtration rate in normal rats or in rats with furosemide resistance.	Furosemide	211-221	adenosine A1 receptor	Rattus norvegicus	44-67
12922924-13	2003	This study shows that the adenosine A(1) receptor antagonist FK838 is orally active and causes potent diuresis and natriuresis and maintains glomerular filtration rate in normal or furosemide-resistant rats.	Furosemide	181-191	adenosine A1 receptor	Rattus norvegicus	26-49
12915681-10	2003	Furosemide increased PAI-1 antigen [27.8 ng/ml (20.6, 35.0), P = 0.002 vs. 19.3 ng/ml (13.4, 25.2) baseline], even in the presence of candesartan [27.2 ng/ml (16.5, 37.8), P = 0.042 vs. baseline] or spironolactone [27.3 ng/ml (17.9, 36.8), P = 0.015 vs. baseline].	Furosemide	0-10	serpin family E member 1	Homo sapiens	21-26
12915681-11	2003	However, coadministration of AT(1) and aldosterone receptor antagonists prevented the furosemide-induced increase in PAI-1 [19.2 ng/ml (9.8, 28.6), P = 0.974 vs. baseline, P < 0.05 vs. candesartan, spironolactone or furosemide alone].	Furosemide	86-96	serpin family E member 1	Homo sapiens	117-122
12897087-0	2003	Up-regulation of organic anion transporter 1 protein is induced by chronic furosemide or hydrochlorothiazide infusion in rat kidney.	Furosemide	75-85	solute carrier family 22 member 6	Rattus norvegicus	17-44
12897087-9	2003	Although OAT1 protein abundance in cortical homogenates was increased by furosemide infusion (271 +/- 35 vs 100 +/- 15%, P < 0.05), Na-K-ATPase alpha1 subunit protein abundance was not affected (113 +/- 14 vs 100 +/- 8%, P = 0.42).	Furosemide	73-83	solute carrier family 22 member 6	Rattus norvegicus	9-13
12897087-12	2003	CONCLUSION: Chronic furosemide or hydrochlorothiazide infusion caused increases in OAT1 protein abundance in rat kidney.	Furosemide	20-30	solute carrier family 22 member 6	Rattus norvegicus	83-87
12840061-6	2003	HEK/EP1 [Ca2+]i responses were observed mainly in preparations from rabbits on a low-salt diet and were completely inhibited by either a selective COX-2 inhibitor or an EP1 antagonist, and also by 100 microM luminal furosemide.	Furosemide	216-226	prostaglandin E receptor 1	Homo sapiens	0-7
14756687-9	2004	After high-dose furosemide, plasma renin activity increased in both groups of lambs, although the effects were greater in 1-week-old lambs.	Furosemide	16-26	renin	Ovis aries	35-40
14510783-7	2003	Facilitation by 100 pm Ang II was inhibited by 100 microm frusemide.	Furosemide	58-67	angiotensinogen	Homo sapiens	23-29
14507972-10	2003	This BDNF-induced effect correlates with the existing level of furosemide-sensitive K+-Cl- transport activity in the postsynaptic cell.	Furosemide	63-73	brain-derived neurotrophic factor	Rattus norvegicus	5-9
12759757-0	2003	Parallel down-regulation of chloride channel CLC-K1 and barttin mRNA in the thin ascending limb of the rat nephron by furosemide.	Furosemide	118-128	chloride voltage-gated channel Ka	Rattus norvegicus	45-51
12759757-0	2003	Parallel down-regulation of chloride channel CLC-K1 and barttin mRNA in the thin ascending limb of the rat nephron by furosemide.	Furosemide	118-128	barttin CLCNK type accessory subunit beta	Rattus norvegicus	56-63
12759757-2	2003	The aim of the present study was to investigate the influence of the loop diuretic furosemide on the gene expression of the kidney chloride channel ClC-K1 and its recently described functional subunit barttin.	Furosemide	83-93	chloride voltage-gated channel Ka	Rattus norvegicus	148-154
12759757-2	2003	The aim of the present study was to investigate the influence of the loop diuretic furosemide on the gene expression of the kidney chloride channel ClC-K1 and its recently described functional subunit barttin.	Furosemide	83-93	barttin CLCNK type accessory subunit beta	Rattus norvegicus	201-208
12759757-7	2003	In furosemide-treated rats ClC-K1 mRNA decreased to half in the inner medulla.	Furosemide	3-13	chloride voltage-gated channel Ka	Rattus norvegicus	27-33
12759757-9	2003	Under furosemide treatment barttin mRNA was regulated in parallel with ClC-K1 mRNA.	Furosemide	6-16	barttin CLCNK type accessory subunit beta	Rattus norvegicus	27-34
12759757-9	2003	Under furosemide treatment barttin mRNA was regulated in parallel with ClC-K1 mRNA.	Furosemide	6-16	chloride voltage-gated channel Ka	Rattus norvegicus	71-77
12759757-12	2003	Microdissection of the inner medullary collecting duct and thin limb of Henle"s loop followed by real-time PCR revealed that CLC-K1 and barttin mRNA regulation in inner medulla was limited to the thin limb; mRNA levels in collecting ducts were not affected by furosemide treatment.	Furosemide	260-270	chloride voltage-gated channel Ka	Rattus norvegicus	125-131
12759757-12	2003	Microdissection of the inner medullary collecting duct and thin limb of Henle"s loop followed by real-time PCR revealed that CLC-K1 and barttin mRNA regulation in inner medulla was limited to the thin limb; mRNA levels in collecting ducts were not affected by furosemide treatment.	Furosemide	260-270	barttin CLCNK type accessory subunit beta	Rattus norvegicus	136-143
12759757-13	2003	Our findings imply that during furosemide treatment selective down-regulation of ClC-K1 and barttin mRNAs in thin limb plays a role in maintaining salt and water homeostasis.	Furosemide	31-41	chloride voltage-gated channel Ka	Rattus norvegicus	81-87
12759757-13	2003	Our findings imply that during furosemide treatment selective down-regulation of ClC-K1 and barttin mRNAs in thin limb plays a role in maintaining salt and water homeostasis.	Furosemide	31-41	barttin CLCNK type accessory subunit beta	Rattus norvegicus	92-99
12595280-3	2003	The pattern of Fos-ir in the brain after furosemide was similar to that seen after peripheral injection of ANG II.	Furosemide	41-51	FBJ osteosarcoma oncogene	Mus musculus	15-18
12798820-10	2003	Plasma renin activity was upregulated by ramipril or ramipril plus furosemide but not influenced by infarction or furosemide alone.	Furosemide	67-77	renin	Rattus norvegicus	7-12
12798820-10	2003	Plasma renin activity was upregulated by ramipril or ramipril plus furosemide but not influenced by infarction or furosemide alone.	Furosemide	114-124	renin	Rattus norvegicus	7-12
12798820-11	2003	CONCLUSIONS: Furosemide and ramipril significantly reduced cardiac ACE and remodeling.	Furosemide	13-23	angiotensin I converting enzyme	Rattus norvegicus	67-70
12393866-3	2002	The chloride channel inhibitor furosemide prevented intracellular alkalinization, Bax translocation, cytochrome c release, and cell death.	Furosemide	31-41	BCL2 associated X, apoptosis regulator	Homo sapiens	82-85
12441308-5	2003	A high-salt diet reduced expression of COX-2, whereas a low-salt diet, furosemide infusion, and renal artery stenosis stimulated COX-2 expression.	Furosemide	71-81	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	129-134
12441308-6	2003	Additional angiotensin-converting enzyme inhibition led to further increases in renocortical COX-2 expression by 62, 136, 300, 50, and 70% for a high-, normal-, and low-salt diet, furosemide infusion, and renal artery stenosis, respectively.	Furosemide	180-190	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	93-98
12388392-6	2003	Semiquantitative immunoblotting revealed that the abundances of thick ascending limb Na(+)-K(+)-2Cl(-) cotransporter and all three subunits of the epithelial Na(+) channel (ENaC) were increased by furosemide infusion.	Furosemide	197-207	sodium channel epithelial 1 subunit gamma	Rattus norvegicus	147-171
12388392-6	2003	Semiquantitative immunoblotting revealed that the abundances of thick ascending limb Na(+)-K(+)-2Cl(-) cotransporter and all three subunits of the epithelial Na(+) channel (ENaC) were increased by furosemide infusion.	Furosemide	197-207	sodium channel epithelial 1 subunit gamma	Rattus norvegicus	173-177
12472779-6	2003	Rats with Li nephropathy were treated with furosemide (3 mg/kg body weight), which blocks the activity of rBSC1, and changes in urine concentration, plasma AVP, medullary accumulation of Li ions, and apical AQP2 expression were determined.	Furosemide	43-53	solute carrier family 12 member 1	Rattus norvegicus	106-111
14580937-4	2003	Our results show that beta-endorphin knockout (KO) and heterozygous (HT) mutant mice consume approximately a 50% less 2% NaCl solution compared with wild type mice (WT), after furosemide and low sodium diet treatment.	Furosemide	176-186	pro-opiomelanocortin-alpha	Mus musculus	22-36
14596865-4	2003	By using the high cellular resolution of the in situ hybridization histochemistry (ISHH), we investigated whether a furosemide-induced fluid and electrolyte depletion might modify both putative GABAergic and glutamatergic systems within the LT. We show that acute furosemide treatment (4 h) significantly reduced the expression of GAD67 mRNA, the active holoenzyme predictive of GABA synthesis, within the SFO.	Furosemide	116-126	glutamate decarboxylase 1	Homo sapiens	331-336
14596865-6	2003	The hydromineral challenge did not alter the expression of GAD65 and type 2 vesicular glutamate transporter (vGlut2) mRNA in all the structures of the LT. Furosemide treatment was associated with a reduction in the population of GAD67-containing neurons in the periphery of the SFO and dorsal part of the MnPO.	Furosemide	155-165	glutamate decarboxylase 1	Homo sapiens	229-234
12608533-0	2003	Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats.	Furosemide	69-79	ATP binding cassette subfamily C member 2	Rattus norvegicus	10-14
12608533-1	2003	PURPOSE: This study assesses the impact of rat multidrug resistance-associated protein 2 (Mrp2) on the biliary excretion and oral absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats (EHBR).	Furosemide	144-154	ATP binding cassette subfamily C member 2	Rattus norvegicus	47-88
12608533-1	2003	PURPOSE: This study assesses the impact of rat multidrug resistance-associated protein 2 (Mrp2) on the biliary excretion and oral absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats (EHBR).	Furosemide	144-154	ATP binding cassette subfamily C member 2	Rattus norvegicus	90-94
12704183-6	2003	Active E217betaG transport by MRP2 was significantly stimulated by the organic anions indomethacin, furosemide, and probenecid and by several conjugated bile acids.	Furosemide	100-110	ATP binding cassette subfamily C member 2	Homo sapiens	30-34
12620696-6	2003	After furosemide, in 67% of patients, decreases in SBP (166 +/- 5 to 134 +/- 5 mm Hg; P <.001), DBP (82 +/- 4 to 71 +/- 4 mm Hg; P =.004), and MAP (111 +/- 3 to 92 +/- 3 mm Hg; P <.001), were associated with increases in PRA (2.1 +/- 1.2 to 5.1 +/- 1.8 ng/mL/h; P =.01) and SA (4.8 +/- 1.0 to 9.4 +/- 1.4 ng/dL; P =.01) and with decreases in ANP (101 +/- 28 to 58 +/- 11 pg/mL; P =.01) and body weight (77.5 +/- 3.6 to 76.4 +/- 3.3 kg; P =.02), findings consistent with volume mediated/salt sensitive hypertension.	Furosemide	6-16	selenium binding protein 1	Homo sapiens	51-54
12620696-6	2003	After furosemide, in 67% of patients, decreases in SBP (166 +/- 5 to 134 +/- 5 mm Hg; P <.001), DBP (82 +/- 4 to 71 +/- 4 mm Hg; P =.004), and MAP (111 +/- 3 to 92 +/- 3 mm Hg; P <.001), were associated with increases in PRA (2.1 +/- 1.2 to 5.1 +/- 1.8 ng/mL/h; P =.01) and SA (4.8 +/- 1.0 to 9.4 +/- 1.4 ng/dL; P =.01) and with decreases in ANP (101 +/- 28 to 58 +/- 11 pg/mL; P =.01) and body weight (77.5 +/- 3.6 to 76.4 +/- 3.3 kg; P =.02), findings consistent with volume mediated/salt sensitive hypertension.	Furosemide	6-16	D-box binding PAR bZIP transcription factor	Homo sapiens	99-102
12388138-6	2003	The prolactin effect on iodide uptake into cultured mammary tissues was abolished by pendrin transport inhibitors, including DIDS, furosemide, and probenecid.	Furosemide	131-141	solute carrier family 26, member 4	Mus musculus	85-92
12393866-3	2002	The chloride channel inhibitor furosemide prevented intracellular alkalinization, Bax translocation, cytochrome c release, and cell death.	Furosemide	31-41	cytochrome c, somatic	Homo sapiens	101-113
12393866-4	2002	Translocation of full-length Bid to the mitochondria was also prevented by furosemide.	Furosemide	75-85	BH3 interacting domain death agonist	Homo sapiens	29-32
12393866-10	2002	Furosemide only delayed full-length Bid depletion and tBid accumulation.	Furosemide	0-10	BH3 interacting domain death agonist	Homo sapiens	36-39
12393866-13	2002	It is concluded that with either staurosporine or TNF a furosemide-sensitive change in pH(i) is linked to Bax translocation, cytochrome c release, and cell killing.	Furosemide	56-66	tumor necrosis factor	Homo sapiens	50-55
12393866-13	2002	It is concluded that with either staurosporine or TNF a furosemide-sensitive change in pH(i) is linked to Bax translocation, cytochrome c release, and cell killing.	Furosemide	56-66	BCL2 associated X, apoptosis regulator	Homo sapiens	106-109
12393866-13	2002	It is concluded that with either staurosporine or TNF a furosemide-sensitive change in pH(i) is linked to Bax translocation, cytochrome c release, and cell killing.	Furosemide	56-66	cytochrome c, somatic	Homo sapiens	125-137
12372766-8	2002	UT-B1 protein expression in rat kidney medulla was downregulated greatly by long-term [deamino-Cys(1),D-Arg(8)]vasopressin infusion and moderately by furosemide treatment.	Furosemide	150-160	solute carrier family 14 member 1 (Kidd blood group)	Rattus norvegicus	0-5
12432442-7	2002	Responses of both plasma renin activity and serum aldosterone level following the furosemide upright provocation were blunted in the hyperkalemic acute phase, but recovered in the normokalemic convalescent phase.	Furosemide	82-92	renin	Homo sapiens	25-30
12358151-9	2002	However, peripheral plasma renin activity (PRA) increased normally after the patient resumed an upright posture following furosemide administration.	Furosemide	122-132	renin	Homo sapiens	27-32
12115021-14	2002	Furosemide exhibited an anti-inflammatory effect through inhibition of production and release of cytokines interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha from peripheral mononuclear cells, which may have a beneficial effect on local inflamed tissue imbalance in the ratio of different cytokines, thus improving the sensitivity of target cells to endogenous glucocorticosteroids.	Furosemide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	127-164
12130981-9	2002	In the atrial natriuretic peptide group, extravascular lung water was significantly (p <.05) lower and Pao2 was significantly (p <.05) higher than in the control and furosemide groups, respectively.	Furosemide	172-182	natriuretic peptide A	Canis lupus familiaris	7-33
12361471-8	2002	However, incubation of the epithelial cells in Cl(-)free medium or with a blocker of the Na(+)-K(+)-2Cl(-) cotransporter (Furosemide) reduced the effect of PAF.	Furosemide	122-132	PCNA clamp associated factor	Homo sapiens	156-159
12323126-3	2002	Furthermore, there is also evidence that furosemide induces prostaglandin synthesis, blocks the sodium-calcium pump, producing relaxation of the smooth muscle that narrows the airway and causes reduced nerve responsiveness to the Neurokinin A produced in acute asthma attacks.	Furosemide	41-51	tachykinin precursor 1	Homo sapiens	230-242
11864976-2	2002	Simultaneous treatment of the cells with wortmannin, cycloheximide, furosemide, cyclosporin A, or decylubiquinone prevented the release of cytochrome c and significantly reduced the loss of viability.	Furosemide	68-78	cytochrome c, somatic	Homo sapiens	139-151
11864976-5	2002	The increase in the content of Bax was followed by the translocation of this protein from the cytosol to the mitochondria, an event that was inhibited by furosemide, a chloride channel inhibitor.	Furosemide	154-164	BCL2 associated X, apoptosis regulator	Homo sapiens	31-34
11996409-6	2002	The aim of our study was to examine the influence of furosemide and spironolactone on leukocyte migration through endothelial cell monolayers (ECM).	Furosemide	53-63	multimerin 1	Homo sapiens	143-146
11996409-10	2002	Furosemide (76 +/- 7.2%) and spironolactone (70 +/- 7.7%) were able to inhibit PMNL migration through ECM significantly, when both cell types were treated simulating the situation after an iv injection.	Furosemide	0-10	multimerin 1	Homo sapiens	102-105
11996409-11	2002	Furosemide and spironolactone were identified as potent inhibitors of leukocyte migration through ECM.	Furosemide	0-10	multimerin 1	Homo sapiens	98-101
11961000-0	2002	Low tonicity mediates a downregulation of cyclooxygenase-1 expression by furosemide in the rat renal papilla.	Furosemide	73-83	prostaglandin-endoperoxide synthase 1	Rattus norvegicus	42-58
11961000-3	2002	Furosemide increased Cox-2 mRNA expression approximately twofold in the cortex, but it left Cox-1 mRNA expression unaltered there.	Furosemide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	21-26
11961000-3	2002	Furosemide increased Cox-2 mRNA expression approximately twofold in the cortex, but it left Cox-1 mRNA expression unaltered there.	Furosemide	0-10	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	92-97
11961000-5	2002	In the inner medulla, however, furosemide decreased Cox-1 and Cox-2 mRNA levels to approximately 30% and 60% of their control levels, respectively.	Furosemide	31-41	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	52-57
11961000-5	2002	In the inner medulla, however, furosemide decreased Cox-1 and Cox-2 mRNA levels to approximately 30% and 60% of their control levels, respectively.	Furosemide	31-41	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	62-67
11961000-8	2002	Furosemide lowered urine osmolality from 1550 mosmol/kg to 480 mosmol/kg; therefore, further consideration was given to the influence of tonicity as a possible mediator of the effects of furosemide on the Cox expression.	Furosemide	187-197	coproporphyrinogen oxidase	Rattus norvegicus	205-208
12115021-4	2002	In neonates, after administration of furosemide, the urinary excretion of endothelin-1 and aldosterone increased markedly, and it is known that endothelin may release ANF and aldosterone in a dose-dependent manner.	Furosemide	37-47	endothelin 1	Homo sapiens	74-86
12115021-4	2002	In neonates, after administration of furosemide, the urinary excretion of endothelin-1 and aldosterone increased markedly, and it is known that endothelin may release ANF and aldosterone in a dose-dependent manner.	Furosemide	37-47	natriuretic peptide A	Homo sapiens	167-170
12115021-6	2002	Because the concomitant use of ANF and furosemide appeared to be diuretically effective in newborns after cardiac surgery, one may suggest that furosemide competes with ANF for its effects on the adrenals.	Furosemide	144-154	natriuretic peptide A	Homo sapiens	31-34
12013228-4	2002	CZE-LIF and MECC-LIF are thereby shown to permit unambiguous recognition of furosemide in urines collected after ingestion of therapeutic doses of this drug.	Furosemide	76-86	LIF interleukin 6 family cytokine	Homo sapiens	4-7
12013228-4	2002	CZE-LIF and MECC-LIF are thereby shown to permit unambiguous recognition of furosemide in urines collected after ingestion of therapeutic doses of this drug.	Furosemide	76-86	LIF interleukin 6 family cytokine	Homo sapiens	17-20
12013228-9	2002	CZE-LIF and CE-MS2 with injection of plain or diluted urine represent simple, rapid and attractive urinary screening and confirmation assays for furosemide in patient urines.	Furosemide	145-155	LIF interleukin 6 family cytokine	Homo sapiens	4-7
11967238-5	2002	We have tested whether the stimulation of COX-2 expression by short- and long-term unilateral renal artery stenosis, low salt, and furosemide treatment depends on co-expression of NOS1.	Furosemide	131-141	prostaglandin-endoperoxide synthase 2	Mus musculus	42-47
12005183-4	2002	DIDS inhibited 10 nM ET-1-induced increase in cell count and [3H]-thymidine incorporation into VSMC in a concentration-dependent manner, whereas other Cl- channel blockers including IAA-94, NPPB, DPC, SITS and furosemide did not produce these effects.	Furosemide	210-220	endothelin 1	Rattus norvegicus	21-25
11807827-6	2002	In Balb/c 3T3 fibroblasts stimulated with FGF, bumetanide, and furosemide inhibited 50-60% of the ERK 1/2 phosphorylation.	Furosemide	63-73	mitogen-activated protein kinase 3	Homo sapiens	98-105
11788444-9	2002	The effects of luminal ANG II were furosemide sensitive and abolished by the AT(1) receptor blocker candesartan.	Furosemide	35-45	angiogenin	Homo sapiens	23-26
11851355-8	2002	Combination therapy with furosemide is less efficient with regard to collagen content and MMP-2 (active form) reduction but did not worsen beneficial effects of ramipril on LV function and mortality rate.	Furosemide	25-35	matrix metallopeptidase 2	Rattus norvegicus	90-95
11849395-5	2002	RESULTS: In situ hybridization analysis and RNase protection assay of the total kidney revealed a down-regulation of CLC-K2 mRNA in the high salt diet rats and an up-regulation of CLC-K2 mRNA in furosemide treated rats, which were restricted to the outer medulla.	Furosemide	195-205	chloride voltage-gated channel Kb	Rattus norvegicus	180-186
11849395-7	2002	Using RT-PCR and real time PCR, the changing levels of CLC-K2 mRNA after furosemide treatment or high salt diet were restricted to the mTAL, whereas CLC-K2 mRNA levels in cTAL and OMCD were not changed in furosemide or high salt rats compared to time paired controls.	Furosemide	73-83	chloride voltage-gated channel Kb	Rattus norvegicus	55-61
11849395-7	2002	Using RT-PCR and real time PCR, the changing levels of CLC-K2 mRNA after furosemide treatment or high salt diet were restricted to the mTAL, whereas CLC-K2 mRNA levels in cTAL and OMCD were not changed in furosemide or high salt rats compared to time paired controls.	Furosemide	205-215	chloride voltage-gated channel Kb	Rattus norvegicus	55-61
11812667-7	2002	RESULTS: N-ANF showed the closest correlations to clinical and echocardiographic measures of heart failure severity, e.g. NYHA functional class, furosemide dose, exercise tolerance, systolic and diastolic function.	Furosemide	145-155	natriuretic peptide A	Homo sapiens	11-14
11725383-0	2001	The influence of inhaled furosemide on adverse effects of ACE-inhibitors in airways.	Furosemide	25-35	angiotensin I converting enzyme	Felis catus	58-61
11489390-0	2001	A spectrophotometric-partial least squares (PLS-1) method for the simultaneous determination of furosemide and amiloride hydrochloride in pharmaceutical formulations.	Furosemide	96-106	plastin 1	Homo sapiens	44-49
11489390-1	2001	A numerical method, based on the use of spectrophotometric data coupled to PLS-1 multivariate calibration, is reported for the simultaneous determination of furosemide and amiloride hydrochloride in synthetic samples and commercial tablets.	Furosemide	157-167	plastin 1	Homo sapiens	75-80
11763992-8	2001	Serum creatinine transiently decreased rather than increased 14 days after cisplatin and furosemide administration, while NAG excretion increased 3 days after cisplatin and furosemide administration.	Furosemide	173-183	N-acetyl-alpha-glucosaminidase	Homo sapiens	122-125
11763992-11	2001	Moreover, the first course morning cisplatin and furosemide treatment was associated with less change in NAG excretion (less kidney toxicity) than the first course of evening cisplatin and furosemide treatment.	Furosemide	49-59	N-acetyl-alpha-glucosaminidase	Homo sapiens	105-108
11763992-12	2001	The second course evening cisplatin and furosemide treatment was associated with an increase in NAG excretion compared to the first course of treatment, while morning cisplatin and furosemide treatment in the second course showed less change in NAG excretion compared to the first course.	Furosemide	40-50	N-acetyl-alpha-glucosaminidase	Homo sapiens	96-99
11763992-12	2001	The second course evening cisplatin and furosemide treatment was associated with an increase in NAG excretion compared to the first course of treatment, while morning cisplatin and furosemide treatment in the second course showed less change in NAG excretion compared to the first course.	Furosemide	181-191	N-acetyl-alpha-glucosaminidase	Homo sapiens	245-248
11549664-0	2001	Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives.	Furosemide	89-99	renin	Homo sapiens	63-68
11549664-0	2001	Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives.	Furosemide	89-99	renin	Homo sapiens	63-68
11549664-3	2001	This study aims to validate the accuracy and efficacy of the basal plasma aldosterone concentration (picomoles per liter) to PRA (nanograms per liter/sec) ratio and of combined stimulation of PRA by the furosemide and upright posture test in screening for aldosterone-producing adenoma in hypertensives with PRA less than 0.28 ng/liter.sec (1 ng/ml.h).	Furosemide	203-213	S100 calcium binding protein A6	Homo sapiens	192-195
11549664-3	2001	This study aims to validate the accuracy and efficacy of the basal plasma aldosterone concentration (picomoles per liter) to PRA (nanograms per liter/sec) ratio and of combined stimulation of PRA by the furosemide and upright posture test in screening for aldosterone-producing adenoma in hypertensives with PRA less than 0.28 ng/liter.sec (1 ng/ml.h).	Furosemide	203-213	S100 calcium binding protein A6	Homo sapiens	192-195
11526200-9	2001	A classic loop diuretic, furosemide (10 mg/kg ip), markedly increased renal medullary Po(2) levels from 22.5 to 52.2 mmHg, which was accompanied by a significant reduction of HIF-1alpha transcripts in renal medullary tissue.	Furosemide	25-35	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	175-185
11443066-6	2001	The oocyte K-Cl cotransporter was sensitive to several inhibitors, including loop diuretics, with apparent half-maximal inhibition values of 200 and 500 microM for furosemide and bumetanide, respectively.	Furosemide	164-174	solute carrier family 12 member 6 L homeolog	Xenopus laevis	11-29
11423756-6	2001	Responses of both plasma renin activity and serum aldosterone level to the furosemide-posture challenge were blunted.	Furosemide	75-85	renin	Homo sapiens	25-30
11510880-4	2001	TSC mRNA increased during furosemide treatment 1.75-fold versus control but was not affected by a high- or a low-salt diet.	Furosemide	26-36	solute carrier family 12 member 3	Rattus norvegicus	0-3
11510880-5	2001	The mRNA for the alpha-subunit of ENaC increased with the low-salt diet (about 1.5-fold) and with furosemide (about 2.1-fold) in all kidney zones, but did not change with the high-salt diet.	Furosemide	98-108	sodium channel epithelial 1 subunit gamma	Rattus norvegicus	34-38
11510880-6	2001	Dietary salt loading down-regulated CIC-K2 mRNA in the outer medulla 0.6-fold versus control whilst furosemide treatment, but not the low-salt diet, increased ClC-K2 mRNA in the outer (1.6-fold) and inner medulla (2.0-fold).	Furosemide	100-110	chloride voltage-gated channel Kb	Rattus norvegicus	159-165
11181077-4	2001	Bumetanide and furosemide, NKCC inhibitors, significantly inhibited the Pin-induced increased [K(+)](i) and apoptosis, whereas K(ATP) inhibitors (glibenclamide and tolbutamide) had no effects.	Furosemide	15-25	dynein light chain LC8-type 1	Homo sapiens	72-75
11410710-15	2001	Thus, in cultured normal and KCC1-transfected cells, K-Cl COT shows significant differences from erythrocytes, and NEM and cell swelling open furosemide-sensitive and Cl-independent K/Rb channels.	Furosemide	142-152	solute carrier family 12 member 4	Homo sapiens	29-33
11592951-3	2001	Rats subjected to various chronic treatments were found to preferentially decrease kidney AT(4) receptor density (furosemide, puromycin aminonucleoside, nitro-L-arginine methyl ester), decrease kidney AT(1) receptor density (bilateral ureteral obstruction), or increase kidney AT(1) receptor distribution in the inner medulla (water diuresis).	Furosemide	114-124	leucyl and cystinyl aminopeptidase	Homo sapiens	90-104
11703026-6	2001	RESULTS: Furosemide treatment significantly decreased plasma Cl concentration and significantly increased plasma renin activity and aldosterone concentration.	Furosemide	9-19	renin	Canis lupus familiaris	113-118
11703026-8	2001	A significant interaction between a low Na diet and furosemide administration resulted in the lowest plasma Cl concentrations, highest plasma renin activities, and highest plasma aldosterone concentrations.	Furosemide	52-62	renin	Canis lupus familiaris	142-147
11703026-9	2001	CONCLUSIONS AND CLINICAL RELEVANCE: In healthy dogs, feeding a low Na diet and administering furosemide resulted in an additive effect on plasma Cl concentration, renin activity, and aldosterone concentration, which may be an important consideration for treating dogs with cardiac disease.	Furosemide	93-103	renin	Canis lupus familiaris	163-168
11849618-3	2001	In view of the fact that some drugs such as furosemide, diclofenac and mefenamic acid, based on the structural similarities to thyroxine could compete for binding to thyroxine binding globulin (TBG) and appears that there are some structural similarities between tamoxifen and thyroxine, one can hypothesize that tamoxifen is also able to compete for TBG binding and thereby affecting thyroid function tests.	Furosemide	44-54	serpin family A member 7	Homo sapiens	166-192
11849618-3	2001	In view of the fact that some drugs such as furosemide, diclofenac and mefenamic acid, based on the structural similarities to thyroxine could compete for binding to thyroxine binding globulin (TBG) and appears that there are some structural similarities between tamoxifen and thyroxine, one can hypothesize that tamoxifen is also able to compete for TBG binding and thereby affecting thyroid function tests.	Furosemide	44-54	serpin family A member 7	Homo sapiens	194-197
11849618-3	2001	In view of the fact that some drugs such as furosemide, diclofenac and mefenamic acid, based on the structural similarities to thyroxine could compete for binding to thyroxine binding globulin (TBG) and appears that there are some structural similarities between tamoxifen and thyroxine, one can hypothesize that tamoxifen is also able to compete for TBG binding and thereby affecting thyroid function tests.	Furosemide	44-54	serpin family A member 7	Homo sapiens	351-354
11849618-4	2001	DESIGN AND METHODS: In this study, we designed an in vitro binding assay as well as computational methods using MOPAC 7 package for evaluation of competitive potency of tamoxifen for TBG binding in comparison with well-known TBG competitors (including furosemide, mefenamic acid and diclofenac).	Furosemide	252-262	serpin family A member 7	Homo sapiens	183-186
11719734-0	2001	Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2.	Furosemide	15-25	renin	Homo sapiens	53-58
11719734-0	2001	Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2.	Furosemide	15-25	prostaglandin-endoperoxide synthase 2	Homo sapiens	88-104
11719734-3	2001	Plasma renin activity increased 2 to 3 times over baseline with a low-sodium diet and 5 times over baseline 30 minutes after intravenous furosemide; it was still elevated nearly 5 times on day 9.	Furosemide	137-147	renin	Homo sapiens	7-12
11719734-7	2001	We have concluded that low-sodium and furosemide-stimulated renin and aldosterone secretion is completely blocked in healthy volunteers during COX-2 inhibition with rofecoxib, suggesting that intact COX-2 is of major importance for stimulation of the renin system under these conditions in man.	Furosemide	38-48	renin	Homo sapiens	60-65
11719734-7	2001	We have concluded that low-sodium and furosemide-stimulated renin and aldosterone secretion is completely blocked in healthy volunteers during COX-2 inhibition with rofecoxib, suggesting that intact COX-2 is of major importance for stimulation of the renin system under these conditions in man.	Furosemide	38-48	prostaglandin-endoperoxide synthase 2	Homo sapiens	199-204
11719734-7	2001	We have concluded that low-sodium and furosemide-stimulated renin and aldosterone secretion is completely blocked in healthy volunteers during COX-2 inhibition with rofecoxib, suggesting that intact COX-2 is of major importance for stimulation of the renin system under these conditions in man.	Furosemide	38-48	renin	Homo sapiens	251-256
11703585-6	2001	RESULTS: Induction of COX-2 mRNA expression due to furosemide was paralleled by increased renal excretion of prostanoids.	Furosemide	51-61	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	22-27
11703585-9	2001	Moreover, the COX-2 inhibitor rofecoxib dose-dependently attenuated diuresis and saluresis, as well as the stimulation of the renin system induced by furosemide.	Furosemide	150-160	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	14-19
11703585-9	2001	Moreover, the COX-2 inhibitor rofecoxib dose-dependently attenuated diuresis and saluresis, as well as the stimulation of the renin system induced by furosemide.	Furosemide	150-160	renin	Rattus norvegicus	126-131
11249848-10	2001	These studies indicate that the mBSC1-A4 isoform of the SLC12A1 gene encodes a hypotonically activated, cAMP- and furosemide-sensitive Na(+)-Cl(-) cotransporter.	Furosemide	114-124	brain size control 1	Mus musculus	32-37
11249848-10	2001	These studies indicate that the mBSC1-A4 isoform of the SLC12A1 gene encodes a hypotonically activated, cAMP- and furosemide-sensitive Na(+)-Cl(-) cotransporter.	Furosemide	114-124	solute carrier family 12, member 1	Mus musculus	56-63
11725383-11	2001	CONCLUSION: The results showed the protective effect of inhaled furosemide against the respiratory adverse effects induced by ACE-inhibitors administration.	Furosemide	64-74	angiotensin I converting enzyme	Felis catus	126-129
11369814-2	2001	The effects of torasemide and furosemide on cell growth induced by angiotensin II (Ang II) were investigated in cultured vascular smooth muscle cells (VSMCs) obtained from the aorta of adult spontaneously hypertensive rats (SHR).	Furosemide	30-40	angiotensinogen	Rattus norvegicus	67-81
11369814-2	2001	The effects of torasemide and furosemide on cell growth induced by angiotensin II (Ang II) were investigated in cultured vascular smooth muscle cells (VSMCs) obtained from the aorta of adult spontaneously hypertensive rats (SHR).	Furosemide	30-40	angiotensinogen	Rattus norvegicus	83-89
11369815-1	2001	BACKGROUND: The direct effects of torasemide and furosemide on vasoconstriction and increases in intracellular free calcium concentration ([Ca(2+)]i) induced by endothelin-1 (ET-1) were investigated in the aorta of spontaneously hypertensive rats (SHR).	Furosemide	49-59	endothelin 1	Rattus norvegicus	161-173
11369815-1	2001	BACKGROUND: The direct effects of torasemide and furosemide on vasoconstriction and increases in intracellular free calcium concentration ([Ca(2+)]i) induced by endothelin-1 (ET-1) were investigated in the aorta of spontaneously hypertensive rats (SHR).	Furosemide	49-59	endothelin 1	Rattus norvegicus	175-179
11369815-4	2001	RESULTS: ET-1-induced vasoconstriction was reduced in a dose-dependent way by torasemide and furosemide (IC(50) values: 4.3+/-1.4x10(-5) and 9.8+/-5.6 x10(-5) M, respectively).	Furosemide	93-103	endothelin 1	Rattus norvegicus	9-13
11369815-6	2001	Furosemide inhibited the initial rise in [Ca(2+)]i induced by ET-1, with no effect on the second rise.	Furosemide	0-10	endothelin 1	Rattus norvegicus	62-66
11057431-6	2000	RESULTS: Before stimulation with frusemide, the plasma renin in Group A was 0.79 +/- 0.13 ng angiotensin l/ml per h, while in Group B the corresponding figure was 1.73 +/- 0.38 ng angiotensin l/ml per h. This difference was statistically significant (P= 0.0127).	Furosemide	33-42	renin	Homo sapiens	55-60
11135058-0	2001	Furosemide stimulates macula densa cyclooxygenase-2 expression in rats.	Furosemide	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	35-51
11135058-8	2001	Furosemide led to a fivefold and threefold increase of plasma renin activity and renocortical renin mRNA level, respectively.	Furosemide	0-10	renin	Rattus norvegicus	62-67
11135058-8	2001	Furosemide led to a fivefold and threefold increase of plasma renin activity and renocortical renin mRNA level, respectively.	Furosemide	0-10	renin	Rattus norvegicus	94-99
11135058-10	2001	Moreover, the percentage of juxtaglomerular apparatuses immunopositive for COX-2 increased threefold in response to furosemide compared with vehicle-infused animals.	Furosemide	116-126	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	75-80
11095476-3	2000	After repeated EE administration, renin stimulation was induced by a single oral dose of 40 mg furosemide, followed by 50 mg captopril, 12 h later.	Furosemide	95-105	renin	Homo sapiens	34-39
11046100-5	2000	Furosemide administration increased plasma renin activity from 1.0 +/- 0.2 to 4.5 +/- 1.2 ng of angiotensin I/ml/h and there was no effect of HOE 140 (from 1.1 +/- 0.2 to 3.9 +/- 0.8 ng of angiotensin I/ml/h).	Furosemide	0-10	renin	Homo sapiens	43-48
11046100-5	2000	Furosemide administration increased plasma renin activity from 1.0 +/- 0.2 to 4.5 +/- 1.2 ng of angiotensin I/ml/h and there was no effect of HOE 140 (from 1.1 +/- 0.2 to 3.9 +/- 0.8 ng of angiotensin I/ml/h).	Furosemide	0-10	angiotensinogen	Homo sapiens	96-109
11046100-5	2000	Furosemide administration increased plasma renin activity from 1.0 +/- 0.2 to 4.5 +/- 1.2 ng of angiotensin I/ml/h and there was no effect of HOE 140 (from 1.1 +/- 0.2 to 3.9 +/- 0.8 ng of angiotensin I/ml/h).	Furosemide	0-10	angiotensinogen	Homo sapiens	189-202
11050128-9	2000	KCC2 inhibition by furosemide caused a change in the intracellular Cl(-) concentration that depended on the concentration of pipette Cl(-); in recordings with low pipette Cl(-), furosemide lowered intracellular Cl(-), whereas in recordings with elevated pipette Cl(-), furosemide raised intracellular Cl(-).	Furosemide	19-29	solute carrier family 12 member 5	Rattus norvegicus	0-4
11050128-9	2000	KCC2 inhibition by furosemide caused a change in the intracellular Cl(-) concentration that depended on the concentration of pipette Cl(-); in recordings with low pipette Cl(-), furosemide lowered intracellular Cl(-), whereas in recordings with elevated pipette Cl(-), furosemide raised intracellular Cl(-).	Furosemide	178-188	solute carrier family 12 member 5	Rattus norvegicus	0-4
11050128-9	2000	KCC2 inhibition by furosemide caused a change in the intracellular Cl(-) concentration that depended on the concentration of pipette Cl(-); in recordings with low pipette Cl(-), furosemide lowered intracellular Cl(-), whereas in recordings with elevated pipette Cl(-), furosemide raised intracellular Cl(-).	Furosemide	178-188	solute carrier family 12 member 5	Rattus norvegicus	0-4
10991988-4	2000	p-[(14)C]Aminohippurate (PAH) uptake by rOAT1-expressing oocytes was inhibited in the presence of a thiazide (chlorothiazide, cyclothiazide, hydrochlorothiazide), a loop diuretic (bumetanide, ethacrynic acid, furosemide), or a carbonic anhydrase inhibitor (acetazolamide, ethoxzolamide, methazolamide).	Furosemide	209-219	solute carrier family 22 member 6	Rattus norvegicus	40-45
10991988-10	2000	Although the loop diuretics had little trans-stimulation effect on [(14)C]PAH efflux via rOAT1, the rOAT1-mediated furosemide uptake was observed.	Furosemide	115-125	solute carrier family 22 member 6	Rattus norvegicus	100-105
11022906-1	2000	A simplified high-performance liquid chromatographic procedure is described for the determination of furosemide (4-chloro-N-furfuryl-5-sulphamoylanthranillic acid), which makes use of UV detection, a C18, reversed-phase column, and micellar mobile phases of sodium dodecyl sulphate (SDS) and 1-propanol at pH 3 buffered with phosphate system.	Furosemide	101-111	Bardet-Biedl syndrome 9	Homo sapiens	200-203
11012899-8	2000	CsA also increased by 38% the ouabain-resistant furosemide-sensitive component (Or-Fs) of 86Rb+ influx, reflecting the Na+-K+-Cl- cotransport activity and stimulated the basolateral efflux of 36Cl- from mTAL cells grown on filters.	Furosemide	48-58	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	0-3
10913127-3	2000	KCC1 and KCC4 exhibit differential sensitivity to transport inhibitors, such that KCC4 is much less sensitive to bumetanide and furosemide.	Furosemide	128-138	solute carrier family 12 (potassium/chloride transporter), member 4 L homeolog	Xenopus laevis	0-4
10942735-4	2000	Injection of Xenopus oocytes with KCC2 cRNA induced a 20-fold increase in Cl(-)-dependent, furosemide-sensitive K(+) uptake.	Furosemide	91-101	solute carrier family 12 member 5 L homeolog	Xenopus laevis	34-38
10988115-8	2000	In addition, inhalation of furosemide attenuated the activity of RARs.	Furosemide	27-37	arginyl-tRNA synthetase 1	Rattus norvegicus	65-69
10988115-9	2000	These findings indicate that SARs are sensitized and RARs desensitized by inhalation of furosemide.	Furosemide	88-98	arginyl-tRNA synthetase 1	Rattus norvegicus	53-57
10975299-5	2000	Baseline renin production was elevated, although the renin response to furosemide was similar in chronic furosemide-treated and vehicle-treated lambs.	Furosemide	71-81	renin	Ovis aries	53-58
10996478-13	2000	However, ALT activity was significantly increased 5 h following FS administration.	Furosemide	64-66	glutamic pyruvic transaminase, soluble	Mus musculus	9-12
10910438-14	2000	The DDAVP-frusemide test revealed that the release of AQP2 into urine is not caused by hypertonicity of tubular fluid.	Furosemide	10-19	aquaporin 2	Homo sapiens	54-58
10910000-2	2000	Furosemide decreased the plasma concentration of hypoxanthine by 39% and increased plasma renin activity (PRA) and the plasma concentration of protein by 3.4-fold and 9%, respectively, at 90 minutes after administration.	Furosemide	0-10	renin	Homo sapiens	90-95
10930521-2	2000	The Na+-ATPase, insensitive to ouabain, but sensitive to furosemide, is stimulated by Ang-(1-7) (68% by 10(-9) M), in a dose-dependent manner.	Furosemide	57-67	angiogenin	Sus scrofa	86-94
10988347-3	2000	Furosemide (100 microM) and 5-nitro-2-(3-phenylpropylamino)-benzoate (NPPB; 300 microM) completely inhibited PAF (10 microM)-induced increase in short-circuit current (Isc) across the mucosa, indicating that PAF caused a Cl(-) secretion in the rat colon.	Furosemide	0-10	PCNA clamp associated factor	Rattus norvegicus	109-112
10988347-3	2000	Furosemide (100 microM) and 5-nitro-2-(3-phenylpropylamino)-benzoate (NPPB; 300 microM) completely inhibited PAF (10 microM)-induced increase in short-circuit current (Isc) across the mucosa, indicating that PAF caused a Cl(-) secretion in the rat colon.	Furosemide	0-10	PCNA clamp associated factor	Rattus norvegicus	208-211
10862634-14	2000	With the ammonium chloride test as the gold standard for diagnosis of distal RTA, the frusemide test showed a sensitivity of 1.0 (95% CI, 0.69-1.0) and a specificity of 0.89 (95% CI, 0.78-0.96) for the diagnosis of distal RTA.	Furosemide	86-95	MAS related GPR family member F	Homo sapiens	77-80
10862634-14	2000	With the ammonium chloride test as the gold standard for diagnosis of distal RTA, the frusemide test showed a sensitivity of 1.0 (95% CI, 0.69-1.0) and a specificity of 0.89 (95% CI, 0.78-0.96) for the diagnosis of distal RTA.	Furosemide	86-95	MAS related GPR family member F	Homo sapiens	222-225
10799304-7	2000	Treating rats with furosemide, a diuretic which decreases the kidney interstitium osmolarity without affecting vasopressin levels, led to decreased levels of the UT-A2 protein.	Furosemide	19-29	arginine vasopressin	Rattus norvegicus	111-122
10856393-5	2000	Three patients restarted furosemide for ankle edema and 1 for blood pressure levels >180/100 mm Hg.	Furosemide	25-35	ankyrin repeat and LEM domain containing 1	Homo sapiens	40-57
10793196-1	2000	The purpose of this study was to determine whether the loop diuretics furosemide, bumetanide and ethacrynic acid, which block the KCC1 potassium-chloride transporter in the kidney loop of Henle and the KCC2 potassium-chloride transporter in neuronal membranes, would prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats.	Furosemide	70-80	solute carrier family 12 member 4	Rattus norvegicus	130-134
10793196-1	2000	The purpose of this study was to determine whether the loop diuretics furosemide, bumetanide and ethacrynic acid, which block the KCC1 potassium-chloride transporter in the kidney loop of Henle and the KCC2 potassium-chloride transporter in neuronal membranes, would prevent sound-triggered seizures in post-ischemic audiogenic seizure-prone rats.	Furosemide	70-80	solute carrier family 12 member 5	Rattus norvegicus	202-206
11054013-5	2000	In conclusion, furosemide could represent a valid therapeutic aid in the prevention of nasosinusal polyps.	Furosemide	15-25	activation induced cytidine deaminase	Homo sapiens	62-65
10799304-7	2000	Treating rats with furosemide, a diuretic which decreases the kidney interstitium osmolarity without affecting vasopressin levels, led to decreased levels of the UT-A2 protein.	Furosemide	19-29	solute carrier family 14 member 2	Homo sapiens	162-167
10786260-8	2000	Seventy-six percent of patients identified by physicians as CHF patients who were taking digoxin and furosemide were treated with an ACE inhibitor.	Furosemide	101-111	angiotensin I converting enzyme	Homo sapiens	133-136
10845684-10	2000	P-glycoprotein and an efflux pump for furosemide were functionally present.	Furosemide	38-48	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
10760498-6	2000	In both experiments, the furosemide-treated rats had significantly more Fos-positive cell nuclei than vehicle-treated rats in the subfornical organ (SFO), organum vasculosum lamina terminalis (OVLT), supraoptic nuclei (SON), and magnocellular region of the paraventricular nuclei (PVN) - areas previously shown to be activated by hypovolemia or peripheral angiotensin.	Furosemide	25-35	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	72-75
10760499-13	2000	We conclude that the receptor-mediated action of angiotensin II is in some way involved in the activation of the pathway that occurs in the SFO, OVLT, SON, and magnocellular region of the paraventricular nucleus (PVN) in response to furosemide treatment.	Furosemide	233-243	angiotensinogen	Rattus norvegicus	49-63
10760499-14	2000	It is possible that the furosemide-induced activation in the SON and PVN is not due to direct actions of angiotensin II on angiotensin receptors in those structures, but instead occurs synaptically as a result of inputs from the SFO and OVLT, which have themselves been activated directly by angiotensin II.	Furosemide	24-34	angiotensinogen	Rattus norvegicus	105-119
10760499-14	2000	It is possible that the furosemide-induced activation in the SON and PVN is not due to direct actions of angiotensin II on angiotensin receptors in those structures, but instead occurs synaptically as a result of inputs from the SFO and OVLT, which have themselves been activated directly by angiotensin II.	Furosemide	24-34	angiotensinogen	Rattus norvegicus	292-306
10760499-17	2000	Thus, the present results also suggest that the central blockade of the formation of angiotensin II or blockade of the actions of angiotensin II prevents in some way the activation of the renal afferent pathway mediated by the renal nerves (the direct pathway) in response to the actions of furosemide.	Furosemide	291-301	angiotensinogen	Rattus norvegicus	85-99
10760499-17	2000	Thus, the present results also suggest that the central blockade of the formation of angiotensin II or blockade of the actions of angiotensin II prevents in some way the activation of the renal afferent pathway mediated by the renal nerves (the direct pathway) in response to the actions of furosemide.	Furosemide	291-301	angiotensinogen	Rattus norvegicus	130-144
10727523-9	2000	Probenecid, sulfinpyrazone, indomethacin, furosemide, and penicillin G all significantly increased MRP2-ATPase activity, whereas these compounds acted more as ATPase inhibitors on MRP1.	Furosemide	42-52	ATP binding cassette subfamily C member 2	Homo sapiens	99-103
10727523-9	2000	Probenecid, sulfinpyrazone, indomethacin, furosemide, and penicillin G all significantly increased MRP2-ATPase activity, whereas these compounds acted more as ATPase inhibitors on MRP1.	Furosemide	42-52	ATP binding cassette subfamily C member 1	Homo sapiens	180-184
10750752-7	2000	The dosage of furosemide was significantly lower and the urine volume was significantly larger in the hANP group.	Furosemide	14-24	natriuretic peptide A	Homo sapiens	102-106
10703687-5	2000	RESULTS: No significant differences between groups were detected at baseline except that patients with higher ACE inhibitor doses were more likely to take nitrates, beta-blockers and amiodarone, received higher furosemide doses and had higher serum gamma-glutamyl transferase levels.	Furosemide	211-221	angiotensin I converting enzyme	Homo sapiens	110-113
10760498-7	2000	In the short-survival experiment, the furosemide-treated rats had more Fos-positive cell nuclei in the nucleus of the solitary tract (NTS) and in the dorsal horn of the spinal cord at spinal levels T(11), T(12), and T(13).	Furosemide	38-48	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	71-74
10760498-12	2000	In this experiment, furosemide administration increased the number of Fos-positive cells in the SFO, OVLT, SON and PVN, but not in the caudal thoracic spinal cord or NTS.	Furosemide	20-30	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	70-73
10760498-15	2000	It is hypothesized that activation in these forebrain regions depends on the action of angiotensin II that is generated after furosemide treatment.	Furosemide	126-136	angiotensinogen	Rattus norvegicus	87-101
10760499-6	2000	In the first experiment, furosemide injection was preceded by treatment with a dose of Captopril, CAP, (an angiotensin-converting enzyme (ACE) inhibitor) that blocks the peripheral but not the central formation of angiotensin II.	Furosemide	25-35	angiotensin I converting enzyme	Rattus norvegicus	107-136
10760499-6	2000	In the first experiment, furosemide injection was preceded by treatment with a dose of Captopril, CAP, (an angiotensin-converting enzyme (ACE) inhibitor) that blocks the peripheral but not the central formation of angiotensin II.	Furosemide	25-35	angiotensin I converting enzyme	Rattus norvegicus	138-141
10760499-7	2000	In the second experiment, furosemide injection was preceded by treatment with a higher dose of CAP; this dosage blocks the peripheral and central formation of angiotensin II.	Furosemide	26-36	angiotensinogen	Rattus norvegicus	159-173
10760499-11	2000	Rats receiving furosemide plus the low CAP dose showed more Fos-positive cells than control rats in the subfornical organ (SFO), organum vasculosum lamina terminalis (OVLT), supraoptic nucleus (SON), magnocellular region of the paraventricular nucleus, nucleus of the solitary tract (NTS), and caudal thoracic/rostral lumbar spinal cord dorsal horn.	Furosemide	15-25	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	60-63
11125222-8	2000	Likewise, a reduction of insulin-induced swelling by the loop diuretics furosemide and bumetanide cause insulin resistance shown by the levels of cell swelling, MAP-kinase activation and proteolysis control.	Furosemide	72-82	insulin	Homo sapiens	25-32
10604960-7	2000	The high dose of furosemide (100 mg/kg) significantly elevated serum renin activity and aldosterone concentration, indicating that furosemide activated the renin-angiotensin-aldosterone system (RAA-system).	Furosemide	17-27	renin	Rattus norvegicus	69-74
10681377-8	2000	Plasma renin activity was increased by the bolus and the infusion of furosemide, even in the presence of 121 ml/h of fluid replacement.	Furosemide	69-79	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	7-12
10567922-7	2000	Furthermore, the two specific inhibitors of the Na(+)/K(+)/Cl(-) cotransporter activity; bumetanide and furosemide inhibited the clonogenic efficiency in the NKCC1 transfected cells.	Furosemide	104-114	solute carrier family 12, member 2	Mus musculus	158-163
10842416-6	2000	The changes in the ETK (erythrocyte transketolase activity in whole blood) and a-ETK (ETK activity coefficient) during the hospital stay correlated with the cumulative dosage of furosemide adjusted for the duration of the therapy (r = 0.36, p < 0.001 and r = - 0.28, p > 0.03).	Furosemide	178-188	EPH receptor A3	Homo sapiens	19-22
10842416-6	2000	The changes in the ETK (erythrocyte transketolase activity in whole blood) and a-ETK (ETK activity coefficient) during the hospital stay correlated with the cumulative dosage of furosemide adjusted for the duration of the therapy (r = 0.36, p < 0.001 and r = - 0.28, p > 0.03).	Furosemide	178-188	EPH receptor A3	Homo sapiens	81-84
10842416-6	2000	The changes in the ETK (erythrocyte transketolase activity in whole blood) and a-ETK (ETK activity coefficient) during the hospital stay correlated with the cumulative dosage of furosemide adjusted for the duration of the therapy (r = 0.36, p < 0.001 and r = - 0.28, p > 0.03).	Furosemide	178-188	EPH receptor A3	Homo sapiens	81-84
10604960-7	2000	The high dose of furosemide (100 mg/kg) significantly elevated serum renin activity and aldosterone concentration, indicating that furosemide activated the renin-angiotensin-aldosterone system (RAA-system).	Furosemide	17-27	renin	Rattus norvegicus	156-161
10604960-7	2000	The high dose of furosemide (100 mg/kg) significantly elevated serum renin activity and aldosterone concentration, indicating that furosemide activated the renin-angiotensin-aldosterone system (RAA-system).	Furosemide	131-141	renin	Rattus norvegicus	69-74
10604960-7	2000	The high dose of furosemide (100 mg/kg) significantly elevated serum renin activity and aldosterone concentration, indicating that furosemide activated the renin-angiotensin-aldosterone system (RAA-system).	Furosemide	131-141	renin	Rattus norvegicus	156-161
10577447-8	1999	Frusemide reduced plasma concentrations of atrial natriuretic factor and increased plasma renin activity.	Furosemide	0-9	renin	Homo sapiens	90-95
11041285-10	2000	A strong immunostaining for FKBP-12, a tacrolimus-binding protein, was observed in the medulla of the kidneys of rats treated with tacrolimus either with or without furosemide.	Furosemide	165-175	FKBP prolyl isomerase 1A	Rattus norvegicus	28-35
10619350-9	1999	RESULTS: There was a significant reduction in levels of TNF-alpha and IL-6 at a furosemide concentration of 0.5 x 10(-2) M and a reduction in IL-8 levels at 10(-2) M. This inhibition was comparable to that found with equivalent molar concentrations of hydrocortisone.	Furosemide	80-90	tumor necrosis factor	Homo sapiens	56-65
10619350-9	1999	RESULTS: There was a significant reduction in levels of TNF-alpha and IL-6 at a furosemide concentration of 0.5 x 10(-2) M and a reduction in IL-8 levels at 10(-2) M. This inhibition was comparable to that found with equivalent molar concentrations of hydrocortisone.	Furosemide	80-90	interleukin 6	Homo sapiens	70-74
10577572-11	1999	Frusemide significantly increased mean plasma renin activity (days 0 and 42), and the mean aldosterone concentration (day 42) in comparison with placebo, whereas candoxatril caused no significant changes in any of the hormonal parameters assessed.	Furosemide	0-9	renin	Homo sapiens	46-51
10690296-3	1999	RESULTS: Bradykinin and thapsigargin significantly decreased the MQAE fluorescence intensity, which indicates increased [Cl-]i; these changes were reversed by removal of extracellular chloride (Cl-o) and were significantly inhibited by Cl(-)-channel inhibitor N-phenylanthranilic acid but not by Na(+)-K(+)-Cl- cotransport inhibitor furosemide.	Furosemide	333-343	kininogen 1	Homo sapiens	9-19
10347239-5	1999	By making alpha1/alpha6 chimeras we have identified a transmembrane region (209-279) responsible for the high furosemide sensitivity of alpha6beta3gamma2s receptors.	Furosemide	110-120	adrenoceptor alpha 1D	Homo sapiens	10-23
10525077-7	1999	CeOAT1 exhibits broad specificity, accepting anions such as folate, indomethacin, furosemide, probenecid, and benzylpenicillin as substrates.	Furosemide	82-92	MFS domain-containing protein	Caenorhabditis elegans	0-6
10604545-7	1999	AT II markedly increased by the stimulation test using furosemide (1 mg/kg i.v.).	Furosemide	55-65	angiotensinogen	Homo sapiens	0-5
10513831-3	1999	In eight healthy subjects, injection of furosemide increased plasma renin activity (PRA) with little or no change in blood pressure or heart rate.	Furosemide	40-50	renin	Homo sapiens	68-73
10510146-0	1999	The effect of nitric oxide inhibition on the renin response to frusemide, in man.	Furosemide	63-72	renin	Homo sapiens	45-50
10347194-6	1999	The expression of mouse KCC3 in Xenopus laevis oocytes reveals the expected functional characteristics of a K+Cl- cotransporter: Cl--dependent uptake of 86Rb+ which is strongly activated by cell swelling and weakly sensitive to furosemide.	Furosemide	228-238	solute carrier family 12, member 6	Mus musculus	24-28
10497143-8	1999	UGT1A8, but not UGT1A10, catalyzed the glucuronidation of opioids, bile acids, fatty acids, retinoids, and clinically useful drugs, such as ciprofibrate, furosemide, and diflunisal.	Furosemide	154-164	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	0-6
10510146-6	1999	L-NMMA completely blocked the renin rise following the bolus of frusemide (1.18+/-0.196 vs 1.96+/-0.333 ng ml-1 h-1 P<0.01).	Furosemide	64-73	renin	Homo sapiens	30-35
10510146-7	1999	Phenylephrine 0.5 microg kg-1 min-1 produced very similar haemodynamic effects to L-NMMA, and also suppressed the renin response to frusemide (1.43+/-0.290 vs 2.67+/-0.342 ng ml-1 h-1 P<0.	Furosemide	132-141	CD59 molecule (CD59 blood group)	Homo sapiens	30-35
10510146-7	1999	Phenylephrine 0.5 microg kg-1 min-1 produced very similar haemodynamic effects to L-NMMA, and also suppressed the renin response to frusemide (1.43+/-0.290 vs 2.67+/-0.342 ng ml-1 h-1 P<0.	Furosemide	132-141	renin	Homo sapiens	114-119
10464063-5	1999	The ATPase-dependent Na(+) pump and Na(+)-K(+)-2Cl(-) co-transport activities were assessed from Na(+)-loaded red blood cells by using nystatine, in the presence of furosemide and ouabain, as appropriate.	Furosemide	165-175	dynein axonemal heavy chain 8	Homo sapiens	4-10
10543284-3	1999	The aim of this study was to assess whether pretreatment with nebulized Fur (40 mg) was able to modulate PAF-induced systemic and respiratory effects in asthma.	Furosemide	72-75	PCNA clamp associated factor	Homo sapiens	105-108
10543284-7	1999	Although Fur did not alter PAF-induced systemic and respiratory effects, it did partially inhibit (63%; p<0.04) the increments of uLTE4 levels shown after PAF inhalation.	Furosemide	9-12	PCNA clamp associated factor	Homo sapiens	158-161
10100306-0	1999	Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum.	Furosemide	17-27	solute carrier family 6 member 2	Rattus norvegicus	0-3
10233039-6	1999	Plasma levels of aldosterone and plasma renin activity are substantially increased 3 h after furosemide treatment, and so the NaCl appetite cannot result simply from progressively increasing levels of these hormones.	Furosemide	93-103	renin	Rattus norvegicus	40-45
10187864-8	1999	An increased initial uptake rate of 86Rb was seen in clones with high KCC3 expression, which was dependent on extracellular Cl- but not Na+ and was inhibitable by the loop diuretic agent furosemide.	Furosemide	187-197	solute carrier family 12 member 6	Homo sapiens	70-74
9950961-9	1999	Like rat OAT1 organic anion transporter, hPAHT was inhibited by furosemide, indomethacin, probenecid, and alpha-ketoglutarate.	Furosemide	64-74	solute carrier family 22 member 6	Homo sapiens	9-13
9950961-9	1999	Like rat OAT1 organic anion transporter, hPAHT was inhibited by furosemide, indomethacin, probenecid, and alpha-ketoglutarate.	Furosemide	64-74	solute carrier family 22 member 6	Homo sapiens	41-46
10100306-5	1999	RESULTS: Net secretion from rat intestine of over 3-fold was observed for 20 microM furosemide.	Furosemide	84-94	solute carrier family 6 member 2	Rattus norvegicus	9-12
10100306-6	1999	Net secretion of furosemide by Caco-2 cells was over 300% greater than for intestinal segments (10-fold vs. 3-fold).	Furosemide	17-27	solute carrier family 6 member 2	Homo sapiens	0-3
9887087-6	1999	hOAT1-mediated PAH uptake was inhibited by bulky inorganic anions, various xenobiotics, and endogenous substances, including benzylpenicillin, furosemide, indomethacin, probenecid, phenol red, urate, and alpha-ketoglutarate.	Furosemide	143-153	solute carrier family 22 member 6	Homo sapiens	0-5
10713865-1	1999	Five years ago, our in vitro and in vivo studies demonstrated for the first time that diuretic agents such as furosemide, hydrochlorothiazide, amiloride, triamterene and spironolactone inhibit carbonic anhydrase (CA) I, II and renal CA IV by a direct mechanism of action.	Furosemide	110-120	carbonic anhydrase 1	Homo sapiens	193-218
10713865-1	1999	Five years ago, our in vitro and in vivo studies demonstrated for the first time that diuretic agents such as furosemide, hydrochlorothiazide, amiloride, triamterene and spironolactone inhibit carbonic anhydrase (CA) I, II and renal CA IV by a direct mechanism of action.	Furosemide	110-120	carbonic anhydrase 4	Homo sapiens	233-238
10077374-8	1999	Intolerance to ACE inhibitor was defined as hypotension (<95 mmHg systolic blood pressure or a decrease exceeding 25 mmHg in systolic blood pressure) leading to oliguria (<0.5 ml/kg per h) which was unresponsive to intravenous furosemide (20 mg).	Furosemide	233-243	angiotensin I converting enzyme	Homo sapiens	15-18
19281395-1	1999	A furosemide-sensitive Na-K-Cl cotransporter (NKCC2 isoform) accounts for almost all luminal NaCl reabsorption in the thick ascending limb of Henle"s loop (TALH).	Furosemide	2-12	solute carrier family 12 member 1	Rattus norvegicus	46-51
9914266-5	1999	In each case, recordings from the CA1 region showed that reduction of [Cl-]o to 21 mM reversibly blocked the bursting within 1 h. Similar to previous observations with furosemide treatment, low-[Cl-]o medium blocked spontaneous hypersynchronous discharges without reducing synaptic hyperexcitability (i.e., hyperexcitable field responses evoked by electrical stimulation).	Furosemide	168-178	carbonic anhydrase 1	Rattus norvegicus	34-37
9929566-2	1999	Acute administration of the loop diuretic furosemide significantly reduced AR, SMIT and BGT gene expression in the inner and outer medulla compared with controls.	Furosemide	42-52	aldo-keto reductase family 1 member B1	Rattus norvegicus	75-77
9929566-2	1999	Acute administration of the loop diuretic furosemide significantly reduced AR, SMIT and BGT gene expression in the inner and outer medulla compared with controls.	Furosemide	42-52	solute carrier family 5 member 3	Rattus norvegicus	79-83
10954127-6	1999	Furosemide and indapamide, diuretics known to have vasodilating effects, induce the fall of blood pressure that parallels the decrease of CA I activity.	Furosemide	0-10	carbonic anhydrase 1	Homo sapiens	138-142
9928060-0	1998	Effect of sodium depletion by frusemide on tissue concentrations and metabolism of VIP.	Furosemide	30-39	vasoactive intestinal peptide	Homo sapiens	83-86
9862246-0	1998	Frusemide inhibits angiotensin II-induced contraction on human vascular smooth muscle.	Furosemide	0-9	angiotensinogen	Homo sapiens	19-33
9862246-3	1998	Since angiotensin II is a highly potent vasoconstrictor involved in the pathophysiology of these diseases, we have investigated the effect of frusemide on the contraction elicited by angiotensin II on human internal mammary artery (IMA) and saphenous vein (SV).	Furosemide	142-151	angiotensinogen	Homo sapiens	183-197
9862246-7	1998	RESULTS: Frusemide induced a concentration-dependent decrease of the contraction elicited by angiotensin II on IMA and SV.	Furosemide	9-18	angiotensinogen	Homo sapiens	93-107
9862246-8	1998	On both vessels, the inhibitory effect on the maximal contraction to angiotensin II was significant with concentrations of frusemide from 10(-5) to 10(-3) M. Angiotensin II potency (pD2) was only reduced by 10(-3) M frusemide.	Furosemide	123-132	angiotensinogen	Homo sapiens	69-83
9862246-8	1998	On both vessels, the inhibitory effect on the maximal contraction to angiotensin II was significant with concentrations of frusemide from 10(-5) to 10(-3) M. Angiotensin II potency (pD2) was only reduced by 10(-3) M frusemide.	Furosemide	123-132	angiotensinogen	Homo sapiens	158-172
9862246-8	1998	On both vessels, the inhibitory effect on the maximal contraction to angiotensin II was significant with concentrations of frusemide from 10(-5) to 10(-3) M. Angiotensin II potency (pD2) was only reduced by 10(-3) M frusemide.	Furosemide	216-225	angiotensinogen	Homo sapiens	69-83
9862246-8	1998	On both vessels, the inhibitory effect on the maximal contraction to angiotensin II was significant with concentrations of frusemide from 10(-5) to 10(-3) M. Angiotensin II potency (pD2) was only reduced by 10(-3) M frusemide.	Furosemide	216-225	angiotensinogen	Homo sapiens	158-172
9862246-10	1998	Bumetanide was less potent than frusemide in inhibiting angiotensin II-induced contractions in both IMA and SV.	Furosemide	32-41	angiotensinogen	Homo sapiens	56-70
9862246-11	1998	CONCLUSIONS: Frusemide, at concentrations in the therapeutic range (10(-5) M), inhibits angiotensin II-induced contraction on human isolated IMA and SV.	Furosemide	13-22	angiotensinogen	Homo sapiens	88-102
9864275-12	1998	When the natriuresis was expressed relative to UFURV (i.e., the natriuretic efficiency), we found that natriuretic efficiency of furosemide was significantly increased in untreated CBL rats (+59%).	Furosemide	129-139	Cbl proto-oncogene	Rattus norvegicus	181-184
9864275-13	1998	However, the natriuretic efficiency of furosemide was normalized in CBL rats treated with canrenoate.	Furosemide	39-49	Cbl proto-oncogene	Rattus norvegicus	68-71
9864275-14	1998	The urinary excretion of furosemide was unchanged in untreated CBL rats, but it was significantly increased in cirrhotic rats treated with canrenoate (+43%).	Furosemide	25-35	Cbl proto-oncogene	Rattus norvegicus	63-66
9596069-5	1998	Simultaneous infusion of the diuretic agent furosemide prevented the AVP-induced decrease in the 117-kD band.	Furosemide	44-54	arginine vasopressin	Rattus norvegicus	69-72
9716718-3	1998	Both the sodium- and chloride-dependent betaine transporter (BGT) and sodium-dependent myo-inositol transporter (SMIT) were expressed preferentially in macula densa cells and for both mRNAs the signal intensity was visibly reduced by furosemide.	Furosemide	234-244	solute carrier family 6 member 12	Rattus norvegicus	9-59
9716718-3	1998	Both the sodium- and chloride-dependent betaine transporter (BGT) and sodium-dependent myo-inositol transporter (SMIT) were expressed preferentially in macula densa cells and for both mRNAs the signal intensity was visibly reduced by furosemide.	Furosemide	234-244	solute carrier family 5 member 3	Rattus norvegicus	70-111
9716718-3	1998	Both the sodium- and chloride-dependent betaine transporter (BGT) and sodium-dependent myo-inositol transporter (SMIT) were expressed preferentially in macula densa cells and for both mRNAs the signal intensity was visibly reduced by furosemide.	Furosemide	234-244	solute carrier family 5 member 3	Rattus norvegicus	113-117
9716718-4	1998	The enzymes aldose reductase (which mediates the conversion of glucose to sorbitol) and sorbitol dehydrogenase (which converts sorbitol into fructose) were expressed not only in macula densa cells but also in the surrounding tubular cells, and the expression was insensitive to furosemide.	Furosemide	278-288	aldo-keto reductase family 1 member B1	Rattus norvegicus	12-28
9735929-0	1998	Renin-aldosterone system can respond to furosemide in patients with hyperkalemic hyporeninism.	Furosemide	40-50	renin	Homo sapiens	0-5
9735929-10	1998	Plasma atrial natriuretic peptide (ANP) fell with furosemide in 8 of 8 responders and in 1 of the 2 nonresponders in whom it was measured.	Furosemide	50-60	natriuretic peptide A	Homo sapiens	7-33
9735929-10	1998	Plasma atrial natriuretic peptide (ANP) fell with furosemide in 8 of 8 responders and in 1 of the 2 nonresponders in whom it was measured.	Furosemide	50-60	natriuretic peptide A	Homo sapiens	35-38
9665357-4	1998	RESULTS: In the 8 hours after furosemide ingestion there were increases in levels of plasma cholesterol (10.1%; P = .001), high-density lipoprotein cholesterol (9.0%; P = .006), and apolipoprotein B (9.8%; P = .003).	Furosemide	30-40	apolipoprotein B	Homo sapiens	182-198
9696953-4	1998	RESULTS: PRA, AII and PA increased significantly after furosemide administration whereas ACTH and potassium did not.	Furosemide	55-65	angiotensinogen	Homo sapiens	14-17
9696953-7	1998	CONCLUSION: These results suggest that, in contrast to cimetidine, the inhibitory effect of omeprazole on AII-stimulated aldosterone production following dosing with furosemide is negligible.	Furosemide	166-176	angiotensinogen	Homo sapiens	106-109
9622326-6	1998	Frusemide significantly affected the right atrial and pulmonary artery pressure and ANP responses to exercise.	Furosemide	0-9	natriuretic peptide A	Equus caballus	84-87
9622326-7	1998	Fluid administration decreased plasma total protein concentrations at rest and during running and abolished the effects of frusemide on the haemodynamic and ANP responses to exercise.	Furosemide	123-132	natriuretic peptide A	Equus caballus	157-160
9832372-4	1998	The photodegradation product of furosemide glucuronide was hydrolyzed to one of the photodegradation products of furosemide by beta-glucuronidase, indicating that the photodegradation product of furosemide glucuronide possessed a glucuronic acid moiety.	Furosemide	32-42	glucuronidase beta	Homo sapiens	127-145
9767530-6	1998	Addition of furosemide, but not chlorothiazide, to animals on the 8.0% NaCl diet further augmented steady-state mRNA levels of THP.	Furosemide	12-22	uromodulin	Rattus norvegicus	127-130
9767530-7	1998	CONCLUSIONS: An increase in dietary salt and the loop diuretic, furosemide, increased expression of THP in the rat.	Furosemide	64-74	uromodulin	Rattus norvegicus	100-103
9737091-3	1998	Therefore, we assessed the effects of meloxicam, a selective inhibitor of COX-2, and indomethacin, an unselective inhibitor of COX-1 and COX-2, on furosemide stimulated plasma renin activity (PRA).	Furosemide	147-157	renin	Homo sapiens	176-181
9737091-13	1998	CONCLUSION: Meloxicam inhibited furosemide stimulated renin release, suggesting that in man COX-2 is responsible for prostaglandin synthesis mediating renin release.	Furosemide	32-42	renin	Homo sapiens	54-59
9737091-13	1998	CONCLUSION: Meloxicam inhibited furosemide stimulated renin release, suggesting that in man COX-2 is responsible for prostaglandin synthesis mediating renin release.	Furosemide	32-42	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	92-97
9737091-13	1998	CONCLUSION: Meloxicam inhibited furosemide stimulated renin release, suggesting that in man COX-2 is responsible for prostaglandin synthesis mediating renin release.	Furosemide	32-42	renin	Homo sapiens	151-156
9682923-1	1998	A furosemide-sensitive Na-K-Cl cotransporter (NKCC2 isoform) accounts for almost all luminal NaCl reabsorption in the thick ascending limb of Henle"s loop (TALH).	Furosemide	2-12	solute carrier family 12 member 1	Rattus norvegicus	46-51
9608012-1	1998	Micropuncture studies of single nephrons have shown that macula densa solute reabsorption via a furosemide-sensitive pathway activates nitric oxide (NO) generation via neuronal NO synthase (nNOS).	Furosemide	96-106	nitric oxide synthase 1	Rattus norvegicus	190-194
9683914-8	1998	In order to differentiate the potential role of elevated renin in the down-regulation of pulmonary ACE, additional rats (n = 12) were treated with furosemide that resulted in a 8-fold rise in plasma renin activity, but only in a marginal decrease of pulmonary ACE mRNA levels and activity (-10% vs. sham (n = 8), P-value n.s.).	Furosemide	147-157	renin	Rattus norvegicus	199-204
9596069-7	1998	However, when AVP-treated rats were infused with furosemide for 5 d, the 117-kD band was markedly accentuated, whereas the 97-kD band was unchanged.	Furosemide	49-59	arginine vasopressin	Rattus norvegicus	14-17
9518596-6	1998	Moreover, the proportion of neurons changing sensitivity to AII after one application of Aldo was increased in the furosemide group (44.2% vs. 20.4%, p=0.0123).	Furosemide	115-125	angiotensinogen	Homo sapiens	60-63
9523993-1	1998	The binding conformations of oxyphenbutazone (OXY), Nepsilon-dansyl-L-lysine (DNS-LYS), and furosemide (FU) to human serum albumin (HSA) have been investigated by molecular dynamics (MD) calculations and transferred nuclear Overhauser effect (TRNOE) measurements.	Furosemide	92-102	albumin	Homo sapiens	117-136
10323004-7	1997	The changes indicate that Ca2+ may play an important role in the mechanism of the furosemide test.	Furosemide	82-92	LOW QUALITY PROTEIN: carbonic anhydrase 2	Cavia porcellus	26-29
9439444-5	1997	Similar cascade effects on furosemide binding in the presence of CMPF were also originated by other long-chain (C18) fatty acids, linoleate and stearate, although to a lesser extent.	Furosemide	27-37	Bardet-Biedl syndrome 9	Homo sapiens	112-115
9388483-0	1997	Angiotensin II mediates cell hypertrophy in vascular smooth muscle cultures from hypertensive Ren-2 transgenic rats by an amiloride- and furosemide-sensitive mechanism.	Furosemide	137-147	angiotensinogen	Rattus norvegicus	0-14
9388483-3	1997	In both SD- and TGR-VSMC, AII increased both cell size, by a furosemide- and amiloride-sensitive mechanism, and Na+/K+/2Cl- cotransport activity, by an amiloride-sensitive mechanism.	Furosemide	61-71	angiotensinogen	Rattus norvegicus	26-29
9374636-6	1997	Both furosemide [inhibition constant (Ki) approximately 25 microM] and bumetanide (Ki approximately 55 microM) inhibited the NEM-stimulated 86Rb influx in the KCC2-9 cells.	Furosemide	5-15	solute carrier family 12 member 5	Homo sapiens	159-163
9514615-3	1998	Mutual displacement experiments indicated that furosemide and valproic acid share a common high affinity binding site on human serum albumin (HSA).	Furosemide	47-57	albumin	Homo sapiens	127-140
9502574-2	1998	Two genes, the gene encoding the furosemide-sensitive apical Na-K-2Cl cotransporter (NKCC2) and the gene encoding the luminal inwardly-rectifying potassium channel Kir 1.1 (ROMK), have been reported to cause the neonatal subtype of Bartter syndrome.	Furosemide	33-43	solute carrier family 12 member 1	Homo sapiens	85-90
9365820-2	1997	injection of 2 mg/kg of furosemide resulted in a sustained increase in heart rate and an age-dependent increase in plasma renin activity.	Furosemide	24-34	renin	Ovis aries	122-127
9247750-5	1997	PRA and PRC respond appropriately to physiologic stimuli in pre-eclampsia except for impaired renin release following frusemide, possibly due to prostacyclin deficiency.	Furosemide	118-127	renin	Homo sapiens	94-99
9371207-0	1997	Changes in neurokinin A (NKA) airway responsiveness with inhaled frusemide in asthma.	Furosemide	65-74	tachykinin precursor 1	Homo sapiens	11-23
9371207-0	1997	Changes in neurokinin A (NKA) airway responsiveness with inhaled frusemide in asthma.	Furosemide	65-74	tachykinin precursor 1	Homo sapiens	25-28
9371207-2	1997	A randomised, double blind, placebo controlled study was performed to investigate the effect of the potent loop diuretic, frusemide, administered by inhalation on the bronchoconstrictor response to neurokinin A (NKA) and histamine in 11 asthmatic subjects.	Furosemide	122-131	tachykinin precursor 1	Homo sapiens	198-210
9371207-2	1997	A randomised, double blind, placebo controlled study was performed to investigate the effect of the potent loop diuretic, frusemide, administered by inhalation on the bronchoconstrictor response to neurokinin A (NKA) and histamine in 11 asthmatic subjects.	Furosemide	122-131	tachykinin precursor 1	Homo sapiens	212-215
9371207-5	1997	RESULTS: Compared with placebo, inhaled frusemide reduced the airway responsiveness to NKA in all the subjects studied, the geometric mean (range) values for PC20NKA increasing significantly (p < 0.001) from 130.3 (35.8-378.8) to 419.9 (126.5-1000) micrograms/ml after placebo and frusemide, respectively.	Furosemide	40-49	tachykinin precursor 1	Homo sapiens	87-90
9371207-7	1997	CONCLUSIONS: The decrease in airway responsiveness to NKA after administration of frusemide by inhalation suggests that this drug may interfere with the activation of neurotransmission in human asthma.	Furosemide	82-91	tachykinin precursor 1	Homo sapiens	54-57
9210443-2	1997	Both drugs were extracted from human plasma with ethyl acetate; furosemide was extracted at pH 1 and amiloride at pH 12.	Furosemide	64-74	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	92-96
9186867-7	1997	In other animals furosemide, a diuretic acting on macula densa cells, activated renin synthesis to a level similar to that found in the ramipril-treated group.	Furosemide	17-27	renin	Rattus norvegicus	80-85
9174082-11	1997	Frusemide gave a similar pattern of staining to desoxycorticosterone, stimulating c-fos expression in the same regions but to a lesser extent.	Furosemide	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	82-87
9136670-2	1997	To this end the renin system in male Sprague Dawley rats was stimulated by unilateral renal artery clipping (0.2 mm clip), by furosemide (60 mg/kg per diem) or isoproterenol (160 microg/kg per diem), and by ingestion of a low-salt diet (0.02%), or was suppressed by setting a contralateral renal artery clip (0.2-mm clip) or by ingestion of a high-salt diet (4%).	Furosemide	126-136	renin	Rattus norvegicus	16-21
9136670-4	1997	Renin gene expression was stimulated four- to fivefold by renal artery clipping and isoproterenol infusion, two- to three-fold by furosemide and a low-salt diet, and about four-fold by losartan.	Furosemide	130-140	renin	Rattus norvegicus	0-5
9186867-8	1997	Addition of L-NAME to the furosemide-treated rats suppressed the increases in renin mRNA levels, total renin content and renin secretion, suggesting that NO acts on renin activation by a mechanism independent of angiotensin II.	Furosemide	26-36	renin	Rattus norvegicus	78-83
9186867-8	1997	Addition of L-NAME to the furosemide-treated rats suppressed the increases in renin mRNA levels, total renin content and renin secretion, suggesting that NO acts on renin activation by a mechanism independent of angiotensin II.	Furosemide	26-36	renin	Rattus norvegicus	103-108
9186867-8	1997	Addition of L-NAME to the furosemide-treated rats suppressed the increases in renin mRNA levels, total renin content and renin secretion, suggesting that NO acts on renin activation by a mechanism independent of angiotensin II.	Furosemide	26-36	renin	Rattus norvegicus	103-108
9186867-8	1997	Addition of L-NAME to the furosemide-treated rats suppressed the increases in renin mRNA levels, total renin content and renin secretion, suggesting that NO acts on renin activation by a mechanism independent of angiotensin II.	Furosemide	26-36	renin	Rattus norvegicus	103-108
8941932-7	1996	Phosphorylation of HSP25 after the 20-minute furosemide diuresis was increased in KC rats.	Furosemide	45-55	heat shock protein family B (small) member 1	Rattus norvegicus	19-24
9196851-2	1997	During ACE inhibition, the rise in heart rate and decrease in renal blood flow in response to furosemide did not occur, and the natriuretic and diuretic responses to furosemide were attenuated by approximately two-thirds.	Furosemide	94-104	angiotensin-converting enzyme	Ovis aries	7-10
9196851-2	1997	During ACE inhibition, the rise in heart rate and decrease in renal blood flow in response to furosemide did not occur, and the natriuretic and diuretic responses to furosemide were attenuated by approximately two-thirds.	Furosemide	166-176	angiotensin-converting enzyme	Ovis aries	7-10
9196851-4	1997	Therefore, the cardiovascular, renal, and endocrine responses to furosemide in conscious lambs were significantly altered by ACE inhibition.	Furosemide	65-75	angiotensin-converting enzyme	Ovis aries	125-128
9170004-0	1997	Role of kinins in basal and furosemide-stimulated renin secretion.	Furosemide	28-38	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	50-55
9170004-7	1997	Injection of furosemide (2 mg/kg) caused a sustained increase i plasma renin activity from 6.7 +/- 1.6 to 15.9 +/- 3.3 ng/ml/2h (P < 0.01), a transient increase in mean arterial pressure from 72 +/- 3 to 78 +/- 3 mmHg (P < 0.05), and a sustained increase in heart rate from 228 +/- 8 to 253 +/- 6 bpm (P < 0.01).	Furosemide	13-23	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	71-76
9088586-7	1997	RESULTS: Plasma renin activity (PRA) was significantly (P < 0.01) increased after prior treatment with frusemide compared with placebo at all time points.	Furosemide	106-115	renin	Homo sapiens	16-21
9088586-12	1997	It is hypothesised that this effect of frusemide may be due to RAS activation with ANG II mediated pulmonary vasoconstriction.	Furosemide	39-48	angiotensinogen	Homo sapiens	83-89
8996639-5	1996	Other ionic flux inhibitors 4,4"-diisothiocyanostilbene-2,2"-disulfonic acid (DIDS) and furosemide slightly inhibited the pHi recovery from an acid load.	Furosemide	88-98	glucose-6-phosphate isomerase	Rattus norvegicus	122-125
9240763-8	1996	The insulin-mediated increase in Vt was abolished by ouabain and furosemide.	Furosemide	65-75	insulin	Oryctolagus cuniculus	4-11
8912747-5	1996	However, the increase in PaO2 (to 386.3 +/- 67.5 mm Hg) after infusion of ANP was significantly higher than the increase in PaO2 (to 275.9 +/- 63.3 mm Hg) after furosemide treatment, and in the no treatment control (to 171.1 +/- 31.5 mm Hg).	Furosemide	161-171	natriuretic peptides A	Sus scrofa	74-77
8930208-7	1996	M17055 and furosemide, but not trichlormethiazide, significantly increased the proportion of cardiac V3 myosin of SHR by enhancing the gene expression of beta-myosin heavy chain.	Furosemide	11-21	myosin heavy chain 7	Rattus norvegicus	154-177
8872956-3	1996	We investigated the localization of BGT-1 mRNA and its acute regulation by NaCl and furosemide administration.	Furosemide	84-94	solute carrier family 6 member 12	Rattus norvegicus	36-41
8872956-8	1996	Intraperitoneal administration of NaCl rapidly increased the signal in the MTAL, and furosemide prevented the increase in BGT-1 mRNA by NaCl loading.	Furosemide	85-95	solute carrier family 6 member 12	Rattus norvegicus	122-127
8794909-11	1996	Furosemide, which non-competitively inhibits the GABAA receptor, showed 700-fold selectivity for alpha 6 beta 3 gamma 2 receptors over alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing receptors and exhibited selectivity for alpha 4 beta 3 gamma 2 receptors (> 50-fold).	Furosemide	0-10	adrenoceptor alpha 1D	Homo sapiens	135-142
8864301-0	1996	Expression of Fos in rat brain in relation to sodium appetite: furosemide and cerebroventricular renin.	Furosemide	63-73	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	14-17
8864301-3	1996	Some rats had access to distilled water, and others had no fluids available during the 24 h. All of the furosemide-treated rats showed Fos-IR in both the subfornical organ (SFO) and around the organum vasculosum laminae terminalis (OVLT).	Furosemide	104-114	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	135-138
8765998-2	1996	Stimulation of the renin system was achieved by unilateral renal artery clipping (2-kidney/1-clip rats), treatment with the angiotensin II (ANG II) antagonist losartan (40 mg/kg), application of furosemide (12 mg x kg-1 x day-1) and a low-sodium diet (0.02% w/w Na+), which increased renin mRNA levels to 464%, 495%, 309% and 219% of those of control animals, respectively.	Furosemide	195-205	renin	Rattus norvegicus	19-24
8928409-3	1996	During dynamic testing of the response of plasma renin activity and aldosterone to the administration of furosemide and a vertical position in diabetics a significantly reduced response was recorded as compared with non-diabetic hypertonic subjects.	Furosemide	105-115	renin	Homo sapiens	49-54
8866635-1	1996	RESULTS: Incubation in vitro of human recombinant and erythrocyte (RBC) thiopurine methyl transferase (TPMT) with furosemide, bendroflumethiazide and trichlormethiazide demonstrated inhibition of both enzyme preparations, with IC50 values of 170 microM, 360 microM and 1 mM, respectively.	Furosemide	114-124	thiopurine S-methyltransferase	Homo sapiens	103-107
8894667-6	1996	Thus we studied the response of the renin-angiotensin-aldosterone system to sodium depletion using a single dose of furosemide.	Furosemide	116-126	renin	Homo sapiens	36-41
8894667-13	1996	During sodium depletion with furosemide, renin as well as aldosterone levels rose significantly in 1 parent and a sibling, respectively.	Furosemide	29-39	renin	Homo sapiens	41-46
8770946-5	1996	TGF blockade did not alter baseline diameter of either arteriole, but significantly blunted the mid-afferent vasoconstriction evoked by 10 nM Ang II (44 +/- 7% inhibition by papillectomy; 43 +/- 10% inhibition by furosemide).	Furosemide	213-223	angiotensinogen	Rattus norvegicus	142-148
8950280-7	1996	Both down-regulation and inhibition of PKC dramatically reduced the furosemide-sensitive Na+/K+/Cl- cotransport, as r fell to 0.239 and 0.032 in bradykinin-stimulated cells after H-7 and 24-h PMA treatments, respectively.	Furosemide	68-78	kininogen 1	Homo sapiens	145-155
8992496-4	1996	10 day gavage with indapamide, amiloride and cicletanine, as well as angiotensin-converting enzyme (ACE) inhibitor perindopril and calcium channel blockers nifedipine and verapamil decreases capillary permeability, whereas furosemide, hydrochlorothiazide, ACE inhibitor captopril and calcium channel blocker clentiazem do not modify or increase EB extravasation.	Furosemide	223-233	angiotensin I converting enzyme	Rattus norvegicus	100-103
9163007-7	1996	Heterogeneity of the peritoneal GAA and GSA transport dynamics in the control series of the experiments, as well as in the series with furosemide, may be related to the physico-chemical differences (e.g. molecular mass) of the analysed derivates.	Furosemide	135-145	alpha glucosidase	Homo sapiens	32-35
8594873-5	1995	Furosemide treatment resulted in a marked increase of both NOS and renin levels compared with controls (P < 0.05).	Furosemide	0-10	renin	Rattus norvegicus	67-72
8594886-8	1995	Treatment of rats with furosemide for 5 days increased expression of TSC message within the DCT but did not induce its expression elsewhere.	Furosemide	23-33	solute carrier family 12 member 3	Rattus norvegicus	69-72
7583049-0	1995	Furosemide treatment alters the distribution of kallikrein gene expression in kidneys of mice.	Furosemide	0-10	kallikrein 1-related peptidase b9	Mus musculus	48-58
7583049-4	1995	Although the overall level of kallikrein gene expression was significantly greater in kidneys from furosemide-treated mice than in any other group, there was no detectable change in renal kallikrein gene expression in the submandibular glands after any of the treatments.	Furosemide	99-109	kallikrein 1-related peptidase b9	Mus musculus	30-40
8586834-2	1995	METHODS: We artificially activated the renin-angiotensin-aldosterone system by two means: by pretreatment with frusemide (40 mg/day orally for 2 days) and by administering exogenous angiotensin II (1 ng/kg per min intravenously).	Furosemide	111-120	renin	Homo sapiens	39-44
8738111-0	1996	Captopril increases renin release stimulated by furosemide and hypotension in isolated perfused guinea pig kidneys.	Furosemide	48-58	renin	Cavia porcellus	20-25
8738111-3	1996	Captopril increased on a dose dependent basis renin release induced by 0.1 mg/ml furosemide; 5.8 +/- 1.3 ng/ml/hr at 0 mg/ml of captopril vs. 8.8 +/- 1.6 ng/ml/hr at 0.01 mg/ml (p < 0.05) and 11.8 +/- 2.4 ng/ml/hr at 0.1 mg/ml (p < 0.01), 15-20 min after furosemide infusion.	Furosemide	81-91	renin	Cavia porcellus	46-51
8706303-12	1996	Residents receiving frusemide had higher PTH than other residents (medians 6.95 vs 3.45 pmol/l, CI 1.9-4.2 pmol/l, P < 0.0001).	Furosemide	20-29	parathyroid hormone	Homo sapiens	41-44
8706303-13	1996	In linear modelling, the most important predictor of the natural logarithm of PTH was daily frusemide dose, adjusted R2 (Ra2) = 31.8%, F = 39.3, P < 0.001.	Furosemide	92-101	parathyroid hormone	Homo sapiens	78-81
8706303-13	1996	In linear modelling, the most important predictor of the natural logarithm of PTH was daily frusemide dose, adjusted R2 (Ra2) = 31.8%, F = 39.3, P < 0.001.	Furosemide	92-101	ribonucleotide reductase regulatory subunit M2	Homo sapiens	121-124
8706303-16	1996	However, the daily frusemide dose is a more important predictor of PTH in this population.	Furosemide	19-28	parathyroid hormone	Homo sapiens	67-70
8648902-4	1996	Renin secretion was increased in isolated afferent arterioles after in vivo treatment with the diuretic furosemide (+300%) or in vitro treatment with the adenylyl cyclase activator forskolin (+50%), indicating that this vascular preparation responds appropriately to regulators of the renin-angiotensin system.	Furosemide	104-114	renin	Rattus norvegicus	0-5
8594876-4	1995	Furosemide infusion increased plasma renin activity (PRA) from 8.8 +/- 1.4 to 41 +/- 5.2 ng angiotensin I (ANG I).h-1.ml-1 and renin mRNA levels from 112 +/- 8 of standard to 249 +/- 18% of standard.	Furosemide	0-10	renin	Rattus norvegicus	37-42
8594876-4	1995	Furosemide infusion increased plasma renin activity (PRA) from 8.8 +/- 1.4 to 41 +/- 5.2 ng angiotensin I (ANG I).h-1.ml-1 and renin mRNA levels from 112 +/- 8 of standard to 249 +/- 18% of standard.	Furosemide	0-10	renin	Rattus norvegicus	127-132
8594876-5	1995	After treatment with indomethacin, the furosemide-induced increases in renin mRNA levels was attenuated to 190 +/- 11% of standard.	Furosemide	39-49	renin	Rattus norvegicus	71-76
8594876-6	1995	After injections of L-NAME, both the furosemide-induced increases of renin mRNA levels and of PRA were reduced to 126 +/- 14% of standard and 22 +/- 5 ng ANG I.h-1.ml-1, respectively.	Furosemide	37-47	renin	Rattus norvegicus	69-74
8553380-2	1995	Results obtained were as follows: (1) GAA synthesis was significantly suppressed with 1 mM GM; (2) GM-induced decrease in GAA synthesis was recognized during incubation longer than 15 min; (3) furosemide significantly enhanced the suppression of GAA synthesis by GM.	Furosemide	193-203	alpha glucosidase	Rattus norvegicus	38-41
8553380-2	1995	Results obtained were as follows: (1) GAA synthesis was significantly suppressed with 1 mM GM; (2) GM-induced decrease in GAA synthesis was recognized during incubation longer than 15 min; (3) furosemide significantly enhanced the suppression of GAA synthesis by GM.	Furosemide	193-203	alpha glucosidase	Rattus norvegicus	122-125
8553380-2	1995	Results obtained were as follows: (1) GAA synthesis was significantly suppressed with 1 mM GM; (2) GM-induced decrease in GAA synthesis was recognized during incubation longer than 15 min; (3) furosemide significantly enhanced the suppression of GAA synthesis by GM.	Furosemide	193-203	alpha glucosidase	Rattus norvegicus	122-125
8708993-5	1995	The mean renal clearance of frusemide was 90.2 +/- 16.9 mL min-1 during the first period and 91.5 +/- 29.3 mL min-1 in the remaining period, during which the stimulation of urine production was absent.	Furosemide	28-37	CD59 molecule (CD59 blood group)	Homo sapiens	59-64
8589285-6	1995	Therapeutic conclusions can be drawn from the observation that both losartan and hydralazine/furosemide reduced osteopontin expression, macrophage infiltration, transforming growth factor-beta expression, and interstitial fibrosis, but did not prevent the decrease in GFR.	Furosemide	93-103	secreted phosphoprotein 1	Rattus norvegicus	112-123
7657791-2	1995	To investigate the physiological role of the SMIT, we sought to determine its localization by in situ hybridization and its acute regulation by NaCl and furosemide administration.	Furosemide	153-163	solute carrier family 5 member 3	Rattus norvegicus	45-49
7607716-0	1995	Effects of furosemide and verapamil on the NaCl dependency of macula densa-mediated renin secretion.	Furosemide	11-21	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	84-89
7586717-11	1995	In the group that received frusemide and the low sodium diet, VIP in the lung was significantly lower than the low sodium (P < 0.005) and normal sodium (P < 0.0001) groups.	Furosemide	27-36	vasoactive intestinal peptide	Rattus norvegicus	62-65
8584500-1	1995	This investigation aimed at examing the hypothesis that furosemide elicits renal sympathoexcitation through stimulation of renal renin release, which in turn produces increased plasma angiotensin II levels, causing centrally mediated sympathoexcitation.	Furosemide	56-66	angiotensinogen	Rattus norvegicus	184-198
7543251-0	1995	Selective neuronal nitric oxide synthase inhibition blocks furosemide-stimulated renin secretion in vivo.	Furosemide	59-69	renin	Rattus norvegicus	81-86
7543251-3	1995	To test whether neuronal NOS mediates renin secretion, renin was stimulated by either the renal baroreceptor or the diuretic furosemide (acting through the macula densa pathway).	Furosemide	125-135	renin	Rattus norvegicus	55-60
7607716-5	1995	Addition of 50 mumol/L furosemide to the luminal fluid caused renin secretion to become essentially independent of macula densa NaCl concentration.	Furosemide	23-33	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	62-67
7594440-2	1995	METHODS: Endogenous levels of angiotensin II in the rats were increased either by unilateral 0.2-mm renal artery clips or by subcutaneous infusions of frusemide (12 mg/day) and by low-sodium diet.	Furosemide	151-160	angiotensinogen	Rattus norvegicus	30-44
7758515-9	1995	Furosemide-induced diuresis resulted in normal rises of plasma renin activity in both patients; however, plasma aldosterone levels increased only in the boy and not in his sister.	Furosemide	0-10	renin	Homo sapiens	63-68
7654491-8	1995	The non-renal clearance of frusemide (36.7 +/- 21.0 vs 15.2 +/- 13.4 ml min-1, P = 0.0068) was also decreased.	Furosemide	27-36	CD59 molecule (CD59 blood group)	Homo sapiens	72-77
7651759-4	1995	Plasma renin activity was elevated by furosemide treatment.	Furosemide	38-48	renin	Rattus norvegicus	7-12
7589163-0	1995	Furosemide inhibits bradykinin-induced contraction of human bronchi: role of thromboxane A2 receptor antagonism.	Furosemide	0-10	kininogen 1	Homo sapiens	20-30
7589163-2	1995	Furosemide 10(-4) to 10(-3) M concentration dependently inhibited bradykinin- and the stable TP receptor agonist U-46619-induced contraction of human isolated small airways.	Furosemide	0-10	kininogen 1	Homo sapiens	66-76
7589163-4	1995	Such an inhibition of TP receptors could a least partly explain the inhibitory effect of furosemide on bradykinin-induced contraction, and could be one of the mechanisms of the protective effect of furosemide in asthma.	Furosemide	89-99	kininogen 1	Homo sapiens	103-113
7589163-4	1995	Such an inhibition of TP receptors could a least partly explain the inhibitory effect of furosemide on bradykinin-induced contraction, and could be one of the mechanisms of the protective effect of furosemide in asthma.	Furosemide	198-208	kininogen 1	Homo sapiens	103-113
7543396-0	1995	Effect of blockade of nitric oxide synthesis on the renin secretory response to frusemide in conscious rabbits.	Furosemide	80-89	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	52-57
7543396-3	1995	In the present study, we investigated the effect of inhibiting nitric oxide synthase on the renin secretory response to frusemide, which stimulates renin secretion by blocking Na(+)-K(+)-2Cl- co-transport in the macula densa.	Furosemide	120-129	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	92-97
7543396-3	1995	In the present study, we investigated the effect of inhibiting nitric oxide synthase on the renin secretory response to frusemide, which stimulates renin secretion by blocking Na(+)-K(+)-2Cl- co-transport in the macula densa.	Furosemide	120-129	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	148-153
7543396-9	1995	Inhibition of nitric oxide synthase with NG-nitro-L-arginine methyl ester increased mean arterial pressure by 9 mmHg, decreased heart rate and plasma renin activity, and markedly suppressed the renin response to frusemide (from 4.6 +/- 0.7 to 7.6 +/- 1.7, 4.7 +/- 1.0 and 4.6 +/- 0.7 pmol 2 h-1 ml-1 at 15, 30 and 45 min respectively).	Furosemide	212-221	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	194-199
7752314-5	1995	Five years postoperatively, ambulation and furosemide administration under low sodium diet stimuli remarkably enhanced plasma renin activity and plasma aldosterone concentration in the aldosterone-producing adenoma enucleation group (p < 0.001), almost similar to that of normal subjects but increment magnitudes were slight (p < 0.05 to < 0.01) in the adrenalectomy group.	Furosemide	43-53	renin	Homo sapiens	126-131
7538611-0	1995	Tubular hypertrophy due to work load induced by furosemide is associated with increases of IGF-1 and IGFBP-1.	Furosemide	48-58	insulin-like growth factor 1	Rattus norvegicus	91-96
7538611-0	1995	Tubular hypertrophy due to work load induced by furosemide is associated with increases of IGF-1 and IGFBP-1.	Furosemide	48-58	insulin-like growth factor binding protein 1	Rattus norvegicus	101-108
8067387-7	1994	When the Na(+)-K(+)-2Cl- cotransporter in the luminal membrane of the MTAL was blocked by 10(-4) mol/l furosemide, the insulin-mediated increase in Vte was also abolished.	Furosemide	103-113	insulin	Oryctolagus cuniculus	119-126
7864228-2	1995	We found that an injection of furosemide (10 mg/kg) produced a transient marked increase in urine output, a moderate 7-10% reduction in blood volume, and a three- to fourfold rise in plasma vasopressin from 1.6 +/- 0.2 to 5.6 +/- 1.0 pmol/l.	Furosemide	30-40	arginine vasopressin	Rattus norvegicus	190-201
7864228-5	1995	However, the lines describing the relationship of log plasma vasopressin to plasma volume and plasma sodium in the rats treated with furosemide for 32 h lay to the left of the same relationships in the rats treated for 8 h or the sham-treated controls.	Furosemide	133-143	arginine vasopressin	Rattus norvegicus	61-72
7599693-3	1995	Oral administration of furosemide, 40 mg for 2 days, under mild salt restriction (50 mEq NaCl/day) for 6 days stimulated the renin-angiotensin system resulting in significant increases in plasma renin activity (PRA) (1.84 +/- 0.12 vs. 1.05 +/- 0.17 ng/l/s; P < 0.01), plasma angiotensin II concentration, and plasma aldosterone concentration (PAC).	Furosemide	23-33	renin	Homo sapiens	125-130
7599693-3	1995	Oral administration of furosemide, 40 mg for 2 days, under mild salt restriction (50 mEq NaCl/day) for 6 days stimulated the renin-angiotensin system resulting in significant increases in plasma renin activity (PRA) (1.84 +/- 0.12 vs. 1.05 +/- 0.17 ng/l/s; P < 0.01), plasma angiotensin II concentration, and plasma aldosterone concentration (PAC).	Furosemide	23-33	renin	Homo sapiens	195-200
7599693-3	1995	Oral administration of furosemide, 40 mg for 2 days, under mild salt restriction (50 mEq NaCl/day) for 6 days stimulated the renin-angiotensin system resulting in significant increases in plasma renin activity (PRA) (1.84 +/- 0.12 vs. 1.05 +/- 0.17 ng/l/s; P < 0.01), plasma angiotensin II concentration, and plasma aldosterone concentration (PAC).	Furosemide	23-33	angiotensinogen	Homo sapiens	278-292
7752176-3	1995	Nifedipine and furosemide reduced blood pressure to the same extent (-14 to -15 mm Hg for supine SBP and -9 to -10 mm Hg for supine DBP, both P < 0.0001).	Furosemide	15-25	selenium binding protein 1	Homo sapiens	97-100
7752176-3	1995	Nifedipine and furosemide reduced blood pressure to the same extent (-14 to -15 mm Hg for supine SBP and -9 to -10 mm Hg for supine DBP, both P < 0.0001).	Furosemide	15-25	D-box binding PAR bZIP transcription factor	Homo sapiens	132-135
7584692-10	1995	After the administration of furosemide 4 patients in Group I were unable to increase aldosterone (2.8 +/- 0.9 ng/dl) secretion in spite of marked elevation of plasma renin activity (28 +/- 7 ng/ml/h), suggesting an impairment of 11-hydroxylase in the zona glomerulosa.	Furosemide	28-38	renin	Homo sapiens	166-171
7996475-8	1994	Thus the hemodynamic effects, and in particular the direct early dilator effect, of furosemide may be explained in part by an enhanced endothelial synthesis and release of bradykinin and related kinins, which in turn stimulates endothelial autacoid formation via B2 kinin receptor activation.	Furosemide	84-94	kininogen 1	Bos taurus	172-182
7977842-3	1994	Rats treated jointly with furosemide and low-dose captopril had exaggerated increases in plasma renin activity and angiotensin I but equivalent increases in plasma aldosterone compared with rats treated with either agent alone.	Furosemide	26-36	renin	Rattus norvegicus	96-101
7977842-4	1994	Treatment with furosemide plus low-dose captopril increased plasma vasopressin but not plasma oxytocin.	Furosemide	15-25	arginine vasopressin	Rattus norvegicus	67-78
7977842-5	1994	The administration of a higher dose of captopril (100 mg/kg) with furosemide, a combination of drugs that does not stimulate fluid intake (29), further increased plasma renin activity and angiotensin I but prevented the rise in plasma vasopressin.	Furosemide	66-76	renin	Rattus norvegicus	169-174
7977842-5	1994	The administration of a higher dose of captopril (100 mg/kg) with furosemide, a combination of drugs that does not stimulate fluid intake (29), further increased plasma renin activity and angiotensin I but prevented the rise in plasma vasopressin.	Furosemide	66-76	arginine vasopressin	Rattus norvegicus	235-246
7863230-6	1994	Volume depletion after furosemide injection, also accompanied by increased levels of angiotensin II, resulted in elevation of PTH(1-84) in controls, cirrhotics, patients with glomerulonephritis without the nephrotic syndrome, but not in nephrotic patients.	Furosemide	23-33	angiotensinogen	Homo sapiens	85-99
7943288-2	1994	This study shows that when furosemide- and bumetanide-inhibitable 86Rb+ uptake is measured in the skeletal muscle-like BC3H1 cell line, insulin and insulin-like growth factor I (IGF-I) activate a loop diuretic-sensitive K+ and Cl- transport system but have no effect on Na(+)-K(+)-ATPase.	Furosemide	27-37	insulin-like growth factor 1	Mus musculus	148-176
7943288-2	1994	This study shows that when furosemide- and bumetanide-inhibitable 86Rb+ uptake is measured in the skeletal muscle-like BC3H1 cell line, insulin and insulin-like growth factor I (IGF-I) activate a loop diuretic-sensitive K+ and Cl- transport system but have no effect on Na(+)-K(+)-ATPase.	Furosemide	27-37	insulin-like growth factor 1	Mus musculus	178-183
7600440-0	1995	Renal and renin responses to furosemide in conscious lambs during postnatal maturation.	Furosemide	29-39	renin	Ovis aries	10-15
7600440-2	1995	To test the hypothesis that the renal and renin responses to furosemide are altered during postnatal maturation, experiments were carried out in conscious chronically instrumented newborn lambs (11 +/- 3 days, n = 7) and older lambs (28 +/- 3 days, n = 6), at least 5 days after surgery under halothane anesthesia for placement of catheters.	Furosemide	61-71	renin	Ovis aries	42-47
7589049-9	1995	The cumulative urinary electrolyte excretion after concomitant administration of meloxicam and furosemide is somewhat lower than after administration of furosemide alone, in particular for the period 0-8 h after administration of furosemide.	Furosemide	95-105	period circadian regulator 2	Homo sapiens	193-203
8641327-8	1995	The total body clearance of furosemide in the volunteers was 138 ml x min(-1) and this was much lower in the CAPD patients (61.9 ml x min(-1)) in whom the renal clearance was negligible.	Furosemide	28-38	CD59 molecule (CD59 blood group)	Homo sapiens	70-76
8641327-8	1995	The total body clearance of furosemide in the volunteers was 138 ml x min(-1) and this was much lower in the CAPD patients (61.9 ml x min(-1)) in whom the renal clearance was negligible.	Furosemide	28-38	CD59 molecule (CD59 blood group)	Homo sapiens	134-140
7900569-8	1995	A case with a high level of plasma renin and aldosterone activity temporarily induced by furosemide was reported.	Furosemide	89-99	renin	Homo sapiens	35-40
7495050-2	1995	Following the retaining of sinus rhythm with the help of lanicor, nitrosorbide and lasix patients of group 1 exhibited increased Vs, Vd, Vcf, EF against decreased left atrial size and left atrial index.	Furosemide	83-88	DiGeorge syndrome chromosome region	Homo sapiens	137-140
7810602-6	1994	An NMDG-Cl- dependent NH4(+)-induced fall in pHi was reduced approximately 33% by 10 mM Ba+, approximately 84% by 0.1 mM bumetanide, and 100% by 1.5 mM furosemide, whereas 1 mM hydrochlorothiazide had no effect; inhibition by Ba+ was observed even in the presence of 0.1 mM verapamil added to block both K+ channels and K+/NH4+ antiport.	Furosemide	152-162	glucose-6-phosphate isomerase	Rattus norvegicus	45-48
7958753-5	1994	In furosemide-treated animals, plasma aldosterone concentrations correlated positively with PRA (r = 0.85; n = 64; P < 0.01) and negatively with plasma sodium concentrations (r = -0.80; n = 64; P < 0.01), suggesting that in sodium-depleted camels the nexus between the renin-angiotensin system and aldosterone was restored.	Furosemide	3-13	renin	Camelus bactrianus	275-280
8065467-7	1994	We conclude that the later generalized vasoconstriction following furosemide involves regional specific stimulation of angiotensin II and alpha-adrenoceptors.	Furosemide	66-76	angiotensinogen	Rattus norvegicus	119-133
8026000-0	1994	Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition.	Furosemide	73-83	angiotensinogen	Homo sapiens	18-32
8026000-0	1994	Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition.	Furosemide	73-83	angiotensin I converting enzyme	Homo sapiens	99-102
8026000-1	1994	BACKGROUND: Contrary to expectation, most studies have demonstrated that initiation of an angiotensin-converting enzyme (ACE) inhibitor in conventional doses in patients with heart failure reduces the diuretic efficacy of furosemide.	Furosemide	222-232	angiotensin I converting enzyme	Homo sapiens	90-119
8026000-1	1994	BACKGROUND: Contrary to expectation, most studies have demonstrated that initiation of an angiotensin-converting enzyme (ACE) inhibitor in conventional doses in patients with heart failure reduces the diuretic efficacy of furosemide.	Furosemide	222-232	angiotensin I converting enzyme	Homo sapiens	121-124
8026000-14	1994	CONCLUSIONS: Intense although transient ACE inhibition with captopril enhances the diuretic effects of furosemide during long-term ACE inhibition.	Furosemide	103-113	angiotensin I converting enzyme	Homo sapiens	40-43
8026000-14	1994	CONCLUSIONS: Intense although transient ACE inhibition with captopril enhances the diuretic effects of furosemide during long-term ACE inhibition.	Furosemide	103-113	angiotensin I converting enzyme	Homo sapiens	131-134
8038908-4	1994	Postural stimulation with or without furosemide administration increased 18-oxoF, 18-OH-F, aldosterone and plasma renin activity (PRA).	Furosemide	37-47	renin	Homo sapiens	114-119
7526657-3	1994	Furosemide inhibited anti-IgE-induced histamine release.	Furosemide	0-10	immunoglobulin heavy constant epsilon	Homo sapiens	26-29
7526657-4	1994	Preincubation of the cells with the drug, prior to anti-IgE stimulation, significantly reduced furosemide"s inhibitory effect.	Furosemide	95-105	immunoglobulin heavy constant epsilon	Homo sapiens	56-59
7515562-4	1994	Na(+)-H+ antiport activity, estimated from the Na(+)-induced initial rate of pHi recovery of Na(+)-depleted acidified cells in the presence of 0.1 mM furosemide to inhibit Na(+)-K(+)-2Cl- cotransport, was inhibited by 300 mM urea and 10(-8) M arginine vasopressin (AVP) in an additive manner.	Furosemide	150-160	glucose-6-phosphate isomerase	Rattus norvegicus	77-80
8033511-3	1994	The aim of this study was to determine whether the plasma active renin concentration could be stimulated in women with pre-eclampsia by intravenous frusemide, which stimulates renin acutely through a prostacyclin-mediated mechanism.	Furosemide	148-157	renin	Homo sapiens	65-70
8033511-3	1994	The aim of this study was to determine whether the plasma active renin concentration could be stimulated in women with pre-eclampsia by intravenous frusemide, which stimulates renin acutely through a prostacyclin-mediated mechanism.	Furosemide	148-157	renin	Homo sapiens	176-181
8033511-11	1994	After frusemide, plasma active renin concentration rose significantly in non-pregnant (P = 0.002) and normal pregnant (P = 0.008) women, but not in women with pre-eclampsia.	Furosemide	6-15	renin	Homo sapiens	31-36
7928730-6	1994	The amount of the decrease in 2f1-f2 emission amplitude after furosemide injection was approximately independent of frequency and consistent for the middle frequency ratios and intensity levels (f2/f1 approximately equal to 1.3, L1 x L2 approximately equal to 55 x 50 dB SPL).	Furosemide	62-72	sphingosine-1-phosphate lyase 1	Homo sapiens	271-274
8062074-5	1994	Rats with CeA or BST lesions also showed significant decreases in their intake of 2% NaCl after furosemide depletion, while intakes of the sham lesion groups remained unchanged.	Furosemide	96-106	carcinoembryonic antigen gene family 4	Rattus norvegicus	10-13
8054254-6	1994	The frusemide-induced rise in plasma renin activity was significantly less with paracetamol than placebo at 60 min (4.3 +/- 2.9 vs 2.7 +/- 1.9 ng ml-1 h-1, P < 0.01; 95% confidence interval of the difference 0.4 to 2.7).	Furosemide	4-13	renin	Homo sapiens	37-42
8058474-4	1994	In non-clipped animals furosemide increased PRA from 10 to 47 ng angiotensin I.h-1.ml-1 and raised renin mRNA levels in both kidneys 2.5-fold.	Furosemide	23-33	renin	Rattus norvegicus	99-104
8016771-0	1994	Effect of inhaled frusemide on responses of airways to bradykinin and adenosine 5"-monophosphate in asthma.	Furosemide	18-27	kininogen 1	Homo sapiens	55-65
8016771-3	1994	The effect of inhaled frusemide on bronchoconstriction induced by inhaled bradykinin, which is thought to cause bronchoconstriction via neural mechanisms, was studied and compared with the effects of adenosine 5"-monophosphate (AMP) which probably produces its airway effects by augmenting mast cell mediator release and interfering with neural pathways.	Furosemide	22-31	kininogen 1	Homo sapiens	74-84
8016771-10	1994	For bradykinin the geometric mean PC20 values following pretreatment with inhaled frusemide and matched placebo were 13.22 (2.53- > 16.0) and 2.52 (0.45-5.61) mg/ml respectively (95% CI 0.43 to 1.01).	Furosemide	82-91	kininogen 1	Homo sapiens	4-14
8016771-11	1994	Frusemide afforded 5.45 and 5.24 fold protection against AMP and bradykinin-induced bronchoconstriction respectively.	Furosemide	0-9	kininogen 1	Homo sapiens	65-75
8016771-13	1994	CONCLUSIONS: These data suggest that inhaled frusemide affords protection against bradykinin-induced bronchoconstriction which is comparable to that against AMP, supporting a common mechanism of action for frusemide.	Furosemide	45-54	kininogen 1	Homo sapiens	82-92
8136154-7	1994	Incubation with furosemide (10(-4) M) for 30 min caused a marked reduction in both basal and arachidonic acid-stimulated production of PGE2 and PGF2 alpha but did not reduce production of 6-keto-PGF1 alpha and PGD2.	Furosemide	16-26	prostaglandin D2 synthase	Homo sapiens	210-214
7880980-8	1994	The greater metabolic activity of furosemide in liver may also be supported by the result that the amount of hepatic cytochrome P-450 (0.7013 versus 0.5186 nmol/mg protein) and the weights of liver (3.52 versus 2.93% of body weight) were significantly greater in SHRs of 16 weeks of age than in age-matched Wistar rats.	Furosemide	34-44	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	117-133
8019837-5	1994	Assessment of the curve parameters collectively revealed that at 5 mg/kg, both furosemide (FUR) and ethacrynic acid (EA) reduced Cl penetration into CSF by one quarter; at 50 mg/kg, these loop agents decreased Cl uptake by about a third.	Furosemide	79-89	colony stimulating factor 2	Rattus norvegicus	149-152
8019837-5	1994	Assessment of the curve parameters collectively revealed that at 5 mg/kg, both furosemide (FUR) and ethacrynic acid (EA) reduced Cl penetration into CSF by one quarter; at 50 mg/kg, these loop agents decreased Cl uptake by about a third.	Furosemide	91-94	colony stimulating factor 2	Rattus norvegicus	149-152
8047284-5	1994	In adult CP, the KCl cotransport inhibitor, furosemide (1 mM), decreased K efflux by 23% or 65%, respectively, when aCSF had Cl or NO3 as the main anion.	Furosemide	44-54	NBL1, DAN family BMP antagonist	Homo sapiens	131-134
24233289-4	1994	A three-factor, three-level factorial design allowed us to establish a calibration matrix of the three diuretics that covered the three ranges from 10 to 40, 1.5 to 6, and 0.1 to 0.4 muM for furosemide, piretanide, and triamterene, respectively.	Furosemide	191-201	latexin	Homo sapiens	183-186
8396158-1	1993	It has been reported that the urinary excretions of chloride (Cl), potassium (K), and magnesium (Mg), but not sodium (Na), after furosemide, a loop diuretic, were decreased by pretreatment with lisinopril, an ACE inhibitor in hypertensive subjects.	Furosemide	129-139	angiotensin I converting enzyme	Homo sapiens	209-212
8035168-6	1994	Luminal furosemide (10(-4) M) reduced the initial rate of cell acidification by 70% and the fall in steady state pHi by 35%.	Furosemide	8-18	glucose-6-phosphate isomerase	Rattus norvegicus	113-116
8035168-10	1994	Addition of furosemide to the lumen abolished net ammonium absorption and caused pHi to increase abruptly (dpHi/dt = 0.8 U/min) to 7.0.	Furosemide	12-22	glucose-6-phosphate isomerase	Rattus norvegicus	81-84
8296708-0	1994	Interaction of intravenous atrial natriuretic factor with furosemide in patients with heart failure.	Furosemide	58-68	natriuretic peptide A	Homo sapiens	27-52
8141403-5	1994	It is concluded that the integrity of renin-angiotensin mechanisms is necessary for the rapid ingestion of water and saline after furosemide and captopril and that arterial pressure modulates the behavioral responses.	Furosemide	130-140	renin	Rattus norvegicus	38-43
7954537-4	1994	Both torasemide and furosemide increased plasma renin activity and aldosterone concentration, but only torasemide significantly inhibited aldosterone-receptor binding in rat kidney.	Furosemide	20-30	renin	Rattus norvegicus	48-53
8179835-3	1993	Also, the renin-aldosterone stimulation testing on this patient performed by sodium restricted diet and furosemide, upright position and by angiotensin converting enzyme inhibition (captopril, 50 mg) showed the blunted renin and aldosterone responses to each of these stimuli, almost no changes from baseline renin and aldosterone levels, it was concluded that the underlying defect responsible for hyperkalemia in this case was hyporeninemic hypoaldosteronism and this was aggravated by other factors or drugs affecting potassium homeostasis.	Furosemide	104-114	renin	Homo sapiens	10-15
8179835-3	1993	Also, the renin-aldosterone stimulation testing on this patient performed by sodium restricted diet and furosemide, upright position and by angiotensin converting enzyme inhibition (captopril, 50 mg) showed the blunted renin and aldosterone responses to each of these stimuli, almost no changes from baseline renin and aldosterone levels, it was concluded that the underlying defect responsible for hyperkalemia in this case was hyporeninemic hypoaldosteronism and this was aggravated by other factors or drugs affecting potassium homeostasis.	Furosemide	104-114	renin	Homo sapiens	219-224
8179835-3	1993	Also, the renin-aldosterone stimulation testing on this patient performed by sodium restricted diet and furosemide, upright position and by angiotensin converting enzyme inhibition (captopril, 50 mg) showed the blunted renin and aldosterone responses to each of these stimuli, almost no changes from baseline renin and aldosterone levels, it was concluded that the underlying defect responsible for hyperkalemia in this case was hyporeninemic hypoaldosteronism and this was aggravated by other factors or drugs affecting potassium homeostasis.	Furosemide	104-114	renin	Homo sapiens	219-224
7910062-0	1993	Correlation between renin responsiveness to furosemide and antihypertensive effect of captopril in patients with normal-renin essential hypertension.	Furosemide	44-54	renin	Homo sapiens	20-25
7910062-1	1993	The relationship between renin responsiveness to furosemide and the antihypertensive effect of captopril in patients with normal-renin essential hypertension were studied in 23 patients including nine men (mean age, 41 years) and 14 women (mean age, 40 years).	Furosemide	49-59	renin	Homo sapiens	25-30
7910062-6	1993	These data suggest that renin responsiveness to a single intravenous dose of furosemide can be a useful test for predicting the therapeutic response to captopril in patients with normal-renin essential hypertension.	Furosemide	77-87	renin	Homo sapiens	24-29
7910062-6	1993	These data suggest that renin responsiveness to a single intravenous dose of furosemide can be a useful test for predicting the therapeutic response to captopril in patients with normal-renin essential hypertension.	Furosemide	77-87	renin	Homo sapiens	186-191
8271212-3	1993	To this end we investigated the effects of frusemide and bumetanide, two different inhibitors of the macula densa Na(+)-K(+)-2Cl- cotransport, on pressure-dependent renin release from isolated perfused rat kidneys.	Furosemide	43-52	renin	Rattus norvegicus	165-170
8271212-10	1993	The vasorelaxant effects of frusemide and bumetanide were paralleled by an increase of renin secretion to a maximum of 21 +/- 4 (ng Ang I h-1) min-1 g-1 (n = 10).	Furosemide	28-37	renin	Rattus norvegicus	87-92
8271212-11	1993	On a molar basis bumetanide was twice as potent as frusemide in stimulating renin secretion.	Furosemide	51-60	renin	Rattus norvegicus	76-81
8255723-0	1993	Furosemide stimulates renin expression in the kidneys of salt-supplemented rats.	Furosemide	0-10	renin	Rattus norvegicus	22-27
8255723-5	1993	Plasma renin activities increased from 2.9 +/- 0.5 ng angiotensin I h-1 ml-1 in controls to 10.6 +/- 2.2 ng angiotensin I h-1 ml-1 in furosemide-treated rats.	Furosemide	134-144	renin	Rattus norvegicus	7-12
8255723-6	1993	In parallel, kidney areas immunoreactive for renin increased by 80% and the renal content of renin mRNA increased by 120% in the animals receiving furosemide.	Furosemide	147-157	renin	Rattus norvegicus	45-50
8255723-6	1993	In parallel, kidney areas immunoreactive for renin increased by 80% and the renal content of renin mRNA increased by 120% in the animals receiving furosemide.	Furosemide	147-157	renin	Rattus norvegicus	93-98
8255723-7	1993	Under the assumption that the effects seen on renal renin expression were primarily due to the inhibition of TALH and macula densa function by furosemide, our findings suggest that salt transport across the TALH and macula densa exerts a negative control function not only on the secretion but also on the expression of renin in the kidney.	Furosemide	143-153	renin	Rattus norvegicus	52-57
8065233-0	1994	Effect of angiotensin II type 1 receptor antagonist on urinary prostaglandin E2 excretion following furosemide in rats.	Furosemide	100-110	angiotensin II receptor, type 1b	Rattus norvegicus	10-40
8065233-1	1994	The present study was undertaken to examine an effect of an angiotensin II type 1 (AT1) receptor antagonist on urinary prostaglandin E2 (PGE2) excretion following furosemide, a loop diuretic, in rats.	Furosemide	163-173	angiotensin II receptor, type 1b	Rattus norvegicus	60-96
8065233-2	1994	Furosemide (30 mg/kg) was given orally with or without pretreatment with derapril (30 mg/kg), an angiotensin converting enzyme inhibitor, TCV-116 (1 mg/kg), an AT1 receptor antagonist, or losartan (10 mg/kg), another AT1 receptor antagonist.	Furosemide	0-10	angiotensin II receptor, type 1a	Rattus norvegicus	160-163
8065233-7	1994	As TCV-116 and losartan are selective AT1 receptor antagonists, the effect of furosemide on renal PGE2 production, as reflected by the urinary PGE2, might be mediated by an activation of AT1 receptors.	Furosemide	78-88	angiotensin II receptor, type 1a	Rattus norvegicus	38-41
8065233-7	1994	As TCV-116 and losartan are selective AT1 receptor antagonists, the effect of furosemide on renal PGE2 production, as reflected by the urinary PGE2, might be mediated by an activation of AT1 receptors.	Furosemide	78-88	angiotensin II receptor, type 1a	Rattus norvegicus	187-190
8146012-9	1994	The dB-cAMP-induced secretion of Ox2- and Cl- were fully abolished by serosal furosemide (10(-4) M) and partially inhibited (35%) by 5 x 10(-4) M mucosal NPPB [5-nitro-2-(3-phenylpropylamino)-benzoic acid], a putative Cl- channel blocker.	Furosemide	78-88	OX-2 membrane glycoprotein	Oryctolagus cuniculus	33-36
8011564-4	1993	The transient systemic arterial constriction and small increase in systemic blood pressure that follows intravenous furosemide probably results from the release of renin and subsequent activation of angiotensin.	Furosemide	116-126	renin	Homo sapiens	164-169
8288156-5	1993	In the present study, the effects of furosemide on the activities of the hexokinase, phosphofructokinase and pyruvate kinase were examined.	Furosemide	37-47	hexokinase 1	Homo sapiens	73-83
8288156-9	1993	The concentration of furosemide required to inhibit phosphofructokinase in muscle was lower than that required to inhibit the activity of this enzyme in the liver or to inhibit the activities of hexokinase and pyruvate kinase in both muscle and liver.	Furosemide	21-31	hexokinase 1	Homo sapiens	195-205
8219659-10	1993	Following furosemide angiotensin II increased significantly even after cilazapril pretreatment.	Furosemide	10-20	angiotensinogen	Homo sapiens	21-35
8219659-13	1993	The study shows that (a) cilazapril increases furosemide-induced natriuresis irrespective of salt intake, (b) antinatriuresis is not affected by cilazapril, and (c) angiotensin II levels rise after furosemide on cilazapril in therapeutic doses.	Furosemide	198-208	angiotensinogen	Homo sapiens	165-179
8400079-4	1993	The third objective was to determine the modulating action of continuous low-dose atrial natriuretic factor (ANF) administration during acute CHF upon these biologic responses, testing the hypothesis that exogenous low-dose ANF would prevent activation of the RAAS and enhance the natriuretic action of furosemide.	Furosemide	303-313	natriuretic peptide A	Canis lupus familiaris	224-227
8400079-7	1993	Low-dose exogenous ANF and furosemide (Group 3; N = 6) in acute CHF were associated with a maintenance of GFR, no activation of the RAAS, and potentiation of furosemide-induced natriuresis.	Furosemide	158-168	natriuretic peptide A	Canis lupus familiaris	19-22
8400079-9	1993	Low-dose ANF in acute CHF with furosemide maintains GFR, attenuates activation of the RAAS, and potentiates natriuresis.	Furosemide	31-41	natriuretic peptide A	Canis lupus familiaris	9-12
8392557-13	1993	However, angiotensin II is an important mediator of renal vasoconstriction during furosemide infusion.	Furosemide	82-92	angiotensinogen	Rattus norvegicus	9-23
8482447-6	1993	RESULTS: Serosal addition of endothelin 1 evoked a sustained increase in short-circuit current that was significantly reduced by tetrodotoxin or atropine, and virtually abolished by a selective endothelin A receptor antagonist (BQ-123), furosemide, piroxicam, d,I-verapamil, or removal of serosal calcium.	Furosemide	237-247	endothelin 1	Rattus norvegicus	29-41
8482447-6	1993	RESULTS: Serosal addition of endothelin 1 evoked a sustained increase in short-circuit current that was significantly reduced by tetrodotoxin or atropine, and virtually abolished by a selective endothelin A receptor antagonist (BQ-123), furosemide, piroxicam, d,I-verapamil, or removal of serosal calcium.	Furosemide	237-247	endothelin receptor type A	Rattus norvegicus	194-215
8389946-2	1993	In this study we examined acid-base composition and ATPase enzyme activities in medullary thick ascending limb of Henle"s loop (MTAL) and collecting tubule (CCT and MCT) after seven days of chronic furosemide therapy.	Furosemide	198-208	FLVCR heme transporter 2	Rattus norvegicus	157-160
1341182-13	1992	CONCLUSION: Furosemide administration reduced RAP, PAWP, HR, COP and PAWP-COP gradient, probably by a redistribution of fluid excess in the interstitial to intravascular space, through changes in driving fluid forces, with predominance in colloid osmotic pressure, which reverse fluid from intravascular to interstitial observed in pulmonary edema.	Furosemide	12-22	LDL receptor related protein associated protein 1	Homo sapiens	46-49
8478172-8	1993	Mannitol and furosemide increased the urinary excretion of N-acetyl-beta-glucosaminidase (NAG) and alkaline phosphatase (ALP) in the period 0 to 4 hours after administration, i.e. during peak diuresis, whereas both CM increased ALP significantly more, their effects still evident at 24 to 48 hours.	Furosemide	13-23	O-GlcNAcase	Homo sapiens	59-88
8478172-8	1993	Mannitol and furosemide increased the urinary excretion of N-acetyl-beta-glucosaminidase (NAG) and alkaline phosphatase (ALP) in the period 0 to 4 hours after administration, i.e. during peak diuresis, whereas both CM increased ALP significantly more, their effects still evident at 24 to 48 hours.	Furosemide	13-23	O-GlcNAcase	Homo sapiens	90-93
8478172-8	1993	Mannitol and furosemide increased the urinary excretion of N-acetyl-beta-glucosaminidase (NAG) and alkaline phosphatase (ALP) in the period 0 to 4 hours after administration, i.e. during peak diuresis, whereas both CM increased ALP significantly more, their effects still evident at 24 to 48 hours.	Furosemide	13-23	alkaline phosphatase, placental	Homo sapiens	99-119
8478172-8	1993	Mannitol and furosemide increased the urinary excretion of N-acetyl-beta-glucosaminidase (NAG) and alkaline phosphatase (ALP) in the period 0 to 4 hours after administration, i.e. during peak diuresis, whereas both CM increased ALP significantly more, their effects still evident at 24 to 48 hours.	Furosemide	13-23	alkaline phosphatase, placental	Homo sapiens	121-124
8478172-8	1993	Mannitol and furosemide increased the urinary excretion of N-acetyl-beta-glucosaminidase (NAG) and alkaline phosphatase (ALP) in the period 0 to 4 hours after administration, i.e. during peak diuresis, whereas both CM increased ALP significantly more, their effects still evident at 24 to 48 hours.	Furosemide	13-23	alkaline phosphatase, placental	Homo sapiens	228-231
8466703-8	1993	The renin response to sodium and volume depletion induced by the low sodium diet and furosemide correlated significantly (P < .001) with the subsequent blood pressure response to the low sodium diet.	Furosemide	85-95	renin	Homo sapiens	4-9
8471406-1	1993	A combination of dietary sodium restriction (40 mmol day-1) and frusemide pretreatment has been used to activate the renin angiotensin system (RAS) in order to characterise the haemodynamic and hormonal responses to enalapril in young normotensives.	Furosemide	64-73	renin	Homo sapiens	117-122
8498970-11	1993	The vascular renin-angiotensin system is subject to the action of a number of drugs and chemicals, most notably specific inhibitors of the angiotensin-converging enzyme and drugs affecting kidney function (furosemide) and/or vessel tone (propranolol).	Furosemide	206-216	renin	Homo sapiens	13-18
8495989-1	1993	Single dose of frusemide 0.1 mg/kg orally was administered in 10 rabbits pretreated with soluble insulin 4 IU intravenously.	Furosemide	15-24	insulin	Oryctolagus cuniculus	97-104
8425246-2	1993	Treatment with epinephrine, calcium chloride, sodium bicarbonate, and furosemide reduced K+ to 6.5 mEq.L-1 within 30 min and myocardial performance was enhanced with amrinone and cardiac rhythm was controlled with A-V segmental pacing.	Furosemide	70-80	immunoglobulin kappa variable 1-16	Homo sapiens	103-106
7506186-5	1993	Furosemide-induced increases in plasma renin activity and aldosterone levels were blunted, and urinary excretion of prostaglandin E2 was markedly reduced by nimesulide.	Furosemide	0-10	renin	Homo sapiens	39-44
1493659-10	1992	Reduced sensitivity of cardiopulmonary baroreceptors and lowered production of ANF due to structural cardiac changes could represent, according to most opinions, the main factors responsible for the prevailing sympathetic activation and hydro-saline retention in CHF.	Furosemide	237-242	natriuretic peptide A	Homo sapiens	79-82
1341182-13	1992	CONCLUSION: Furosemide administration reduced RAP, PAWP, HR, COP and PAWP-COP gradient, probably by a redistribution of fluid excess in the interstitial to intravascular space, through changes in driving fluid forces, with predominance in colloid osmotic pressure, which reverse fluid from intravascular to interstitial observed in pulmonary edema.	Furosemide	12-22	WBP2 N-terminal like	Homo sapiens	51-55
1341182-13	1992	CONCLUSION: Furosemide administration reduced RAP, PAWP, HR, COP and PAWP-COP gradient, probably by a redistribution of fluid excess in the interstitial to intravascular space, through changes in driving fluid forces, with predominance in colloid osmotic pressure, which reverse fluid from intravascular to interstitial observed in pulmonary edema.	Furosemide	12-22	caspase recruitment domain family member 16	Homo sapiens	61-64
1341182-13	1992	CONCLUSION: Furosemide administration reduced RAP, PAWP, HR, COP and PAWP-COP gradient, probably by a redistribution of fluid excess in the interstitial to intravascular space, through changes in driving fluid forces, with predominance in colloid osmotic pressure, which reverse fluid from intravascular to interstitial observed in pulmonary edema.	Furosemide	12-22	WBP2 N-terminal like	Homo sapiens	69-73
1341182-13	1992	CONCLUSION: Furosemide administration reduced RAP, PAWP, HR, COP and PAWP-COP gradient, probably by a redistribution of fluid excess in the interstitial to intravascular space, through changes in driving fluid forces, with predominance in colloid osmotic pressure, which reverse fluid from intravascular to interstitial observed in pulmonary edema.	Furosemide	12-22	caspase recruitment domain family member 16	Homo sapiens	74-77
1436675-0	1992	Effect of furosemide treatment on the central and peripheral pressor responses to cholinergic and adrenergic agonists, angiotensin II, hypertonic solution and vasopressin.	Furosemide	10-20	angiotensinogen	Rattus norvegicus	119-133
1393272-6	1992	Frusemide increased AVP levels to 134.1 +/- 73.6 pg ml-1 (P less than 0.05) and lignocaine totally prevented this increase, e.g. mean AVP levels of 2.7 pg ml-1.	Furosemide	0-9	vasopressin-neurophysin 2-copeptin	Oryctolagus cuniculus	20-23
1393272-12	1992	It is concluded that in healthy rabbits lignocaine reduces baseline secretion of AVP and its antidiuretic effect; in addition, lignocaine prevents the rise in AVP induced by frusemide.	Furosemide	174-183	vasopressin-neurophysin 2-copeptin	Oryctolagus cuniculus	159-162
1523447-3	1992	The best-fit Cox regression model identified six significant predictors of infiltration (P less than .05): catheter material, age, anatomic insertion site, hyperalimentation, and use of furosemide and dopamine.	Furosemide	186-196	cytochrome c oxidase subunit 8A	Homo sapiens	13-16
1436675-11	1992	ANGII and norepinephrine, but not AVP, was also reduced after treatment with furosemide.	Furosemide	77-87	angiotensinogen	Rattus norvegicus	0-5
1436675-12	1992	These results show that the treatment with furosemide impairs the pressor responses induced by central or peripheral administration of adrenergic agonist or ANGII, as well as those induced by central cholinergic activation.	Furosemide	43-53	angiotensinogen	Rattus norvegicus	157-162
1436675-13	1992	The results suggest that the treatment with furosemide impairs central and peripheral pressor responses mediated by sympathetic activation and ANGII, but not those produced by AVP.	Furosemide	44-54	angiotensinogen	Rattus norvegicus	143-148
1633064-0	1992	Captopril augments both basal and frusemide-induced natriuresis in normal man by suppression of circulating angiotensin II.	Furosemide	34-43	angiotensinogen	Homo sapiens	108-122
1633064-10	1992	Captopril augmented frusemide-induced natriuresis and again this effect was reversed by angiotensin II reinfusion.	Furosemide	20-29	angiotensinogen	Homo sapiens	88-102
1436675-0	1992	Effect of furosemide treatment on the central and peripheral pressor responses to cholinergic and adrenergic agonists, angiotensin II, hypertonic solution and vasopressin.	Furosemide	10-20	arginine vasopressin	Rattus norvegicus	159-170
1436675-8	1992	Treatment with furosemide reduced the pressor response induced by carbachol, norepinephrine and ANGII i.c.v., but no change was observed in the pressor response to i.c.v.	Furosemide	15-25	angiotensinogen	Rattus norvegicus	96-101
1295687-0	1992	Effect of vasopressin on brain swelling at the cellular level: do astrocytes exhibit a furosemide--vasopressin-sensitive mechanism for volume regulation?	Furosemide	87-97	arginine vasopressin	Homo sapiens	99-110
1576058-2	1992	We therefore measured lymphocyte free Mg2+ concentrations in patients with congestive cardiac failure treated with loop diuretics or a frusemide/amiloride mixture (Frumil) and compared them with control subjects.	Furosemide	135-144	mucin 7, secreted	Homo sapiens	38-41
1572111-1	1992	Furosemide causes not only natriuresis, but a rapid (5-10 min) increase in plasma renin activity.	Furosemide	0-10	renin	Homo sapiens	82-87
1572111-3	1992	Drugs like indomethacin abolish the renin increment and could potentially affect both mechanisms: they inhibit cyclooxygenase but could also compete with furosemide for transport into the tubular lumen, reducing furosemide concentration at its site of action.	Furosemide	154-164	renin	Homo sapiens	36-41
1572111-3	1992	Drugs like indomethacin abolish the renin increment and could potentially affect both mechanisms: they inhibit cyclooxygenase but could also compete with furosemide for transport into the tubular lumen, reducing furosemide concentration at its site of action.	Furosemide	212-222	renin	Homo sapiens	36-41
1290347-10	1992	It has also been found that the decrease in the intravascular fluid volume induced by furosemide administration resulted in the reduction of ANP concentration in plasma.	Furosemide	86-96	natriuretic peptide A	Homo sapiens	141-144
1552700-6	1992	When the apical Na-K-2Cl cotransport was blocked by furosemide or bumetanide, a net K secretion occurred (-1.1 +/- 0.2 pmol/min), which was significantly decreased by PAF (-0.06 +/- 0.3 pmol/min).	Furosemide	52-62	patchy fur	Mus musculus	167-170
1473090-8	1992	Compared to data derived from the literature, the solute-free water generation during administration of furosemide (CH2O/GFR) was significantly reduced in patients with CF (6.8 +/- 1.5%) as compared with healthy subjects (13.3 +/- 6.1%).	Furosemide	104-114	Rap guanine nucleotide exchange factor 5	Homo sapiens	116-124
1924052-6	1991	The increase in plasma renin activity after frusemide was inhibited by ketoprofen on both Day 1 and Day 5.	Furosemide	44-53	renin	Homo sapiens	23-28
1623899-5	1992	Metamizole significantly reduced furosemide clearance (175 vs 141 ml.min-1), furosemide-stimulated plasma renin activity (1.42 vs 0.79 ng AI.ml-1.h-1) and the urinary excretion of prostacyclin metabolites and of prostaglandin F2 alpha (by 70-81%).	Furosemide	77-87	renin	Homo sapiens	106-111
1316586-1	1992	It has been suggested that frusemide affects plasma parathyroid hormone (PTH) concentrations.	Furosemide	27-36	parathyroid hormone	Homo sapiens	52-71
1316586-1	1992	It has been suggested that frusemide affects plasma parathyroid hormone (PTH) concentrations.	Furosemide	27-36	parathyroid hormone	Homo sapiens	73-76
1316586-3	1992	The rate of increase of plasma PTH observed with progression of renal failure was faster in patients who received frusemide as compared to patients who did not receive the drug.	Furosemide	114-123	parathyroid hormone	Homo sapiens	31-34
1316586-4	1992	The slope of the regression line of PTH on CCr was steeper (P less than 0.02) for patients with frusemide (n = 40, slope -0.34) than without frusemide (n = 37, slope -0.20).	Furosemide	96-105	parathyroid hormone	Homo sapiens	36-39
1316586-4	1992	The slope of the regression line of PTH on CCr was steeper (P less than 0.02) for patients with frusemide (n = 40, slope -0.34) than without frusemide (n = 37, slope -0.20).	Furosemide	141-150	parathyroid hormone	Homo sapiens	36-39
1655330-0	1991	Plasma and tissue kallikrein-kinin systems during acute administration of frusemide in normotensive and hypertensive humans.	Furosemide	74-83	kallikrein related peptidase 4	Homo sapiens	18-28
1655330-5	1991	Frusemide increased plasma pre-kallikrein, angiotensin II and aldosterone concentrations and plasma renin activity, whereas the plasma level of tissue kallikrein remained unchanged.	Furosemide	0-9	kallikrein related peptidase 4	Homo sapiens	31-41
1655330-5	1991	Frusemide increased plasma pre-kallikrein, angiotensin II and aldosterone concentrations and plasma renin activity, whereas the plasma level of tissue kallikrein remained unchanged.	Furosemide	0-9	angiotensinogen	Homo sapiens	43-57
1655330-5	1991	Frusemide increased plasma pre-kallikrein, angiotensin II and aldosterone concentrations and plasma renin activity, whereas the plasma level of tissue kallikrein remained unchanged.	Furosemide	0-9	renin	Homo sapiens	100-105
1655330-8	1991	Frusemide increased the urine volume and the excretion of Na+, K+, Mg2+, Cl-, aldosterone, prostaglandin E2 and tissue kallikrein.	Furosemide	0-9	kallikrein related peptidase 4	Homo sapiens	119-129
1655330-12	1991	Thus, acute administration of frusemide to hypertensive patients and normal subjects increased the plasma level of pre-kallikrein, possibly indicating less activation to kallikrein and subsequently less kinin generation in the blood stream.	Furosemide	30-39	kallikrein related peptidase 4	Homo sapiens	119-129
1655330-12	1991	Thus, acute administration of frusemide to hypertensive patients and normal subjects increased the plasma level of pre-kallikrein, possibly indicating less activation to kallikrein and subsequently less kinin generation in the blood stream.	Furosemide	30-39	kallikrein related peptidase 4	Homo sapiens	170-180
1655330-16	1991	Urinary excretion of kallikrein is reduced in patients with primary hypertension after the administration of frusemide, apparently without affecting the renal excretory response.	Furosemide	109-118	kallikrein related peptidase 4	Homo sapiens	21-31
1853956-11	1991	At the doses studied, hydrochlorothiazide was also more potent than furosemide in increasing plasma renin activity, increasing sodium excretion, and decreasing lithium excretion.	Furosemide	68-78	renin	Homo sapiens	100-105
1907105-9	1991	Administration of the renin inhibitor CGP 29287 (1 mg/kg) to furosemide-pretreated conscious marmosets lowered blood pressure and increased renal blood flow.	Furosemide	61-71	renin	Callithrix jacchus	22-27
1941559-5	1991	The contents of hepatic cytochrome P-450 (1.29 versus 2.15 nmol/mg protein) and the weights of liver and stomach increased significantly in PB-treated rats, suggesting that the metabolizing enzymes for furosemide are induced by pretreatment with PB.	Furosemide	202-212	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	24-40
1316586-7	1992	To clarify mechanisms involved in the effect of frusemide on plasma PTH values, seven normal subjects were studied for 24 h before and for 24 h after oral administration of 80 mg frusemide.	Furosemide	48-57	parathyroid hormone	Homo sapiens	68-71
1812004-5	1991	Higher doses of torasemide (10 mg/kg) and furosemide (100 mg/kg) increased both plasma renin activity and aldosterone concentration in normotensive rats in a similar manner.	Furosemide	42-52	renin	Rattus norvegicus	87-92
1935501-0	1991	Verapamil and furosemide prevent cholecystokinin-induced translocation of immunoglobulins in rat intestine.	Furosemide	14-24	cholecystokinin	Rattus norvegicus	33-48
1935501-3	1991	The effect of CCK on the translocation of immunoglobulins, albumin, and electrolytes is reduced by the prior injection of the calcium-channel blocker verapamil and the chloride-channel blocker furosemide.	Furosemide	193-203	cholecystokinin	Rattus norvegicus	14-17
1822524-4	1991	About 96% of Cd2+ uptake was inhibited by DIDS (4,4"-diisothiocyanatostilbene-2,2"-disulphonic acid) with IC50 (concentration giving 50% of maximal inhibition) of 0.3 microM and by furosemide with IC50 of 500 microM and was resistant to ouabain and amiloride.	Furosemide	181-191	CD2 molecule	Homo sapiens	13-16
1666052-2	1991	This study was to determine whether antagonism of Na+/K+/Cl- co-transport by loop diuretics (furosemide or bumetanide) and thereby Cl- entry could block ACTH secretion.	Furosemide	93-103	pro-opiomelanocortin-alpha	Mus musculus	153-157
1666052-7	1991	Forskolin did not affect the activity of the Na+/K+/Cl- co-transporter but both basal and forskolin-stimulated secretion of ACTH were inhibited by furosemide (IC50 of 5 x 10(-4) M; maximal inhibition: 50%).	Furosemide	147-157	pro-opiomelanocortin-alpha	Mus musculus	124-128
1924052-7	1991	These results suggest that ketoprofen reduces the diuresis and renin release induced by frusemide, but that the reduction in diuretic response may become less important after their repeated coadministration.	Furosemide	88-97	renin	Homo sapiens	63-68
1873917-5	1991	During furosemide infusion, PAI, PAII, PRA, as well as UV-AI and UV-AII increased.	Furosemide	7-17	serpin family E member 1	Homo sapiens	28-31
1873917-5	1991	During furosemide infusion, PAI, PAII, PRA, as well as UV-AI and UV-AII increased.	Furosemide	7-17	NLR family pyrin domain containing 3	Homo sapiens	34-37
1986589-2	1991	This study assesses the predictive diagnostic value of furosemide-131I-hippuran renography after angiotensin-converting enzyme (ACE) inhibition in patients with and without RVH.	Furosemide	55-65	angiotensin I converting enzyme	Homo sapiens	128-131
1780509-5	1991	Urinary kallikrein in hypertense non-diabetic patients who are not treated with diuretics (furosemide) has a behaviour as in normal controls, but it is much higher in patients treated with captopril, being this finding of great importance since it can suggest new therapeutic approaches to diabetic nephropathy.	Furosemide	91-101	kallikrein related peptidase 4	Homo sapiens	8-18
2022640-6	1991	The stimulation of the furosemide-sensitive influx by Ha-ras is paralleled by an increase in mean cell volume which can be inhibited by furosemide.	Furosemide	23-33	Harvey rat sarcoma virus oncogene	Mus musculus	54-60
2022640-6	1991	The stimulation of the furosemide-sensitive influx by Ha-ras is paralleled by an increase in mean cell volume which can be inhibited by furosemide.	Furosemide	136-146	Harvey rat sarcoma virus oncogene	Mus musculus	54-60
2022640-7	1991	A rapid stimulation of the furosemide-sensitive Rb+ influx is also observed after addition of bombesin to growth-arrested cells.	Furosemide	27-37	gastrin releasing peptide	Homo sapiens	94-102
2022640-8	1991	Furosemide inhibits the mitogenic response after expression of Ha-ras or addition of bombesin.	Furosemide	0-10	Harvey rat sarcoma virus oncogene	Mus musculus	63-69
2022640-8	1991	Furosemide inhibits the mitogenic response after expression of Ha-ras or addition of bombesin.	Furosemide	0-10	gastrin releasing peptide	Homo sapiens	85-93
2022640-9	1991	Both the Ha-ras and the bombesin-induced stimulation of the furosemide-sensitive Rb+ transport can be blocked by protein kinase C depletion or the protein kinase C inhibitor staurosporine.	Furosemide	60-70	Harvey rat sarcoma virus oncogene	Mus musculus	9-15
2022640-9	1991	Both the Ha-ras and the bombesin-induced stimulation of the furosemide-sensitive Rb+ transport can be blocked by protein kinase C depletion or the protein kinase C inhibitor staurosporine.	Furosemide	60-70	gastrin releasing peptide	Homo sapiens	24-32
2022640-10	1991	In contrast to bombesin-induced phosphatidylinositol-4,5-bisphosphate hydrolysis which is down-modulated by Ha-ras, the stimulation of the furosemide-sensitive Rb+ influx by bombesin is elevated in Ha-ras-expressing cells.	Furosemide	139-149	gastrin releasing peptide	Homo sapiens	174-182
2022640-10	1991	In contrast to bombesin-induced phosphatidylinositol-4,5-bisphosphate hydrolysis which is down-modulated by Ha-ras, the stimulation of the furosemide-sensitive Rb+ influx by bombesin is elevated in Ha-ras-expressing cells.	Furosemide	139-149	Harvey rat sarcoma virus oncogene	Mus musculus	198-204
1864454-2	1991	Prostaglandin E1 also increased the total serum protein and serum albumin concentrations, and reduced creatinine clearance and plasma renin activity following frusemide loading.	Furosemide	159-168	renin	Homo sapiens	134-139
1986589-15	1991	CONCLUSION: Furosemide-131I-hippuran renography with ACE inhibition is highly predictive in identifying patients with RVH.	Furosemide	12-22	angiotensin I converting enzyme	Homo sapiens	53-56
1832596-4	1991	After upright posture and furosemide administration plasma ANP was decreased (p less than 0.01) in patients with low renin and, less markedly, with normal renin essential hypertension, however not in IHA and APA.	Furosemide	26-36	natriuretic peptide A	Homo sapiens	59-62
1832596-4	1991	After upright posture and furosemide administration plasma ANP was decreased (p less than 0.01) in patients with low renin and, less markedly, with normal renin essential hypertension, however not in IHA and APA.	Furosemide	26-36	renin	Homo sapiens	117-122
1832596-5	1991	In about half of the patients with low renin essential hypertension, unchanged PRA after upright posture and furosemide administration was associated with increased plasma Aldo and decreased ANP levels.	Furosemide	109-119	natriuretic peptide A	Homo sapiens	191-194
2087934-0	1990	Plasma renin activity and urinary kallikrein excretion in response to intravenous furosemide in diabetic patients.	Furosemide	82-92	renin	Homo sapiens	7-12
1943567-1	1991	Assessment of vasopressin by radioimmunoassay has shown an increase in its blood concentration and a disturbed reaction of the vasopressinergic structures of the hypothalamus to metoclopramide, furosemide, insulin hypoglycemia, and exercise.	Furosemide	194-204	arginine vasopressin	Homo sapiens	14-25
1823389-0	1991	Evaluation of insulin-induced changes in the renal response to furosemide in normal subjects.	Furosemide	63-73	insulin	Homo sapiens	14-21
1823389-2	1991	We analyzed the response of the kidney to furosemide in 5 healthy men, in the presence of both normal physiological serum insulin levels and levels at the upper limit of the physiological range, obtained by the hyperinsulinemic-euglycemic clamp technique.	Furosemide	42-52	insulin	Homo sapiens	122-129
1823389-3	1991	After furosemide administration, glomerular filtration rate, urine flow, urine sodium excretion, free water clearance, urine pH, plasma renin activity and plasma aldosterone exhibited the same behavior in the presence of both serum insulin concentrations.	Furosemide	6-16	insulin	Homo sapiens	232-239
1823389-4	1991	The rise in urinary potassium excretion following furosemide administration was significantly lower in the presence of high insulin concentrations.	Furosemide	50-60	insulin	Homo sapiens	124-131
1823389-6	1991	Thus, in conditions in which natriuresis is mildly stimulated, as in the case of the administration of low doses of furosemide, insulin does not affect the rate of renal sodium reabsorption.	Furosemide	116-126	insulin	Homo sapiens	128-135
1784627-6	1991	Plasma renin activity (PRA) increased following furosemide administration in animals on an NSD and an LSD, but not in those on an HSD.	Furosemide	48-58	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	7-12
1784627-11	1991	In animals on an LSD, the increase in furosemide response appears to be associated with changes in the activity of the renin-angiotensin system and in rabbits on an HSD, the decrease in furosemide effect is probably the net result of several factors.	Furosemide	38-48	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	119-124
1964125-7	1990	After furosemide ANF and cGMP decreased slightly in both groups whereas AII and Aldo increased; AVP increased in the controls, but not in the cirrhotic patients.	Furosemide	6-16	natriuretic peptide A	Homo sapiens	17-20
2242386-4	1990	Furosemide, an inhibitor of Na+, K+, Cl- co-transport, reduced the 86Rb+ influx and the effect was partly additive to the effect of 2 mM Ba2+.	Furosemide	0-10	bone area 2	Mus musculus	137-140
2242386-5	1990	When the islets were preincubated with Ba2+ (2 mM) the specific effect of 1 mM furosemide on the 86Rb+ influx was reduced, whereas, in acute experiments, Ba2+ (2 mM) did not affect the specific effect of furosemide on 86Rb+ influx.	Furosemide	79-89	bone area 2	Mus musculus	39-42
2242386-5	1990	When the islets were preincubated with Ba2+ (2 mM) the specific effect of 1 mM furosemide on the 86Rb+ influx was reduced, whereas, in acute experiments, Ba2+ (2 mM) did not affect the specific effect of furosemide on 86Rb+ influx.	Furosemide	204-214	bone area 2	Mus musculus	39-42
2242386-6	1990	86Rb+ efflux from preloaded islets was significantly reduced by 2 mM Ba2+ and during the first 5 min of ion efflux the effect of the combination of 2 mM Ba2+ and 1 mM furosemide was stronger than the effect of Ba2+ alone.	Furosemide	167-177	bone area 2	Mus musculus	69-72
1831170-2	1991	Dopamine (DA) infusion enhanced the diuresis, natriuresis and kaliuresis evoked by furosemide, but this increase was significantly lower in the presence of SCH 23390, a selective DA1-dopaminergic antagonist.	Furosemide	83-93	RT1 class II, locus Da	Rattus norvegicus	179-182
1831170-8	1991	Our data show that renal responses to furosemide are attenuated by the DA1-dopaminergic antagonist.	Furosemide	38-48	RT1 class II, locus Da	Rattus norvegicus	71-74
1831170-9	1991	It is possible that endogenous DA, stimulating DA1 receptors in the rat kidney may be an important factor involved in the Na+, K+ and water excretion evoked by furosemide.	Furosemide	160-170	RT1 class II, locus Da	Rattus norvegicus	47-50
2087934-0	1990	Plasma renin activity and urinary kallikrein excretion in response to intravenous furosemide in diabetic patients.	Furosemide	82-92	kallikrein related peptidase 4	Homo sapiens	34-44
2087934-1	1990	The responsiveness of renin-angiotensin and kallikrein-kinin systems to furosemide challenge has been investigated in forty-six diabetic patients (34 NIDDM/12 IDDM), subdivided into Group I (uncomplicated DM), Group II (DM with hypertension), Group III (DM with nephropathy), Group IV (DM with hypertension and nephropathy) and a control group of 10 healthy volunteers.	Furosemide	72-82	renin	Homo sapiens	22-27
2087934-2	1990	Plasma renin activity (PRA) was estimated by radioimmunoassay in blood samples drawn before and 10 min after furosemide administration (0.5 mg/kg i.v.).	Furosemide	109-119	renin	Homo sapiens	7-12
2087934-6	1990	Both PRA and kallikrein levels increased after furosemide in controls while in diabetics this response was severely blunted.	Furosemide	47-57	kallikrein related peptidase 4	Homo sapiens	13-23
2403378-8	1990	CEF free fraction (fp) in isolated human serum albumin (CEF fp = 7.7%) was increased by drugs which bind to Site I: sulfisoxazole (CEF fp = 68.1%), warfarin (CEF fp = 56.0%) and furosemide (CEF fp = 55.0%).	Furosemide	178-188	albumin	Homo sapiens	41-54
2221139-2	1990	Intraperitoneal injection of the angiotensin-converting enzyme inhibitor captopril at 1.7 mg/mouse (high dose) decreased the Na intake of the Na-depleted (furosemide-treated) mice by 80-85%.	Furosemide	155-165	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	33-62
2203682-5	1990	Renin release in intact hydropenic rats was not altered by diuretic therapy, but furosemide increased plasma renin activity in hydropenic as well as in volume-expanded rats.	Furosemide	81-91	renin	Rattus norvegicus	109-114
1830313-6	1991	The only significant treatment effect was observed for high-density-lipoprotein3 cholesterol concentration (HDL3 cholesterol concentration), which was higher when patients were on furosemide therapy (p less than 0.05).	Furosemide	180-190	HDL3	Homo sapiens	108-112
2203682-6	1990	This demonstrates the importance of furosemide inhibition of transport in the macula densa for its renin secretory action.	Furosemide	36-46	renin	Rattus norvegicus	99-104
2118863-13	1990	Furosemide (50 micrograms/ml) stimulated the release of active and inactive renins significantly at 20 and 40 min (p less than 0.05 vs. control) but did not affect the release of either renin at 60 min.	Furosemide	0-10	renin	Rattus norvegicus	76-81
2167800-10	1990	After frusemide there was a small transient increase in excretion of active kallikrein 1-2 h after dosing which coincided with the maximum diuresis and natriuresis.	Furosemide	6-15	kallikrein related peptidase 4	Homo sapiens	76-86
1694396-5	1990	Furosemide increased Rb by 22%, which indicates that furosemide reduces basolateral membrane Gcl.	Furosemide	53-63	germ cell-less 2, spermatogenesis associated	Homo sapiens	93-96
2083062-1	1990	The study has been performed in an attempt to provide further data on the supposed direct action of insulin on the kidney, based on the assumption that any effect of insulin on sodium reabsorption via co-transport should shift the dose-response curve to the furosemide administration.	Furosemide	258-268	insulin	Homo sapiens	100-107
2083062-1	1990	The study has been performed in an attempt to provide further data on the supposed direct action of insulin on the kidney, based on the assumption that any effect of insulin on sodium reabsorption via co-transport should shift the dose-response curve to the furosemide administration.	Furosemide	258-268	insulin	Homo sapiens	166-173
1694396-3	1990	Furosemide could in principle decrease the basolateral membrane Cl- conductance (Gcl), increase the basolateral membrane K+ conductance, or have a combined effect.	Furosemide	0-10	germ cell-less 2, spermatogenesis associated	Homo sapiens	81-84
1694396-5	1990	Furosemide increased Rb by 22%, which indicates that furosemide reduces basolateral membrane Gcl.	Furosemide	0-10	germ cell-less 2, spermatogenesis associated	Homo sapiens	93-96
2203383-2	1990	It is possible that these factors may play a role in changes in insulin sensitivity in vivo produced by such diverse conditions as treatment with furosemide, thyroid status or catecholamine status.	Furosemide	146-156	insulin	Homo sapiens	64-71
2199209-1	1990	Recent studies have shown that inhaled frusemide exerts a protective effect against various bronchoconstrictor stimuli in asthma including exercise, fog and allergen.	Furosemide	39-48	zinc finger protein, FOG family member 1	Homo sapiens	149-152
2185908-18	1990	Furosemide has two documented metabolites--furosemide glucuronide and saluamine (CSA).	Furosemide	0-10	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	81-84
2319462-0	1990	Intratubular albumin blunts the response to furosemide-A mechanism for diuretic resistance in the nephrotic syndrome.	Furosemide	44-54	albumin	Rattus norvegicus	13-20
2319462-4	1990	After addition of albumin to furosemide perfusate, fractional loop chloride reabsorption was 45 +/- 1%; a value greater (P less than .01) than that observed in furosemide perfused loop segments, but less (P less than .05) than that observed in control loop segments.	Furosemide	160-170	albumin	Rattus norvegicus	18-25
2319462-9	1990	Thus, albumin in renal tubule fluid attenuates the effect of furosemide on loop segment chloride reabsorption in the rat.	Furosemide	61-71	albumin	Rattus norvegicus	6-13
2319462-10	1990	This blunted response presumably occurs because of a reduction in the amount of pharmacologically active drug due to albumin-furosemide binding.	Furosemide	125-135	albumin	Rattus norvegicus	117-124
2319462-11	1990	Consequently, albumin-furosemide binding in the renal tubule may contribute to the diuretic resistance in nephrotic syndrome.	Furosemide	22-32	albumin	Rattus norvegicus	14-21
2106127-4	1990	Parathyroid hormone concentrations were high in furosemide-treated patients (0.95 +/- 0.15 ng/mL) compared with patients not treated with furosemide and receiving either moderate (0.49 +/- 0.05 ng/mL) or low (0.42 +/- 0.07 ng/mL) phosphorus intakes.	Furosemide	48-58	parathyroid hormone	Homo sapiens	0-19
2178660-9	1990	Both nonsteroidal agents inhibited equally the rise in renin activity seen after frusemide.	Furosemide	81-90	renin	Homo sapiens	55-60
2160342-4	1990	Renin was responsive to posture, low sodium diet, saline infusion and frusemide, but relatively unresponsive to raising or lowering circulating levels of angiotensin II.	Furosemide	70-79	renin	Homo sapiens	0-5
2253658-0	1990	Effect of furosemide on angiotensin II-mediated prostaglandin I2 production in hypertensive subjects.	Furosemide	10-20	angiotensinogen	Homo sapiens	24-38
2253658-1	1990	The role of angiotensin II (AII) in Prostaglandin I2 (PGI2) production following furosemide has been examined in a placebo-controlled, cross-over study.	Furosemide	81-91	angiotensinogen	Homo sapiens	12-26
2253658-1	1990	The role of angiotensin II (AII) in Prostaglandin I2 (PGI2) production following furosemide has been examined in a placebo-controlled, cross-over study.	Furosemide	81-91	angiotensinogen	Homo sapiens	28-31
2253658-3	1990	Urinary excretion of 6-keto-PGF1 alpha (a metabolite of PGI2) and PGE2, PRA and AII was increased following furosemide without captopril pretreatment.	Furosemide	108-118	angiotensinogen	Homo sapiens	80-83
2136743-4	1990	The infusion of furosemide increased urine volume, sodium excretion, osmolal clearance, and PRA, but decreased circulating ANP levels and urinary clearance and fractional excretion of AVP.	Furosemide	16-26	arginine vasopressin	Homo sapiens	184-187
2266774-0	1990	Disproportional release of differently glycosylated forms of human renin by furosemide.	Furosemide	76-86	renin	Homo sapiens	67-72
2266774-7	1990	These results provide evidence for the presence of differently glycosylated forms of AR and PR in human plasma and suggest the preferential release of AR-III with the acute stimulation of renin, by furosemide.	Furosemide	198-208	renin	Homo sapiens	188-193
3184174-2	1988	Furosemide-sensitive cation effluxes from cells with nearly normal membrane potential and pH were lower in NO3- media than in Cl- media; they were reduced when pH was lowered in Cl- media.	Furosemide	0-10	NBL1, DAN family BMP antagonist	Homo sapiens	107-110
35635321-7	2022	One proposed role of NHE3 relates to furosemide-induced urinary acidification.	Furosemide	37-47	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	21-25
9691010-2	1998	In addition, the expression of the furosemide-sensitive type 1 Na-K-2Cl cotransporter (BSC-1) and the natriuretic response to an intravenous test dose furosemide (7.5 mg/kg) during acute V2-receptor blockade was measured.	Furosemide	35-45	solute carrier family 12 member 1	Rattus norvegicus	87-92
34599018-10	2021	Of those, the increases of plasma kynurenic acid exposure are comparable to the increases of furosemide by OAT1/3 inhibition.	Furosemide	93-103	potassium two pore domain channel subfamily K member 3	Homo sapiens	107-113
34988469-7	2021	We found that furosemide sensitive sodium transport (NKCC2) is only increased during late pregnancy, thiazide sensitive sodium transport (NDCBE/pendrin) is increased in all stages of pregnancy, and that benzamil sensitive sodium transport (ENaC) is increased beginning in mid-pregnancy.	Furosemide	14-24	solute carrier family 12 member 1	Rattus norvegicus	53-58
34114742-1	2021	AIM: The phosphorylation level of the furosemide-sensitive Na+ -K+ -2Cl- cotransporter (NKCC2) in the thick ascending limb (TAL) is used as a surrogate marker for NKCC2 activation and TAL function.	Furosemide	38-48	solute carrier family 12, member 1	Mus musculus	88-93
2253658-4	1990	The rises in urinary 6-keto-PGF1 alpha and PGE2, and plasma AII after furosemide were prevented by the captopril pretreatment.	Furosemide	70-80	angiotensinogen	Homo sapiens	60-63
2253658-6	1990	The data indicate that the effect of furosemide on PGI2 production, as reflected by the urinary excretion of 6-keto-PGF1 alpha, was mediated by an action of AII.	Furosemide	37-47	angiotensinogen	Homo sapiens	157-160
8418022-0	1993	Time course of stimulation of renal renin messenger RNA by furosemide.	Furosemide	59-69	renin	Rattus norvegicus	36-41
8418022-3	1993	In the first series, Sprague-Dawley rats received furosemide (10 mg/kg) intraperitoneally and a low sodium diet (0.05% sodium); renin secretion was significantly stimulated at 8 or 16 hours after treatment, but renin mRNA levels did not change.	Furosemide	50-60	renin	Rattus norvegicus	128-133
8418022-6	1993	In additional animals, the response of renin mRNA 4 hours after furosemide was found not to be potentiated by the converting enzyme inhibitor quinapril (5 mg/kg).	Furosemide	64-74	renin	Rattus norvegicus	39-44
34851962-9	2021	RESULTS: By including 13 studies with 422 participants, the meta-analysis revealed that furosemide with albumin co-administration increased urine output by 31.45 ml/hour and increased urine excretion by 1.76 mEq/hour in comparison to furosemide treatment alone.	Furosemide	234-244	albumin	Homo sapiens	104-111
34851962-10	2021	The diuretic effect of albumin and furosemide co-administration was better in participants with low baseline serum albumin levels (< 2.5 g/dL) and high prescribed albumin infusion doses (> 30 g), and the effect was more significant within 12 hours after administration.	Furosemide	35-45	albumin	Homo sapiens	115-122
34851962-10	2021	The diuretic effect of albumin and furosemide co-administration was better in participants with low baseline serum albumin levels (< 2.5 g/dL) and high prescribed albumin infusion doses (> 30 g), and the effect was more significant within 12 hours after administration.	Furosemide	35-45	albumin	Homo sapiens	163-170
34851962-12	2021	CONCLUSION: Co-administration of furosemide with albumin might enhance diuresis and natriuresis effects than furosemide treatment alone but with high heterogeneity in treatment response.	Furosemide	33-43	albumin	Homo sapiens	49-56
34851962-13	2021	According to the present meta-analysis, combination therapy might provide advantages compared to the furosemide therapy alone in patients with baseline albumin levels lower than 2.5 g/dL or in patients receiving higher albumin infusion doses or in patients with impaired renal function.	Furosemide	101-111	albumin	Homo sapiens	152-159
34851962-13	2021	According to the present meta-analysis, combination therapy might provide advantages compared to the furosemide therapy alone in patients with baseline albumin levels lower than 2.5 g/dL or in patients receiving higher albumin infusion doses or in patients with impaired renal function.	Furosemide	101-111	albumin	Homo sapiens	219-226
34288546-6	2021	Patients treated with furosemide plus HSS compared with controls treated with furosemide alone showed a comparable degree of reduction in the serum levels of interleukin (IL)-6, soluble suppression of tumorigenicity 2 (sST2), and N-terminal pro-brain natriuretic peptide (NT-proBNP) in the "between-group" analysis.	Furosemide	78-88	interleukin 6	Homo sapiens	158-176
34107482-4	2021	Incomplete dRTA (idRTA) is defined as impaired urinary acidification that does not lead to overt metabolic acidosis and therefore can be diagnosed if patients fail to adequately acidify urine after an ammonium chloride (NH4Cl) challenge or furosemide and fludrocortisone test.	Furosemide	240-250	rta	Drosophila melanogaster	11-15
35635321-10	2022	Compared to vehicle, chronic furosemide treatment in control mice resulted in greater NKCC2 and lower Npt2a abundances, effects that were absent in NHE3TAL-KO mice.	Furosemide	29-39	solute carrier family 12, member 1	Mus musculus	86-91
35635321-10	2022	Compared to vehicle, chronic furosemide treatment in control mice resulted in greater NKCC2 and lower Npt2a abundances, effects that were absent in NHE3TAL-KO mice.	Furosemide	29-39	solute carrier family 34 (sodium phosphate), member 1	Mus musculus	102-107
35635321-11	2022	In summary, NHE3 in the TAL plays a role for the sustained acidification effect of furosemide.	Furosemide	83-93	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	12-16
35508593-3	2022	METHODS: Physiologically based pharmacokinetic models were constructed for four OAT1/3 substrates in healthy individuals: acyclovir, meropenem, furosemide, and ciprofloxacin.	Furosemide	144-154	solute carrier family 22 member 6	Homo sapiens	80-86
35163352-13	2022	The NKCC1 inhibitor furosemide showed a weaker effect on ejection fraction in isolated renal lymphatics of PAN vs controls.	Furosemide	20-30	solute carrier family 12 member 2	Rattus norvegicus	4-9
35557955-0	2022	Multiple Poses and Thermodynamics of Ligands Targeting Protein Surfaces: The Case of Furosemide Binding to mitoNEET in Aqueous Solution.	Furosemide	85-95	CDGSH iron sulfur domain 1	Homo sapiens	107-115
35557955-6	2022	This is the X-ray structure of furosemide bound to oxidized mitoNEET.	Furosemide	31-41	CDGSH iron sulfur domain 1	Homo sapiens	60-68
35557955-7	2022	Here we employ an enhanced sampling approach, Localized Volume-based Metadynamics, developed by some of us, to identify binding poses of furosemide to human mitoNEET protein in solution.	Furosemide	137-147	CDGSH iron sulfur domain 1	Homo sapiens	157-165
35631326-5	2022	LOS and FUR showed the high affinity for human serum albumin, and the binding reactions between them were spontaneous and exothermic.	Furosemide	8-11	albumin	Homo sapiens	47-60
35392272-0	2022	The Acute Effects of Furosemide on Na-K-Cl Cotransporter-1, Fetuin-A and Pigment Epithelium-Derived Factor in the Guinea Pig Cochlea.	Furosemide	21-31	alpha-2-HS-glycoprotein	Cavia porcellus	60-68
35392272-0	2022	The Acute Effects of Furosemide on Na-K-Cl Cotransporter-1, Fetuin-A and Pigment Epithelium-Derived Factor in the Guinea Pig Cochlea.	Furosemide	21-31	pigment epithelium-derived factor	Cavia porcellus	73-106
35392272-11	2022	Furosemide induced an increased staining intensity of Fetuin-A at 120 min.	Furosemide	0-10	alpha-2-HS-glycoprotein	Cavia porcellus	54-62
35392272-14	2022	Furosemide induced an increased staining intensity of PEDF in type I neurons and pillar cells after 120 min.	Furosemide	0-10	pigment epithelium-derived factor	Cavia porcellus	54-58
35392272-17	2022	Fetuin-A and PEDF are present in many cells of the cochlea and probably increase after furosemide exposure, possibly as an otoprotective response.	Furosemide	87-97	alpha-2-HS-glycoprotein	Cavia porcellus	0-8
35392272-17	2022	Fetuin-A and PEDF are present in many cells of the cochlea and probably increase after furosemide exposure, possibly as an otoprotective response.	Furosemide	87-97	pigment epithelium-derived factor	Cavia porcellus	13-17
35239032-5	2022	We conducted a systematic review with the objective of evaluating the change in urine volume and urine sodium excretion after treatment with furosemide only versus furosemide with albumin in edematous patients with NS.	Furosemide	164-174	albumin	Homo sapiens	180-187
35239032-6	2022	OBJECTIVES: (1) To evaluate efficacy of furosemide alone versus furosemide with albumin in the treatment of nephrotic edema in adults and children.	Furosemide	64-74	albumin	Homo sapiens	80-87
35163352-14	2022	High sodium within the renal interstitium following proteinuric injury is associated with impaired renal lymphatic pumping that may, in part, involve the SPAK-NKCC1-eNOS pathway, which may contribute to sodium retention and reduce lymphatic responsiveness to furosemide.	Furosemide	259-269	serine threonine kinase 39	Rattus norvegicus	154-158
35163352-14	2022	High sodium within the renal interstitium following proteinuric injury is associated with impaired renal lymphatic pumping that may, in part, involve the SPAK-NKCC1-eNOS pathway, which may contribute to sodium retention and reduce lymphatic responsiveness to furosemide.	Furosemide	259-269	solute carrier family 12 member 2	Rattus norvegicus	159-164
35163352-14	2022	High sodium within the renal interstitium following proteinuric injury is associated with impaired renal lymphatic pumping that may, in part, involve the SPAK-NKCC1-eNOS pathway, which may contribute to sodium retention and reduce lymphatic responsiveness to furosemide.	Furosemide	259-269	nitric oxide synthase 3	Rattus norvegicus	165-169
2686391-0	1989	Attenuation of the pressor response to intravenous furosemide by angiotensin converting enzyme inhibition in congestive heart failure.	Furosemide	51-61	angiotensin I converting enzyme	Homo sapiens	65-94
2615191-6	1989	In further studies, the effects of ouabain (10(-3) M), furosemide (10(-4) M) or acidosis (pH 7.0 rather than the usual pH 7.4) on TAL transport activity and adenine nucleotide levels were compared.	Furosemide	55-65	leucine rich repeat and sterile alpha motif containing 1	Homo sapiens	130-133
2532921-4	1989	Frusemide increased natriuresis (UNaV), kaliuresis (UKV), inulin clearance and plasma renin activity (PRA) and ramipril pretreatment significantly enhanced these effects suggesting that the acute generation of angiotensin II (AII) may attenuate these actions of intravenous frusemide.	Furosemide	0-9	angiotensinogen	Homo sapiens	210-224
2532921-4	1989	Frusemide increased natriuresis (UNaV), kaliuresis (UKV), inulin clearance and plasma renin activity (PRA) and ramipril pretreatment significantly enhanced these effects suggesting that the acute generation of angiotensin II (AII) may attenuate these actions of intravenous frusemide.	Furosemide	274-283	angiotensinogen	Homo sapiens	210-224
2532921-15	1989	AII may therefore inhibit the rise in urinary dopamine excretion after frusemide.	Furosemide	71-80	angiotensinogen	Homo sapiens	0-3
2553866-3	1989	When the effect of rANP was investigated on in vitro 22Na+ uptake into isolated cerebral capillaries, 10(-7) M rANP significantly inhibited the uptake in the presence of 1.0 mM ouabain, 1.0 mM furosemide, and 2.0 mM LiCl in the uptake buffer, a finding suggesting a specific inhibitory effect of rANP on amiloride-sensitive Na+ transport.	Furosemide	193-203	natriuretic peptide A	Rattus norvegicus	111-115
2553866-3	1989	When the effect of rANP was investigated on in vitro 22Na+ uptake into isolated cerebral capillaries, 10(-7) M rANP significantly inhibited the uptake in the presence of 1.0 mM ouabain, 1.0 mM furosemide, and 2.0 mM LiCl in the uptake buffer, a finding suggesting a specific inhibitory effect of rANP on amiloride-sensitive Na+ transport.	Furosemide	193-203	natriuretic peptide A	Rattus norvegicus	111-115
2586018-0	1989	Interference of different ACE-inhibitors with the diuretic action of furosemide and hydrochlorothiazide.	Furosemide	69-79	angiotensin I converting enzyme	Homo sapiens	26-29
2615191-8	1989	Addition of ouabain or furosemide reduced CH2O and TAL necrosis in parallel while acidosis had no effect on CH2O during perfusion.	Furosemide	23-33	leucine rich repeat and sterile alpha motif containing 1	Homo sapiens	51-54
2534930-0	1989	[Effect of furosemide on the plasma level of atrial natriuretic peptide (ANP) in healthy persons and in patients with uncomplicated primary arterial hypertension].	Furosemide	11-21	natriuretic peptide A	Homo sapiens	45-71
2677316-0	1989	Caffeine potentiates the renin response to furosemide in rats.	Furosemide	43-53	renin	Rattus norvegicus	25-30
2677316-6	1989	We therefore wanted to determine if: 1) adenosine modulates furosemide-induced renin release and 2) sodium-chloride reabsorption at the macula densa is essential for adenosine actions.	Furosemide	60-70	renin	Rattus norvegicus	79-84
2677316-9	1989	In the vehicle group, furosemide increased urinary volume, sodium and potassium excretion and increased plasma renin activity from 6 +/- 1 to 45 +/- 11 ngAl/ml/hr.	Furosemide	22-32	renin	Rattus norvegicus	111-116
2677316-10	1989	Caffeine and 1,3-dipropyl-8-(p-sulfophenyl)xanthine potentiated the increase in plasma renin activity produced by furosemide (to 120 +/- 15 and 147 +/- 21 ng Al/ml/hr, respectively), whereas having no significant effects on urinary volume, sodium excretion or blood pressure.	Furosemide	114-124	renin	Rattus norvegicus	87-92
2677316-11	1989	These results suggest that furosemide-induced renin release in vivo is restrained by endogenous adenosine.	Furosemide	27-37	renin	Rattus norvegicus	46-51
2809941-5	1989	Compared to a group of similarly fed VLBW infants without BPD and not treated with the diuretic, the furosemide-treated infants excreted a larger percent of the calcium intake in the urine but had similar total urinary calcium and phosphorus losses (mg/kg/day) and serum calcium, phosphorus, alkaline phosphatase, and parathyroid hormone (PTH) levels.	Furosemide	101-111	parathyroid hormone	Homo sapiens	318-337
2534930-0	1989	[Effect of furosemide on the plasma level of atrial natriuretic peptide (ANP) in healthy persons and in patients with uncomplicated primary arterial hypertension].	Furosemide	11-21	natriuretic peptide A	Homo sapiens	73-76
2534930-4	1989	A significant decrease in ANP plasma levels was noted in all examined individuals following furosemide administration in all time intervals comparing with baseline values.	Furosemide	92-102	natriuretic peptide A	Homo sapiens	26-29
2534930-5	1989	An increase in 1-minute urine output and 1-minute sodium excretion with the urine significantly correlated with plasma ANP decrease during 90 minutes following furosemide administration.	Furosemide	160-170	natriuretic peptide A	Homo sapiens	119-122
2534930-6	1989	The obtained results suggest that furosemide inhibits ANP secretion in the patients with uncomplicated primary hypertension similarly to healthy individuals.	Furosemide	34-44	natriuretic peptide A	Homo sapiens	54-57
2792351-4	1989	It was also found that furosemide and ethacrynic acid by binding to human serum albumin molecule produce its conformational alterations.	Furosemide	23-33	albumin	Homo sapiens	80-87
2498379-7	1989	The binding of T4 to apoA-I was reduced by known inhibitors of T4 binding to serum proteins (diclofenac = mefenamic acid = furosemide = 8-anilinonaphthalene sulfonic acid much greater than dilantin greater than heparin greater than barbital) and by lipids (unsaturated fatty acids greater than cholesterol = cholesterol esters = phospholipids greater than saturated fatty acids = diglycerides = triglycerides).	Furosemide	123-133	apolipoprotein A1	Homo sapiens	21-27
2498384-8	1989	In contrast, furosemide, the drug most highly reactive with TBG, was only 0.11 +/- 0.03% (n = 7) as potent as T4, followed by meclofenamic acid greater than mefenamic acid greater than fenclofenac greater than flufenamic acid greater than diflunisal greater than milrinone.	Furosemide	13-23	serpin family A member 7	Homo sapiens	60-63
2732945-5	1989	Angiotensin II blockade with saralasin (2 micrograms/kg/min) prevented the fall in medullary plasma flow in indomethacin-treated rats during furosemide infusion but did not alter mean arterial pressure, inulin clearance or total renal blood flow.	Furosemide	141-151	angiotensinogen	Rattus norvegicus	0-14
2655681-8	1989	Plasma renin activity was increased acutely by both doses of frusemide and by bumetanide (2.5 mg) compared with placebo and to bumetanide (250 micrograms).	Furosemide	61-70	renin	Homo sapiens	7-12
2655691-9	1989	Significant increments in plasma renin activity, which were suppressed by all treatments, were observed after frusemide.	Furosemide	110-119	renin	Homo sapiens	33-38
2655691-13	1989	In the presence of frusemide, indomethacin had more anti-natriuretic and renin-suppressing effect than ibuprofen.	Furosemide	19-28	renin	Homo sapiens	73-78
2539125-3	1989	This action of ANP was mimicked by 8-bromo-cGMP and completely diminished by furosemide.	Furosemide	77-87	natriuretic peptide A	Bos taurus	15-18
2655681-10	1989	Angiotensin II was increased significantly 30 min after frusemide 100 mg and bumetanide 2.5 mg, and by all four treatments at 50 min when compared with placebo.	Furosemide	56-65	angiotensinogen	Homo sapiens	0-14
2655681-14	1989	Frusemide 100 mg and bumetanide 2.5 mg have the same effects on the renal vasculature and the renin-angiotensin-prostaglandin system.	Furosemide	0-9	renin	Homo sapiens	94-99
2655681-15	1989	Under the conditions of this study, frusemide 10 mg had different effects on plasma renin activity than bumetanide 250 micrograms.	Furosemide	36-45	renin	Homo sapiens	84-89
2521333-0	1989	Atrial natriuretic factor inhibits isoproterenol- and furosemide-stimulated renin release in humans.	Furosemide	54-64	renin	Homo sapiens	76-81
2543544-2	1989	Hyporeninemic hypoaldosteronism was disclosed on the basis of a lack of response of plasma renin activity to furosemide administration or tilting with marked hypotension and a subnormal response of aldosterone to furosemide stimulation, tilting, angiotensin II infusion and ACTH administration, as well as increased vascular responsiveness to angiotensin II infusion.	Furosemide	109-119	renin	Homo sapiens	4-9
2543544-2	1989	Hyporeninemic hypoaldosteronism was disclosed on the basis of a lack of response of plasma renin activity to furosemide administration or tilting with marked hypotension and a subnormal response of aldosterone to furosemide stimulation, tilting, angiotensin II infusion and ACTH administration, as well as increased vascular responsiveness to angiotensin II infusion.	Furosemide	213-223	renin	Homo sapiens	4-9
2919032-9	1989	This was confirmed by the exaggerated response to frusemide reflected by urinary flow measurements in patients with a creatinine clearance of 10 ml min-1 or less.	Furosemide	50-59	CD59 molecule (CD59 blood group)	Homo sapiens	148-153
2645910-3	1989	Reduction of renal perfusion pressure, intravenous infusion of furosemide, and captopril administration cause a greater increase in renin release from innervated kidneys than from denervated kidneys.	Furosemide	63-73	renin	Homo sapiens	132-137
2566466-8	1989	Although the fraction unbound of furosemide was unchanged between treatments (0.770 for treatment I vs. 0.695% for treatment II), the renal and secretion clearances of furosemide were reduced by about 30% in the presence of angiotensin II.	Furosemide	168-178	angiotensinogen	Rattus norvegicus	224-238
2792172-2	1989	Decreased renal sensitivity to frusemide was found in only one patient, who also had hypovolaemia and an activated renin-angiotensin-aldosterone system.	Furosemide	31-40	renin	Homo sapiens	115-120
2510079-4	1989	Furosemide injection resulted in increases of all variables, albeit that PAI and PAII were elevated to a lesser extent then PRA.	Furosemide	0-10	serpin family E member 1	Homo sapiens	73-76
2654919-3	1989	An acute furosemide test made it possible to establish 3 types of responses of vasopressin secretion in such patients: normal, paradoxical and areactive.	Furosemide	9-19	arginine vasopressin	Homo sapiens	79-90
2787038-3	1989	The effects of CGRP were nearly abolished in chloride-free solutions or after treatment with furosemide.	Furosemide	93-103	calcitonin related polypeptide alpha	Homo sapiens	15-19
3061717-0	1988	Effects of frusemide and captopril on the relationship between biologically and immunologically active renin in human plasma.	Furosemide	11-20	renin	Homo sapiens	103-108
2521333-4	1989	Atrial natriuretic factor abolished the rise in plasma renin activity caused by isoproterenol (p = 0.003) and significantly (p = 0.048) attenuated the rise in plasma renin activity after a bolus injection of furosemide.	Furosemide	208-218	renin	Homo sapiens	55-60
2521333-4	1989	Atrial natriuretic factor abolished the rise in plasma renin activity caused by isoproterenol (p = 0.003) and significantly (p = 0.048) attenuated the rise in plasma renin activity after a bolus injection of furosemide.	Furosemide	208-218	renin	Homo sapiens	166-171
2855542-2	1988	Each measurement was repeated before and after stimulation of renin activity induced by furosemide.	Furosemide	88-98	renin	Homo sapiens	62-67
3148912-3	1988	The addition of albumin (45 g/l) abolished the furosemide response whereas the nitroglycerin response was unaffected.	Furosemide	47-57	albumin	Oryctolagus cuniculus	16-23
3148912-4	1988	Similarly the pronounced effect of nitroglycerin on electrically evoked contractions was unaffected by the presence of albumin whereas the furosemide effect was weakened by albumin.	Furosemide	139-149	albumin	Oryctolagus cuniculus	173-180
3220046-5	1988	However, plasma renin activity (PRA) was normal or slightly high, and responded normally to furosemide-upright stimulation and fluorohydrocortisone suppression.	Furosemide	92-102	renin	Homo sapiens	16-21
2972152-1	1988	The effects of an oral water load and iv administration of isotonic glucose, hypertonic saline, mannitol and furosemide on release of human atrial natriuretic peptide (hANP) were examined in normal subjects to determine the main factors causing its release.	Furosemide	109-119	natriuretic peptide A	Homo sapiens	168-172
2972152-5	1988	The plasma hANP level decreased from 17.3 +/- 2.5 to 9.0 +/- 2.5 ng/l after injection of 40 mg of furosemide.	Furosemide	98-108	natriuretic peptide A	Homo sapiens	11-15
3238049-6	1988	GRP-induced Isc increases were halved by serosal furosemide (0.3 mM) and reduced by 65% and 90% in tissue bathing solutions lacking Cl- or Cl- and HCO3-, respectively.	Furosemide	49-59	gastrin releasing peptide	Homo sapiens	0-3
2967740-9	1988	A single oral dose of the diuretic furosemide increased angiotensin I significantly from 21 (+/- 1) to 32 (+/- 1.7) pmol/L (n = 5); P less than 0.001), whereas angiotensin II remained unchanged, 6.6 (+/- 0.5) vs 6.4 (+/- 0.4) pmol/L (n = 5).	Furosemide	35-45	angiotensinogen	Homo sapiens	56-69
3073092-3	1988	So, for instance, drugs that increase prostaglandins synthesis as colchicine or furosemide inhibit insulin secretion while non steroid anti-inflammator drugs, mainly salicylates, which inhibit cyclo-oxygenase, enhance the insulin response to various stimuli.	Furosemide	80-90	insulin	Homo sapiens	99-106
3134540-0	1988	Effect of cyclooxygenase inhibition on the pulmonary vasodilator response to furosemide.	Furosemide	77-87	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	10-24
3134540-11	1988	We conclude that: 1) the vasodilatory activity of furosemide is mediated by increased production and not decreased metabolism of an endogenous cyclooxygenase product; 2) the effect of prostacyclin on vascular reactivity is similar to that of furosemide; and 3) local formation of prostacyclin by vascular tissue most likely mediates the vascular activity of furosemide.	Furosemide	50-60	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	143-157
2967740-9	1988	A single oral dose of the diuretic furosemide increased angiotensin I significantly from 21 (+/- 1) to 32 (+/- 1.7) pmol/L (n = 5); P less than 0.001), whereas angiotensin II remained unchanged, 6.6 (+/- 0.5) vs 6.4 (+/- 0.4) pmol/L (n = 5).	Furosemide	35-45	angiotensinogen	Rattus norvegicus	160-174
3341836-1	1988	Thirty-five patients with severe chronic congestive heart failure that was refractory to conventional therapy were given high dosages of furosemide (250 to 4000 mg/d) because of significantly reduced renal function (mean endogenous creatinine clearance, 0.53 mL/s/1.73 m2 [32 mL/min/1.73 m2]).	Furosemide	137-147	CD59 molecule (CD59 blood group)	Homo sapiens	279-284
3277563-3	1988	We studied the renin-aldosterone response to intravenous furosemide (60 mg) and upright posture and the renin response to converting enzyme inhibition (captopril, 50 mg) and upright posture in five patients with SLE and hyperkalemia (group 1) and five normokalemic patients with SLE (group 2).	Furosemide	57-67	renin	Homo sapiens	15-20
3284821-0	1988	Role of angiotensin II in renal prostaglandin E2 production after furosemide administration.	Furosemide	66-76	angiotensinogen	Homo sapiens	8-22
3284821-1	1988	The role of plasma angiotensin II (Ang II) in furosemide-stimulated renal prostaglandin E2 (PGE2) production was evaluated in eight healthy subjects.	Furosemide	46-56	angiotensinogen	Homo sapiens	19-33
3284821-1	1988	The role of plasma angiotensin II (Ang II) in furosemide-stimulated renal prostaglandin E2 (PGE2) production was evaluated in eight healthy subjects.	Furosemide	46-56	angiotensinogen	Homo sapiens	35-41
3284821-5	1988	Urinary PGE2 excretion, PRA, and Ang II increased after furosemide administration without captopril pretreatment, and there was a significant correlation between the increment in Ang II and that in urinary PGE2 excretion.	Furosemide	56-66	angiotensinogen	Homo sapiens	33-39
3284821-5	1988	Urinary PGE2 excretion, PRA, and Ang II increased after furosemide administration without captopril pretreatment, and there was a significant correlation between the increment in Ang II and that in urinary PGE2 excretion.	Furosemide	56-66	angiotensinogen	Homo sapiens	179-185
3284821-8	1988	These results suggest that Ang II may play an important role in furosemide-stimulated PGE2 production.	Furosemide	64-74	angiotensinogen	Homo sapiens	27-33
3386517-1	1988	We have studied the effects of two diuretics, selective for renal cortical (furosemide) and inner medullary (vasopressin antagonist) water handling, in rat kidney at 1.5 T and find that furosemide completely dissipates the cortical-inner medullary T2 gradient whereas the vasopressin antagonist has little effect.	Furosemide	186-196	arginine vasopressin	Rattus norvegicus	109-120
3386517-1	1988	We have studied the effects of two diuretics, selective for renal cortical (furosemide) and inner medullary (vasopressin antagonist) water handling, in rat kidney at 1.5 T and find that furosemide completely dissipates the cortical-inner medullary T2 gradient whereas the vasopressin antagonist has little effect.	Furosemide	186-196	arginine vasopressin	Rattus norvegicus	272-283
3064599-12	1988	In conclusion, furosemide modulates coronary reserve, and it is likely that this is because furosemide mediates activation of renin-angiotensin system, thus reducing the vasodilatory capacity of the coronary arteries.	Furosemide	15-25	renin	Homo sapiens	126-131
3064599-12	1988	In conclusion, furosemide modulates coronary reserve, and it is likely that this is because furosemide mediates activation of renin-angiotensin system, thus reducing the vasodilatory capacity of the coronary arteries.	Furosemide	92-102	renin	Homo sapiens	126-131
3346341-4	1988	When the rate of 86Rb+ efflux (as a tracer for K+) was measured from each of the three cell lines, a furosemide- and TPA-inhibitable component of efflux was clearly evident in parental and TNR-9 cells but was virtually absent in TNR-2 cells.	Furosemide	101-111	tenascin R	Mus musculus	189-192
3346341-4	1988	When the rate of 86Rb+ efflux (as a tracer for K+) was measured from each of the three cell lines, a furosemide- and TPA-inhibitable component of efflux was clearly evident in parental and TNR-9 cells but was virtually absent in TNR-2 cells.	Furosemide	101-111	tenascin R	Mus musculus	229-232
3346341-5	1988	86Rb+ influx measurements indicated the presence in parental 3T3 cells and the TNR-9 line of a substantial furosemide-sensitive flux that could be inhibited by TPA.	Furosemide	107-117	tenascin R	Mus musculus	79-82
3346341-6	1988	In contrast, much less furosemide-sensitive influx was present in 3T3-TNR-2 cells and it was relatively unaffected by TPA.	Furosemide	23-33	tenascin R	Mus musculus	70-73
3346341-7	1988	In both parental 3T3 and 3T3-TNR-2 cells, most of the furosemide-sensitive 86Rb+ influx is dependent on extracellular Na+ and Cl-.	Furosemide	54-64	tenascin R	Mus musculus	29-32
2826469-11	1988	After exposure to fMLP, protein I-treated neutrophils underwent a furosemide-sensitive hyperpolarization rather than the usual depolarization.	Furosemide	66-76	formyl peptide receptor 1	Homo sapiens	18-22
2826469-11	1988	After exposure to fMLP, protein I-treated neutrophils underwent a furosemide-sensitive hyperpolarization rather than the usual depolarization.	Furosemide	66-76	annexin A2	Homo sapiens	24-33
2828800-4	1988	Administration of furosemide to rats for five days resulted in a profound diuresis (approximately equal to 350% increase in urine volume) accompanied by a significant increase in PBR density (43%) that was apparent by the fifth day of treatment.	Furosemide	18-28	translocator protein	Rattus norvegicus	179-182
3060993-8	1988	It is proposed that activation of the sympathetic nervous system and/or the renin-angiotensin-aldosterone system may play a role in mediating the acute tolerance to furosemide diuresis.	Furosemide	165-175	renin	Homo sapiens	76-81
2960866-5	1987	Intravenous injection of saline elevated circulating ANF, whereas acute volume depletion by hemorrhage, water deprivation and furosemide diuresis greatly lowered plasma ANF.	Furosemide	126-136	natriuretic peptide A	Rattus norvegicus	169-172
2963164-9	1987	Pretreatment of rabbits with furosemide for two days before experiments resulted in greater basal renin release rates from microdissected afferent arterioles (1.70 +/- 0.35 ng AI.hr-1.Af-1/hr, N = 14).	Furosemide	29-39	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	98-103
2822455-2	1987	In the submitted paper the influence of therapeutic doses of the calmodulin inhibitor, trifluoperazine, on aldosterone and cortisol secretion stimulated by ACTH or by activation of endogenous angiotensin by furosemide was investigated in healthy subjects.	Furosemide	207-217	calmodulin 1	Homo sapiens	65-75
3694431-5	1987	On the basis of the results, it was demonstrated that disposition of furosemide in man can be described by a two-compartment open model with the following average parameters: t1/2 alpha = 0.237 +/- 0.069 h, t1/2 beta = 1.29 +/- 0.20 h and Vss = 8.46 +/- 2.171.	Furosemide	69-79	interleukin 1 receptor like 1	Homo sapiens	207-223
3555065-4	1987	Renin/aldosterone stimulation testing was performed by intravenous injection of 80 mg of furosemide followed by four hours of upright posture.	Furosemide	89-99	renin	Homo sapiens	0-5
2832173-6	1988	Addition of frusemide to enalapril therapy resulted in a greater fall in mean blood pressure (87 +/- 5 mmHg to 79 +/- 4 mmHg; P less than 0.01) and an increase in cardiac output (3.1 +/- 1.1 l min-1 to 3.6 +/- 1.0 l min-1; P less than 0.02).	Furosemide	12-21	CD59 molecule (CD59 blood group)	Homo sapiens	193-198
2832173-6	1988	Addition of frusemide to enalapril therapy resulted in a greater fall in mean blood pressure (87 +/- 5 mmHg to 79 +/- 4 mmHg; P less than 0.01) and an increase in cardiac output (3.1 +/- 1.1 l min-1 to 3.6 +/- 1.0 l min-1; P less than 0.02).	Furosemide	12-21	CD59 molecule (CD59 blood group)	Homo sapiens	216-221
3276725-4	1988	Four of the 5 diabetic patients whose PRA failed to rise to the usual level after furosemide treatment attained a plasma prorenin level higher than any normal subject, suggesting that furosemide stimulated synthesis and secretion of prorenin, but that conversion of prorenin to active renin was impaired.	Furosemide	184-194	renin	Homo sapiens	124-129
2973989-0	1988	Frusemide pretreatment blunts the inhibition of renal tubular sodium reabsorption by ANF in man.	Furosemide	0-9	natriuretic peptide A	Homo sapiens	85-88
2973989-5	1988	In contrast, after frusemide pretreatment, ANF caused an increase in water excretion (urinary flow rate) but no change in sodium excretion.	Furosemide	19-28	natriuretic peptide A	Homo sapiens	43-46
2853446-2	1988	The role of the renin-angiotensin-aldosterone system in the development of tolerance to the diuretic effect of furosemide was investigated in 12 healthy male volunteers.	Furosemide	111-121	renin	Homo sapiens	16-21
3506626-1	1987	Changes in plasma active and inactive renin and angiotensin II in response to tilt and intravenous frusemide were assessed in ten patients with essential hypertension, before treatment and again during chronic therapy with the alpha 1-adrenoceptor antagonist prazosin.	Furosemide	99-108	renin	Homo sapiens	38-43
3506626-1	1987	Changes in plasma active and inactive renin and angiotensin II in response to tilt and intravenous frusemide were assessed in ten patients with essential hypertension, before treatment and again during chronic therapy with the alpha 1-adrenoceptor antagonist prazosin.	Furosemide	99-108	angiotensinogen	Homo sapiens	48-62
3506626-3	1987	Both before and during prazosin, tilt and frusemide each led to significant elevation of plasma active renin (P less than 0.001) and angiotensin II (P less than 0.05).	Furosemide	42-51	renin	Homo sapiens	103-108
3506626-3	1987	Both before and during prazosin, tilt and frusemide each led to significant elevation of plasma active renin (P less than 0.001) and angiotensin II (P less than 0.05).	Furosemide	42-51	angiotensinogen	Homo sapiens	133-147
3506626-4	1987	Inactive renin tended to fall with tilt, and fell significantly following frusemide (P less than 0.05).	Furosemide	74-83	renin	Homo sapiens	9-14
3653395-4	1987	Furosemide but not tetraethylammonium inhibited the gastrin-induced depolarization.	Furosemide	0-10	gastrin	Homo sapiens	52-59
3652622-7	1987	Indomethacin attenuated the natriuretic and renin responses to frusemide, but did not alter urine dopamine output.	Furosemide	63-72	renin	Homo sapiens	44-49
2956192-4	1987	Volume contraction induced by furosemide treatment of chronic water restriction significantly reduced the circulating immunoreactive ANF.	Furosemide	30-40	natriuretic peptide A	Rattus norvegicus	133-136
3032710-1	1987	Renin secretion was stimulated in rats by adrenalectomy (ADX), by treatment with the converting enzyme inhibitor enalapril (MK 421), or by feeding a low salt diet plus furosemide treatment (FUR).	Furosemide	168-178	renin	Rattus norvegicus	0-5
3828657-10	1987	AII responses were totally inhibited by the chloride channel blocker, diphenylamine-2-carboxylate (DPC) while cotransport inhibitors e.g. piretanide and frusemide significantly reduced the size of AII responses in colon and jejunum.	Furosemide	153-162	angiotensinogen	Rattus norvegicus	0-3
3828657-10	1987	AII responses were totally inhibited by the chloride channel blocker, diphenylamine-2-carboxylate (DPC) while cotransport inhibitors e.g. piretanide and frusemide significantly reduced the size of AII responses in colon and jejunum.	Furosemide	153-162	angiotensinogen	Rattus norvegicus	197-200
3549504-5	1987	Serum renin and serum aldosterone correlated mutually before and after intravenous furosemide.	Furosemide	83-93	renin	Homo sapiens	6-11
3296006-2	1987	PGI2 may mediate, in part, the early increment in plasma renin activity (PRA) after furosemide.	Furosemide	84-94	renin	Rattus norvegicus	57-62
3296006-3	1987	We hypothesized that thromboxane synthetase inhibition should direct prostaglandin endoperoxide metabolism toward PGI2, thereby enhancing the effects of furosemide on renin release.	Furosemide	153-163	renin	Rattus norvegicus	167-172
3326401-8	1987	In DI rats was found a paradoxical antidiuretic effect of furanthril after either an acute or chronic treatment, which was attributed to the per se stimulated renin-angiotensin system and suppressed PG-synthesis typical for these rats.	Furosemide	58-68	renin	Rattus norvegicus	159-164
3324714-0	1987	Diminution by captopril of the diuretic, natriuretic and kallikrein stimulating action of furosemide by reduction in its renal secretion.	Furosemide	90-100	kallikrein related peptidase 4	Homo sapiens	57-67
3324714-6	1987	After furosemide injection changes in plasma aldosterone concentration paralleled changes in renal kallikrein and kinin excretion.	Furosemide	6-16	kallikrein related peptidase 4	Homo sapiens	99-109
3324714-7	1987	However, after captopril there was a sharp dissociation between aldosterone, which was diminished by captopril continuously, and renal kallikrein and kinins, which were still stimulated by furosemide.	Furosemide	189-199	kallikrein related peptidase 4	Homo sapiens	135-145
3324714-8	1987	These results suggest that renal kallikrein-kinin system is stimulated by furosemide directly and independently of aldosterone secretion.	Furosemide	74-84	kallikrein related peptidase 4	Homo sapiens	33-43
3105853-0	1987	Effect of cyclooxygenase and thromboxane synthetase inhibition on furosemide-stimulated plasma renin activity.	Furosemide	66-76	renin	Rattus norvegicus	95-100
3105853-1	1987	We studied the effects of a specific thromboxane (TX) synthetase inhibitor (U-63,557A) and a cyclooxygenase inhibitor on furosemide-induced renin release.	Furosemide	121-131	renin	Rattus norvegicus	140-145
3105853-5	1987	Plasma renin activity was measured in blood samples collected 0, 10, 20, and 40 min after the injection of furosemide.	Furosemide	107-117	renin	Rattus norvegicus	7-12
3105853-7	1987	The results demonstrated that plasma renin activity rose with time following furosemide in the various groups of rats; indomethacin suppressed the furosemide-induced increments in plasma renin activity, while U-63,557A at doses of 4-8 mg X kg-1 augmented it.	Furosemide	77-87	renin	Rattus norvegicus	37-42
3105853-7	1987	The results demonstrated that plasma renin activity rose with time following furosemide in the various groups of rats; indomethacin suppressed the furosemide-induced increments in plasma renin activity, while U-63,557A at doses of 4-8 mg X kg-1 augmented it.	Furosemide	147-157	renin	Rattus norvegicus	37-42
3105853-7	1987	The results demonstrated that plasma renin activity rose with time following furosemide in the various groups of rats; indomethacin suppressed the furosemide-induced increments in plasma renin activity, while U-63,557A at doses of 4-8 mg X kg-1 augmented it.	Furosemide	147-157	renin	Rattus norvegicus	187-192
3105853-10	1987	Thus, these experiments suggest that thromboxane synthetase inhibition, within a narrow dosage range, potentiates furosemide-induced renin release while cyclooxygenase inhibition suppresses it.	Furosemide	114-124	renin	Rattus norvegicus	133-138
3107857-9	1987	We conclude that intravenous frusemide administration to a rat reduces sympathetic vasoconstrictor responses of the ex vivo blood perfused tail artery segment by a diuresis-independent but prostaglandin and angiotensin II dependent release of another hormone from the kidney.	Furosemide	29-38	angiotensinogen	Rattus norvegicus	207-221
3549322-6	1987	These results suggest that urinary PGE2 excretion after frusemide administration may be reduced by propranolol and that the mechanism responsible for the effect of propranolol on the frusemide-induced renal PGE2 production may be, at least in part, secondary to inhibition of the renin-angiotensin system.	Furosemide	183-192	renin	Homo sapiens	280-285
3644819-4	1987	The Ca2+ concentration in endolymph was abruptly increased by anoxia or the intravenous administration of 60 mg/kg furosemide and was slightly increased by the intravenous administration of 30 mg/kg furosemide or 100 mg/kg acetazolamide.	Furosemide	115-125	LOW QUALITY PROTEIN: carbonic anhydrase 2	Cavia porcellus	4-7
3644819-4	1987	The Ca2+ concentration in endolymph was abruptly increased by anoxia or the intravenous administration of 60 mg/kg furosemide and was slightly increased by the intravenous administration of 30 mg/kg furosemide or 100 mg/kg acetazolamide.	Furosemide	199-209	LOW QUALITY PROTEIN: carbonic anhydrase 2	Cavia porcellus	4-7
3549580-0	1987	Acute effect of furosemide on renal kallikrein and prostaglandin systems in mild to moderate essential hypertension.	Furosemide	16-26	kallikrein related peptidase 4	Homo sapiens	36-46
3549580-9	1987	In both H and N furosemide caused a significant rise of PRA1 (p less than 0.001 in H and p less than 0.01 in N) and PRA2 (p less than 0.001 in H and p less than 0.05 in N).	Furosemide	16-26	Rab acceptor 1	Homo sapiens	56-60
3600908-4	1987	In the biopsy carried out after the cessation of furosemide intake, these morphological changes were markedly improved with a reduced activity of the renin-angiotensin system.	Furosemide	49-59	renin	Homo sapiens	150-155
3328888-6	1987	The renin secretion rate was increased by furosemide but not by verapamil.	Furosemide	42-52	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	4-9
3099310-3	1986	With the exception of HCT, the other drugs also suppressed the production of thromboxane A2 (IND greater than SPI greater than FUR); lipoxygenase formation of hydroxyeicosatetraenoic acid was also enhanced by SPI and IND.	Furosemide	127-130	chromogranin A	Homo sapiens	209-212
3553421-0	1987	System dynamics modeling of renin aldosterone and electrolyte changes induced by furosemide in hypertensive patients.	Furosemide	81-91	renin	Homo sapiens	28-33
3096336-9	1986	PB, 3-MC and PCN increased F-UDP-GT activity to 208%, 282% and 342% of vehicle-treated animals, respectively, while F pretreatment did not affect the conjugation of F. In comparison, 1-naphthol glucuronidation was preferentially induced by 3-MC (4.4-fold of control) while estrone glucuronidation was induced by PB and PCN (4.9- and 2.5-fold of control, respectively).	Furosemide	27-28	UDP glucuronosyltransferase family 1 member A6	Rattus norvegicus	29-35
2425102-2	1986	Recently, we have shown that aprotinin, a kallikrein inhibitor, inhibits the stimulation of plasma renin activity (PRA) by either furosemide or a low sodium diet.	Furosemide	130-140	renin	Homo sapiens	99-104
3099310-2	1986	All four compounds augmented the synthesis of prostaglandins (PGs) D2 (HCT,FUR), E2 (SPI) and I2 (FUR,IND), probably through facilitated reorientation of endoperoxide biotransformation.	Furosemide	98-101	chromogranin A	Homo sapiens	81-96
2871955-6	1986	The co-administration of other potentially nephrotoxic agents (e.g., gentamicin), the diuretic frusemide, or inhibitors or suppressors of hepatic drug metabolism increases the degree of NAG enzymuria, whilst inducers of drug metabolism (e.g., phenobarbitone) have the reverse effect.	Furosemide	95-104	O-GlcNAcase	Rattus norvegicus	186-189
3528445-3	1986	Twenty children with chronic renal failure never had hyperkalemia, and both renin and aldosterone were normally stimulated by intravenous administration of furosemide, whereas three patients had moderate hyperkalemia (serum potassium concentration between 5.3 and 5.6 mEq/L) and failed to raise plasma renin activity and aldosterone values in response to furosemide.	Furosemide	156-166	renin	Homo sapiens	76-81
3539582-0	1986	Changes in central and peripheral renin-angiotensin system after furosemide injection.	Furosemide	65-75	renin	Canis lupus familiaris	34-39
3539582-2	1986	Administration of furosemide induced marked increases in PRA, Ang I-ir, PAng II-ir and CSF Ang II-ir, however, neither plasma nor CSF angiotensinogen was changed.	Furosemide	18-28	ANG	Canis lupus familiaris	62-65
3539582-2	1986	Administration of furosemide induced marked increases in PRA, Ang I-ir, PAng II-ir and CSF Ang II-ir, however, neither plasma nor CSF angiotensinogen was changed.	Furosemide	18-28	ANG	Canis lupus familiaris	73-76
3023151-5	1986	In 27 DP, plasma renin activity (PRA) increased from 0.8 +/- 0.6 SD to 2.4 +/- 2.2 ng/ml/h (normal: 1.2 +/- 0.7 to 3.2 +/- 1.7 ng/ml/h) 2 hours after intravenous administration of furosemide (1 mg/kg) and assumption of the upright posture.	Furosemide	180-190	renin	Homo sapiens	17-22
3099700-2	1986	The sodium depletion (furosemide: 30 mg/kg/d for 2 days) was used to potentiate the contribution of the renin-angiotensin system in the blood pressure (BP) control.	Furosemide	22-32	renin	Callithrix jacchus	104-109
2944248-6	1986	In patients with RVH, inactive renin was markedly decreased by furosemide but unchanged by captopril, in spite of significant increase in active renin.	Furosemide	63-73	renin	Homo sapiens	31-36
2944248-8	1986	These data support the idea that in patients with RVH, the increase in active renin by furosemide is at least partly due to the activation of inactive renin.	Furosemide	87-97	renin	Homo sapiens	78-83
2944248-8	1986	These data support the idea that in patients with RVH, the increase in active renin by furosemide is at least partly due to the activation of inactive renin.	Furosemide	87-97	renin	Homo sapiens	151-156
2874909-0	1986	Effects of furosemide and indapamide upon pancreatic insulin and somatostatin secretion in vitro.	Furosemide	11-21	somatostatin	Canis lupus familiaris	65-77
2874909-2	1986	To study if this was due to a direct effect on the endocrine pancreas, we examined the effects of furosemide and indapamide on the release of insulin and somatostatin from the isolated perfused pancreas of normal dogs.	Furosemide	98-108	insulin	Canis lupus familiaris	142-149
2874909-2	1986	To study if this was due to a direct effect on the endocrine pancreas, we examined the effects of furosemide and indapamide on the release of insulin and somatostatin from the isolated perfused pancreas of normal dogs.	Furosemide	98-108	somatostatin	Canis lupus familiaris	154-166
2874909-3	1986	Furosemide at concentrations ranging between 1-30 micrograms/ml inhibited insulin in a dose-dependent manner (2p less than 0.01) whereas the somatostatin secretion was left unchanged.	Furosemide	0-10	insulin	Canis lupus familiaris	74-81
2874909-5	1986	The results suggest, that furosemide and indapamide possess the ability to directly inhibit insulin secretion.	Furosemide	26-36	insulin	Canis lupus familiaris	92-99
2937798-0	1986	Effects of acute water load, hypertonic saline infusion, and furosemide administration on atrial natriuretic peptide and vasopressin release in humans.	Furosemide	61-71	arginine vasopressin	Homo sapiens	121-132
3735922-5	1986	The rise in electrolyte excretion following lasix administration was accompanied with a fall in Prl in hyperprolactinemic patients.	Furosemide	44-49	prolactin	Homo sapiens	96-99
3735922-6	1986	Following the chronic furosemide test, all patients showed a tendency to Prl rise, while the hyperprolactinemic patients also exhibited sodium retention.	Furosemide	22-32	prolactin	Homo sapiens	73-76
3518770-7	1986	Plasma aldosterone concentrations were unchanged after either drug but plasma renin activity (PRA) was increased after frusemide 10 mg (4.42 +/- 1.01----8.50 +/- 1.90 ng A I ml-1 h-1 P less than 0.01) and 20 mg (4.01 +/- 0.72----7.81 +/- 2.27 ng A I ml-1 h-1 P less than 0.05).	Furosemide	119-128	renin	Homo sapiens	78-83
3019648-1	1986	Furosemide has been reported to have a suppressive effect on ADH-, PTH- and adrenaline-stimulated adenosine 3":5"-cyclic monophosphate (cAMP) production, but the effect on adrenocorticotropin (ACTH) action has not yet been elucidated.	Furosemide	0-10	parathyroid hormone	Rattus norvegicus	67-70
3512619-9	1986	The brisk increment in plasma renin activity seen ten minutes after furosemide, as well as later values (30 and 240 min) were not changed by aspirin.	Furosemide	68-78	renin	Homo sapiens	30-35
3947689-0	1986	Plasma prolactin levels in full-term newborn infants with idiopathic edema: response to furosemide.	Furosemide	88-98	prolactin	Homo sapiens	7-16
3161339-7	1985	6-Aminonicotinamide also completely blocked furosemide-stimulated renin release without having any effect on glomerular filtration rate or furosemide-induced natriuresis.	Furosemide	44-54	renin	Rattus norvegicus	66-71
3529267-6	1986	TGF responses are inhibitable by furosemide, and the renin secretion produced by furosemide seems to be in part macula densa dependent.	Furosemide	81-91	renin	Homo sapiens	53-58
3519847-0	1986	[Furosemide stimulation of renin-secretion in essential hypertension].	Furosemide	1-11	renin	Homo sapiens	27-32
4052780-1	1985	Infusions of angiotensin II (AII) or carbachol (CBC) into the lateral ventricles of rats which had been depleted of sodium 4 h previously with either furosemide or polyethylene glycol produced significant changes in salt appetite and sodium and water balances relative to rats infused with saline vehicle.	Furosemide	150-160	angiotensinogen	Rattus norvegicus	13-27
4052780-1	1985	Infusions of angiotensin II (AII) or carbachol (CBC) into the lateral ventricles of rats which had been depleted of sodium 4 h previously with either furosemide or polyethylene glycol produced significant changes in salt appetite and sodium and water balances relative to rats infused with saline vehicle.	Furosemide	150-160	angiotensinogen	Rattus norvegicus	29-32
2867875-3	1985	Furosemide 1-O-acyl glucuronide (FG) was specifically hydrolyzed by beta-glucuronidase (BG) and was also labile to alkaline hydrolysis.	Furosemide	0-10	glucuronidase, beta	Rattus norvegicus	68-86
3161339-9	1985	We conclude that 6-aminonicotinamide interferes with renin release by nonfiltering kidneys and also inhibits furosemide-stimulated renin release but does not affect beta-adrenergic-stimulated renin secretion.	Furosemide	109-119	renin	Rattus norvegicus	131-136
3161339-9	1985	We conclude that 6-aminonicotinamide interferes with renin release by nonfiltering kidneys and also inhibits furosemide-stimulated renin release but does not affect beta-adrenergic-stimulated renin secretion.	Furosemide	109-119	renin	Rattus norvegicus	131-136
3897676-0	1985	[Responses of plasma bradykinin and the renin-angiotensin axis to furosemide in essential hypertension].	Furosemide	66-76	kininogen 1	Homo sapiens	21-31
3903651-3	1985	With a normal perfusate chloride the addition of furosemide 10(-4) M to the perfusate also led to an increase in renin and a reduction in tubule chloride reabsorption.	Furosemide	49-59	renin	Rattus norvegicus	113-118
3893163-0	1985	Renin release in turtles: effects of volume depletion and furosemide administration.	Furosemide	58-68	renin	Rattus norvegicus	0-5
3893163-6	1985	In other studies 48 h of furosemide administration in awake turtles increased renin more than threefold (P less than 0.05) and were accompanied by concomitant reductions in plasma sodium and potassium (P less than 0.05).	Furosemide	25-35	renin	Rattus norvegicus	78-83
3926510-10	1985	When compared with salt-insensitive patients, salt-sensitives had lower levels of urinary kallikrein excretion and a blunted kallikrein response to dietary sodium restriction and furosemide.	Furosemide	179-189	kallikrein related peptidase 4	Homo sapiens	125-135
2579968-1	1985	The diuretic furosemide inhibits serum protein binding of T4 in equilibrium dialysis, dextran-charcoal, and competitive ligand binding separation systems and displaces [125I]T4 from isolated preparations of T4-binding globulin (TBG), prealbumin, and albumin.	Furosemide	13-23	serpin family A member 7	Homo sapiens	207-226
2579968-1	1985	The diuretic furosemide inhibits serum protein binding of T4 in equilibrium dialysis, dextran-charcoal, and competitive ligand binding separation systems and displaces [125I]T4 from isolated preparations of T4-binding globulin (TBG), prealbumin, and albumin.	Furosemide	13-23	serpin family A member 7	Homo sapiens	228-231
2579968-4	1985	Binding of [14C]furosemide to TBG was inhibited by unlabeled T4, suggesting that furosemide and T4 share a common binding site.	Furosemide	16-26	serpin family A member 7	Homo sapiens	30-33
2579968-7	1985	These studies demonstrate that furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower total T4 and T3 levels.	Furosemide	31-41	serpin family A member 7	Homo sapiens	75-78
2984947-3	1985	The disulfonic stilbenes SITS and DIDS and the diuretic furosemide, agents known to interfere with anion transport and with the regulation of intracellular pH in other tissues, inhibited the water flow response to vasopressin and C1PhS-cAMP in a pH-dependent manner when added to the serosal bathing medium.	Furosemide	56-66	arginine vasopressin	Homo sapiens	214-225
3888240-1	1985	To examine the importance of acute frusemide-induced renin release in the production of the acute peripheral venous and arterial responses to frusemide in man, the effects of two drugs, previously described as inhibitors of acute frusemide-induced renin release, propranolol and digoxin, were examined.	Furosemide	35-44	renin	Homo sapiens	53-58
3888240-5	1985	The study provides further evidence of a relationship between acute frusemide-induced renin release and the acute peripheral vascular effects of frusemide in man.	Furosemide	68-77	renin	Homo sapiens	86-91
3888240-5	1985	The study provides further evidence of a relationship between acute frusemide-induced renin release and the acute peripheral vascular effects of frusemide in man.	Furosemide	145-154	renin	Homo sapiens	86-91
3891172-3	1985	The daily maintenance dose of frusemide correlated closely and in a positive fashion with plasma levels of renin activity, angiotensin II and aldosterone (P less than 0.001), and to a lesser extent with plasma noradrenaline.	Furosemide	30-39	renin	Homo sapiens	107-112
3891172-3	1985	The daily maintenance dose of frusemide correlated closely and in a positive fashion with plasma levels of renin activity, angiotensin II and aldosterone (P less than 0.001), and to a lesser extent with plasma noradrenaline.	Furosemide	30-39	angiotensinogen	Homo sapiens	123-137
2982287-8	1985	Acetazolamide and vanadate were also found to strongly inhibit both Cl- and HCO3- -ATPase activities, whereas 10 microM 4-acetamido-4"-isothiocyanostilbene-2,2"-disulfonic acid, 1 mM furosemide, or 1 mM ouabain had little or no effect.	Furosemide	183-193	dynein axonemal heavy chain 8	Homo sapiens	83-89
3881208-1	1985	Prostaglandin-dependent, frusemide-induced changes in renal plasma flow, glomerular filtration rate and plasma renin activity were measured in 14 patients with mild essential hypertension.	Furosemide	25-34	renin	Homo sapiens	111-116
3881302-4	1985	furosemide, which stimulates renal prostaglandin (PG) synthesis and renin release, to compare these vasoactive systems in 14 diabetic and 23 normal control subjects.	Furosemide	0-10	renin	Homo sapiens	68-73
3968633-0	1985	Early furosemide therapy of RDS.	Furosemide	6-16	peripherin 2	Homo sapiens	28-31
4025007-4	1985	After furosemide, sodium excretion (NaE) increased less and changes in AVP, AII and Aldo were blunted in the patients.	Furosemide	6-16	angiotensinogen	Homo sapiens	76-79
3929754-1	1985	We tested the hypothesis that furosemide interferes with energy generation in the cochlea, and determined its effect on CO2 formation from glucose and glyceroaldehyde-3-phosphate dehydrogenase (GAPDH) activity by examining biochemical and histochemical changes in the cochlea, the kidney, and the liver.	Furosemide	30-40	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	194-199
3929754-5	1985	We concluded that furosemide does interfere with energy generation in the cochlea, kidney, and liver as a result of its inhibition of GAPDH.	Furosemide	18-28	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	134-139
4074410-6	1985	When the concentration of microinjected PAH was greater than or equal to 5 mmol/l, fractional recovery of [3H]-PAH from the micropunctured kidney was significantly decreased by torasemide from 252% (control) to 210% (P less than 0.005), by furosemide to 217% (P less than 0.005), and by probenecid to 205% (P less than 0.01).	Furosemide	240-250	phenylalanine hydroxylase	Rattus norvegicus	40-43
3896657-6	1985	Piretanide and furosemide both induced a short-term increase in plasma renin activity with a maximum about 4 hours after dosing which returned to initial levels after approximately 12 hours regardless of whether a single or twice daily dose had been given.	Furosemide	15-25	renin	Homo sapiens	71-76
3892078-2	1985	Acute administration of furosemide led to a significant increase in plasma renin activity, plasma noradrenaline levels and heart rate, and also to a slight rise of blood pressure.	Furosemide	24-34	renin	Canis lupus familiaris	75-80
3903529-0	1985	Sulindac and ibuprofen inhibit furosemide-stimulated renin release but not natriuresis in men on a normal sodium diet.	Furosemide	31-41	renin	Homo sapiens	53-58
3903529-5	1985	Mean basal plasma renin activity levels prior to furosemide administration on day 6 were significantly lower in the presence of ibuprofen (1.5 +/- 2.0 ng/ml/h;p less than 0.01) and sulindac (2,3 +/- 0.9 ng/ml/h; p less than 0.05), compared with placebo (3.3 +/- 1.1 ng/ml/h); the difference between the two NSAIDs was also significant (p less than 0.05).	Furosemide	49-59	renin	Homo sapiens	18-23
3903529-6	1985	Mean plasma renin activity levels in the 4 h after furosemide increased significantly at all time points in comparison to basal values, but were significantly less for ibuprofen and sulindac groups in the first hour.	Furosemide	51-61	renin	Homo sapiens	12-17
3928488-4	1985	In furosemide-treated marmosets, CGP 29 287 lowered blood pressure and inhibited plasma renin activity during intravenous infusion and after intravenous bolus injection.	Furosemide	3-13	renin	Rattus norvegicus	88-93
6509197-1	1984	The correlation was established between the increase in diuresis and natriuresis and fall of CSF pressure after intravenous injection of 10 mg/kg furosemide into dogs.	Furosemide	146-156	colony stimulating factor 2	Canis lupus familiaris	93-96
3890391-9	1985	A significant increase of plasma renin activity was observed after furosemide.	Furosemide	67-77	renin	Homo sapiens	33-38
6498676-6	1984	However, the level rose in two of them when they were given furosemide, which suggests an osmoreceptor defect and a normal ADH response to volume change.	Furosemide	60-70	arginine vasopressin	Homo sapiens	123-126
6389735-9	1984	In normal participants, plasma renin concentration determined by direct radioimmunoassay was increased by standing and furosemide injection.	Furosemide	119-129	renin	Homo sapiens	31-36
6518981-4	1984	Changes in lacrimal peroxidase secretion were found after administration of atropine, aspirin, furosemide, indomethacine and pilocarpine.	Furosemide	95-105	peroxidase 42-like	Gossypium hirsutum	20-30
6594069-1	1984	Studies were conducted to investigate the interaction of renal prostaglandin E2 (PGE2) production and the renin-angiotensin system in the mechanism of furosemide-induced natriuresis.	Furosemide	151-161	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	106-111
6594069-2	1984	In conscious rabbits with permanent urinary bladder cannulation, furosemide in vivo (10 mg/kg) increased urinary water, sodium, and PGE2 excretion and plasma renin activity (PRA) over 50 min.	Furosemide	65-75	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	158-163
6384651-4	1984	Patients with low-renin essential hypertension (LREH) had a significantly reduced excretion of both PGE2 and PGF2 alpha before and after administration of furosemide as compared to controls.	Furosemide	155-165	renin	Homo sapiens	18-23
6487901-5	1984	This dose of frusemide inhibited the vasoconstrictor responses to both angiotensin II and noradrenaline (P less than 0.01, two way analysis of variance).	Furosemide	13-22	angiotensinogen	Rattus norvegicus	71-103
6487901-8	1984	completely prevented the inhibitory effect of frusemide on the responses to angiotensin II and noradrenaline.	Furosemide	46-55	angiotensinogen	Rattus norvegicus	76-90
6487901-9	1984	To test whether frusemide-induced increased endogenous levels of angiotensin II may be responsible for the effects of frusemide on the vasoconstrictor responses, a separate group of rats were not given frusemide but were infused with exogenous angiotensin II (12.5-25 ng kg-1 min-1).	Furosemide	16-25	angiotensinogen	Rattus norvegicus	65-79
3895336-3	1985	Captopril test, upright posture, and furosemide administration provoked in our patients changes of renin and prorenin similar to those found in normal and hypertensive subjects.	Furosemide	37-47	renin	Homo sapiens	99-104
6085642-2	1984	When applied to digitoxin and frusemide, two drugs highly bound to bovine serum albumin, the fraction of drug unbound could be continuously varied over approximately a 30-fold range.	Furosemide	30-39	albumin	Rattus norvegicus	74-87
6090761-7	1984	Plasma renin activity was tripled and rose after furosemide.	Furosemide	49-59	renin	Homo sapiens	7-12
6380995-2	1984	The APA activities increased after treatment with furosemide or captopril.	Furosemide	50-60	glutamyl aminopeptidase	Rattus norvegicus	4-7
6517623-0	1984	[The effects of furosemide and reserpine on plasma concentrations of vasopressin and aldosterone].	Furosemide	16-26	arginine vasopressin	Homo sapiens	69-80
6387403-3	1984	The decreased pressor sensitivity to infused angiotensin II seen in the patient with pseudo-Bartter"s syndrome was corrected with indomethacin and the enhanced pressor sensitivity seen in hyporeninaemic hypoaldosteronism was reversed with frusemide.	Furosemide	239-248	angiotensinogen	Homo sapiens	45-59
6383811-1	1984	Plasma renin substrate concentration was measured in 18, four-day-old pony foals after the administration of the natriuretic agent frusemide.	Furosemide	131-140	renin	Equus caballus	7-12
6328073-6	1984	Plasma renin activity was normal but responded to a greater extent to furosemide plus upright posture.	Furosemide	70-80	renin	Homo sapiens	7-12
6375797-0	1984	Frusemide releases renin in the rat kidney when prostacyclin synthesis is suppressed.	Furosemide	0-9	renin	Rattus norvegicus	19-24
6375797-1	1984	The effect of inhibiting prostaglandin (PG) synthesis on basal and frusemide-stimulated renin secretion was examined in the rat isolated perfused kidney.	Furosemide	67-76	renin	Rattus norvegicus	88-93
6375797-7	1984	Although renin secretion was increased during frusemide infusion, there was no significant difference between control (1,806 +/- 384 ng angiotensin I (AI) min-1) and treated (2,310 +/- 554 ng AI min-1) rats (P greater than 0.05).	Furosemide	46-55	renin	Rattus norvegicus	9-14
6375797-9	1984	These results demonstrate that frusemide-stimulated renin secretion in the rat kidney does not require intact renal PGI2 synthesis and is independent of beta-adrenergic mechanisms.	Furosemide	31-40	renin	Rattus norvegicus	52-57
6378806-5	1984	Such a stimulation of the renin-angiotensin-aldosterone system was greater with azosemide than with furosemide.	Furosemide	100-110	renin	Homo sapiens	26-31
6144266-5	1984	The final addition of the beta-1 adrenoceptor agonist, prenalterol, increased systemic arterial systolic pressure (p less than 0.05), cardiac output (p less than 0.05), and heart rate (p less than 0.01), and reduced systemic vascular resistance (p less than 0.01) in both groups; these changes were greatest in those pretreated with furosemide and isosorbide dinitrate.	Furosemide	333-343	adrenoceptor beta 1	Homo sapiens	26-45
6428443-3	1984	The early increase in plasma renin activity after frusemide was inhibited by indomethacin.	Furosemide	50-59	renin	Homo sapiens	29-34
6325474-0	1984	Effect of ouabain and furosemide on pepsinogen secretion by gastric glands in vitro.	Furosemide	22-32	pepsin II-2/3	Oryctolagus cuniculus	36-46
6425870-3	1984	The variations of these corresponding kinetic parameters (Km, Vmax, specific activities) must correspond to different inhibition mechanisms of furosemide, for example different site(s) of fixation in the area of the active site of UDPGT.	Furosemide	143-153	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	231-236
6425870-4	1984	Because these variations were not as classically described, we checked the impact of furosemide pretreatment on in vitro levels of different UDPGT activities.	Furosemide	85-95	UDP glucuronosyltransferase family 1 member A4	Homo sapiens	141-146
6399315-5	1984	Renin secretion and renal inner medullary blood flow (tissue clearance of 133Xe) were simultaneously measured before and after frusemide-induced renin release.	Furosemide	127-136	renin	Rattus norvegicus	145-150
6388913-0	1984	Synchronous changes in active and inactive renin secretion after furosemide in patients with primary aldosteronism.	Furosemide	65-75	renin	Homo sapiens	43-48
6587654-5	1984	In contrast, the diuretic effect of furosemide in vasopressin (2 U/kg)-infused (or dehydrated) rats was greatly inhibited by indomethacin.	Furosemide	36-46	arginine vasopressin	Rattus norvegicus	50-61
6363244-1	1983	We examined the renin-angiotensin-aldosterone system in seven patients with Shy-Drager syndrome by studying their response to the stimulation of 1 mg/kg furosemide injection followed by sitting for 1 hour.	Furosemide	153-163	renin	Homo sapiens	16-21
6363244-5	1983	The five patients who showed a low plasma renin activity response and a normal aldosterone response to furosemide administration also showed low plasma aldosterone response to angiotensin II.	Furosemide	103-113	angiotensinogen	Homo sapiens	176-190
6668785-5	1983	The patients with an excessive response to lasix had a significantly lower baseline urine excretion of stable sodium, a higher sodium concentration in the red blood cells and, in cases of stable hypertension, a higher activity of plasma renin as well.	Furosemide	43-48	renin	Homo sapiens	237-242
6349901-1	1983	To examine the importance of angiotensin II formation in the production of frusemide"s acute peripheral venous and arterial responses, the effect of pretreatment with captopril was studied.	Furosemide	75-84	angiotensinogen	Homo sapiens	29-43
6349901-3	1983	The study provides evidence that angiotensin II formation performs an essential role in the production of the acute vascular effects of frusemide in man.	Furosemide	136-145	angiotensinogen	Homo sapiens	33-47
6685566-8	1983	Furosemide might also act at the same tubular site or inhibit tubular secretion of the atrial natriuretic factor.	Furosemide	0-10	natriuretic peptide A	Rattus norvegicus	87-112
6352481-0	1983	Inhibition of furosemide-induced increases in plasma renin activity by amiloride.	Furosemide	14-24	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	53-58
6352481-2	1983	Furosemide elicited a rapid and persistent rise in plasma renin activity (PRA), but pretreatment of the same rabbits with a 15-minute intravenous infusion of amiloride, which amounted to 1 mg/kg and commenced at 30 minutes before furosemide, completely prevented this rise.	Furosemide	0-10	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	58-63
6345362-6	1983	A positive correlation (r = + 0.425; p less than 0.05) was found between plasma renin activity after intravenous furosemide and Lii-Nao countertransport in essential hypertension.	Furosemide	113-123	renin	Homo sapiens	80-85
6645209-4	1983	These data suggest that, in FHH, tubular calcium reabsorption is enhanced in the thick ascending limb of Henle"s loop, the site of action of furosemide.	Furosemide	141-151	calcium sensing receptor	Homo sapiens	28-31
6361711-0	1983	[Intra-erythrocytic sodium and plasma renin activity in primary arterial hypertension before and after furosemide therapy].	Furosemide	103-113	renin	Homo sapiens	38-43
6195464-6	1983	Twenty minutes after administration of furosemide, plasma renin activity was increased and remained elevated during the following 8 h. Heart rate and plasma noradrenaline concentration were unchanged after 20 min, but both increased gradually as blood pressure started to fall.	Furosemide	39-49	renin	Homo sapiens	58-63
6141075-13	1983	The present data also suggested that both furosemide and prostaglandins stimulated aldosterone secretion via the renin-angiotensin system, rather than by acting directly on the adrenal cortex.	Furosemide	42-52	renin	Canis lupus familiaris	113-118
6345888-4	1983	Intravenous or prolonged furosemide administration was shown to be the test of choice for the diagnosis of renin suppression.	Furosemide	25-35	renin	Homo sapiens	107-112
6350561-6	1983	Furosemide (10 mg/kg) in anaesthetized animals produced a similar diuresis and natriuresis response to conscious sheep, but plasma active renin increased by 270% and inactive renin decreased to zero.	Furosemide	0-10	renin	Ovis aries	138-143
6350561-6	1983	Furosemide (10 mg/kg) in anaesthetized animals produced a similar diuresis and natriuresis response to conscious sheep, but plasma active renin increased by 270% and inactive renin decreased to zero.	Furosemide	0-10	renin	Ovis aries	175-180
6350561-7	1983	In conscious sheep given an infusion of papaverine, furosemide also produced an increase in plasma active renin and a concurrent decrease in the inactive form.	Furosemide	52-62	renin	Ovis aries	106-111
6133986-3	1983	During the 39 month (range 28-48) period of antihypertensive treatment with metoprolol, hydralazine, and frusemide (furosemide) or thiazide, arterial blood pressure fell from 144/97 mm Hg (mean of all pretreatment values) to 128/84 mm Hg (mean of all post-treatment values), urinary albumin excretion from 977 micrograms/min to 433 micrograms/min, and GFR from 80 to 62 ml/min/1 .	Furosemide	105-114	CD59 molecule (CD59 blood group)	Homo sapiens	373-378
6133986-3	1983	During the 39 month (range 28-48) period of antihypertensive treatment with metoprolol, hydralazine, and frusemide (furosemide) or thiazide, arterial blood pressure fell from 144/97 mm Hg (mean of all pretreatment values) to 128/84 mm Hg (mean of all post-treatment values), urinary albumin excretion from 977 micrograms/min to 433 micrograms/min, and GFR from 80 to 62 ml/min/1 .	Furosemide	116-126	CD59 molecule (CD59 blood group)	Homo sapiens	373-378
6405027-2	1983	The clearance of renin was 0.61 +/- 0.19 ml/min in control experiments and increased significantly to 1.26 +/- 0.38 ml/min after furosemide.	Furosemide	129-139	renin	Canis lupus familiaris	17-22
6405027-3	1983	The fractional excretion of renin increased from 1.51 +/- 0.45% during control to 3.90 +/- 0.98% after furosemide.	Furosemide	103-113	renin	Canis lupus familiaris	28-33
6405027-4	1983	The rate of excretion of renin was increased 10-fold during furosemide diuresis associated with a 10-fold increase in plasma renin concentration.	Furosemide	60-70	renin	Canis lupus familiaris	25-30
6339312-11	1983	The diuretic response to furosemide and spironolactone was related to the activity of the renin-aldosterone system.	Furosemide	25-35	renin	Homo sapiens	90-95
6339312-13	1983	These results indicate that (a) at the dosages used in the study, spironolactone is more effective than furosemide in nonazotemic cirrhosis with ascites, and (b) the activity of the renin-aldosterone system influences the diuretic response to furosemide and spironolactone in these patients.	Furosemide	243-253	renin	Homo sapiens	182-187
6187220-3	1983	Plasma renin activity (PRA) was increased by furosemide and also by the low-sodium diet.	Furosemide	45-55	renin	Rattus norvegicus	7-12
6187220-6	1983	These results suggest that furosemide and low-sodium diet act on the kidney to release renin via protease production.	Furosemide	27-37	renin	Rattus norvegicus	87-92
6187220-7	1983	Because SBTI affected neither PRA nor urinary kallikrein excretion stimulated by these sodium depletions, it is suggested that renal kallikrein may play an important role in the control of renin release stimulated by furosemide and by low-sodium diet.	Furosemide	217-227	renin	Rattus norvegicus	189-194
6188888-4	1983	Plasma renin concentration (PRC) prior to the administration of captopril was highest in the furosemide group, followed by the HCTZ, TCTZ, and control groups, in this order.	Furosemide	93-103	renin	Rattus norvegicus	7-12
6339771-5	1983	The administration of furosemide produced significant increases in plasma NE (142.4 +/- 23.7%, p less than 0.01), plasma renin activity (PRA) (158.6 +/- 26.3%, p less than 0.01) and HR (32.3 +/- 6.0 beats/min, p less than 0.01).	Furosemide	22-32	renin	Canis lupus familiaris	121-126
6662065-5	1983	The increasing edemas of the shank and a stasis ulcer which were the reason for the patients admission to the hospital could be treated successfully by Furosemid and Phenprocoumon within a period of 4 weeks.	Furosemide	152-161	SH3 and multiple ankyrin repeat domains 2	Homo sapiens	29-34
6354727-0	1983	Sequential changes in plasma renin activity and plasma catecholamines in mildly hypertensive patients during acute, furosemide-induced body-fluid loss.	Furosemide	116-126	renin	Homo sapiens	29-34
6354727-1	1983	To evaluate the role of adrenergic mechanisms in the acute response of renin to furosemide, plasma renin activity (PRA) and plasma catecholamine concentrations were measured for 3 h after i.v.	Furosemide	80-90	renin	Homo sapiens	71-76
6354727-3	1983	Furosemide induced a prompt and long-lasting increase in renin, with PRA more than doubled at all times.	Furosemide	0-10	renin	Homo sapiens	57-62
6755768-5	1982	There is a tendency for furosemide to elevate serum aldosterone levels and renin activity regardless of the time of administration.	Furosemide	24-34	renin	Homo sapiens	75-80
6293314-2	1982	Furosemide (2 mg/kg) induced significant diuresis, natriuresis, an increase in renal blood flow (RBF), and a fivefold increase in renin secretory rate (RSR), but no changes in glomerular filtration rate (GFR).	Furosemide	0-10	renin	Canis lupus familiaris	130-135
6293314-11	1982	These results indicate that inhibition of renal Na+-K+-ATPase abolishes furosemide-induced renin secretion despite potentiation of the natriuretic effect of the diuretic.	Furosemide	72-82	renin	Canis lupus familiaris	91-96
7139885-8	1982	At the time papillary plasma flow was measured, extracellular fluid volume was similar among the four groups of dogs; however, plasma renin activity increased significantly in furosemide and ethacrynic acid dogs (P less than 0.01) and remained unchanged in normal and chlorothiazide dogs.	Furosemide	176-186	renin	Canis lupus familiaris	134-139
6757970-2	1982	In each renin subgroup, the administration of furosemide and 2 hours upright posture induced marked increases in urinary excretion of PGE and sodium, and in plasma renin activity.	Furosemide	46-56	renin	Homo sapiens	8-13
7153909-3	1982	With intra-arterial administration of furosemide, short-term reversible elevation occurred of the low threshold sharply tuned ;tip" segment of the frequency threshold (;tuning") curve (f.t.c.)	Furosemide	38-48	TOR signaling pathway regulator	Homo sapiens	127-130
7153909-12	1982	It is concluded that the selective effects of furosemide on the tip segment of cochlear fibre f.t.c.s offer further evidence for a physiologically vulnerable ;second filter" in the cochlea.	Furosemide	46-56	TOR signaling pathway regulator	Homo sapiens	64-67
6805839-0	1982	Inappropriate secretion of antidiuretic hormone treated with frusemide.	Furosemide	61-70	arginine vasopressin	Homo sapiens	27-47
6805839-5	1982	These findings add further weight to evidence that Frusemide is a good alternative for the treatment of patients with inappropriate secretion of antidiuretic hormone who cannot tolerate water restriction.	Furosemide	51-60	arginine vasopressin	Homo sapiens	145-165
7184313-7	1982	Furosemide caused a statistically significant decrease of BAO at rest (p less than 0.02) and during exercise (p less than 0.01), this was due to a significant reduction in gastric juice volume (p less than 0.001) and in the second hour of furosemide action also to a decrease of HCI concentration (p less than 0.05).	Furosemide	0-10	HEMC	Homo sapiens	279-282
6282524-0	1982	Canrenoate reversal of inhibitory effects of digoxin on basal and furosemide-stimulated renin secretion.	Furosemide	66-76	renin	Homo sapiens	88-93
6282524-7	1982	This result indicates that furosemide stimulates renin release by affecting a biochemical system other than that affected by digoxin.	Furosemide	27-37	renin	Homo sapiens	49-54
7043184-4	1982	While the mean plasma aldosterone concentrations were normal, the mean plasma renin activity in response to furosemide stimulation was subnormal in subjects with hyperparathyroidism.	Furosemide	108-118	renin	Homo sapiens	78-83
6125538-1	1982	It has been demonstrated that somatostatin (SRIF) can suppress hypophyseal and extrahypophyseal hormones; moreover, many studies have shown that SRIF inhibits frusemide-induced hyperreninemia in normal man, and renin and aldosterone in renovascular hypertension, possibly through a beta-adrenergic block.	Furosemide	159-168	renin	Homo sapiens	182-187
7042955-9	1982	injection of furosemide, by decreasing cardiac preload, mainly due to venodilation, reduces cardiac output of renin-dependent hypertensive animals, whereas mean arterial blood pressure and heart rate remain unaltered.	Furosemide	13-23	renin	Rattus norvegicus	110-115
6750183-0	1982	[Urinary electrolyte excretion and plasma corticoid level at the furosemide administration test in low renin hypertension].	Furosemide	65-75	renin	Homo sapiens	103-108
6343667-0	1983	Contributions of central sympathetic neural activity to furosemide-induced increases in plasma renin activity and noradrenaline.	Furosemide	56-66	renin	Homo sapiens	95-100
6291543-1	1982	Diethyldithiocarbamate (DTC) and carbon disulfide (CS2), at nearly equimolar oral dose levels, protected mice against liver damage induced by carbon tetrachloride, chloroform, bromotrichloromethane, thioacetamide, bromobenzene, furosemide, acetaminophen, dimethylnitrosamine and trichloroethylene, as evidenced by the suppression of elevations in plasma GPT activity and liver calcium content, and of histopathological alterations.	Furosemide	228-238	calsyntenin 2	Mus musculus	51-54
7083731-3	1982	When hemodynamics returned to control after stopping nitroprusside, furosemide was given ase a 200-mg rapid infusion.	Furosemide	68-78	arylsulfatase L	Homo sapiens	89-92
6813454-0	1982	Active and inactive renin release from rabbit kidney cortex slices: effect of sodium concentration and of furosemide.	Furosemide	106-116	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	20-25
6813454-19	1982	The action of furosemide on secretion of active and inactive renin in vivo is therefore secondary to altered renal function.	Furosemide	14-24	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	61-66
6809473-2	1982	The serum clearance of furosemide (Cls) was between 140 and 201 ml min-1 and on the average the renal clearance was 60% of Cls.	Furosemide	23-33	CD59 molecule (CD59 blood group)	Homo sapiens	67-72
6809473-3	1982	During the initial 30 min period a maximum additional excretion rate of sodium of 3.3 mmol min-1 was reached at an excretion rate of 0.8 mg furosemide min-1.	Furosemide	140-150	CD59 molecule (CD59 blood group)	Homo sapiens	91-96
6809473-3	1982	During the initial 30 min period a maximum additional excretion rate of sodium of 3.3 mmol min-1 was reached at an excretion rate of 0.8 mg furosemide min-1.	Furosemide	140-150	CD59 molecule (CD59 blood group)	Homo sapiens	151-156
7045443-0	1982	Renin response to furosemide differs with the routes of administration in health men.	Furosemide	18-28	renin	Homo sapiens	0-5
7045443-12	1982	These findings suggest that the response of renin release to furosemide in healthy men differs with the routes of administration and renin release with p.o.	Furosemide	61-71	renin	Homo sapiens	44-49
7045443-12	1982	These findings suggest that the response of renin release to furosemide in healthy men differs with the routes of administration and renin release with p.o.	Furosemide	61-71	renin	Homo sapiens	133-138
6461704-5	1982	Continuous intravenous loading with saline and furosemide, although increasing renal renin levels, afforded as much protection as saline loading alone.	Furosemide	47-57	renin	Rattus norvegicus	85-90
6281634-11	1982	Potassium delays the increase of plasma renin activity after furosemide and propranolol inhibits the furosemide-induced renin release, both without impairing aldosterone secretion.	Furosemide	101-111	renin	Homo sapiens	40-45
6281634-11	1982	Potassium delays the increase of plasma renin activity after furosemide and propranolol inhibits the furosemide-induced renin release, both without impairing aldosterone secretion.	Furosemide	101-111	renin	Homo sapiens	120-125
6757970-2	1982	In each renin subgroup, the administration of furosemide and 2 hours upright posture induced marked increases in urinary excretion of PGE and sodium, and in plasma renin activity.	Furosemide	46-56	renin	Homo sapiens	164-169
7057463-11	1982	Furosemide inhibition is of high affinity (K1/2 = 3 micrometer).	Furosemide	0-10	keratin 1	Canis lupus familiaris	43-51
6120716-0	1982	Response of the renin-angiotensin-aldosterone system to upright tilting and to intravenous frusemide: effect of prior metoprolol and propranolol.	Furosemide	91-100	renin	Homo sapiens	16-21
6749346-8	1982	The mechanism of this sustained renin response several days after cessation of diuretic therapy may be best explained by a prolonged action of furosemide or by partial ongoing volume depletion with reduced sodium load to the distal nephron.	Furosemide	143-153	renin	Homo sapiens	32-37
7033292-8	1982	The intravenous infusion of furosemide, which is known to stimulate renin release via a cyclooxygenase-dependent mechanism, caused a three-to fourfold increase of urinary 6-keto-PGF(1alpha) excretion rate, concomitant with the elevation of plasma renin activity levels, in six healthy women.	Furosemide	28-38	renin	Homo sapiens	68-73
7033292-8	1982	The intravenous infusion of furosemide, which is known to stimulate renin release via a cyclooxygenase-dependent mechanism, caused a three-to fourfold increase of urinary 6-keto-PGF(1alpha) excretion rate, concomitant with the elevation of plasma renin activity levels, in six healthy women.	Furosemide	28-38	renin	Homo sapiens	247-252
6120716-5	1982	4 Intravenous frusemide caused immediate rises in plasma active, total and inactive renin, angiotensin II, and aldosterone, which then declined over 2 h despite increasing cumulative sodium losses.	Furosemide	14-23	renin	Homo sapiens	84-89
6120716-5	1982	4 Intravenous frusemide caused immediate rises in plasma active, total and inactive renin, angiotensin II, and aldosterone, which then declined over 2 h despite increasing cumulative sodium losses.	Furosemide	14-23	angiotensinogen	Homo sapiens	91-105
6120716-6	1982	5 Intravenous propranolol or metoprolol attenuated, without abolishing, these early increases in the components of the renin-angiotensin-aldosterone system after frusemide.	Furosemide	162-171	renin	Homo sapiens	119-124
6120716-9	1982	8 Also in contrast to earlier work, we found attenuation by both intravenous propranolol and metoprolol of the immediate rise in renin after intravenous frusemide.	Furosemide	153-162	renin	Homo sapiens	129-134
7033708-3	1982	Renin classification was determined after furosemide (80 mg) stimulation; control measurements were made after each patient had been off all medications for at least 1 week.	Furosemide	42-52	renin	Homo sapiens	0-5
6121670-2	1982	The effect of the diuretic drug furosemide was studied in detail on ouabain-insensitive, SCN- and OCN- -sensitive C1-/HCO-3-ATPase in homogenates from larval dragonfly rectum (Aeshna cyanea), frog (Rana temporaria) and mouse (Mus musculus) kidney.	Furosemide	32-42	dynein, axonemal, heavy chain 8	Mus musculus	124-130
6121670-6	1982	Furosemide even at 10 mM concentration which completely inhibits the anion-dependent ATPase has only a little inhibitory effect on the Na+/K+-ATPase of the 3 tissues.	Furosemide	0-10	dynein, axonemal, heavy chain 8	Mus musculus	85-91
6121670-8	1982	The data suggest that furosemide may affect an active chloride transport system involving a C1-/HCO-3-ATPase.	Furosemide	22-32	dynein, axonemal, heavy chain 8	Mus musculus	102-108
7028367-10	1981	The magnitude of the isoprenaline-induced changes in plasma active renin was similar to that in a previous study of frusemide diuresis, but the time course was quite different.	Furosemide	116-125	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	67-72
7028367-11	1981	Inactive renin disappeared from plasma during frusemide diuresis.	Furosemide	46-55	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	9-14
7029027-4	1981	Following stimulation with furosemide and ambulation, the levels of active renin increased but its responsiveness to the stimulus decreased with age in both groups.	Furosemide	27-37	renin	Homo sapiens	75-80
7031155-12	1981	We conclude that prostaglandins mediate baseline renin secretion and renin stimulation in response to furosemide.	Furosemide	102-112	renin	Homo sapiens	69-74
7026766-5	1981	The initial decrease in conductance seen in furosemide-treated animals appears to be mediated via the renin-angiotensin system.	Furosemide	44-54	renin	Canis lupus familiaris	102-107
7029027-6	1981	These data show that an acute stimulation with furosemide and ambulation affects mainly the active form of plasma renin, and that the effect of age on inactive plasma renin in normal subjects may be different from that in patients with essential hypertension.	Furosemide	47-57	renin	Homo sapiens	114-119
7026766-6	1981	In volume-repleted as well as volume-depleted animals, the plasma concentrations of renin and angiotensin II, but not antidiuretic hormone, were increased 10 min after furosemide administration.	Furosemide	168-178	renin	Canis lupus familiaris	84-108
7026766-9	1981	When fluid losses were not replaced, plasma levels of angiotensin II and renin, as well as antidiuretic hormone, were increased 40 min after furosemide administration.	Furosemide	141-151	renin	Canis lupus familiaris	54-78
7021994-0	1981	Renin release after furosemide and ethacrynic acid in man.	Furosemide	20-30	renin	Homo sapiens	0-5
7315959-6	1981	Parathyroid hormone increased fractional calcium and magnesium reabsorption in Henle"s loop and the distal tubule in the presence of intraluminal furosemide.	Furosemide	146-156	parathyroid hormone	Rattus norvegicus	0-19
7028226-1	1981	Dose-response relationships of furosemide to its diuretic and cardiovascular actions and its effects on plasma renin activity (PRA) were evaluated in unanesthetized rats.	Furosemide	31-41	renin	Rattus norvegicus	111-116
7028226-7	1981	Furosemide did not induce significant changes in blood pressure and heart rate, but it did alter the renin dependency of the blood pressure as assessed by Saralasin.	Furosemide	0-10	renin	Rattus norvegicus	101-106
7021646-4	1981	Following stimulation with furosemide and ambulation, the levels of active renin increased but the responsiveness to stimulus decreased with age in both groups.	Furosemide	27-37	renin	Homo sapiens	75-80
7021646-5	1981	In contrast, inactive renin levels slightly increased after furosemide administration and ambulation, resulting in increased proportion of active to total renin.	Furosemide	60-70	renin	Homo sapiens	22-27
7021646-5	1981	In contrast, inactive renin levels slightly increased after furosemide administration and ambulation, resulting in increased proportion of active to total renin.	Furosemide	60-70	renin	Homo sapiens	155-160
7021646-6	1981	These data show that an acute stimulation with furosemide and ambulation affects mainly the active form of plasma renin, and the effect of age on inactive plasma renin in normal subjects may be different from that in patients with essential hypertension.	Furosemide	47-57	renin	Homo sapiens	114-119
7021994-2	1981	The mechanisms of renin release after furosemide (F) and ethacrynic acid (EA) in man were examined.	Furosemide	38-48	renin	Homo sapiens	18-23
7023561-0	1981	Renin responsiveness to furosemide in the homotransplanted kidney.	Furosemide	24-34	renin	Homo sapiens	0-5
7023561-1	1981	Plasma renin activity (PRA) was measured after repetitive furosemide stimulations in 16 normotensive homotransplanted patients who previously had bilateral nephrectomies.	Furosemide	58-68	renin	Homo sapiens	7-12
7023561-4	1981	These data indicate that the juxtaglomerular cell responsiveness to furosemide is quantitatively time dependent after transplantation, and it is a factor that should be considered in the evaluation of renin-angiotensin system in such patients.	Furosemide	68-78	renin	Homo sapiens	201-206
7291040-5	1981	Circulating plasma levels of alpha-MSH in control animals were 2.5 +/- 0.4 x 10(-10) moles per 1, but were unchanged by dietary sodium restriction or by sodium loss induced by diuretic (LASIX) administration.	Furosemide	186-191	proopiomelanocortin	Rattus norvegicus	29-38
7040751-6	1981	PA responses to furosemide had significant positive correlation with those to angiotensin II.	Furosemide	16-26	angiotensinogen	Homo sapiens	78-92
7018795-6	1981	Plasma active renin increased during frusemide diuresis but inactive renin disappeared from the circulation.	Furosemide	37-46	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	14-19
7018773-0	1981	Effects of furosemide-induced plasma volume reduction on plasma antidiuretic hormone in normal and hypertensive subjects.	Furosemide	11-21	arginine vasopressin	Homo sapiens	64-84
7018800-9	1981	In contrast, indomethacin pretreatment caused renin to rise in response to frusemide in spontaneously hypertensive rats (4.7 +/- 0.8 to 27.1 +/- 1.8 ng h-1 ml-1).	Furosemide	75-84	renin	Rattus norvegicus	46-51
7018800-11	1981	These findings suggest that a prostaglandin normally inhibits the renin response of spontaneously hypertensive rats to frusemide-induced volume contraction.	Furosemide	119-128	renin	Rattus norvegicus	66-71
7231484-0	1981	Furosemide in inappropriate secretion of antidiuretic hormone.	Furosemide	0-10	arginine vasopressin	Homo sapiens	41-61
7018795-9	1981	The peak of the frusemide-induced changes in renal function (urine flow, sodium and potassium excretion and creatinine clearance) preceded the maximum changes in the two forms of renin by 90 min.	Furosemide	16-25	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	179-184
6258416-3	1981	Plasma renin activity increased with sodium depletion (30 mEq sodium intake for 3 days after furosemide treatment) from 1.26 +/- 0.07 to 3.26 +/- 0.48 ng/ml/hr (p less than 0.001).	Furosemide	93-103	renin	Homo sapiens	7-12
6785094-4	1981	In normal men, furosemide (n = 9) within 15 min increased active renin from 29.9 +/- 5.8 to 82.4 +/- 14.8 microunits/ml (P less than 0.001), while inactive renin slightly but not significantly decreased from 136.3 +/- 29.9 to 121.1 +/- 19.2 microunits/ml; orthostasis (n = 15) within 4 h stimulated active renin (P less than 0.001) and slightly raised inactive renin (P less than 0.05).	Furosemide	15-25	renin	Homo sapiens	65-70
7014479-2	1981	In renal patients furosemide elicited comparably high increment (delta) of EF osm, Na, and K in both the stage of renal insufficiency and at normal Cin.	Furosemide	18-28	pyridoxal phosphatase	Homo sapiens	148-151
6111397-0	1981	[Renal excretion of kallikrein after water loading and administration of furosemide or the beta-adrenergic blocker, trimepranol.	Furosemide	73-83	kallikrein related peptidase 4	Homo sapiens	20-30
6111403-9	1981	From these results it may be concluded that Na, K, ATPase -- which in kidney is a site of action for furosemide, a potent diuretic -- is unaffected in PE and PIH and, hence, treatment with diuretics -- is unaffected in PE and PIH and, hence, treatment with diuretics in such patients may be ineffective.	Furosemide	101-111	TANK binding kinase 1	Homo sapiens	44-57
7328628-5	1981	We took the furosemide-sensitive fluxes to be a measure of Na-K cotransport.	Furosemide	12-22	TANK binding kinase 1	Homo sapiens	59-63
7026261-1	1981	The role of the sympathetic nervous system in furosemide-induced renin release was investigated in six normal subjects.	Furosemide	46-56	renin	Homo sapiens	65-70
7026261-2	1981	After intravenous administration of furosemide, plasma renin concentrations increased more than two-fold within 15 min.	Furosemide	36-46	renin	Homo sapiens	55-60
6160345-0	1981	Involvement of kallikrein in the antihypertensive response to furosemide in essential hypertension.	Furosemide	62-72	kallikrein related peptidase 4	Homo sapiens	15-25
6160345-2	1981	Furosemide therapy significantly reduced mean arterial pressure (108.6 +/- 2.4 vs. 101.0 +/- 2.7 mm Hg, p &lt; 0.02) in association with a significant increase in 24 hr urinary kallikrein activity (7.9 +/- 1.8 vs. 13.4 +/- 2.8 esterase units/24 hr, p &lt; 0.02).	Furosemide	0-10	kallikrein related peptidase 4	Homo sapiens	177-187
6160345-4	1981	A significant (p &lt; 0.05) inverse correlation between mean arterial pressure and urinary kallikrein activity suggests a possible role for the kallikrein-kinin system in the antihypertensive mechanism of furosemide.	Furosemide	205-215	kallikrein related peptidase 4	Homo sapiens	91-101
6160345-4	1981	A significant (p &lt; 0.05) inverse correlation between mean arterial pressure and urinary kallikrein activity suggests a possible role for the kallikrein-kinin system in the antihypertensive mechanism of furosemide.	Furosemide	205-215	kallikrein related peptidase 4	Homo sapiens	144-154
7267702-0	1981	Effect of free fatty acid concentration on furosemide binding to human serum albumin.	Furosemide	43-53	albumin	Homo sapiens	71-84
6459589-0	1981	Response of peripheral plasma renin activity (PRA) to furosemide stimulation; reduction of the renal parenchyma as a limiting factor.	Furosemide	54-64	renin	Homo sapiens	30-35
7267702-1	1981	The effect of varying concentrations of sodium oleate on the binding of furosemide to human serum albumin was investigated using continuous ultrafiltration.	Furosemide	72-82	albumin	Homo sapiens	92-105
7003179-0	1980	The effect of angiotensin II antagonist, Sar1-Ile8-angiotensin II, on furosemide-induced increase in plasma noradrenaline, renin activity and aldosterone in unanesthetized dogs.	Furosemide	70-80	renin	Canis lupus familiaris	123-128
7029689-3	1981	Renin activity was increased to varying levels by raising ureteric pressure and by the administration of different doses of furosemide.	Furosemide	124-134	renin	Canis lupus familiaris	0-5
7013722-8	1980	It is concluded that the stimulation of insulin and glucagon secretion observed in vitro with high furosemide concentrations (5 mmol/l) are not observed under usual therapeutic conditions.	Furosemide	99-109	insulin	Homo sapiens	40-47
7003179-2	1980	Furthermore, the role of the renin-angiotensin system in the increased sympathetic nerve activity induced by furosemide was assessed by using Sar1-Ile8-angiotensin II, an angiotensin II antagonist.	Furosemide	109-119	renin	Canis lupus familiaris	29-34
7003179-6	1980	There results suggest that an administration of furosemide induced the increase in PNA and the increase in PNA by furosemide might by mediated by the renin-angiotensin system.	Furosemide	48-58	renin	Canis lupus familiaris	150-155
7003179-6	1980	There results suggest that an administration of furosemide induced the increase in PNA and the increase in PNA by furosemide might by mediated by the renin-angiotensin system.	Furosemide	114-124	renin	Canis lupus familiaris	150-155
7010287-5	1980	Furosemide increased cryorenin and trypsin-activated renin in parallel to active renin from 2.9 +/- 1.1 ng/ml/hr and a6.9 +/- 1.5 of PRA to 5.0 +/- 1.0 and 11.2 +/- 1.5 at 65 min, respectively (P less than 0.05).	Furosemide	0-10	renin	Homo sapiens	25-30
7010289-5	1980	In contrast, when indomethacin was given but the sodium retention prevented by concomitant administration of furosemide, the blunted vasopressor response to angiotensin II and the hyperreninemia were not corrected.	Furosemide	109-119	angiotensinogen	Homo sapiens	157-171
7010287-5	1980	Furosemide increased cryorenin and trypsin-activated renin in parallel to active renin from 2.9 +/- 1.1 ng/ml/hr and a6.9 +/- 1.5 of PRA to 5.0 +/- 1.0 and 11.2 +/- 1.5 at 65 min, respectively (P less than 0.05).	Furosemide	0-10	renin	Homo sapiens	53-58
7439260-4	1980	It is concluded that treatment with furosemide or bumetanide may cause hypocalcaemia, resulting in elevation of s-PTH.	Furosemide	36-46	parathyroid hormone	Homo sapiens	114-117
6108811-2	1980	The response of plasma renin activity to frusemide 40 mg given intravenously, was examined before and after oral propranolol 160 mg daily for 7 days in normal and hypertensive subjects.	Furosemide	41-50	renin	Homo sapiens	23-28
6108811-9	1980	Preservation of the renin stimulatory effect of frusemide during beta blockade confirms the value of this procedure in the investigation of mineralocorticoid and renovascular hypertension were discontinuation of treatment may be undesirable.	Furosemide	48-57	renin	Homo sapiens	20-25
6996896-6	1980	A rise in plasma renin activity was observed 2 hr after an 80-mg dose of furosemide but not after indacrinone.	Furosemide	73-83	renin	Homo sapiens	17-22
7005123-0	1980	Response of renin, aldosterone and antidiuretic hormone to furosemide and furosemide-triamterene combination.	Furosemide	59-69	renin	Homo sapiens	12-17
7005123-0	1980	Response of renin, aldosterone and antidiuretic hormone to furosemide and furosemide-triamterene combination.	Furosemide	59-69	arginine vasopressin	Homo sapiens	35-55
7005123-0	1980	Response of renin, aldosterone and antidiuretic hormone to furosemide and furosemide-triamterene combination.	Furosemide	74-84	renin	Homo sapiens	12-17
7005123-0	1980	Response of renin, aldosterone and antidiuretic hormone to furosemide and furosemide-triamterene combination.	Furosemide	74-84	arginine vasopressin	Homo sapiens	35-55
7005123-8	1980	The results show a fast but transient response of the renin-aldosterone system after furosemide and the furosemide-triamterene combination which could not be correlated with the natriuretic effects.	Furosemide	85-95	renin	Homo sapiens	54-59
7005123-8	1980	The results show a fast but transient response of the renin-aldosterone system after furosemide and the furosemide-triamterene combination which could not be correlated with the natriuretic effects.	Furosemide	104-114	renin	Homo sapiens	54-59
7017323-0	1980	[Plasma renin activity in patients with acute renal failure treated with furosemide (author"s transl)].	Furosemide	73-83	renin	Homo sapiens	8-13
6996879-6	1980	This was in contrast to the rapid rise seen in normal humans thus indicating a dissociation between the diuretic and renin-releasing activities of frusemide in acute nephritis.	Furosemide	147-156	renin	Homo sapiens	117-122
6989757-10	1980	Administration of furosemide was utilized to increase plasma renin activity (PRA) in another series of experiments.	Furosemide	18-28	renin	Canis lupus familiaris	61-66
393525-4	1979	It is concluded that furosemide induces a generalized activation of the renal PG system temporally related to the increase of renin release and natriuresis.	Furosemide	21-31	renin	Homo sapiens	126-131
518220-3	1979	Renin status was categorized by (1) the intravenous furosemide test, (2) ambulation during placebo, and (3) ambulation during spironolactone and hydrochlorothiazide treatment.	Furosemide	52-62	renin	Homo sapiens	0-5
393505-2	1979	The angiotensin II antagonist was infused at a rate of 600 ng/kg/min for 30 min 1.5 hrs after intravenous injection of 40 mg of furosemide.	Furosemide	128-138	angiotensinogen	Homo sapiens	4-18
522308-1	1979	Renal prostaglandins and their relation to renin in rabbits treated with furosemide (author"s transl)].	Furosemide	73-83	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	43-48
501896-5	1979	In 13 normal subjects, in whom 40 mg of furosemide was injected intravenously, plasma angiotensin II concentration before and after 30 and 120 minutes in an upright position was 14.6 +/- 2.2, 56.6 +/- 5.7 and 74.3 +/- 9.0 pg/ml, respectively.	Furosemide	40-50	angiotensinogen	Homo sapiens	86-100
6785094-4	1981	In normal men, furosemide (n = 9) within 15 min increased active renin from 29.9 +/- 5.8 to 82.4 +/- 14.8 microunits/ml (P less than 0.001), while inactive renin slightly but not significantly decreased from 136.3 +/- 29.9 to 121.1 +/- 19.2 microunits/ml; orthostasis (n = 15) within 4 h stimulated active renin (P less than 0.001) and slightly raised inactive renin (P less than 0.05).	Furosemide	15-25	renin	Homo sapiens	156-161
6785094-4	1981	In normal men, furosemide (n = 9) within 15 min increased active renin from 29.9 +/- 5.8 to 82.4 +/- 14.8 microunits/ml (P less than 0.001), while inactive renin slightly but not significantly decreased from 136.3 +/- 29.9 to 121.1 +/- 19.2 microunits/ml; orthostasis (n = 15) within 4 h stimulated active renin (P less than 0.001) and slightly raised inactive renin (P less than 0.05).	Furosemide	15-25	renin	Homo sapiens	156-161
6785094-4	1981	In normal men, furosemide (n = 9) within 15 min increased active renin from 29.9 +/- 5.8 to 82.4 +/- 14.8 microunits/ml (P less than 0.001), while inactive renin slightly but not significantly decreased from 136.3 +/- 29.9 to 121.1 +/- 19.2 microunits/ml; orthostasis (n = 15) within 4 h stimulated active renin (P less than 0.001) and slightly raised inactive renin (P less than 0.05).	Furosemide	15-25	renin	Homo sapiens	156-161
6785094-5	1981	Both furosemide and orthostasis increased (P less than 0.001 each) the proportion of active renin in normal persons.	Furosemide	5-15	renin	Homo sapiens	92-97
6785094-9	1981	The stimulation of active renin by furosemide and orthostasis is bound to the presence of the kidney.	Furosemide	35-45	renin	Homo sapiens	26-31
7004088-0	1980	Effects of clonidine, guanethidine and furosemide on the development of vasopressin hypertension in rat.	Furosemide	39-49	arginine vasopressin	Rattus norvegicus	72-83
6992754-4	1980	The concomitant rise in plasma renin level after furosemide was also blocked by indomethacin.	Furosemide	49-59	renin	Homo sapiens	31-36
6997818-1	1980	Circulating arginine vasopressin (AVP) and plasma renin activity responses to furosemide (2 mg/kg) and acute hypertonic saline (10 mEq/kg) were studied in the fetal lamb from 100 days gestation to term.	Furosemide	78-88	renin	Ovis aries	50-55
6997818-6	1980	The fetal lamb also manifests a hypothalamus-posterior pituitary AVP response to furosemide that is proportional to the maturing renal renin response.	Furosemide	81-91	vasopressin-neurophysin 2-copeptin	Ovis aries	65-68
6997818-6	1980	The fetal lamb also manifests a hypothalamus-posterior pituitary AVP response to furosemide that is proportional to the maturing renal renin response.	Furosemide	81-91	renin	Ovis aries	135-140
6996661-0	1980	Effect of propranolol on the renin response to frusemide in man.	Furosemide	47-56	renin	Homo sapiens	29-34
6996661-1	1980	The response of plasma renin activity (PRA) to frusemide, 40 mg given intravenously, was examined before and after oral propranolol 160 mg daily for seven days in normal and hypertensive subjects.	Furosemide	47-56	renin	Homo sapiens	23-28
6996661-5	1980	Stimulation of renin release by oral frusemide, examined in one subject, was also unaltered by propranolol therapy.	Furosemide	37-46	renin	Homo sapiens	15-20
6996661-8	1980	The fact that the renin stimulating effect of frusemide is preserved during beta blockade indicates that this procedure can be used in the investigation of hypertension even in those patients in whom discontinuation of beta blocking treatment may be undesirable.	Furosemide	46-55	renin	Homo sapiens	18-23
6993779-1	1980	Dissociation between plasma renin and catecholamines or aldosterone following furosemide.	Furosemide	78-88	renin	Homo sapiens	28-33
7428185-6	1980	Some patients with a raised blood pressure appear to have an enhanced adrenal corticosteroid response to frusemide; this probably reflects an increased sensitivity to angiotensin II.	Furosemide	105-114	angiotensinogen	Homo sapiens	167-181
6992087-0	1980	Furosemide-induced alterations in the electrolyte status, the function of renin-angiotensin-aldosterone system, and the urinary excretion of prostaglandins in newborn infants.	Furosemide	0-10	renin	Homo sapiens	74-79
6992087-1	1980	To assess the responsiveness of the renin-angiotensin-aldosterone system of the neonate to acute furosemide stimulation and the role of renal prostaglandins in mediating the response of the renin-angiotensin-aldosterone system, this study was carried out to determine simultaneously plasma renin activity, plasma aldosterone concentration, urinary aldosterone, prostaglandin E, and prostaglandin F2 alpha excretion along with determination of plasma electrolyte concentration and urinary electrolyte excretion.	Furosemide	97-107	renin	Homo sapiens	36-41
6992087-4	1980	Furosemide administration also resulted in a significant increase from 4.41 +/- 2.00 to 9.70 +/- 2.32 ng/ml/hr (P less than 0.02) in plasma renin activity, from 1.17 +/- 0.22 to 1.68 +/- 0.36 ng/ml (P less than 0.025) in plasma aldosterone, from 0.93 +/- 0.16 to 1.53 +/- 0.35 microgram/12 hr (P less than 0.025) in urinary aldosterone, from 17.53 +/- 3.37 to 23.73 +/- 3.16 ng/12 hr (P less than 0.025) in prostaglandin E, and from 16.48 +/- 4.12 to 26.27 +/- 4.12 ng/12 hr (P less than 0.05) in prostaglandin F2 alpha.	Furosemide	0-10	renin	Homo sapiens	140-145
6992087-5	1980	It is concluded that the renin-angiotensin-aldosterone system of the neonate responds to acute furosemide challenge in spite of its high baseline activity, and its response may be mediated by increased renal prostaglandin production.	Furosemide	95-105	renin	Homo sapiens	25-30
6998800-0	1980	Effect of furosemide on insulin and glucagon responses to arginine in normal subjects.	Furosemide	10-20	insulin	Homo sapiens	24-31
6998800-1	1980	This study aimed at evaluating the influence of furosemide upon insulin and glucagon responses to arginine in healthy subjects.	Furosemide	48-58	insulin	Homo sapiens	64-71
6998800-3	1980	The acute insulin response (mean change from 3-10 min) to the second arginine pulse was significantly inhibited by furosemide (mean increase: 14.8 +/- 3.0 microU/ml versus 11.7 +/- 2.5 microU/ml, p &lt; 0.01).	Furosemide	115-125	insulin	Homo sapiens	10-17
6998800-7	1980	The effect of furosemide on insulin and glucagon secretion might be mediated through enhanced release of endogenous prostaglandin E.	Furosemide	14-24	insulin	Homo sapiens	28-35
6987415-7	1980	Of the 16 patients (all normotensive) who had 6-month followup tests 5 had elevated peripheral renin activity, probably owing to furosemide stimulation.	Furosemide	129-139	renin	Homo sapiens	95-100
6987603-2	1980	The baseline to peak plasma renin activity (PRA) response to furosemide increased from delta 3.0 +/- 1.3 ng/ml/hr (M and SEM) and 95--106 days of gestation to delta 18.4 +/- 4.0 (P less than 0.01) at 123--142 days and delta 33.6 +/- 6.5 (P less than 0.001) in the newborn.	Furosemide	61-71	renin	Ovis aries	28-33
6987603-4	1980	The newborn plasma aldosterone response to furosemide via the endogenous renin-angiotensin was delta 17.1 +/- 4.2 ng/dl (P less than 0.01); the fetal lamb plasma aldosterone level did not increase.	Furosemide	43-53	renin	Ovis aries	73-78
6987097-6	1980	3) In low renin EH, the response of PNE to the stimulation of standing with furosemide was significantly greater than in normal renin EH (p less than 0.05).	Furosemide	76-86	renin	Homo sapiens	10-15
7004092-1	1980	The furosemide-induced increase in protein excretion, and its relations to 1) the size of protein molecules as reflected by three enzymes, and 2) glomerular filtration rate (GFR), plasma renin activity (PRA) and prostaglandin (PG) E2 and F2 alpha excretions were studied in 14 outpatients with normal renal function and 13 healthy males.	Furosemide	4-14	renin	Homo sapiens	187-192
7014055-0	1980	Peripheral renin activity before and after furosemide in normotensives and hypertensives.	Furosemide	43-53	renin	Homo sapiens	11-16
7002508-3	1980	Both isoproterenol and furosemide stimulated release of renin in all age animals while propranolol supressed renin release.	Furosemide	23-33	renin	Sus scrofa	56-61
6991284-0	1980	[Mechanism of the stimulating effect of furosemide, ethacrynic acid and novurit on renin secretion by the kidneys].	Furosemide	40-50	renin	Canis lupus familiaris	83-88
396070-5	1979	Plasma noradrenaline concentration and plasma renin concentration at rest supine and after acute stimulation, as induced by frusemide intravenously and ambulation, did not differ from reference values in the 40-year-old normotensive controls.	Furosemide	124-133	renin	Homo sapiens	46-51
396074-4	1979	Frusemide increased urinary kallikrein excretion in normotensive subjects and in patients with essential hypertension.	Furosemide	0-9	kallikrein related peptidase 4	Homo sapiens	28-38
396074-5	1979	The stimulating effect of frusemide on urinary kallikrein was significantly diminished in patients with essential hypertension.	Furosemide	26-35	kallikrein related peptidase 4	Homo sapiens	47-57
518124-3	1979	In the present study, plasma renin concentration following intravenous administration of frusemide was measured in eleven subjects with moderate or severe lead poisoning of industrial origin.	Furosemide	89-98	renin	Homo sapiens	29-34
474601-3	1979	High plasma renin substrate concentrations, and normal basal and furosemide-stimulated plasma renin activities and plasma renin concentrations which were present before surgery, decreased after adrenalectomy, and the hypertension diminished.	Furosemide	65-75	renin	Homo sapiens	94-99
474601-3	1979	High plasma renin substrate concentrations, and normal basal and furosemide-stimulated plasma renin activities and plasma renin concentrations which were present before surgery, decreased after adrenalectomy, and the hypertension diminished.	Furosemide	65-75	renin	Homo sapiens	94-99
467810-0	1979	Acetylsalicyclic acid restores acute insulin response reduced by furosemide in man.	Furosemide	65-75	insulin	Homo sapiens	37-44
467810-6	1979	Infusion of lysine acetylsalicylate (LAS), an inhibitor of endogenous PGE synthesis, completely reversed the inhibitory effect of furosemide on insulin secretion and also augmented acute insulin response to glucose (response before furosemide + LAS: 41 +/- 6 muU/ml; during furosemide + LAS: 50 +/- 7 muU/ml, N = 10, P less than 0.02).	Furosemide	130-140	insulin	Homo sapiens	144-151
467810-8	1979	These findings demonstrate that (1) furosemide inhibits glucose-induced acute insulin responses and (2) LAS completely reverses the inhibitory effect of furosemide and also accelerates glucose disposal.	Furosemide	36-46	insulin	Homo sapiens	78-85
467810-9	1979	It is suggested that furosemide acts via the release of endogenous PGEs, which are known to inhibit insulin responses in man.	Furosemide	21-31	insulin	Homo sapiens	100-107
507503-0	1979	Effect of exercise, phenylbutazone, and furosemide on the plasma renin activity and angiotensin I in horses.	Furosemide	40-50	renin	Equus caballus	65-70
479736-2	1979	The diuretic drug frusemide brought about a rapid increase in plasma renin activity and aldosterone concentration in serum.	Furosemide	18-27	renin	Rattus norvegicus	69-74
503889-0	1979	[Evaluation of the effect of intravenous furosemide on the plasma renin activity of renal vein blood in patients with renovascular hypertension].	Furosemide	41-51	renin	Homo sapiens	66-71
477626-1	1979	Intravenous infusion of somatostatin in mongrel dogs caused a significant decrease in the peripheral plasma renin activity (PRA) enhanced by pentobarbital sodium anesthesia or furosemide treatment.	Furosemide	176-186	somatostatin	Canis lupus familiaris	24-36
477626-1	1979	Intravenous infusion of somatostatin in mongrel dogs caused a significant decrease in the peripheral plasma renin activity (PRA) enhanced by pentobarbital sodium anesthesia or furosemide treatment.	Furosemide	176-186	renin	Canis lupus familiaris	108-113
477626-3	1979	Intrarenal arterial infusion of somatostatin decreased furosemide-enhanced PRA in renal vein by 24.0%, 16.6% and 8.6% in dose of 0.1, 0.5 and 1.0 microgram, respectively.	Furosemide	55-65	somatostatin	Canis lupus familiaris	32-44
449254-2	1979	In essential hypertension mean basal (supine) and stimulated plasma renin activity (2 h upright posture + 40 mg furosemide intraveneously) decreased progressively with age.	Furosemide	112-122	renin	Homo sapiens	68-73
424524-0	1979	Effects of furosemide on renal venous plasma renin activity.	Furosemide	11-21	renin	Homo sapiens	45-50
489926-12	1979	Intravenous injection of furosemide (50 mg) in a female volunteer was followed by an immediate rise of urinary sodium, PGE2, PGF2 alpha and PGE2/PGF2 alpha ratio and plasma renin activity.	Furosemide	25-35	renin	Homo sapiens	173-178
449049-0	1979	Change in plasma renin substrate level after the intravenous furosemide administration.	Furosemide	61-71	renin	Homo sapiens	17-22
471592-3	1979	Plasma renin activity (PRA) increases from 23 +/- 2.7 ng/ml/hr (M and SE) to 85.8 +/- 16.5 (P less than 0.05) during infusion of saralasin alone and remained at this level after injection of furosemide.	Furosemide	191-201	renin	Ovis aries	7-12
424524-4	1979	Acute stimulation of renin by furosemide does not increase the predictive value of renal venous renin measurements and may actually result in a higher percentage of false-negatives.	Furosemide	30-40	renin	Homo sapiens	21-26
760897-0	1979	A comparative study of the action of frusemide and methyclothiazide on renin release by rat kidney slices and the interaction with indomethacin.	Furosemide	37-46	renin	Rattus norvegicus	71-76
761310-0	1979	Effects of digoxin and digoxin plus furosemide on plasma renin activity of hypertensive patients.	Furosemide	36-46	renin	Homo sapiens	57-62
760897-2	1979	2 Frusemide at concentrations of 1.5 and 7.5 mmol/l produced significant increases in renin release but had no effect at 0.15 mmol/l.	Furosemide	2-11	renin	Rattus norvegicus	86-91
763247-1	1979	In 10 healthy and 27 diabetic children aged 11--17 years plasma renin activity was determined in horizontal position (PRA-I) and after stimulation by furosemid and upright position (PRA-II).	Furosemide	150-159	renin	Homo sapiens	64-69
429554-4	1979	Plasma renin activity increased from a mean (+/-SEM) of 21.3+/-3.4 ng/ml per h in the 10 control lambs to 39.4+/-8.2 ng/ml per h at 8 min (P &lt; 0.001) and remained high through 120 min after furosemide.	Furosemide	193-203	renin	Ovis aries	7-12
429554-11	1979	These data support the view that the observed AVP response to furosemide in the newborn lamb was mediated through the renin-angiotensin system.	Furosemide	62-72	renin	Ovis aries	118-123
758231-6	1979	Similarly, furosemide stimulated the release of both active and inactive renin.	Furosemide	11-21	renin	Sus scrofa	73-78
517244-6	1979	The present data show that basal level of urinary excretion of PGE and kallikrein was lower in essential hypertension than in normal subjects and that the release of renal kallikrein and PGE after the furosemide administration was also suppressed in patients with essential hypertension compared with that in normal subjects, suggesting that there exists, in this disease, an impaired defense mechanism against the renin-angiotensin-aldosterone system resulting in sodium retention.	Furosemide	201-211	renin	Homo sapiens	415-420
282044-2	1978	The response of active and inactive plasma renin to orthostasis and frusemide and to inhibition of prostaglandin synthesis by indomethacin was tested in normal human volunteers.	Furosemide	68-77	renin	Homo sapiens	43-48
757587-2	1978	The binding to a biological macromolecule (human serum albumin, HSA) of small molecules (two drugs: warfarin and furosemide) has been studied by high-performance liquid chromatography.	Furosemide	113-123	albumin	Homo sapiens	49-62
757587-2	1978	The binding to a biological macromolecule (human serum albumin, HSA) of small molecules (two drugs: warfarin and furosemide) has been studied by high-performance liquid chromatography.	Furosemide	113-123	albumin	Homo sapiens	64-67
397653-5	1979	Likewise, furosemide will stimulate renin release.	Furosemide	10-20	renin	Homo sapiens	36-41
545821-7	1979	Of the 16 patients (all normotensive) who had 6-month followup tests 5 had elevated peripheral renin activity, probably owing to furosemide stimulation.	Furosemide	129-139	renin	Homo sapiens	95-100
282041-7	1978	An acute stimulation induced by frusemide and ambulation led to a considerable rise in active renin and a slight, but significant, rise of inactive renin.	Furosemide	32-41	renin	Homo sapiens	94-99
282041-7	1978	An acute stimulation induced by frusemide and ambulation led to a considerable rise in active renin and a slight, but significant, rise of inactive renin.	Furosemide	32-41	renin	Homo sapiens	148-153
282044-4	1978	Active renin increased by orthostasis and frusemide and decreased by indomethacin.	Furosemide	42-51	renin	Homo sapiens	7-12
713174-0	1978	[The influence of aging on renin release stimulated by furosemide and upright posture in essential hypertension (author"s transl)].	Furosemide	55-65	renin	Homo sapiens	27-32
741062-1	1978	The effects of orthostatism and furosemide tests on different parameters of renin-angiotensin system have been studied in 14 normal human subjects.	Furosemide	32-42	renin	Homo sapiens	76-81
712172-0	1978	[Plasma renin activity in essential hypertension with respect to aging, hypertension severity and furosemide test (author"s transl)].	Furosemide	98-108	renin	Homo sapiens	8-13
741539-4	1978	Elevation of renin activity in lymph is noted following infusion with either chlorothiazide or furosemide, while a reduction of renin activity in renal lymph is noted after mannitol infusion.	Furosemide	95-105	renin	Canis lupus familiaris	13-18
568077-0	1978	[Change in renin activity in the venous blood plasma of dogs under the influence of furosemide, novurit, ethacrynic acid and mannitol].	Furosemide	84-94	renin	Canis lupus familiaris	11-16
713284-3	1978	The rise in plasma renin activity on standing or after frusemide was proportional to the resting level, and it was generally less in hypertensives, but small or absent responses were also seen in those with normal blood pressure.	Furosemide	55-64	renin	Homo sapiens	19-24
720703-0	1978	[The responsiveness of plasma renin activity to furosemide administration in diabetic patients (author"s transl)].	Furosemide	48-58	renin	Homo sapiens	30-35
657458-10	1978	Renin secretion was 118 +/- 62 ng/min during the control period and averaged 240 +/- 67 ng/min after ouabain plus furosemide.	Furosemide	114-124	renin	Ovis aries	0-5
657458-13	1978	Ouabain also blocks the normal stimulatory effects of furosemide on renin secretion.	Furosemide	54-64	renin	Ovis aries	68-73
353767-6	1978	PRA also increased in relation to frusemide-induced fluid loss.	Furosemide	34-43	S100 calcium binding protein A6	Homo sapiens	0-3
26691-3	1978	The mobile phase used for chromatography on a reversed-phase column (C15 hydrocarbon permanently bonded to silica particles) is sufficiently acidic to induce fluorescence of furosemide.	Furosemide	174-184	placenta associated 8	Homo sapiens	69-72
624779-2	1978	The mean prothrombin times after a single oral dose of 50 mg warfarin were 18.8 +/- 0.7 sec before and 19.6 +/- 1.7 sec during furosemide administration, and 18.3 +/- 1.4 sec before and 19.7 +/- 1.3 sec during bumetanide administration.	Furosemide	127-137	coagulation factor II, thrombin	Homo sapiens	9-20
722978-0	1978	[Renin-angiotensin-aldosterone system and electrolytes metabolism on furosemide stimulation test (author"s transl)].	Furosemide	69-79	renin	Homo sapiens	1-6
645884-1	1978	Under inactin anesthesia, intravenous infusion of [Sar1,Thr8]angiotensin II produced a hypotensive effect in young spontaneously hypertensive rats (SHR) treated with furosemide and in mature SH rats fed a low-sodium diet.	Furosemide	166-176	angiotensinogen	Rattus norvegicus	61-75
637637-1	1978	Seventy-nine patients with essential hypertension were evaluated for peripheral renin activity in response to injection of 60 mg of furosemide and to upright posture.	Furosemide	132-142	renin	Homo sapiens	80-85
398707-0	1978	[Reliability and diagnostic use of the furosemide test in the study of the renin-angiotensin-aldosterone system].	Furosemide	39-49	renin	Homo sapiens	75-80
581995-15	1978	It is concluded that the decrease in renal medullary hemodynamics of furosemide-treated rats is due to a stimulation of the renin-angiotensin system.	Furosemide	69-79	renin	Rattus norvegicus	124-129
699607-3	1978	In vivo stimulation of renal PG synthesis by arachidonic acid (C20:4) or furosemide increases renin release.	Furosemide	73-83	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	94-99
215821-2	1978	b) Does AII mediate the antidiuresis induced by furosemide?	Furosemide	48-58	angiotensinogen	Rattus norvegicus	8-11
215821-6	1978	Furosemide led to a two-fold increase of AII plasma concentrations and a decrease of plasma sodium levels.	Furosemide	0-10	angiotensinogen	Rattus norvegicus	41-44
732253-3	1978	of colchicine or vinblastine to furosemide treated rats on a low salt diet resulted in a decrease of plasma renin as well as plasma angiotensinogen concentration during a 5 h observation period.	Furosemide	32-42	renin	Rattus norvegicus	108-113
732253-3	1978	of colchicine or vinblastine to furosemide treated rats on a low salt diet resulted in a decrease of plasma renin as well as plasma angiotensinogen concentration during a 5 h observation period.	Furosemide	32-42	angiotensinogen	Rattus norvegicus	132-147
202362-2	1977	The hypothesis that acetazolamide and parathyroid hormone (PTH), inhibit renal carbonic anhydrase by a cyclic adenosine 3",5"-monophosphate (cyclic AMP)-dependent mechanism was also tested.2In vitro, acetazolamide, frusemide and ethacrynic acid at high concentrations (10(-3)M) all produced some inhibition of basal and stimulated rat kidney plasma membrane adenylate cyclase.	Furosemide	215-224	parathyroid hormone	Rattus norvegicus	38-57
202362-2	1977	The hypothesis that acetazolamide and parathyroid hormone (PTH), inhibit renal carbonic anhydrase by a cyclic adenosine 3",5"-monophosphate (cyclic AMP)-dependent mechanism was also tested.2In vitro, acetazolamide, frusemide and ethacrynic acid at high concentrations (10(-3)M) all produced some inhibition of basal and stimulated rat kidney plasma membrane adenylate cyclase.	Furosemide	215-224	parathyroid hormone	Rattus norvegicus	59-62
591619-1	1977	Plasma renin activity (PRA) was stimulated by oral frusemide (60 mg) in 4 normal male subjects.	Furosemide	51-60	renin	Homo sapiens	7-12
599792-3	1977	Decrease of the renin-angiotensin-aldosterone system compensatory reaction and the prostaglandin F level in patients with stable, high arterial pressur in response to furosemide administration may be among the causes of the hypotensive and natriuretic effect of this preparation.	Furosemide	167-177	renin	Homo sapiens	16-21
599795-0	1977	[Change in plasma renin activity in patients with hypertension and healthy persons after furosemide intake].	Furosemide	89-99	renin	Homo sapiens	18-23
599795-1	1977	Blood plasma renin activity was studied by the radioimmune method in clino- and orthostatism in 36 males with hypertensive disease and in 15 healthy males before and after 3-day medication with furosemide in a daily dose of 120 mg under in-patient conditions.	Furosemide	194-204	renin	Homo sapiens	13-18
599795-2	1977	Renin activity proved to be higher in double stimulation (in orthostatism after furosemide intake) than in orthostatism before the intake of the drug.	Furosemide	80-90	renin	Homo sapiens	0-5
905911-0	1977	The effect of furosemide on serum prolactin levels in the postpartum period.	Furosemide	14-24	prolactin	Homo sapiens	34-43
873120-1	1977	The effect of furosemide on secretin-stimulated pancreatic secretion was examined in 12 normal subjects using a perfusion method to quantitate pancreatic output.	Furosemide	14-24	secretin	Homo sapiens	28-36
873120-3	1977	When a bolus injection of furosemide (20 mg) was given during continuous secretin infusion, mean secretory volume increased further to a maximum value of 110 +/- 14.7 ml per min.	Furosemide	26-36	secretin	Homo sapiens	73-81
328540-4	1977	A significant increase in plasma renin activity and a significantly greater increase in aldosterone excretion were found in the spironolactone/thiazide group compared to the furosemide group.	Furosemide	174-184	renin	Homo sapiens	33-38
874065-0	1977	Inhibition of the renin-aldosterone response to furosemide by indomethacin.	Furosemide	48-58	renin	Homo sapiens	18-23
874065-2	1977	The increases in plasma renin activity and plasma and urinary aldosterone following acute furosemide challenge were markedly blunted in the presence of indomethacin.	Furosemide	90-100	renin	Homo sapiens	24-29
876706-0	1977	The renin-angiotensin-aldosterone system in the newborn lamb: response to furosemide.	Furosemide	74-84	renin	Ovis aries	4-9
876706-2	1977	Plasma renin activity (PRA) increased within 8 min after furosemide from a baseline value of 12.6 +/- 3.5 ng/ml/hr (mean and SEM) to a level of 24.1 +/- 8.6 ng/ml/hr (P less than 0.05), and peaked 20 mins after the furosemide infusion at a level of 33.1 +/- 8.0 ng/ml/hr.	Furosemide	57-67	renin	Ovis aries	7-12
876706-2	1977	Plasma renin activity (PRA) increased within 8 min after furosemide from a baseline value of 12.6 +/- 3.5 ng/ml/hr (mean and SEM) to a level of 24.1 +/- 8.6 ng/ml/hr (P less than 0.05), and peaked 20 mins after the furosemide infusion at a level of 33.1 +/- 8.0 ng/ml/hr.	Furosemide	215-225	renin	Ovis aries	7-12
876706-5	1977	The results indicate that the renin-angiotensin-aldosterone system responds promptly to furosemide stimulation despite initially high PRA and aldosterone levels.	Furosemide	88-98	renin	Ovis aries	30-35
871171-0	1977	Effects of renal denervation on renin release in response to tilting and furosemide.	Furosemide	73-83	renin	Felis catus	32-37
871171-1	1977	In anesthetized cats head-up tilting for 30 min and infusion of furosemide at 0.75 mg/kg in 30 min significantly raised renin release from the innervated kidney (increments of 90.7 +/- 21.4 ng/min on tilting and 105.4 +/- 26.4 ng/min after furosemide); a small and inconstant increase from the contralateral denervated kidney (increments of 16.8 +/- 16.0 and 16.3 +/- 17.7 ng/min, respectively) was abolished by acute bilateral adrenalectomy.	Furosemide	64-74	renin	Felis catus	120-125
871171-2	1977	Larger doses of furosemide (6.0 mg/kg) could release renin from the denervated kidney also, but the response was still more marked on the innervated side especially in the early period of infusion (increments of 132.7 +/- 23.8 and 33.7 +/- 23.8 ng/min of innervated and denervated sides at 10 min).	Furosemide	16-26	renin	Felis catus	53-58
884392-0	1977	Intrarenal stimulation of renin secretion by frusemide in the isolated kidney of the rat.	Furosemide	45-54	renin	Rattus norvegicus	26-31
884392-2	1977	Intrarenal infusion of frusemide markedly stimulated renin secretion in the isolated perfused kidney of the rat.	Furosemide	23-32	renin	Rattus norvegicus	53-58
884392-4	1977	Renin vales increased from 24+/-6 to 195+/-34 units of secretion rate (renin concentration (nmol angiotensin I/h per litre) X flow rate (ml/min)) following administration of frusemide for 8 min, compared with corresponding control values of 13 +/- 2 (P greater than 0.05) and 47 +/-18 (P less than 0.001).	Furosemide	174-183	renin	Rattus norvegicus	0-5
884392-4	1977	Renin vales increased from 24+/-6 to 195+/-34 units of secretion rate (renin concentration (nmol angiotensin I/h per litre) X flow rate (ml/min)) following administration of frusemide for 8 min, compared with corresponding control values of 13 +/- 2 (P greater than 0.05) and 47 +/-18 (P less than 0.001).	Furosemide	174-183	renin	Rattus norvegicus	71-76
884392-9	1977	These findings indicate the existence of an intrarenal site of action for frusemide on renin secretion.	Furosemide	74-83	renin	Rattus norvegicus	87-92
884392-12	1977	A direct effect of frusemide on the renin secreting cell is therefore suggested.	Furosemide	19-28	renin	Rattus norvegicus	36-41
870268-2	1977	With intraperitoneal furosemide, mean net ultrafilrate sodium concentration increased significantly to 121.2 mE1/l while ethacrynic acid had no such effect and both drugs affected dialyzate volume very slightly.	Furosemide	21-31	small nucleolar RNA, H/ACA box 73a	Mus musculus	109-112
190262-8	1977	Four hours after administration of 80 mg of Lasix at 0800 h to 10 normal subjects, the ratios of DOC to B and S to F increased significantly (P less than .02), an effect possibly related to a decreased secretion of ACTH.	Furosemide	44-49	proopiomelanocortin	Homo sapiens	215-219
844016-3	1977	The furosemide screening test for renovascular hypertension revealed elevated plasma renin activity (PRA) but an intravenous pyelogram revealed a right suprarenal mass and no evidence of renovascular compression.	Furosemide	4-14	renin	Homo sapiens	85-90
844250-4	1977	Frusemide, ethacrynic acid and bumetanide cause an immediate rise in renin secretion which is not inhibited either by DL-propranolol or by a bilateral ureterovenous anastomosis which prevents salt and water loss.	Furosemide	0-9	renin	Canis lupus familiaris	69-74
838842-7	1977	Overall, in the hypertensive patients, there was a significant positive correlation (r= +0.58; P less than 0.01) between PRR and the PRA response to furosemide.	Furosemide	149-159	ATPase H+ transporting accessory protein 2	Homo sapiens	121-124
840860-0	1977	Renin secretion after papaverine and furosemide in conscious sheep.	Furosemide	37-47	renin	Ovis aries	0-5
1071582-0	1976	Stimulation of renin secretion by frusemide and diazoxide in the isolated rat kidney.	Furosemide	34-43	renin	Rattus norvegicus	15-20
699607-4	1978	PG synthesis inhibitors decrease basal renin release and reduce the renin release following stimulation with C20:4, furosemide and renal ischemia.	Furosemide	116-126	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	68-73
1027472-0	1976	[Behavior of sodium and water excretion and of plasma renin activity (PRA) after administration of furosemide in patients with glomerulonephritis with various degrees of functional deficiency and arterial pressure levels].	Furosemide	99-109	renin	Homo sapiens	54-59
1071628-10	1976	The diuresis and natriuresis induced by frusemide in rats was associated with increased urinary kallikrein excretion and acute rises in plasma renin.	Furosemide	40-49	renin	Rattus norvegicus	143-148
1005885-2	1976	Furosemide greatly inhibits platelet aggregation, with ADP, epinephrine, collagen, ristocetin, thrombin and serotonin.	Furosemide	0-10	coagulation factor II, thrombin	Homo sapiens	95-103
1001347-0	1976	Natriuresis and renin release by the denervated dog kidney during furosemide administration.	Furosemide	66-76	renin	Canis lupus familiaris	16-21
12404-0	1976	[Cyclic AMP and plasma renin activity in renal vein blood after amitryptiline, theophylline, furosemide and beta adrenergic blocking substances (author"s transl)].	Furosemide	93-103	renin	Homo sapiens	23-28
12404-1	1976	The influence of amitryptiline, theophylline and furosemide on the concentration of cyclic-AMP and plasma renin activity (PRA) was investigated in renal vein plasma.	Furosemide	49-59	renin	Homo sapiens	106-111
824442-1	1976	The effects of furosemide on stimulation of renin secretion and urinary sodium excretion were studied in dogs pretreated with the prostaglandin synthetase inhibitors, indomethacin and meclofenamate.	Furosemide	15-25	renin	Canis lupus familiaris	44-49
824442-6	1976	Indomethacin apparently affects furosemide-induced renin secretion at both the vascular and macula densa sites.	Furosemide	32-42	renin	Canis lupus familiaris	51-56
1053468-1	1976	Changes in arterial blood pressure, renal electrolyte excretion, and plasma renin activity in response to repeated doses of furosemide were measured in 12 patients with essential hypertension admitted to the medical service for electrolyte balance studies.	Furosemide	124-134	renin	Homo sapiens	76-81
1053468-7	1976	However, the average increase in plasma renin activity after repeated doses of furosemide was not statistically significant and no correlation was demonstrated between the level of plasma renin activity after furosemide and the blood pressure lowering effect of the drug.	Furosemide	79-89	renin	Homo sapiens	40-45
22216503-8	1976	At the time of peak diuresis, both drugs caused a significant reduction of euglobulin lysis time; levels of available plasmin were significantly lowered after frusemide, and levels of active plasmin were significantly raised after bumetanide.	Furosemide	159-168	plasminogen	Homo sapiens	118-125
956367-4	1976	The lowering effect of indomethacin on plasma renin activity is not specifically related to hemorrhage because it also prevented the increase in plasma renin activity elicited by 5 mg/kg of furosemide.	Furosemide	190-200	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	46-51
956367-4	1976	The lowering effect of indomethacin on plasma renin activity is not specifically related to hemorrhage because it also prevented the increase in plasma renin activity elicited by 5 mg/kg of furosemide.	Furosemide	190-200	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	152-157
965879-5	1976	After the first dose of frusemide in study A, the mean plasma prolactin concentration correlated negatively with the urinary Na and K excretion over 5 h. After 38 h sodium depletion, the plasma prolactin concentration correlated positively with urinary Na excretion following the second dose of frusemide.	Furosemide	24-33	prolactin	Homo sapiens	62-71
965879-5	1976	After the first dose of frusemide in study A, the mean plasma prolactin concentration correlated negatively with the urinary Na and K excretion over 5 h. After 38 h sodium depletion, the plasma prolactin concentration correlated positively with urinary Na excretion following the second dose of frusemide.	Furosemide	24-33	prolactin	Homo sapiens	194-203
965879-5	1976	After the first dose of frusemide in study A, the mean plasma prolactin concentration correlated negatively with the urinary Na and K excretion over 5 h. After 38 h sodium depletion, the plasma prolactin concentration correlated positively with urinary Na excretion following the second dose of frusemide.	Furosemide	295-304	prolactin	Homo sapiens	194-203
937875-0	1976	The intravenous furosemide test: a simple way to evaluate renin responsiveness.	Furosemide	16-26	renin	Homo sapiens	58-63
937875-1	1976	To identify patients with low-renin hypertension, we measured plasma renin activity after the administration of 40 mg of furosemide intravenously and 30 minutes of upright posture in 127 normotensive subjects and 363 patients with essential hypertension.	Furosemide	121-131	renin	Homo sapiens	69-74
937875-2	1976	Plasma renin activity 30 minutes after intravenous furosemide was found to be closely correlated to the level found after either 2 or 4 h of standing or 3 days of a low-salt diet plus 2 h of upright posture.	Furosemide	51-61	renin	Homo sapiens	7-12
1264120-0	1976	Letter: Furosemide stimulation of peripheral renin in men and women.	Furosemide	8-18	renin	Homo sapiens	45-50
987428-1	1976	Response of plasma renin activity to furosemide].	Furosemide	37-47	renin	Homo sapiens	19-24
56589-3	1976	Injection of frusemide alone produced hyperreninaemia; but, under somatostatin, renin release was inhibited by 45%.	Furosemide	13-22	somatostatin	Homo sapiens	66-78
56589-3	1976	Injection of frusemide alone produced hyperreninaemia; but, under somatostatin, renin release was inhibited by 45%.	Furosemide	13-22	renin	Homo sapiens	43-48
187035-1	1976	15-Hydroxyprostaglandin dehydrogenase was inhibited by xylocaine, furosemide, and ethacrynic acid, but was activated by imipramine and other related drugs.	Furosemide	66-76	carbonyl reductase 1	Homo sapiens	0-37
1267539-5	1976	The excretion of furosemide by the kidney is competitively inhibited by p-aminohippuric acid (PAH).	Furosemide	17-27	phenylalanine hydroxylase	Rattus norvegicus	94-97
1267539-6	1976	The relative small inhibitory effect of PAH in young rats is caused by a smaller participation of tubular secretion in the renal excretion of furosemide in this age group.	Furosemide	142-152	phenylalanine hydroxylase	Rattus norvegicus	40-43
1001004-6	1976	Mannitol infusion was able to bring the insulin/inulin clearance ratio up the values of the sieving coefficient of insulin (insulin filtration rate) without modifying the permeability of the glomerular wall; saline infusion displayed a similar effect; furosemide, only a minute one although it induced a more marked polyuria.	Furosemide	252-262	insulin	Canis lupus familiaris	40-47
1022409-0	1976	The effect of furosemide stimulation on renin secretion and its application in examining activity of the renin-angiotensin system.	Furosemide	14-24	renin	Homo sapiens	40-45
1022409-0	1976	The effect of furosemide stimulation on renin secretion and its application in examining activity of the renin-angiotensin system.	Furosemide	14-24	renin	Homo sapiens	105-110
1022409-1	1976	The response of plasma renin concentration [PRC] to Furosemide administration and orthostasis stimulation was studied in 9 healthy volunteers and in 30 patients with essential hypertension.	Furosemide	52-62	renin	Homo sapiens	23-28
1249195-8	1976	When furosemide was administered intravenously under this condition, both plasma ADH and PRA increased to 3.1 +/- 0.5 muU/ml and 15.5 +/- 1.6 ng/ml with 11.2 +/- 1.1% decrease in plasma volume.	Furosemide	5-15	arginine vasopressin	Homo sapiens	81-84
1053607-6	1975	Ten patients dropped out voluntarily and 39 were controlled for an additional four weeks at a dose of 20 mg bid furosemide.	Furosemide	112-122	BH3 interacting domain death agonist	Homo sapiens	108-111
1192694-0	1975	Effect of intravenous frusemide on plasma renin concentration: suppression of response in hypertension.	Furosemide	22-31	renin	Homo sapiens	42-47
1192694-2	1975	Intravenous frusemide produced in normal subjects a prompt rise of plasma renin concentration which correlated with urinary sodium.	Furosemide	12-21	renin	Homo sapiens	74-79
1192694-4	1975	The renin response to frusemide was suppressed in patients with primary hyperaldosteronism.	Furosemide	22-31	renin	Homo sapiens	4-9
1192694-6	1975	In patients with low-renin hypertension and normal renin essential hypertension, the renin response to frusemide was similarly suppressed.	Furosemide	103-112	renin	Homo sapiens	21-26
1192694-8	1975	Suppression of the renin response to frusemide is therefore a feature of hypertension not confined to patients with primary hyperaldosteronism and low-renin hypertension.	Furosemide	37-46	renin	Homo sapiens	19-24
1192694-8	1975	Suppression of the renin response to frusemide is therefore a feature of hypertension not confined to patients with primary hyperaldosteronism and low-renin hypertension.	Furosemide	37-46	renin	Homo sapiens	151-156
1179572-2	1975	Peripheral plasma renin activity was elevated following furosemide challenge, and there was increased renal vein renin activity on the affected side with suppression of renin secretion from the contralateral kidney.	Furosemide	56-66	renin	Homo sapiens	18-23
802648-0	1975	Effect of oxprenolol on catecholamines and plasma renin activity: acute response to frusemide in hypertensive patients.	Furosemide	84-93	renin	Homo sapiens	50-55
172005-0	1975	[Effect of furosemide and ACTH on plasma renin, aldosterone and cortisol levels in normal man].	Furosemide	11-21	renin	Homo sapiens	41-46
1149327-0	1975	Abolition of the renin-releasing action of frusemide by acute renal denervation in dogs.	Furosemide	43-52	renin	Canis lupus familiaris	17-22
1149327-2	1975	The effects of infusions of frusemide at low (0.05-0.1 mg.kg-1.min-1) and high (0.5-2.0 mg.kg-1.min-1) rates were studied on renin secretion and urinary outputs of sodium and potassium in anaesthetized dogs in which one kidney was removed and the remaining kidney was either innervated or denervated.	Furosemide	28-37	renin	Canis lupus familiaris	125-130
1149327-7	1975	High rates of infusion of frusemide caused an immediate increase in renin secretion from innervated kidneys which was not related to urinary losses.	Furosemide	26-35	renin	Canis lupus familiaris	68-73
1149327-11	1975	Denervation of the kidney abolished the renin-releasing action of frusemide at both low and high infusion rates even when the sodium deficit amounted to 4.3 mmol.kg-1.	Furosemide	66-75	renin	Canis lupus familiaris	40-45
1149327-13	1975	Constriction of the aorta producing a fall of 10-30 mmHg in perfusion pressure raised the rate of renin secretion from denervated kidneys to control levels and partially restored the renin-releasing action of frusemide at high infusion rates.	Furosemide	209-218	renin	Canis lupus familiaris	98-103
1149327-13	1975	Constriction of the aorta producing a fall of 10-30 mmHg in perfusion pressure raised the rate of renin secretion from denervated kidneys to control levels and partially restored the renin-releasing action of frusemide at high infusion rates.	Furosemide	209-218	renin	Canis lupus familiaris	183-188
1149327-15	1975	The findings indicate that frusemide has a site of action apart from the macula densa in mediating renin release.	Furosemide	27-36	renin	Canis lupus familiaris	99-104
1233219-0	1975	Effects of metoprolol and propranolol on furosemide-stimulated renin release in healthy subjects.	Furosemide	41-51	renin	Homo sapiens	63-68
1233219-1	1975	The effects of single doses of the beta1-receptor antagonist metoprolol (40 mg orally), propranolol (40 mg orally) and placebo were compared on furosemide-stimulated plasma renin activity (PRA) in seven healthy subjects.	Furosemide	144-154	renin	Homo sapiens	173-178
1159891-0	1975	[Effect of furosemide and d-1-propranolol on glomerular filtration and renin secretin in rats].	Furosemide	11-21	secretin	Rattus norvegicus	77-85
164581-7	1975	With Furosemid treatment the activities of beta-glucuronidase and cathepsin D increased in the lysosomal supernatant and the lysosomal sediment of the 1-year old rats, whereas the activities of the collagenolytic enzyme increased in the lysosomal sediment of the same group.	Furosemide	5-14	glucuronidase, beta	Rattus norvegicus	43-61
164581-7	1975	With Furosemid treatment the activities of beta-glucuronidase and cathepsin D increased in the lysosomal supernatant and the lysosomal sediment of the 1-year old rats, whereas the activities of the collagenolytic enzyme increased in the lysosomal sediment of the same group.	Furosemide	5-14	cathepsin D	Rattus norvegicus	66-77
637637-4	1978	Aldosterone responses in relation to changes in peripheral renin activity were found to be nearly random with both furosemide and with posture.	Furosemide	115-125	renin	Homo sapiens	59-64
1263402-2	1976	Stimulation of the renin activity was achieved by orthostasis or by furosemide.	Furosemide	68-78	renin	Homo sapiens	19-24
938983-0	1976	Effects of furosemide and chlorothiazide on blood pressure and plasma renin activity.	Furosemide	11-21	renin	Homo sapiens	70-75
1083996-0	1976	[Influence of furosemide and propranolol (beta blocking agent) on plasmatic renin liberation in dogs].	Furosemide	14-24	renin	Canis lupus familiaris	76-81
937140-5	1976	Furosemide 5 mg in hyperhydrated animals produced in the same period an excretion of 645 +/- 52 ng BR of Kal, which is 147% higher to that excreted by the hyperhydrated controls.	Furosemide	0-10	kallikrein related-peptidase 5 like	Rattus norvegicus	105-108
937140-6	1976	The same dose of furosemide in 2% NaCl loaded rats, produced an excretion of Kal equivalent to 1333 +/- 72 ng BR which is 180% greater than in controls similarly loaded.	Furosemide	17-27	kallikrein related-peptidase 5 like	Rattus norvegicus	77-80
937140-7	1976	Acetazoleamide 20 mg and furosemide 5 mg produced similar excretions of Kal even though natriuresis is greater tna kalliuresis is lesser in furosemide injected rats.	Furosemide	25-35	kallikrein related-peptidase 5 like	Rattus norvegicus	72-75
937140-8	1976	Evaluation of total kidney Kal has shown that a single (10 mg) or a series of furosemide injections (8 days 5 mg + 1 day 10 mg), brings about a significant (p is less than 0.001) decrease in renal Kal, but the increase of Kal excreted in the urine (120 min) is 3.5 times more (under a single injection) and 42 times more (under 9 injections) than the amount which disappears from the kidneys.	Furosemide	78-88	kallikrein related-peptidase 5 like	Rattus norvegicus	27-30
937140-8	1976	Evaluation of total kidney Kal has shown that a single (10 mg) or a series of furosemide injections (8 days 5 mg + 1 day 10 mg), brings about a significant (p is less than 0.001) decrease in renal Kal, but the increase of Kal excreted in the urine (120 min) is 3.5 times more (under a single injection) and 42 times more (under 9 injections) than the amount which disappears from the kidneys.	Furosemide	78-88	kallikrein related-peptidase 5 like	Rattus norvegicus	197-200
937140-8	1976	Evaluation of total kidney Kal has shown that a single (10 mg) or a series of furosemide injections (8 days 5 mg + 1 day 10 mg), brings about a significant (p is less than 0.001) decrease in renal Kal, but the increase of Kal excreted in the urine (120 min) is 3.5 times more (under a single injection) and 42 times more (under 9 injections) than the amount which disappears from the kidneys.	Furosemide	78-88	kallikrein related-peptidase 5 like	Rattus norvegicus	197-200
937140-9	1976	Apparently furosemide not only stimulates Kal excretion, but also Kal synthesis in the kidney.	Furosemide	11-21	kallikrein related-peptidase 5 like	Rattus norvegicus	42-45
937140-9	1976	Apparently furosemide not only stimulates Kal excretion, but also Kal synthesis in the kidney.	Furosemide	11-21	kallikrein related-peptidase 5 like	Rattus norvegicus	66-69
985607-12	1976	High concentrations of furosemide stimulated renin release by a direct intrarenal mechanism.	Furosemide	23-33	renin	Bos taurus	45-50
183224-3	1976	Both acetaminophen and furosemide decreased the concentrations of cytochrome P-450 and cytochrome b5 in microsomes, and the activity of microsomal ethylmorphine N-demethylase and aniline hydroxylase.	Furosemide	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	66-100
1257693-0	1976	Unimpeded plasma renin increase after intravenous furosemide during saline replacement.	Furosemide	50-60	renin	Homo sapiens	17-22
1257693-1	1976	The effect on plasma renin activity of intravenous furosemide combined with saline replacement of the volume depletion was studied in twelve patients with insignificant heart disease.	Furosemide	51-61	renin	Homo sapiens	21-26
1182938-2	1975	Experiments were undertaken to investigate further the effect of furosemide on renin secretion in the anesthetized dog.	Furosemide	65-75	renin	Canis lupus familiaris	79-84
1182938-4	1975	Furosemide, in a dose of 5 mg/kg, increased renin secretion and decreased renal resistance in dogs with a nonfiltering kidney.	Furosemide	0-10	renin	Canis lupus familiaris	44-49
1182938-6	1975	However, following dilation of the intact filtering kidney with acetylcholine, furosemide caused an increase in renin secretion.	Furosemide	79-89	renin	Canis lupus familiaris	112-117
1182938-8	1975	Following propranolol treatment, furosemide increased renin secretion in the filtering kidney but had no effect on renal resistance.	Furosemide	33-43	renin	Canis lupus familiaris	54-59
1182938-9	1975	These experiments indicate that furosemide stimulates renin secretion by both the macula densa and the baroreceptor mechanisms.	Furosemide	32-42	renin	Canis lupus familiaris	54-59
1105697-3	1975	Furosemide alone resulted in a significant blood pressure fall with a rise in plasma renin and urinary aldosterone with a marked increase in urinary sodium loss.	Furosemide	0-10	renin	Homo sapiens	85-90
1150481-4	1975	In the patients who were given substitution therapy with hydrocortisone, studies of plasma renin and aldosterone revealed impairment of plasma aldosterone response to salt restriction, orthostatism and furosemide-induced diuresis combined with postural change.	Furosemide	202-212	renin	Homo sapiens	91-96
1138585-1	1975	A standardized test for renin responsiveness, employing the dual stimulus of upright posture and the loop diuretic furosemide, was applied to 19 hypertensive patients in the untreated state and during therapy with the antihypertensive agents guanethidine and methyldopa.	Furosemide	115-125	renin	Homo sapiens	24-29
1155613-5	1975	The addition of furosemide (from 10 minus 5 to 10 minus 3 M) stimulated renin secretion.	Furosemide	16-26	renin	Rattus norvegicus	72-77
802648-11	1975	Oxprenolol suppressed the response of noradrenaline and plasma renin activity to frusemide in all cases.	Furosemide	81-90	renin	Homo sapiens	63-68
1129331-6	1975	Stimulation of renin secretion occurred after furosemide in indomethacin-treated animals.	Furosemide	46-56	renin	Canis lupus familiaris	15-20
1168122-2	1975	They were divided into two groups according to the change in plasma-renin activity in response to furosemide administration: those with and those without response to stimulation, and sub-groups with low, normal or high plasma-renin activity (low renin hypertension; normal renin hypertension; high renin hypertension).	Furosemide	98-108	renin	Homo sapiens	68-73
1223821-1	1975	In 22 patients with chronic cor pulmonale syndrome plasma renin activity (PRA) was determined at rest and after stimulation by means of intravenous injection of furosemide.	Furosemide	161-171	renin	Homo sapiens	58-63
1135521-0	1975	Marked elevation of plasma renin activity during post diuretic sodium conservation in furosemide stimulated subjects.	Furosemide	86-96	renin	Homo sapiens	27-32
1116335-4	1975	Secondly, renin activity was measured after frusemide stimualtion [0.42 mmol (140 mg) in 18 h] and 3 h ambulation.	Furosemide	44-53	renin	Homo sapiens	10-15
172003-3	1975	The sodium depletion induced by furosemide during continuous ACTH infusion increases plasma renin activity but does not change PA.	Furosemide	32-42	proopiomelanocortin	Homo sapiens	61-65
172003-3	1975	The sodium depletion induced by furosemide during continuous ACTH infusion increases plasma renin activity but does not change PA.	Furosemide	32-42	renin	Homo sapiens	92-97
1071582-2	1976	The effect of diazoxide (17-3 micronmol min-1 g-1) and frusemide (0-12 micronmol min-1 g-1) on renin secretion was examined in the isolated perfused rat kidney.	Furosemide	55-64	renin	Rattus norvegicus	95-100
1071582-10	1976	These observations identify an intrarenal site of action for diazoxide and frusemide on renin secretion.	Furosemide	75-84	renin	Rattus norvegicus	88-93
1071587-8	1976	Frusemide effectively reduced blood pressure and renin at all phases.	Furosemide	0-9	renin	Rattus norvegicus	49-54
1071603-2	1976	Supine plasma renin activity and its responsiveness to erect posture and frusemide were reduced in fifty-one patients with essential hypertension, compared with fifty-one age- and sex-matched control subjects.	Furosemide	73-82	renin	Homo sapiens	14-19
180717-0	1975	[Cyclic AMP and renin secretion following furosemide, beta-sympathicolysis and amitryptiline].	Furosemide	42-52	renin	Homo sapiens	16-21
4443232-0	1974	Renin response to furosemide and hypertonic saline infusion.	Furosemide	18-28	renin	Homo sapiens	0-5
4376467-0	1974	[Furosemide action on the liberation of renin in vitro].	Furosemide	1-11	renin	Homo sapiens	40-45
4859545-0	1974	The nature of renin released in the dog followin haemorrhage and frusemide.	Furosemide	65-74	renin	Canis lupus familiaris	14-19
1186924-0	1975	Inhibition of furosemide-induced renin release by vasoconstrictors.	Furosemide	14-24	renin	Homo sapiens	33-38
4821039-7	1974	Frusemide had no clear effect on the rate of beating of the controls, but it tended to reverse both the acceleration produced by 50 ng/ml prolactin and the slowing produced by the higher dose.	Furosemide	0-9	prolactin	Homo sapiens	138-147
4659318-0	1972	Effects of hemorrhage and furosemide on renin release in dogs.	Furosemide	26-36	renin	Canis lupus familiaris	40-45
4454541-0	1974	[Effect of propranolol on the stimulation of renin secretion due to orthostasis and furosemide].	Furosemide	84-94	renin	Homo sapiens	45-50
4366973-4	1973	Activity of this enzyme in the presence of 0.1 muM cAMP was significantly inhibited by 100 muM mercuderamide, bumetanide and frusemide.	Furosemide	125-134	latexin	Homo sapiens	47-50
4366973-4	1973	Activity of this enzyme in the presence of 0.1 muM cAMP was significantly inhibited by 100 muM mercuderamide, bumetanide and frusemide.	Furosemide	125-134	latexin	Homo sapiens	91-94
4724467-0	1973	[The influence of mannitol and furosemide on plasma renin activity in dogs with expansion of the extracellular volume].	Furosemide	31-41	renin	Canis lupus familiaris	52-57
5074393-0	1972	Release of renin into the peripheral circulation of the ewe and foetus, following administration of frusemide, a natriuretic agent.	Furosemide	100-109	renin	Homo sapiens	11-16
4354807-0	1973	Effect of propranolol and theophylline on renin release caused by furosemide in the cat.	Furosemide	66-76	renin	Homo sapiens	42-47
4265384-12	1973	Furosemide at high concentrations inhibited ATPase, reducing both ouabain-sensitive and ouabain-insensitive enzyme at 1.0 mM concentration while showing no effect on ATPase at 0.05-0.1 mM concentration.	Furosemide	0-10	dynein axonemal heavy chain 8	Homo sapiens	44-50
4265384-13	1973	The effects of furosemide on ATPase and on Na flux were dissociable on a dose-response curve.	Furosemide	15-25	dynein axonemal heavy chain 8	Homo sapiens	29-35
4318270-0	1970	Effect of furosemide and hydrochlorothiazide on plasma renin activity in man.	Furosemide	10-20	renin	Homo sapiens	55-60
4708961-0	1973	Renin output by diseased and contralateral normal dog kidneys following extracellular fluid volume expansion and furosemide.	Furosemide	113-123	renin	Canis lupus familiaris	0-5
4996929-0	1970	[Glucagon test and electrolytes in long term administration of furosemide to insulin requiring diabetics].	Furosemide	63-73	insulin	Homo sapiens	77-84
5163370-1	1971	Effects of methylclothiazide and frusemide on blood pressure and plasma renin activity and electrolytes.	Furosemide	33-42	renin	Homo sapiens	72-77
4308808-0	1969	Mechanism of the effects of furosemide on renin secretion in anesthetized dogs.	Furosemide	28-38	renin	Canis lupus familiaris	42-47
4159219-0	1965	Effect of angiotensin and of frusemide on plasma aldosterone, corticosterone, cortisol and renin in man.	Furosemide	29-38	renin	Homo sapiens	91-96
4976775-0	1969	[Action of furosemide on renin secretion in dogs].	Furosemide	11-21	renin	Canis lupus familiaris	25-30
5676393-0	1968	Mechanism of renin release following furosemide diuresis in rabbit.	Furosemide	37-47	LOW QUALITY PROTEIN: renin	Oryctolagus cuniculus	13-18
5642446-0	1968	Acute changes in plasma volume, renin activity, and free aldosterone levels in healthy subjects following Fursemide administration.	Furosemide	106-115	renin	Homo sapiens	32-37
6065850-0	1967	Frusemide induced diuresis as an aid to transfusion in severe anaemia.	Furosemide	0-9	activation induced cytidine deaminase	Homo sapiens	33-36
33356948-6	2021	Two of the KCC2 screens identified new inhibitors that are 3-4 orders of magnitude more potent than furosemide.	Furosemide	100-110	solute carrier family 12 member 5	Homo sapiens	11-15
33988989-4	2021	The HD-CNTf rod mu-ES has been evaluated by electrochemical determination of biologically important analytes, i.e., dopamine (DA), beta-nicotinamide adenine dinucleotide (NADH), a diuretic drug, i.e., furosemide, and a heavy metal, i.e., lead ions (Pb2+).	Furosemide	201-211	ciliary neurotrophic factor	Homo sapiens	7-11
33828237-6	2021	Furthermore, the therapeutic effects of the diuretic furosemide on Abeta clearance via the kidney were assessed.	Furosemide	53-63	amyloid beta (A4) precursor protein	Mus musculus	67-72
33828237-9	2021	In addition, chronic furosemide treatment reduced blood and brain Abeta levels and attenuated AD pathologies and cognitive deficits in APP/PS1 mice.	Furosemide	21-31	amyloid beta (A4) precursor protein	Mus musculus	66-71
33828237-9	2021	In addition, chronic furosemide treatment reduced blood and brain Abeta levels and attenuated AD pathologies and cognitive deficits in APP/PS1 mice.	Furosemide	21-31	presenilin 1	Mus musculus	139-142
33647281-5	2021	Compared to euhydrated condition, the treatment with the diuretic furosemide + low dose of captopril (angiotensin converting enzyme blocker) increased the number of hedonic and reduced the number of aversive responses to intra-oral NaCl in normotensive rats, without changing the number of hedonic or aversive responses in SHRs.	Furosemide	66-76	angiotensin I converting enzyme	Rattus norvegicus	102-131
33742787-6	2021	In Trial 2, 40 mg furosemide (OAT3 substrate) was administered alone and in presence of DM-4103.	Furosemide	18-28	solute carrier family 22 member 8	Homo sapiens	30-34
33969697-5	2021	Here we show that levels of Na+-K+-2Cl- cotransporter isoform 2 (NKCC2) and Na+/H+ exchanger isoform 3 (NHE3) are reduced at baseline in SMKOs, accompanied by attenuated natriuretic and diuretic responses to furosemide.	Furosemide	208-218	solute carrier family 12, member 1	Mus musculus	28-63
33969697-5	2021	Here we show that levels of Na+-K+-2Cl- cotransporter isoform 2 (NKCC2) and Na+/H+ exchanger isoform 3 (NHE3) are reduced at baseline in SMKOs, accompanied by attenuated natriuretic and diuretic responses to furosemide.	Furosemide	208-218	solute carrier family 12, member 1	Mus musculus	65-70
33969697-5	2021	Here we show that levels of Na+-K+-2Cl- cotransporter isoform 2 (NKCC2) and Na+/H+ exchanger isoform 3 (NHE3) are reduced at baseline in SMKOs, accompanied by attenuated natriuretic and diuretic responses to furosemide.	Furosemide	208-218	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	76-102
33969697-5	2021	Here we show that levels of Na+-K+-2Cl- cotransporter isoform 2 (NKCC2) and Na+/H+ exchanger isoform 3 (NHE3) are reduced at baseline in SMKOs, accompanied by attenuated natriuretic and diuretic responses to furosemide.	Furosemide	208-218	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	104-108
33356004-7	2021	Urinary excretion of NKCC2 increased after furosemide and the increase in NKCC2 correlated with an increase in urine output and a decrease in ECW.	Furosemide	43-53	solute carrier family 12 member 1	Homo sapiens	21-26
33239392-7	2021	The kidney furosemide clearance correlated with iGFR (r=0.84) and the summary secretion score (r=0.86).	Furosemide	11-21	insulin like growth factor 1 receptor	Homo sapiens	48-52
33239392-8	2021	The mean proportionate error (MPE) between iGFR-predicted and measured furosemide clearance was 30.0%.	Furosemide	71-81	insulin like growth factor 1 receptor	Homo sapiens	43-47
33166587-6	2021	The blockade of ERK1/2 activation with icv injections of U0126 (MEK1/2 inhibitor, 2 mM; 2 mul) reduced 0.3 M NaCl induced by furosemide + captopril (5.0 +- 1.0, vs. vehicle: 7.3 +- 0.7 ml/120 min) or WD-PR (4.6 +- 1.3, vs. vehicle: 10.3 +- 1.4 ml/120 min).	Furosemide	125-135	mitogen activated protein kinase 3	Rattus norvegicus	16-22
33166587-6	2021	The blockade of ERK1/2 activation with icv injections of U0126 (MEK1/2 inhibitor, 2 mM; 2 mul) reduced 0.3 M NaCl induced by furosemide + captopril (5.0 +- 1.0, vs. vehicle: 7.3 +- 0.7 ml/120 min) or WD-PR (4.6 +- 1.3, vs. vehicle: 10.3 +- 1.4 ml/120 min).	Furosemide	125-135	mitogen activated protein kinase kinase 1	Rattus norvegicus	64-70
33514009-0	2021	Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs.	Furosemide	29-39	ATP binding cassette subfamily B member 1	Homo sapiens	58-72
33514009-1	2021	In this study, the amino acid arginine (ARG) and P-glycoprotein (P-gp) inhibitors verapamil hydrochloride (VER), piperine (PIP) and quercetin (QRT) were used as co-formers for co-amorphous mixtures of a Biopharmaceutics classification system (BCS) class IV drug, furosemide (FUR).	Furosemide	263-273	ATP binding cassette subfamily B member 1	Homo sapiens	65-69
33514009-1	2021	In this study, the amino acid arginine (ARG) and P-glycoprotein (P-gp) inhibitors verapamil hydrochloride (VER), piperine (PIP) and quercetin (QRT) were used as co-formers for co-amorphous mixtures of a Biopharmaceutics classification system (BCS) class IV drug, furosemide (FUR).	Furosemide	275-278	ATP binding cassette subfamily B member 1	Homo sapiens	65-69
33580790-0	2021	The FAST-FURO study: effect of very early administration of intravenous furosemide in the prehospital setting to patients with acute heart failure attending the emergency department.	Furosemide	72-82	Fas activated serine/threonine kinase	Homo sapiens	4-8
33435470-4	2021	Rosmarinic acid inhibited the transport activities of OAT1, OAT3, organic anion transporting polypeptide (OATP)1B1, and OATP1B3 with IC50 values of 60.6 muM, 1.52 muM, 74.8 muM, and 91.3 muM, respectively, and the inhibitory effect of rosmarinic acid on OAT3 transport activity caused an in vivo pharmacokinetic interaction with furosemide by inhibiting its renal excretion and by increasing its plasma concentration.	Furosemide	329-339	solute carrier family 22 member 6	Homo sapiens	54-58
33356004-1	2021	BACKGROUND: Furosemide inhibits the sodium potassium chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle and increases urinary water and sodium excretion.	Furosemide	12-22	solute carrier family 12 member 1	Homo sapiens	77-82
33410279-0	2021	ENaC expression correlates with the acute furosemide-induced K+ excretion.	Furosemide	42-52	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	0-4
33410279-11	2021	In contrast, furosemide-induced kaliuresis was greatly enhanced in animals fed a high K+ or low Na+ diet, conditions with increased ENaC expression.	Furosemide	13-23	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	132-136
33410279-13	2021	CONCLUSION: Acute furosemide-induced kaliuresis differs greatly and depends on the a priori molecular expression level of ENaC.	Furosemide	18-28	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	122-126
33356004-10	2021	Finally, urinary proteins from NKCC2 increases after furosemide with a good correlation with diuresis end the decrease in ECW.	Furosemide	53-63	solute carrier family 12 member 1	Homo sapiens	31-36
32905120-3	2020	The angiotensin-converting enzyme (ACE) is an important element for the cardiovascular system, through its actions on hydro-salin balance and vascular tone.	Furosemide	118-123	angiotensin I converting enzyme	Homo sapiens	4-33
33225679-7	2020	Our data demonstrate that furosemide inhibits the secretion of proinflammatory TNF-alpha, IL-6, and nitric oxide; downregulates the mRNA level of Cd86 and the protein expression of COX-2, iNOS; promotes phagocytic activity; and enhances the expression of anti-inflammatory IL-1RA and arginase.	Furosemide	26-36	tumor necrosis factor	Homo sapiens	79-88
33225679-7	2020	Our data demonstrate that furosemide inhibits the secretion of proinflammatory TNF-alpha, IL-6, and nitric oxide; downregulates the mRNA level of Cd86 and the protein expression of COX-2, iNOS; promotes phagocytic activity; and enhances the expression of anti-inflammatory IL-1RA and arginase.	Furosemide	26-36	interleukin 6	Homo sapiens	90-94
33225679-7	2020	Our data demonstrate that furosemide inhibits the secretion of proinflammatory TNF-alpha, IL-6, and nitric oxide; downregulates the mRNA level of Cd86 and the protein expression of COX-2, iNOS; promotes phagocytic activity; and enhances the expression of anti-inflammatory IL-1RA and arginase.	Furosemide	26-36	CD86 molecule	Homo sapiens	146-150
33225679-7	2020	Our data demonstrate that furosemide inhibits the secretion of proinflammatory TNF-alpha, IL-6, and nitric oxide; downregulates the mRNA level of Cd86 and the protein expression of COX-2, iNOS; promotes phagocytic activity; and enhances the expression of anti-inflammatory IL-1RA and arginase.	Furosemide	26-36	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	181-186
33225679-7	2020	Our data demonstrate that furosemide inhibits the secretion of proinflammatory TNF-alpha, IL-6, and nitric oxide; downregulates the mRNA level of Cd86 and the protein expression of COX-2, iNOS; promotes phagocytic activity; and enhances the expression of anti-inflammatory IL-1RA and arginase.	Furosemide	26-36	inositol-3-phosphate synthase 1	Homo sapiens	188-192
33225679-7	2020	Our data demonstrate that furosemide inhibits the secretion of proinflammatory TNF-alpha, IL-6, and nitric oxide; downregulates the mRNA level of Cd86 and the protein expression of COX-2, iNOS; promotes phagocytic activity; and enhances the expression of anti-inflammatory IL-1RA and arginase.	Furosemide	26-36	interleukin 1 receptor antagonist	Homo sapiens	273-279
33225679-8	2020	Our mechanism of action studies further demonstrate that furosemide reduces LPS-induced upregulation of endoplasmic reticulum (ER) stress marker genes, including Grp78, Atf4, Chop, tXbp1, and sXbp1.	Furosemide	57-67	heat shock protein family A (Hsp70) member 5	Homo sapiens	162-167
33225679-8	2020	Our mechanism of action studies further demonstrate that furosemide reduces LPS-induced upregulation of endoplasmic reticulum (ER) stress marker genes, including Grp78, Atf4, Chop, tXbp1, and sXbp1.	Furosemide	57-67	activating transcription factor 4	Homo sapiens	169-173
33225679-8	2020	Our mechanism of action studies further demonstrate that furosemide reduces LPS-induced upregulation of endoplasmic reticulum (ER) stress marker genes, including Grp78, Atf4, Chop, tXbp1, and sXbp1.	Furosemide	57-67	DNA damage inducible transcript 3	Homo sapiens	175-179
33225679-8	2020	Our mechanism of action studies further demonstrate that furosemide reduces LPS-induced upregulation of endoplasmic reticulum (ER) stress marker genes, including Grp78, Atf4, Chop, tXbp1, and sXbp1.	Furosemide	57-67	internexin neuronal intermediate filament protein alpha	Homo sapiens	181-186
33369473-1	2020	OBJECTIVE: The aim of current study is to evaluate the role of diuretic assisted 68Ga-PSMA PET-CT, on image quality and clinical interpretation of indeterminate/equivocal lesions in pre-Lasix imaging of Prostate cancer.	Furosemide	186-191	folate hydrolase 1	Homo sapiens	86-90
33202945-4	2020	This work aimed to study the compatibility of furosemide and torsemide with PN used in clinical practice.	Furosemide	46-56	U6 snRNA biogenesis phosphodiesterase 1	Homo sapiens	76-78
32892950-11	2020	Further, pre-treatment with furosemide, a KCC2 inhibitor, during CTZ stimulation followed by washout significantly prevented convulsant stimulation-induced membrane KCC2 downregulation and significantly attenuated GABAAR downregulation concomitant with recovery of suppressed KCC2-independent GABAergic mIPSC amplitude.	Furosemide	28-38	solute carrier family 12 member 5	Homo sapiens	42-46
32892950-11	2020	Further, pre-treatment with furosemide, a KCC2 inhibitor, during CTZ stimulation followed by washout significantly prevented convulsant stimulation-induced membrane KCC2 downregulation and significantly attenuated GABAAR downregulation concomitant with recovery of suppressed KCC2-independent GABAergic mIPSC amplitude.	Furosemide	28-38	solute carrier family 12 member 5	Homo sapiens	165-169
32892950-11	2020	Further, pre-treatment with furosemide, a KCC2 inhibitor, during CTZ stimulation followed by washout significantly prevented convulsant stimulation-induced membrane KCC2 downregulation and significantly attenuated GABAAR downregulation concomitant with recovery of suppressed KCC2-independent GABAergic mIPSC amplitude.	Furosemide	28-38	solute carrier family 12 member 5	Homo sapiens	165-169
32799423-8	2020	The expression level of TMPRSS2 was increased with a number of medications, such as diclofenac, furosemide, and dexamethasone, whereas other medications, such as allopurinol, suppressed the expression of this gene.	Furosemide	96-106	transmembrane serine protease 2	Rattus norvegicus	24-31
32905120-3	2020	The angiotensin-converting enzyme (ACE) is an important element for the cardiovascular system, through its actions on hydro-salin balance and vascular tone.	Furosemide	118-123	angiotensin I converting enzyme	Homo sapiens	35-38
31422111-8	2020	Over 72h, the CA125-guided group received higher furosemide equivalent dose compared to usual care (p=0.011), which translated into higher urine volume (p=0.042).	Furosemide	49-59	mucin 16, cell surface associated	Homo sapiens	14-19
31928473-0	2020	Re: WNK4 Limits Distal Calcium Losses following Acute Furosemide Treatment.	Furosemide	54-64	WNK lysine deficient protein kinase 4	Homo sapiens	4-8
32622469-5	2020	Inhaled furosemide, a small molecule capable of inhibiting IL-6 and TNFalpha, may be an agent capable of treating the Coronavirus Disease 2019 cytokine storm in both resource-rich and developing countries.	Furosemide	8-18	interleukin 6	Homo sapiens	59-63
32622469-5	2020	Inhaled furosemide, a small molecule capable of inhibiting IL-6 and TNFalpha, may be an agent capable of treating the Coronavirus Disease 2019 cytokine storm in both resource-rich and developing countries.	Furosemide	8-18	tumor necrosis factor	Homo sapiens	68-76
32743772-6	2020	Clearance of MDR1-mediated digoxin, OAT3-mediated furosemide, and OCT2-mediated metformin increased by 3.04-fold, 1.47-fold, and 1.26-fold, respectively.	Furosemide	50-60	solute carrier family 22 (organic anion transporter), member 8	Mus musculus	36-40
32647034-3	2020	METHOD: We initiated a community-based continuous subcutaneous infusion (CSCI) furosemide service for the treatment of advanced heart failure.	Furosemide	79-89	CSCI	Homo sapiens	73-77
32647034-8	2020	There was a reduction in mean hospital admission rates from 2.87 to 0.73 (p<0.001) in the 6-month periods either side of the first episode of CSCI furosemide.	Furosemide	147-157	CSCI	Homo sapiens	142-146
32704455-10	2020	Upon treatment with furosemide, LPS-induced production of pro-inflammatory cytokines was reduced, indicating that furosemide suppresses the M1 polarization, including IL-6 and TNF-alpha release.	Furosemide	20-30	interleukin 6	Homo sapiens	167-171
32704455-10	2020	Upon treatment with furosemide, LPS-induced production of pro-inflammatory cytokines was reduced, indicating that furosemide suppresses the M1 polarization, including IL-6 and TNF-alpha release.	Furosemide	20-30	tumor necrosis factor	Homo sapiens	176-185
32704455-10	2020	Upon treatment with furosemide, LPS-induced production of pro-inflammatory cytokines was reduced, indicating that furosemide suppresses the M1 polarization, including IL-6 and TNF-alpha release.	Furosemide	114-124	interleukin 6	Homo sapiens	167-171
32704455-10	2020	Upon treatment with furosemide, LPS-induced production of pro-inflammatory cytokines was reduced, indicating that furosemide suppresses the M1 polarization, including IL-6 and TNF-alpha release.	Furosemide	114-124	tumor necrosis factor	Homo sapiens	176-185
32704455-11	2020	In addition, we found that furosemide promotes the production of anti-inflammatory cytokine products (IL-1RA, arginase), indicating M2 polarization.	Furosemide	27-37	interleukin 1 receptor antagonist	Homo sapiens	102-108
32704455-12	2020	Accordingly, we conclude that furosemide is a reasonably potent inhibitor of IL-6 and TNF-alpha that is also safe, inexpensive and well-studied.	Furosemide	30-40	interleukin 6	Homo sapiens	77-81
32704455-12	2020	Accordingly, we conclude that furosemide is a reasonably potent inhibitor of IL-6 and TNF-alpha that is also safe, inexpensive and well-studied.	Furosemide	30-40	tumor necrosis factor	Homo sapiens	86-95
32426035-5	2020	In this model system and in the setting of furosemide-induced sodium excretion, alpha 2-AR activation inhibited adenylate cyclase, suppressed cAMP formation, and caused sodium retention.	Furosemide	43-53	glycoprotein hormone subunit alpha 2	Homo sapiens	80-87
32105765-0	2020	miR-182 prevented ototoxic deafness induced by co-administration of kanamycin and furosemide in rats.	Furosemide	82-92	microRNA 182	Rattus norvegicus	0-7
32105765-8	2020	miR-182 treatment also increased the level of phosphoinositide-3 kinase regulatory subunit p85alpha in the outer hair cells after co-administration of kanamycin and furosemide.	Furosemide	165-175	microRNA 182	Rattus norvegicus	0-7
29947262-3	2020	In this study, the effects of the antibiotics, furosemide, cefazolin, cefuroxime, gentamicin and clindamycin on rat erythrocyte G6PD enzyme was studied in in vitro conditions.	Furosemide	47-57	glucose-6-phosphate dehydrogenase	Rattus norvegicus	128-132
29947262-6	2020	The inhibition studies of these antibiotics were carried out on the enzyme revealing that gentamicin, clindamycin and furosemide inhibited the activity of the G6PD with an IC50 of 1.75, 34.65 and 0.526 mM, respectively with Ki of 0.7, 39.8 and 0.860 mM, respectively.	Furosemide	118-128	glucose-6-phosphate dehydrogenase	Rattus norvegicus	159-163
31985207-9	2020	Per-6-thiolated alpha-CD was not cytotoxic to Caco-2 cells in 0.5% (m/v) concentration within 24 h. It improved the solubility of FUR in the same manner as unmodified alpha-CD.	Furosemide	130-133	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	16-24
31985207-10	2020	The addition of per-6-thiolated alpha-CD (0.5% m/v) increased the mucus viscosity up to 5.8-fold at 37  C within 4 h. Because of the incorporation in per-6-thiolated alpha-CD, the apparent permeability coefficient (Papp) of FUR was 6.87-fold improved on the Caco-2 cell monolayer and 6.55-fold on the intestinal mucosa.	Furosemide	224-227	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	32-40
31985207-11	2020	Moreover, in vivo studies showed a 4.9-fold improved oral bioavailability of FUR due to the incorporation in per-6-thiolated alpha-CD.	Furosemide	77-80	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	125-133
31422111-9	2020	Moreover, patients in the active arm with CA125&gt;35U/mL received the highest furosemide equivalent dose (p&lt;0.001) and had higher diuresis (p=0.013).	Furosemide	79-89	mucin 16, cell surface associated	Homo sapiens	42-47
31633875-0	2019	The displacement study of 99m Tc-DTPA-Human serum albumin binding in presence of furosemide and metformin by using equilibrium dialysis and molecular docking.	Furosemide	81-91	albumin	Homo sapiens	50-57
31896111-2	2020	OBJECTIVE: This study tested the hypothesis that the fall in GFR with furosemide is due to volume depletion or activation of angiotensin type 1 (AT1) receptors or renal nerves.	Furosemide	70-80	angiotensin II receptor, type 1a	Rattus norvegicus	125-143
31896111-2	2020	OBJECTIVE: This study tested the hypothesis that the fall in GFR with furosemide is due to volume depletion or activation of angiotensin type 1 (AT1) receptors or renal nerves.	Furosemide	70-80	angiotensin II receptor, type 1a	Rattus norvegicus	145-148
31724190-7	2020	Positive DAT occurred in 53 (30 3%) and was related to high MELD score (P = 0 048), HCV (P = 0 005) and furosemide use (P = 0 001).	Furosemide	104-114	solute carrier family 6 member 3	Homo sapiens	9-12
32734228-7	2020	In our patient with long-term activated tubuloglomerular feedback due to SGLT-2 mutations, we show that the sensitivity of tubuloglomerular feedback is maintained, demonstrated by an increase in GFR measured using iohexol clearance following furosemide administration.	Furosemide	242-252	solute carrier family 5 member 2	Homo sapiens	73-79
31760770-6	2020	In vivo, Sox6 expression is upregulated after a low-Na+ diet and furosemide.	Furosemide	65-75	SRY-box transcription factor 6	Rattus norvegicus	9-13
31760770-7	2020	Importantly, knockout of Sox6 in Ren1d+ cells halts the increase in renin-expressing cells normally seen during a low-Na+ diet and furosemide as well as the typical increase in renin.	Furosemide	131-141	SRY-box transcription factor 6	Rattus norvegicus	25-29
31365295-1	2019	The Na+K+2Cl- cotransporter-2 (Nkcc2, Slc12a1) is abundantly expressed in the kidney and its inhibition with the loop-diuretics bumetanide and furosemide has been linked to transient or permanent hyperglycemia in mice and humans.	Furosemide	143-153	solute carrier family 12, member 1	Mus musculus	4-29
31809955-0	2019	Comparison between the effects of torsemide and furosemide on the renin-angiotensin-aldosterone system of normal dogs.	Furosemide	48-58	renin	Canis lupus familiaris	66-71
31809955-1	2019	INTRODUCTION/OBJECTIVES: We hypothesized that torsemide and furosemide, at approximately equipotent dosages (similar diuresis), would have comparable effects on the circulating renin-angiotensin-aldosterone system.	Furosemide	60-70	renin	Canis lupus familiaris	177-182
31809955-11	2019	CONCLUSIONS: At approximately equipotent dosages (20:1), torsemide and furosemide produced comparable renin-angiotensin-aldosterone system activation.	Furosemide	71-81	renin	Canis lupus familiaris	102-107
31779627-8	2019	The degradation of furosemide and trimethoprim by soybean peroxidase and chloroperoxidase, respectively, was investigated in detail by examining the transformation products generated during their degradation.	Furosemide	19-29	peroxidase	Glycine max	58-68
31365295-1	2019	The Na+K+2Cl- cotransporter-2 (Nkcc2, Slc12a1) is abundantly expressed in the kidney and its inhibition with the loop-diuretics bumetanide and furosemide has been linked to transient or permanent hyperglycemia in mice and humans.	Furosemide	143-153	solute carrier family 12, member 1	Mus musculus	31-36
31365295-1	2019	The Na+K+2Cl- cotransporter-2 (Nkcc2, Slc12a1) is abundantly expressed in the kidney and its inhibition with the loop-diuretics bumetanide and furosemide has been linked to transient or permanent hyperglycemia in mice and humans.	Furosemide	143-153	solute carrier family 12, member 1	Mus musculus	38-45
28358186-4	2019	After full body acquisition, 58 patients were administered 20 mg of furosemide 90 min post injection of FDG (P90).	Furosemide	68-78	cellular inhibitor of PP2A	Homo sapiens	109-112
31496133-0	2019	WNK4 limits distal calcium losses following acute furosemide treatment.	Furosemide	50-60	WNK lysine deficient protein kinase 4	Homo sapiens	0-4
31496133-7	2019	Following acute treatment with the loop diuretic, furosemide, which causes hypercalciuria through TAL inhibition, WNK4-/- animals demonstrated increased calcium wasting compared with wild-type controls.	Furosemide	50-60	WNK lysine deficient protein kinase 4	Homo sapiens	114-118
31496133-11	2019	Our data show that WNK4, via regulation of TRPV5, limits distal calcium losses following acute treatment with furosemide; however, WNK4 deletion does not affect the chronic renal response to dietary calcium depletion.	Furosemide	110-120	WNK lysine deficient protein kinase 4	Homo sapiens	19-23
31496133-11	2019	Our data show that WNK4, via regulation of TRPV5, limits distal calcium losses following acute treatment with furosemide; however, WNK4 deletion does not affect the chronic renal response to dietary calcium depletion.	Furosemide	110-120	transient receptor potential cation channel subfamily V member 5	Homo sapiens	43-48
30578654-9	2019	CONCLUSION: Sodium-glucose cotransporter 2 inhibitor DAPA predominantly decreased the ECW with a mild increase in urine volume, but the change in the ECW/total body water was smaller than that in patients treated with FR, and larger than that in patients treated with TLV, suggesting that the effects of SGLT2 inhibitors on fluid distribution may differ from those of conventional diuretics.	Furosemide	218-220	solute carrier family 5 member 2	Homo sapiens	12-42
28358186-5	2019	For 44 patients, 20 mg of furosemide was administered 30 min post injection of FDG (P30).	Furosemide	26-36	centromere protein V	Homo sapiens	84-87
31274842-6	2019	Furosemide dose-dependently induced plasma renin and angiotensin I levels, while an equiefficient diuretic BAY 1753011 dose did not activate the renin-angiotensin system.	Furosemide	0-10	renin	Homo sapiens	43-48
31274842-6	2019	Furosemide dose-dependently induced plasma renin and angiotensin I levels, while an equiefficient diuretic BAY 1753011 dose did not activate the renin-angiotensin system.	Furosemide	0-10	angiotensinogen	Homo sapiens	53-66
30417726-4	2019	Furosemide, a recognized KCC2 antagonist in animals, blocks the formation of inhibitory post-synaptic potentials in spinal motoneurons without affecting excitatory post-synaptic potentials.	Furosemide	0-10	solute carrier family 12 member 5	Homo sapiens	25-29
31053298-6	2019	Furosemide treatment dramatically decreased RNF183 expression in the renal medulla, consistent with the decrease in NFAT5 protein and target gene mRNA expression.	Furosemide	0-10	ring finger protein 183	Mus musculus	44-50
31053298-6	2019	Furosemide treatment dramatically decreased RNF183 expression in the renal medulla, consistent with the decrease in NFAT5 protein and target gene mRNA expression.	Furosemide	0-10	nuclear factor of activated T cells 5	Mus musculus	116-121
31053298-8	2019	These results indicated that RNF183 is predominantly expressed in the renal medullary collecting ducts, and that decreased renal medullary tonicity by furosemide treatment decreases RNF183 expression by NFAT5 downregulation.	Furosemide	151-161	ring finger protein 183	Mus musculus	29-35
31053298-8	2019	These results indicated that RNF183 is predominantly expressed in the renal medullary collecting ducts, and that decreased renal medullary tonicity by furosemide treatment decreases RNF183 expression by NFAT5 downregulation.	Furosemide	151-161	ring finger protein 183	Mus musculus	182-188
31053298-8	2019	These results indicated that RNF183 is predominantly expressed in the renal medullary collecting ducts, and that decreased renal medullary tonicity by furosemide treatment decreases RNF183 expression by NFAT5 downregulation.	Furosemide	151-161	nuclear factor of activated T cells 5	Mus musculus	203-208
31316818-4	2019	To address this structural gap, the present work is primarily focused on sulfonamide-lactam and sulfonamide-syn-amide synthons with drugs such as celecoxib, hydro-chloro-thia-zide and furosemide.	Furosemide	184-194	synemin	Homo sapiens	108-111
31159750-8	2019	The increase in u-NGAL was absent when furosemide was given simultaneously, and the responses in u-NGAL were not significantly different from placebo control.	Furosemide	39-49	lipocalin 2	Homo sapiens	18-22
31159750-9	2019	Furosemide changed responses in u-KIM-1 where a delayed increase was observed.	Furosemide	0-10	hepatitis A virus cellular receptor 1	Homo sapiens	34-39
31159750-16	2019	p-AVP was increased by 3% saline, with a larger increase during furosemide.	Furosemide	64-74	arginine vasopressin	Homo sapiens	2-5
31159750-17	2019	CONCLUSION: This study shows minor increases in markers of kidney injury after 3% saline infusion Furosemide abolished the increase in NGAL and postponed the increase in u-KIM-1.	Furosemide	98-108	lipocalin 2	Homo sapiens	135-139
31159750-17	2019	CONCLUSION: This study shows minor increases in markers of kidney injury after 3% saline infusion Furosemide abolished the increase in NGAL and postponed the increase in u-KIM-1.	Furosemide	98-108	hepatitis A virus cellular receptor 1	Homo sapiens	172-177
30992124-2	2019	An early study using furosemide to reversibly reduce EP showed that distortion product otoacoustic emissions (DPOAEs) recovered before EP.	Furosemide	21-31	epiregulin	Homo sapiens	53-55
30706760-4	2019	Here, we showed that in degenerated SGNs, induced by sensory epithelial cell loss in the cochlea of mice following kanamycin and furosemide administration, the lipofuscin area and oxidative stress level were increased, the nuclear-to-cytoplasmic TFEB ratio was decreased, and the late stage of autophagic flux was impaired.	Furosemide	129-139	transcription factor EB	Mus musculus	246-250
30417726-5	2019	Based on observations in animals studies, we hypothesized that furosemide may be used to unmask KCC2 downregulation after spinal cord injury in humans, which contributes to reflex hyperexcitability.	Furosemide	63-73	solute carrier family 12 member 5	Homo sapiens	96-100
30892891-8	2019	Dihydrophenanthrene 1 markedly altered the pharmacokinetic parameters of the diuretic drug furosemide, a known substrate of both OAT1 and OAT3, in vivo.	Furosemide	91-101	solute carrier family 22 member 6	Homo sapiens	129-133
30892891-8	2019	Dihydrophenanthrene 1 markedly altered the pharmacokinetic parameters of the diuretic drug furosemide, a known substrate of both OAT1 and OAT3, in vivo.	Furosemide	91-101	solute carrier family 22 member 8	Homo sapiens	138-142
31086839-12	2019	Conclusion: Furosemide may influence the pharmacokinetics of P-gp-interfering drugs.	Furosemide	12-22	phosphoglycolate phosphatase	Homo sapiens	61-65
31001127-9	2019	Daily diuresis increased from 867 +- 413 to 1221 +- 680 ml; P = 0.25, while the dose of furosemide could be reduced from 620 +- 256 to 360 +- 110 mg/d; P = 0.0005, however, the kidney function deteriorated, with eGFR drop from 32 +- 11 to 25.6 +- 13 ml/min/1.73m2; P = 0.01).	Furosemide	88-98	epidermal growth factor receptor	Homo sapiens	212-216
30839176-7	2019	Administering Ang-(1-7) decreased VO2 ; an effect prevented by dimethyl amiloride and furosemide, signifying that Ang-(1-7) inhibits transport-dependent VO2 in TAL.	Furosemide	86-96	angiopoietin 1	Homo sapiens	14-22
30839176-7	2019	Administering Ang-(1-7) decreased VO2 ; an effect prevented by dimethyl amiloride and furosemide, signifying that Ang-(1-7) inhibits transport-dependent VO2 in TAL.	Furosemide	86-96	angiopoietin 1	Homo sapiens	114-122
30839176-7	2019	Administering Ang-(1-7) decreased VO2 ; an effect prevented by dimethyl amiloride and furosemide, signifying that Ang-(1-7) inhibits transport-dependent VO2 in TAL.	Furosemide	86-96	transaldolase 1	Homo sapiens	160-163
30484346-3	2019	Furosemide acidifies the urine by increasing acid secretion via the Na+-H+ exchanger 3 (NHE3) in TAL and vacuolar H+-ATPase (V-ATPase) in the distal nephron.	Furosemide	0-10	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	68-86
30484346-3	2019	Furosemide acidifies the urine by increasing acid secretion via the Na+-H+ exchanger 3 (NHE3) in TAL and vacuolar H+-ATPase (V-ATPase) in the distal nephron.	Furosemide	0-10	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	88-92
30484346-3	2019	Furosemide acidifies the urine by increasing acid secretion via the Na+-H+ exchanger 3 (NHE3) in TAL and vacuolar H+-ATPase (V-ATPase) in the distal nephron.	Furosemide	0-10	talipes	Mus musculus	97-100
30484346-3	2019	Furosemide acidifies the urine by increasing acid secretion via the Na+-H+ exchanger 3 (NHE3) in TAL and vacuolar H+-ATPase (V-ATPase) in the distal nephron.	Furosemide	0-10	ATPase, H+ transporting, lysosomal V0 subunit D2	Mus musculus	105-123
30484346-6	2019	Treating with furosemide (drinking water) for 11 days led to decreased urine pH in both wild-type (WT) and BK-beta4-knockout mice (BK-beta4-KO) with increased V-ATPase expression and elevated plasma aldosterone levels.	Furosemide	14-24	potassium large conductance calcium-activated channel, subfamily M, beta member 4	Mus musculus	107-115
30484346-6	2019	Treating with furosemide (drinking water) for 11 days led to decreased urine pH in both wild-type (WT) and BK-beta4-knockout mice (BK-beta4-KO) with increased V-ATPase expression and elevated plasma aldosterone levels.	Furosemide	14-24	ATPase, H+ transporting, lysosomal V0 subunit D2	Mus musculus	159-167
30484346-8	2019	Western blotting and immunofluorescence staining showed that furosemide treatment decreased cortical expression of BK-beta4 and reduced apical localization of BK-alpha in connecting tubules.	Furosemide	61-71	potassium large conductance calcium-activated channel, subfamily M, beta member 4	Mus musculus	115-123
30484346-10	2019	Acetazolamide plus furosemide also restored the cortical expression of BK-beta4 and BK-alpha in connecting tubules.	Furosemide	19-29	potassium large conductance calcium-activated channel, subfamily M, beta member 4	Mus musculus	71-79
30539654-4	2019	WT, UT-A3 KO, and UT-A1/A3 KO acutely respond to hydrochlorothiazide and furosemide; however, UT-A1/A3 KO fail to show a diuretic or natriuretic response following amiloride administration, indicating that baseline epithelial Na+ channel (ENaC) activity is impaired.	Furosemide	73-83	solute carrier family 14 (urea transporter), member 2	Mus musculus	4-9
30539654-4	2019	WT, UT-A3 KO, and UT-A1/A3 KO acutely respond to hydrochlorothiazide and furosemide; however, UT-A1/A3 KO fail to show a diuretic or natriuretic response following amiloride administration, indicating that baseline epithelial Na+ channel (ENaC) activity is impaired.	Furosemide	73-83	solute carrier family 14 (urea transporter), member 2	Mus musculus	18-29
30866733-6	2019	It is found that the Furosemide and Triamterene have significant cytotoxic effects on normal human astrocytes, in which the Triamterene can inhibit the neurokinase ROCK2, a representative of putative unexpected targets, with a high activity, which is comparable with the sophisticated ROCK2 inhibitor Fasudil.	Furosemide	21-31	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	164-169
30866733-6	2019	It is found that the Furosemide and Triamterene have significant cytotoxic effects on normal human astrocytes, in which the Triamterene can inhibit the neurokinase ROCK2, a representative of putative unexpected targets, with a high activity, which is comparable with the sophisticated ROCK2 inhibitor Fasudil.	Furosemide	21-31	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	285-290
32382661-3	2019	Here we report the crystal structure of the soluble domain of human mitoNEET with a sulfonamide ligand, furosemide.	Furosemide	104-114	CDGSH iron sulfur domain 1	Homo sapiens	68-76
30123180-1	2018	Objective: The peak-to-peak amplitude of the p13-n23 wave in cervical vestibular evoked myogenic potential can increase after furosemide administration in patients with Meniere"s disease [furosemide-loading VEMP (FVEMP) testing].	Furosemide	126-136	H3 histone pseudogene 6	Homo sapiens	45-48
30292441-3	2018	PATIENTS AND METHOD: We carried out a prospective inventory of the prescription of furosemide with the general practitioners of the universities of Bordeaux, between May 1, 2017 and July 30, 2017.	Furosemide	83-93	protein kinase C delta	Homo sapiens	166-171
30196524-9	2018	In addition, after drug exposure, the average hearing threshold of rats in the experimental group was significantly higher than that in the control group, with increased HSP60 expression level in response to kanamycin and furosemide treatments.	Furosemide	222-232	heat shock protein family D (Hsp60) member 1	Rattus norvegicus	170-175
31287791-8	2019	Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison.	Furosemide	159-169	natriuretic peptide B	Homo sapiens	123-148
31287791-8	2019	Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison.	Furosemide	159-169	natriuretic peptide B	Homo sapiens	150-153
31287791-8	2019	Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison.	Furosemide	159-169	natriuretic peptide B	Homo sapiens	123-148
31287791-8	2019	Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison.	Furosemide	159-169	natriuretic peptide B	Homo sapiens	150-153
31287791-8	2019	Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison.	Furosemide	159-169	natriuretic peptide B	Homo sapiens	123-148
31287791-8	2019	Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison.	Furosemide	159-169	natriuretic peptide B	Homo sapiens	150-153
30332442-3	2018	Our main goal was to measure the effects of the combination of furosemide and hydration for reducing bladder signal directly on mouse bowel 18F-FDG-PET images.	Furosemide	63-73	thyroid stimulating hormone receptor	Mus musculus	148-151
30332442-12	2018	Our study shows the effect of furosemide on bladder spillover directly on 18F-FDG-PET images by measuring SUVmean in the bladder, colon, liver, muscle, and bone marrow.	Furosemide	30-40	thyroid stimulating hormone receptor	Mus musculus	82-85
30041982-7	2018	Our adjusted analysis suggests delaying furosemide administration until after serum creatinine results resulted in a 41% lower chance of successful discharge home relative to someone who had furosemide administered prior to creatinine results (aHR 1.41, 95%CI 1.07, 1,84).	Furosemide	40-50	aryl hydrocarbon receptor	Homo sapiens	244-247
29412704-8	2018	Although the initial response to furosemide was similar in wnk4-/- mice and controls, the response was lower in the knockout mice when reabsorption along the distal convoluted tubule was inhibited.	Furosemide	33-43	WNK lysine deficient protein kinase 4	Mus musculus	59-63
30007527-6	2018	By increasing the distal sodium chloride and calcium ion load with chronic furosemide administration, an intrinsic compensatory defect in the DCT from Umod-/- compared to wild type mice was found manifested as sodium wasting and hypercalciuria.	Furosemide	75-85	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2	Mus musculus	142-145
30007527-6	2018	By increasing the distal sodium chloride and calcium ion load with chronic furosemide administration, an intrinsic compensatory defect in the DCT from Umod-/- compared to wild type mice was found manifested as sodium wasting and hypercalciuria.	Furosemide	75-85	uromodulin	Mus musculus	151-155
30248150-6	2018	Results showed a significant increase in phosphorylation of the activating S130 site in NKCC2, the drug target for frusemide, in women with pre-eclampsia compared with normal pregnant women.	Furosemide	115-124	solute carrier family 12 member 1	Homo sapiens	88-93
30120768-2	2018	Simultaneously, drug-drug interactions (DDIs) mediated by OAT1 occur at high altitude, severely affecting furosemide pharmacokinetics.	Furosemide	106-116	solute carrier family 22 member 6	Rattus norvegicus	58-62
30123180-1	2018	Objective: The peak-to-peak amplitude of the p13-n23 wave in cervical vestibular evoked myogenic potential can increase after furosemide administration in patients with Meniere"s disease [furosemide-loading VEMP (FVEMP) testing].	Furosemide	188-198	H3 histone pseudogene 6	Homo sapiens	45-48
30193887-4	2018	OBJECTIVE: This study was planned to investigate whether the enhancing effect of furosemide for albuterol in ovalbumin-induced asthmatic BALB/c mice is diuretic-related or not.	Furosemide	81-91	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	109-118
29715039-9	2018	An optimized CNF-furosemide drug-delivery vehicle thus needs to have a maximized specific surface area irrespective of the surface charge with which it is achieved.	Furosemide	17-27	NPHS1 adhesion molecule, nephrin	Homo sapiens	13-16
29344743-0	2018	Response to different furosemide doses predicts AKI progression in ICU patients with elevated plasma NGAL levels.	Furosemide	22-32	lipocalin 2	Homo sapiens	101-105
30193887-15	2018	CONCLUSIONS: Inhaled subdiuretic dose of furosemide enhanced effects of albuterol more in ovalbumin-asthmatic mice rather than bumetanide, while oral diuretic doses of both drugs failed to improve asthma, indicating that this enhancing effect is not diuretic-related.	Furosemide	41-51	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	90-99
29682811-0	2018	Upregulation of hypothalamic arginine vasopressin by peripherally administered furosemide in transgenic rats expressing arginine vasopressin-enhanced green fluorescent protein.	Furosemide	79-89	arginine vasopressin	Rattus norvegicus	38-49
29682811-0	2018	Upregulation of hypothalamic arginine vasopressin by peripherally administered furosemide in transgenic rats expressing arginine vasopressin-enhanced green fluorescent protein.	Furosemide	79-89	arginine vasopressin	Rattus norvegicus	129-140
30119980-11	2018	Adding R-to-D&lt;1.2 mg/40 mg furosemide to galectin-3&gt;17.6 pg/mL and BNP&gt;500 pg/mL the predictive value improved (log rank 23.59; p = 0.0001).	Furosemide	30-40	galectin 3	Homo sapiens	44-54
29527380-2	2018	It is caused by loss-of-function mutations of the SLC12A1 gene, encoding the furosemide-sensitive Na-K-Cl cotransporter.	Furosemide	77-87	solute carrier family 12 member 1	Homo sapiens	50-57
29046296-10	2018	Consistent with the furosemide-like effect, in X. laevis oocytes, geraniin significantly reduced the activity of NKCC2, with no effect on NCC activity.	Furosemide	20-30	solute carrier family 12 member 1 L homeolog	Xenopus laevis	113-118
29162614-4	2018	As expected, PROB increased the area under the plasma concentration-time curve (AUC) of coadministered furosemide, a known substrate of OAT1 and OAT3, by 4.1-fold, consistent with the values reported in humans (3.1- to 3.7-fold).	Furosemide	103-113	solute carrier family 22 member 6	Homo sapiens	136-140
29162614-4	2018	As expected, PROB increased the area under the plasma concentration-time curve (AUC) of coadministered furosemide, a known substrate of OAT1 and OAT3, by 4.1-fold, consistent with the values reported in humans (3.1- to 3.7-fold).	Furosemide	103-113	solute carrier family 22 member 8	Homo sapiens	145-149
28688582-11	2017	These results indicate mice on LNaHK exhibited furosemide-sensitive net K+ secretion in the TAL that is dependent on increased NKCC2 activity and mediated by ROMK.	Furosemide	47-57	talipes	Mus musculus	92-95
31749411-9	2018	CONCLUSIONS: Both furosemide and scatter correction algorithm play a role in reducing scatter in PSMA PET.	Furosemide	18-28	folate hydrolase 1	Homo sapiens	97-101
29212491-5	2017	Load tests of captopril or furosemide in the standing position demonstrated autonomous aldosterone secretion and renin suppression.	Furosemide	27-37	renin	Homo sapiens	113-118
28623852-0	2017	Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer.	Furosemide	0-9	folate hydrolase 1	Homo sapiens	50-54
28623852-3	2017	We evaluated if intravenous Frusemide at the time of 68 Ga-PSMA injection reduces excreted activity artefact and improves diagnostic certainty.	Furosemide	28-37	folate hydrolase 1	Homo sapiens	59-63
28623852-13	2017	Reporter confidence on the presence/absence of PSMA avid disease in the prostate fossa improved from 63% (19/30) without Frusemide, to 91% (29/32) with Frusemide (P &lt; 0.015).	Furosemide	121-130	folate hydrolase 1	Homo sapiens	47-51
28623852-13	2017	Reporter confidence on the presence/absence of PSMA avid disease in the prostate fossa improved from 63% (19/30) without Frusemide, to 91% (29/32) with Frusemide (P &lt; 0.015).	Furosemide	152-161	folate hydrolase 1	Homo sapiens	47-51
28623852-14	2017	CONCLUSION: Intravenous Frusemide given with 68 Ga-PSMA reduces excretion artefact, and improves diagnostic certainty.	Furosemide	24-33	folate hydrolase 1	Homo sapiens	51-55
28623852-15	2017	Frusemide should be considered for all 68 Ga-PSMA PET/CT imaging protocols.	Furosemide	0-9	folate hydrolase 1	Homo sapiens	45-49
28402032-0	2017	Furosemide loading test in a case of homozygous solute carrier family 12, member 1 (SLC12A1) mutation (g.62382825G&gt;A, p.Pro372Leu) in Japanese Black cattle.	Furosemide	0-10	solute carrier family 12 member 1	Bos taurus	48-82
28402032-0	2017	Furosemide loading test in a case of homozygous solute carrier family 12, member 1 (SLC12A1) mutation (g.62382825G&gt;A, p.Pro372Leu) in Japanese Black cattle.	Furosemide	0-10	solute carrier family 12 member 1	Bos taurus	84-91
28402032-5	2017	In order to validate these observations, we performed confirmation tests for the genotype and a diuretic loading test using furosemide, which inhibits the transporter activity of the SLC12A1 protein.	Furosemide	124-134	solute carrier family 12 member 1	Bos taurus	183-190
28980452-4	2017	METHODS AND RESULTS: This is a prospective, multicentre, randomized study that compares continuous infusion to intermittent infusion and a low vs. high diuretic dose of furosemide in patients with a diagnosis of acute heart failure, BNP &gt;= 100 pg/mL, and specific chest X-ray signs.	Furosemide	169-179	natriuretic peptide B	Homo sapiens	233-236
28688582-11	2017	These results indicate mice on LNaHK exhibited furosemide-sensitive net K+ secretion in the TAL that is dependent on increased NKCC2 activity and mediated by ROMK.	Furosemide	47-57	solute carrier family 12, member 1	Mus musculus	127-132
28688582-11	2017	These results indicate mice on LNaHK exhibited furosemide-sensitive net K+ secretion in the TAL that is dependent on increased NKCC2 activity and mediated by ROMK.	Furosemide	47-57	potassium inwardly-rectifying channel, subfamily J, member 1	Mus musculus	158-162
28688582-12	2017	We conclude that furosemide is a K-sparing diuretic by decreasing the TAL net K+ secretion in subjects on LNaHK.	Furosemide	17-27	talipes	Mus musculus	70-73
28951361-4	2017	In rats with subcutaneous injection of furosemide (FURO) combined with captopril (CAP) (FURO+CAP), bilateral intra-CeA injections of DAMGO (2 nmol) caused increased NaCl and water intake in the two-bottle tests, but such effects were suppressed by pretreatment with CTAP injection into the CeA; in the one-bottle tests, bilateral intra-CeA injections of DAMGO had no effect on water intake of the rats.	Furosemide	39-49	carcinoembryonic antigen gene family 4	Rattus norvegicus	115-118
28951361-4	2017	In rats with subcutaneous injection of furosemide (FURO) combined with captopril (CAP) (FURO+CAP), bilateral intra-CeA injections of DAMGO (2 nmol) caused increased NaCl and water intake in the two-bottle tests, but such effects were suppressed by pretreatment with CTAP injection into the CeA; in the one-bottle tests, bilateral intra-CeA injections of DAMGO had no effect on water intake of the rats.	Furosemide	39-49	carcinoembryonic antigen gene family 4	Rattus norvegicus	290-293
28951361-4	2017	In rats with subcutaneous injection of furosemide (FURO) combined with captopril (CAP) (FURO+CAP), bilateral intra-CeA injections of DAMGO (2 nmol) caused increased NaCl and water intake in the two-bottle tests, but such effects were suppressed by pretreatment with CTAP injection into the CeA; in the one-bottle tests, bilateral intra-CeA injections of DAMGO had no effect on water intake of the rats.	Furosemide	39-49	carcinoembryonic antigen gene family 4	Rattus norvegicus	290-293
28951361-4	2017	In rats with subcutaneous injection of furosemide (FURO) combined with captopril (CAP) (FURO+CAP), bilateral intra-CeA injections of DAMGO (2 nmol) caused increased NaCl and water intake in the two-bottle tests, but such effects were suppressed by pretreatment with CTAP injection into the CeA; in the one-bottle tests, bilateral intra-CeA injections of DAMGO had no effect on water intake of the rats.	Furosemide	51-55	carcinoembryonic antigen gene family 4	Rattus norvegicus	115-118
28951361-4	2017	In rats with subcutaneous injection of furosemide (FURO) combined with captopril (CAP) (FURO+CAP), bilateral intra-CeA injections of DAMGO (2 nmol) caused increased NaCl and water intake in the two-bottle tests, but such effects were suppressed by pretreatment with CTAP injection into the CeA; in the one-bottle tests, bilateral intra-CeA injections of DAMGO had no effect on water intake of the rats.	Furosemide	88-93	carcinoembryonic antigen gene family 4	Rattus norvegicus	115-118
28598867-6	2017	We identified mutations in melanoma-associated antigen D2 in all study participants and showed, in vivo and in vitro, reduced expression of the furosemide and thiazide sensitive transporters sodium-potassium-2-chloride cotransporter and sodium chloride cotransporter, respectively.	Furosemide	144-154	MAGE family member D2	Homo sapiens	27-57
28583224-0	2017	Anti-parasitic effect of the diuretic and Na+-ATPAse inhibitor furosemide in cutaneous leishmaniasis.	Furosemide	63-73	dynein, axonemal, heavy chain 8	Mus musculus	46-52
28583224-1	2017	Leishmania amazonensis promastigotes are known to express furosemide (Lasix )-sensitive P-type membrane Na+-ATPase.	Furosemide	58-68	dynein, axonemal, heavy chain 8	Mus musculus	108-114
28583224-1	2017	Leishmania amazonensis promastigotes are known to express furosemide (Lasix )-sensitive P-type membrane Na+-ATPase.	Furosemide	70-75	dynein, axonemal, heavy chain 8	Mus musculus	108-114
28583224-8	2017	To summarize, furosemide control of intracellular leishmanial growth by means of parasite Na+-ATPase inhibition, and macrophage ROS activation may help explain its sole and SSG-combined therapeutic effect against murine CL.	Furosemide	14-24	dynein, axonemal, heavy chain 8	Mus musculus	94-100
27282888-0	2017	Impact of the induced organic anion transporter 1 (Oat1) renal expression by furosemide on the pharmacokinetics of organic anions.	Furosemide	77-87	solute carrier family 22 member 6	Rattus norvegicus	22-49
27282888-0	2017	Impact of the induced organic anion transporter 1 (Oat1) renal expression by furosemide on the pharmacokinetics of organic anions.	Furosemide	77-87	solute carrier family 22 member 6	Rattus norvegicus	51-55
27282888-3	2017	This study was undertaken to simultaneously evaluate the effects of furosemide pretreatment on organic anion transporter 1 (Oat1) and multidrug resistance protein 2 (Mrp2) renal expressions, on p-aminohippurate (PAH) pharmacokinetics and on renal and urinary PAH levels in rats.	Furosemide	68-78	solute carrier family 22 member 6	Rattus norvegicus	95-122
27282888-3	2017	This study was undertaken to simultaneously evaluate the effects of furosemide pretreatment on organic anion transporter 1 (Oat1) and multidrug resistance protein 2 (Mrp2) renal expressions, on p-aminohippurate (PAH) pharmacokinetics and on renal and urinary PAH levels in rats.	Furosemide	68-78	solute carrier family 22 member 6	Rattus norvegicus	124-128
27282888-3	2017	This study was undertaken to simultaneously evaluate the effects of furosemide pretreatment on organic anion transporter 1 (Oat1) and multidrug resistance protein 2 (Mrp2) renal expressions, on p-aminohippurate (PAH) pharmacokinetics and on renal and urinary PAH levels in rats.	Furosemide	68-78	ATP binding cassette subfamily B member 4	Rattus norvegicus	134-164
27282888-3	2017	This study was undertaken to simultaneously evaluate the effects of furosemide pretreatment on organic anion transporter 1 (Oat1) and multidrug resistance protein 2 (Mrp2) renal expressions, on p-aminohippurate (PAH) pharmacokinetics and on renal and urinary PAH levels in rats.	Furosemide	68-78	ATP binding cassette subfamily B member 4	Rattus norvegicus	166-170
27282888-8	2017	RESULTS: Furosemide pretreatment increased both the expression of Oat1 and Mrp2.	Furosemide	9-19	solute carrier family 22 member 6	Rattus norvegicus	66-70
27282888-8	2017	RESULTS: Furosemide pretreatment increased both the expression of Oat1 and Mrp2.	Furosemide	9-19	ATP binding cassette subfamily B member 4	Rattus norvegicus	75-79
28228405-1	2017	The Na+-K+-2Cl- cotransporter (NKCC2) on the loop of Henle is the site of action of furosemide.	Furosemide	84-94	solute carrier family 12 member 1	Rattus norvegicus	31-36
29441935-10	2017	Based on cell culture studies, permeability of furosemide was low (Papp=1x10-5 cm/s) but increased when prepared in the ODT form (ODT1: Papp=2x10-5 cm/s; ODT2: Papp=3.6x10-5 cm/s).	Furosemide	47-57	ectodysplasin A	Homo sapiens	130-134
28105515-5	2017	The decrease in plasma BNP levels was larger in the azosemide group than in the furosemide group (p &lt; 0.01).	Furosemide	80-90	natriuretic peptide B	Homo sapiens	23-26
28105515-7	2017	In conclusion, the decrease in plasma BNP levels was larger in the azosemide group than in the furosemide group.	Furosemide	95-105	natriuretic peptide B	Homo sapiens	38-41
28808364-0	2017	The Effect of Furosemide on the Level of Neutrophil Gelatinase-associated Lipocalin in Critically Hospitalized Patients with Acute Kidney Injury.	Furosemide	14-24	lipocalin 2	Homo sapiens	41-83
28560096-8	2017	The extract of Juncus effusus, a well-known traditional Chinese medicine, was assessed for its effect on the in vivo pharmacokinetic parameters of furosemide, a diuretic drug which is a known substrate of both OAT1 and OAT3.	Furosemide	147-157	solute carrier family 22 member 6	Homo sapiens	210-214
28488084-10	2017	The NKCC1 inhibitors furosemide and bumetanide concentration-dependently inhibit HlyA-induced lysis of human and murine erythrocytes.	Furosemide	21-31	solute carrier family 12 member 2	Homo sapiens	4-9
28488084-10	2017	The NKCC1 inhibitors furosemide and bumetanide concentration-dependently inhibit HlyA-induced lysis of human and murine erythrocytes.	Furosemide	21-31	hemolysin transport protein	Escherichia coli	81-85
28340405-8	2017	Analysis of covariates showed that CRCL was significantly influencing the clearance of furosemide.	Furosemide	87-97	CRCL	Homo sapiens	35-39
31994099-8	2017	Analysis of covariates showed that CRCL was significantly influencing the clearance of furosemide.	Furosemide	87-97	CRCL	Homo sapiens	35-39
28951782-2	2017	The aim of this study was to determine whether variation in SLC2A9 or SLC22A11 influences acute renal handling of uric acid in response to frusemide.	Furosemide	139-148	solute carrier family 2 member 9	Homo sapiens	60-66
28417963-4	2017	We investigated this issue using the NKCC1 inhibitors bumetanide and furosemide, which are commonly used loop diuretics.	Furosemide	69-79	solute carrier family 12 member 2	Homo sapiens	37-42
28951782-2	2017	The aim of this study was to determine whether variation in SLC2A9 or SLC22A11 influences acute renal handling of uric acid in response to frusemide.	Furosemide	139-148	solute carrier family 22 member 11	Homo sapiens	70-78
28153413-4	2017	Exposure potential given by the ratio amount of the drug exported to the sea/amount emitted to the environment was higher than 50% for 7 drugs (Piperacillin, Lorazepam, Metformin, Hydroxycarbamide, Hydrochlorothiazide, Furosemide and Cetirizine), implying that a high proportion of them will reach the sea, and below 10% for 27 drugs, implying high catchment attenuation.	Furosemide	219-229	S13 erythroblastosis (avian) oncogene homolog	Homo sapiens	73-76
28100655-10	2017	We conclude that furosemide decreases axonal excitability and prevents HFS-induced hyperexcitability via mechanisms downstream of blockage of anion transport, which could include hyperpolarization of axonal membranes.NEW &amp; NOTEWORTHY This study shows that the anion transporter antagonists furosemide and DIDS cause a marked decrease of axonal excitability in rat hippocampal CA1 region and prevent the induction of activity-dependent hyperexcitability in Schaffer collateral axons.	Furosemide	17-27	carbonic anhydrase 1	Rattus norvegicus	380-383
28043731-3	2017	However, animal studies show that the simultaneous downregulation of pendrin with acetazolamide and inhibition of the sodium-chloride cotransporter with hydrochlorothiazide generates significant diuresis, and furosemide administration following a pendrin inhibitor potentiates furosemide"s diuretic effect.	Furosemide	209-219	solute carrier family 26 member 4	Homo sapiens	69-76
28043731-3	2017	However, animal studies show that the simultaneous downregulation of pendrin with acetazolamide and inhibition of the sodium-chloride cotransporter with hydrochlorothiazide generates significant diuresis, and furosemide administration following a pendrin inhibitor potentiates furosemide"s diuretic effect.	Furosemide	277-287	solute carrier family 26 member 4	Homo sapiens	69-76
26927285-3	2017	Moreover, a common variant in the multidrug resistance protein-4 coding gene (ABCC4, rs17268282) was associated with weight loss with furosemide use (P=0.0001).	Furosemide	134-144	ATP binding cassette subfamily C member 4	Homo sapiens	78-83
27335120-4	2017	Because inactivating mutations in ClC-Kb/K2 cause Bartter syndrome, a disease that mimics the effects of the loop diuretic furosemide, ClC-Kb/K2 is assumed to have a critical role in salt handling by the thick ascending limb.	Furosemide	123-133	chloride channel, voltage-sensitive Kb	Mus musculus	34-40
26879122-10	2017	During a second exposure to furosemide 24H after CYP injection, the micturition pattern returned to control, however, the micturition volume was still lower than in control.	Furosemide	28-38	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	49-52
29430461-3	2017	We developed a mouse model with maximal increase in SDF-1 levels in the inner ear, according to the "one-shot" doses of kanamycin and furosemide.	Furosemide	134-144	chemokine (C-X-C motif) ligand 12	Mus musculus	52-57
29430461-7	2017	Results: There were a significant reduction in hearing thresholds and a maximal increase of SDF-1 levels in the furosemide 130 mg/kg + kanamycin 550 mg/kg group, but severe hearing deterioration over time was observed in the furosemide 130 mg/kg + kanamycin 600 mg/kg group and four mice were dead.	Furosemide	112-122	chemokine (C-X-C motif) ligand 12	Mus musculus	92-97
27335120-4	2017	Because inactivating mutations in ClC-Kb/K2 cause Bartter syndrome, a disease that mimics the effects of the loop diuretic furosemide, ClC-Kb/K2 is assumed to have a critical role in salt handling by the thick ascending limb.	Furosemide	123-133	chloride channel, voltage-sensitive Kb	Mus musculus	135-141
27818782-10	2016	Although catecholamine improvements after treatment were not significantly different, plasma renin activity was enhanced in the furosemide group.	Furosemide	128-138	renin	Homo sapiens	93-98
27302598-8	2017	Administration of furosemide induced diuresis, reduced GFR and activated the renin-aldosterone-angiotensin system.	Furosemide	18-28	renin	Canis lupus familiaris	77-82
29197870-8	2017	Furosemide led to a significant decrease in the medullary and cortical R2* of healthy subjects and NSS contralateral kidneys (p&lt;0.05 each), whereas there was no significant change of R2* in ATN-induced AKI and the NSS-I/R kidneys (p&gt;0.05 each).	Furosemide	0-10	serine and arginine rich splicing factor 10	Homo sapiens	217-224
27183025-12	2016	In addition to an altered pharmacokinetics (p &lt; 0.01), a reduced pharmacodynamics response to furosemide also became important when creatinine clearance was reduced to less than 40 mL/min/1.73 m (p = 0.01).	Furosemide	97-107	CD59 molecule (CD59 blood group)	Homo sapiens	187-192
27821322-10	2016	We conclude that treatment with (higher total cumulative dose of) cisplatin, young age and furosemide co-medication independently are associated with an increased risk of ototoxicity in CCS.	Furosemide	91-101	copper chaperone for superoxide dismutase	Homo sapiens	186-189
27153921-0	2016	Small-Molecule Inhibitors of Pendrin Potentiate the Diuretic Action of Furosemide.	Furosemide	71-81	solute carrier family 26, member 4	Mus musculus	29-36
27153921-8	2016	In mice treated long term with furosemide, in which renal pendrin is upregulated, PDSinh-C01 produced a 60% increase in urine output.	Furosemide	31-41	solute carrier family 26, member 4	Mus musculus	58-65
27166146-2	2016	While furosemide is a loop diuretic prescribed for the majority of CHF patients to reduce fluid retention, it also activates the renin-angiotensin aldosterone system (RAAS) which further contributes to the accelerated progression of heart failure.	Furosemide	6-16	renin	Canis lupus familiaris	129-134
27421685-12	2016	Clckb-/- mice showed a reduced sensitivity to furosemide and were completely resistant to thiazides.	Furosemide	46-56	chloride channel, voltage-sensitive Kb	Mus musculus	0-5
27230512-10	2016	The significantly larger furosemide-induced decrease in medullary R2* levels in the healthy group and unaffected contralateral kidneys of the VUR group points towards more intense renal sodium transport in these kidneys.	Furosemide	25-35	VUR	Homo sapiens	142-145
27388150-4	2016	Furosemide, the selective antagonist of Gabra6-containing GABAARs, strongly increased peak amplitude of evoked IPSCs at CA3-CA1 synapses and the frequency of miniature IPSPs recorded from CA1 pyramidal cells in naive control animals, and this effect was occluded in MS animals.	Furosemide	0-10	gamma-aminobutyric acid type A receptor subunit alpha6	Rattus norvegicus	40-46
27388150-4	2016	Furosemide, the selective antagonist of Gabra6-containing GABAARs, strongly increased peak amplitude of evoked IPSCs at CA3-CA1 synapses and the frequency of miniature IPSPs recorded from CA1 pyramidal cells in naive control animals, and this effect was occluded in MS animals.	Furosemide	0-10	carbonic anhydrase 3	Rattus norvegicus	120-127
27388150-5	2016	Knockdown of Gabra6 expression in hippocampus mimicked furosemide"s effect and was sufficient to produce similar depressive symptoms that were observed in MS animals.	Furosemide	55-65	gamma-aminobutyric acid type A receptor subunit alpha6	Rattus norvegicus	13-19
27404696-12	2016	This increase in lung congestion, myocardial remodeling, could be prevented by co-administration of furosemide, which resulted in normalized serum osmolality, neurohormonal activation, and renal aquaporin 1 expression, and hence decreased mortality post-MI.	Furosemide	100-110	aquaporin 1	Mus musculus	195-206
26550796-10	2016	The alterations in furosemide pharmacokinetics and pharmacodynamics were explained by changes in the expression of renal organic anion transporters 1 and 3, and sodium-potassium-chloride cotransporter-2.	Furosemide	19-29	solute carrier family 22 member 6	Rattus norvegicus	115-155
27338786-9	2016	Administration of furosemide induced diuresis, reduced GFR and activated the renin-aldosterone-angiotensin system, evidenced from increased plasma renin activity and plasma aldosterone concentrations.	Furosemide	18-28	renin	Felis catus	77-82
27338786-9	2016	Administration of furosemide induced diuresis, reduced GFR and activated the renin-aldosterone-angiotensin system, evidenced from increased plasma renin activity and plasma aldosterone concentrations.	Furosemide	18-28	renin	Felis catus	147-152
29100270-6	2017	Interestingly, we discovered that albuminuria downregulated NKCC2 protein expression in murine kidney and impaired the renal response to loop diuretic furosemide.	Furosemide	151-161	solute carrier family 12, member 1	Mus musculus	60-65
26530829-7	2016	Na(+)-K(+)-Cl(-) co-transporter inhibitors (10 muM bumetanide, 30 muM furosemide) suppressed spontaneous Ca(2+) transients and vasoconstrictions.	Furosemide	70-80	latexin	Homo sapiens	66-69
26820767-0	2016	Purification and Characterization of Glucose 6-Phosphate Dehydrogenase, 6-Phosphogluconate Dehydrogenase, and Glutathione Reductase from Rat Heart and Inhibition Effects of Furosemide, Digoxin, and Dopamine on the Enzymes Activities.	Furosemide	173-183	glucose-6-phosphate dehydrogenase	Rattus norvegicus	37-70
26911852-1	2016	Furosemide is a widely used, potent natriuretic drug, which inhibits the Na(+)-K(+)-2Cl(-) cotransporter (NKCC)-2 in the ascending limb of the loop of Henle applied to reduce extracellular fluid volume expansion in heart and kidney disease.	Furosemide	0-10	solute carrier family 12 member 1	Homo sapiens	73-113
26982381-1	2016	OBJECTIVE: Experiments were carried out to investigate whether diuretics (hydrochlorothiazide + furosemide) impact on the effects of a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor on glucose metabolism and blood pressure (BP) in metabolic syndrome SHR/NDmcr-cp(+/+) rats (SHRcp).	Furosemide	96-106	solute carrier family 5 member 2	Rattus norvegicus	135-175
26982381-1	2016	OBJECTIVE: Experiments were carried out to investigate whether diuretics (hydrochlorothiazide + furosemide) impact on the effects of a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor on glucose metabolism and blood pressure (BP) in metabolic syndrome SHR/NDmcr-cp(+/+) rats (SHRcp).	Furosemide	96-106	solute carrier family 5 member 2	Rattus norvegicus	177-182
26715481-9	2015	IRRs during the first 14 days of treatment were for furosemide IRR 1.74 (95% CI 1.61 to 1.89) and for thiazides IRR 1.41 (1.28 to 1.55); IRR during the first 30 days of treatment with digoxin was 1.18 (1.02 to 1.37).	Furosemide	52-62	insulin receptor related receptor	Homo sapiens	0-3
27231243-3	2016	We sought to investigate, in CKD patients not on dialysis, the influence of either hydrochlorothiazide (Hydro) or furosemide (Furo) on circulating parathyroid hormone (PTH) and whether such actions are determined by the effects of these compounds on calcium excretion.	Furosemide	114-124	parathyroid hormone	Homo sapiens	147-166
26384643-5	2016	To estimate the competitive inhibition of tetraiodothyroacetic acid, diclofenac, genistein, ibuprofen, carbamazepine, and furosemide, reported to be competitive or noncompetitive pharmaceuticals for T4 binding to TTR or TBG, their 50% inhibition concentrations (IC50) (or 80% inhibition concentration, IC80) were calculated from the change of T4 responses in sensorgrams obtained with various concentrations of the pharmaceuticals.	Furosemide	122-132	transthyretin	Homo sapiens	213-216
26384643-5	2016	To estimate the competitive inhibition of tetraiodothyroacetic acid, diclofenac, genistein, ibuprofen, carbamazepine, and furosemide, reported to be competitive or noncompetitive pharmaceuticals for T4 binding to TTR or TBG, their 50% inhibition concentrations (IC50) (or 80% inhibition concentration, IC80) were calculated from the change of T4 responses in sensorgrams obtained with various concentrations of the pharmaceuticals.	Furosemide	122-132	serpin family A member 7	Homo sapiens	220-223
27161422-5	2016	RESULTS: Pendrin activity was significantly hampered by 0.1 mM 5-nitro-2-[(3-phenylpropyl)amino]benzoic acid (NPPB), niflumic acid and tenidap, but was resistant to 0.1 mM 4, 4"-diisothiocyano-2, 2"-stilbene-disulfonic acid (DIDS), furosemide and probenecid.	Furosemide	232-242	solute carrier family 26 member 4	Homo sapiens	9-16
25967121-1	2016	The furosemide-sensitive Na(+)-K(+)-2Cl(-)-cotransporter (NKCC2) is crucial for NaCl reabsorption in kidney thick ascending limb (TAL) and drives the urine concentrating mechanism.	Furosemide	4-14	solute carrier family 12, member 1	Mus musculus	58-63
26634699-0	2015	Effect of Cyclooxygenase(COX)-1 and COX-2 inhibition on furosemide-induced renal responses and isoform immunolocalization in the healthy cat kidney.	Furosemide	56-66	cytochrome c oxidase subunit II	Felis catus	36-41
25771846-0	2015	The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs.	Furosemide	27-37	renin	Canis lupus familiaris	48-53
26301821-2	2015	The current study investigates the effect of furosemide on Cs-induced epileptiform activity (Cs-FP) evoked in area CA1 of rat hippocampal slices in the presence of Cs(+) (5mM) and ionotropic glutamatergic and GABAergic receptor antagonists.	Furosemide	45-55	carbonic anhydrase 1	Rattus norvegicus	115-118
26301821-10	2015	Based on these results we propose that the anticonvulsant action of furosemide in the Cs(+)-model is exerted through blockade of the neuronal KCC2 and Na(+)-independent Cl(-)/HCO3(-)-exchanger (AE3) leading to stabilization of the activity-induced intracellular acidification in CA1 pyramidal neurons.	Furosemide	68-78	solute carrier family 12 member 5	Rattus norvegicus	142-146
26301821-10	2015	Based on these results we propose that the anticonvulsant action of furosemide in the Cs(+)-model is exerted through blockade of the neuronal KCC2 and Na(+)-independent Cl(-)/HCO3(-)-exchanger (AE3) leading to stabilization of the activity-induced intracellular acidification in CA1 pyramidal neurons.	Furosemide	68-78	carbonic anhydrase 1	Rattus norvegicus	279-282
26438710-10	2015	This hypothesis was confirmed by a video recording that revealed the administration by the mother of multiple drugs (insulin, glyburide, progesterone, and furosemide) that mimicked most of the features of Rabson-Mendenhall syndrome, including hirsutism and hypoglycemia with coincident, inappropriately normal c-peptide values due to the administration of the insulin secretagogue.	Furosemide	155-165	insulin	Homo sapiens	310-319
26438710-10	2015	This hypothesis was confirmed by a video recording that revealed the administration by the mother of multiple drugs (insulin, glyburide, progesterone, and furosemide) that mimicked most of the features of Rabson-Mendenhall syndrome, including hirsutism and hypoglycemia with coincident, inappropriately normal c-peptide values due to the administration of the insulin secretagogue.	Furosemide	155-165	insulin	Homo sapiens	360-367
26344240-5	2015	The negative effect of muscimol on sodium and water intake could also be blocked by pretreatment with losartan microinjected into the CeA in rats given FURO (n=8 rats/group).	Furosemide	152-156	carcinoembryonic antigen gene family 4	Rattus norvegicus	134-137
26634699-14	2015	CONCLUSIONS: These data suggest that both COX-1 and COX-2 could generate the signal from the MD to the renin secreting cells in cats exposed to furosemide.	Furosemide	144-154	cytochrome c oxidase subunit I	Felis catus	42-47
26634699-14	2015	CONCLUSIONS: These data suggest that both COX-1 and COX-2 could generate the signal from the MD to the renin secreting cells in cats exposed to furosemide.	Furosemide	144-154	cytochrome c oxidase subunit II	Felis catus	52-57
26634699-14	2015	CONCLUSIONS: These data suggest that both COX-1 and COX-2 could generate the signal from the MD to the renin secreting cells in cats exposed to furosemide.	Furosemide	144-154	renin	Felis catus	103-108
25555706-5	2015	Intense excitation is followed by extracellular K(+) undershoot which is decreased by furosemide, an NKCC1 inhibitor.	Furosemide	86-96	solute carrier family 12 member 2	Homo sapiens	101-106
26089029-0	2015	Furosemide stimulation of parathormone in humans: role of the calcium-sensing receptor and the renin-angiotensin system.	Furosemide	0-10	renin	Homo sapiens	95-100
26089029-2	2015	Parathyroid hormone (PTH) levels are increased shortly after furosemide treatment by an unknown mechanism, and this effect is blunted by the previous administration of a calcimimetic in animal studies.	Furosemide	61-71	parathyroid hormone	Homo sapiens	0-19
26089029-2	2015	Parathyroid hormone (PTH) levels are increased shortly after furosemide treatment by an unknown mechanism, and this effect is blunted by the previous administration of a calcimimetic in animal studies.	Furosemide	61-71	parathyroid hormone	Homo sapiens	21-24
26089029-7	2015	Subjects under placebo presented a sharp increase in PTH levels after furosemide injection.	Furosemide	70-80	parathyroid hormone	Homo sapiens	53-56
26089029-9	2015	No significant changes in electrolytes and urinary excretion were identified that could explain the furosemide-induced increase in PTH levels.	Furosemide	100-110	parathyroid hormone	Homo sapiens	131-134
26089029-12	2015	In conclusion, our results indicate that furosemide acutely stimulates PTH secretion in the absence of any detectable electrolyte changes in healthy adults.	Furosemide	41-51	parathyroid hormone	Homo sapiens	71-74
26500550-13	2015	The potencies with which indomethacin, furosemide, cyclosporine A and cimetidine inhibited OAT2-tv1 are in good agreement with previous studies using this variant, but inconsistent with studies using OAT2 with an unidentified sequence.	Furosemide	39-49	solute carrier family 22 member 7	Homo sapiens	91-95
26035408-10	2015	Pharmacologic inhibition of sodium-potassium-chloride cotransporter by inhaled furosemide improved animal survival in WNK4(D561A/+) mice.	Furosemide	79-89	WNK lysine deficient protein kinase 4	Mus musculus	118-122
26183401-0	2015	Regulation of the Na(+)-K(+)-2Cl(-) cotransporter by cGMP/cGMP-dependent protein kinase I after furosemide administration.	Furosemide	96-106	protein kinase, cGMP-dependent, type I	Mus musculus	58-89
26183401-2	2015	The loop diuretic furosemide is a potent inhibitor of NKCC2.	Furosemide	18-28	solute carrier family 12, member 1	Mus musculus	54-59
26183401-11	2015	The administration of furosemide significantly increased the phosphorylated NKCC2 signal in wt but not in cGKIalpha-rescue mice.	Furosemide	22-32	solute carrier family 12, member 1	Mus musculus	76-81
26183401-15	2015	We hypothesize that furosemide administration activated cGKI, leading to NKCC2 phosphorylation and membrane translocation.	Furosemide	20-30	protein kinase, cGMP-dependent, type I	Mus musculus	56-60
26183401-15	2015	We hypothesize that furosemide administration activated cGKI, leading to NKCC2 phosphorylation and membrane translocation.	Furosemide	20-30	solute carrier family 12, member 1	Mus musculus	73-78
26183401-16	2015	This cGKI-mediated pathway could be a mechanism to compensate for the inhibitory effect of furosemide on NKCC2.	Furosemide	91-101	protein kinase, cGMP-dependent, type I	Mus musculus	5-9
26183401-16	2015	This cGKI-mediated pathway could be a mechanism to compensate for the inhibitory effect of furosemide on NKCC2.	Furosemide	91-101	solute carrier family 12, member 1	Mus musculus	105-110
25986441-7	2015	The inhibition by bumetanide (IC50=26.4 muM) and furosemide (IC50=315.4 muM) resembled the pharmacological fingerprint of the mammalian NKCC1 isoform.	Furosemide	49-59	latexin	Homo sapiens	72-75
25986441-7	2015	The inhibition by bumetanide (IC50=26.4 muM) and furosemide (IC50=315.4 muM) resembled the pharmacological fingerprint of the mammalian NKCC1 isoform.	Furosemide	49-59	solute carrier family 12 member 2	Homo sapiens	136-141
25981193-4	2015	Furosemide was evaluated in vitro, and is a substrate of OAT1 and OAT3, with Km values of 38.9 and 21.5 muM, respectively.	Furosemide	0-10	solute carrier family 22 member 6	Homo sapiens	57-61
25981193-4	2015	Furosemide was evaluated in vitro, and is a substrate of OAT1 and OAT3, with Km values of 38.9 and 21.5 muM, respectively.	Furosemide	0-10	solute carrier family 22 member 8	Homo sapiens	66-70
25981193-4	2015	Furosemide was evaluated in vitro, and is a substrate of OAT1 and OAT3, with Km values of 38.9 and 21.5 muM, respectively.	Furosemide	0-10	latexin	Homo sapiens	104-107
25981193-5	2015	Furosemide was also identified as a substrate of BCRP, OATP1B1, and OATP1B3.	Furosemide	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	49-53
25981193-5	2015	Furosemide was also identified as a substrate of BCRP, OATP1B1, and OATP1B3.	Furosemide	0-10	solute carrier organic anion transporter family member 1B1	Homo sapiens	55-62
25981193-5	2015	Furosemide was also identified as a substrate of BCRP, OATP1B1, and OATP1B3.	Furosemide	0-10	solute carrier organic anion transporter family member 1B3	Homo sapiens	68-75
25981193-6	2015	Furosemide inhibited BCRP (50% inhibition of drug transport: 170 muM), but did not inhibit OATP1B1, OATP1B3, OCT2, MATE1, and MATE2-K at concentrations below 300 muM, and P-gp at concentrations below 2000 muM.	Furosemide	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	21-25
25981193-6	2015	Furosemide inhibited BCRP (50% inhibition of drug transport: 170 muM), but did not inhibit OATP1B1, OATP1B3, OCT2, MATE1, and MATE2-K at concentrations below 300 muM, and P-gp at concentrations below 2000 muM.	Furosemide	0-10	latexin	Homo sapiens	65-68
23946287-6	2013	This shift from NKCC2A to NKCC2B during a low-salt diet could be mimicked by furosemide in vivo and in cultured kidney slices.	Furosemide	77-87	solute carrier family 12, member 1	Mus musculus	16-21
26114157-3	2015	Both NKCC1 and NKCC2 are inhibited by furosemide and other high-ceiling diuretics widely used for attenuation of extracellular fluid volume.	Furosemide	38-48	solute carrier family 12 member 2	Homo sapiens	5-10
26114157-3	2015	Both NKCC1 and NKCC2 are inhibited by furosemide and other high-ceiling diuretics widely used for attenuation of extracellular fluid volume.	Furosemide	38-48	solute carrier family 12 member 1	Homo sapiens	15-20
25168165-3	2015	A mild NKCC2 inhibition was induced using a slow intravenous furosemide infusion.	Furosemide	61-71	solute carrier family 12 member 1	Rattus norvegicus	7-12
25715987-3	2015	Furosemide inhibits NKCC2 and TGF.	Furosemide	0-10	solute carrier family 12 member 1	Homo sapiens	20-25
25715987-11	2015	With furosemide and NHE inhibitor, dimethylamiloride (DMA), increase in tubular flow increased PSF (furosemide+DMA: 2.7 +- 0.5 mmHg, n = 6), and benzamil blocked this (furosemide+DMA+benzamil: -1.1 +- 0.2 mmHg; P &lt; 0.01, n = 6).	Furosemide	5-15	insulin like growth factor binding protein 7	Homo sapiens	95-98
25715987-11	2015	With furosemide and NHE inhibitor, dimethylamiloride (DMA), increase in tubular flow increased PSF (furosemide+DMA: 2.7 +- 0.5 mmHg, n = 6), and benzamil blocked this (furosemide+DMA+benzamil: -1.1 +- 0.2 mmHg; P &lt; 0.01, n = 6).	Furosemide	100-110	solute carrier family 9 member C1	Homo sapiens	20-23
25715987-11	2015	With furosemide and NHE inhibitor, dimethylamiloride (DMA), increase in tubular flow increased PSF (furosemide+DMA: 2.7 +- 0.5 mmHg, n = 6), and benzamil blocked this (furosemide+DMA+benzamil: -1.1 +- 0.2 mmHg; P &lt; 0.01, n = 6).	Furosemide	100-110	solute carrier family 9 member C1	Homo sapiens	20-23
25627679-7	2015	Plasma renin activity also increased appropriately when the patient was upright and after furosemide-induced volume depletion.	Furosemide	90-100	renin	Homo sapiens	7-12
25644429-2	2015	METHODS: Using solubility, dissolution kinetics, gastrointestinal (GI) parameters and disposition parameters, a PBPK model for furosemide was developed with STELLA software.	Furosemide	127-137	developmental pluripotency associated 3	Homo sapiens	157-163
25423287-0	2015	The role of the c-Jun N-terminal kinases 1/2 and receptor-interacting protein kinase 3 in furosemide-induced liver injury.	Furosemide	90-100	mitogen-activated protein kinase 8	Mus musculus	16-86
25653502-4	2015	The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3).	Furosemide	179-189	solute carrier family 22 member 8	Homo sapiens	44-48
25653502-4	2015	The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3).	Furosemide	179-189	solute carrier organic anion transporter family member 1B1	Homo sapiens	50-57
25653502-4	2015	The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3).	Furosemide	179-189	solute carrier organic anion transporter family member 1B3	Homo sapiens	63-70
25653502-4	2015	The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3).	Furosemide	179-189	solute carrier family 22 member 8	Homo sapiens	211-215
25653502-4	2015	The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3).	Furosemide	179-189	solute carrier organic anion transporter family member 1B1	Homo sapiens	267-274
25653502-4	2015	The increased uptake of catalposide via the OAT3, OATP1B1, and OATP1B3 transporters was decreased to basal levels in the presence of representative inhibitors such as probenecid, furosemide, and cimetidine (for OAT3) and cyclosporin A, gemfibrozil, and rifampin (for OATP1B1 and OATP1B3).	Furosemide	179-189	solute carrier organic anion transporter family member 1B3	Homo sapiens	279-286
25362991-12	2015	This intracellular alkalization is mediated through an increased apical NHE3 activity, similar to what we previously observed when tubular transport is inhibited with furosemide.	Furosemide	167-177	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	72-76
26411965-5	2015	The selective inhibitors of NKCC1 including bumetanide and furosemide are conventionally employed as diuretics.	Furosemide	59-69	solute carrier family 12 member 2	Homo sapiens	28-33
25710042-9	2015	However, OAT2-dependent uptake of cGMP was inhibited by furosemide.	Furosemide	56-66	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	9-13
25710042-10	2015	The strongly decreased expression of Oat2 and other transporters in female diabetic ZSF1 rats could possibly impair renal drug excretion, for example, of furosemide.	Furosemide	154-164	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	37-41
25598374-0	2014	[The spiral ganglion degeneration and the expression of EFR3A in the cochlea of the deaf mice induced by co-administration of kanamycin and furosemide].	Furosemide	140-150	EFR3 homolog A	Mus musculus	56-61
25598374-1	2014	OBJECTIVE: To investigate the spiral ganglion degeneration and the expression of EFR3A in the cochlea of the deaf mice induced by co-administration of kanamycin and furosemide.	Furosemide	165-175	EFR3 homolog A	Mus musculus	81-86
24813929-0	2014	Nrf2 protects against furosemide-induced hepatotoxicity.	Furosemide	22-32	nuclear factor, erythroid derived 2, like 2	Mus musculus	0-4
24813929-6	2014	The two genotypes of over-expressed Nrf2 mice had increased expression of the Nrf2 target genes Gclm, Gclc and Nqo1 prior to furosemide administration, and the expressions of these genes were increased further after furosemide administration.	Furosemide	125-135	nuclear factor, erythroid derived 2, like 2	Mus musculus	36-40
24813929-6	2014	The two genotypes of over-expressed Nrf2 mice had increased expression of the Nrf2 target genes Gclm, Gclc and Nqo1 prior to furosemide administration, and the expressions of these genes were increased further after furosemide administration.	Furosemide	125-135	nuclear factor, erythroid derived 2, like 2	Mus musculus	78-82
24813929-6	2014	The two genotypes of over-expressed Nrf2 mice had increased expression of the Nrf2 target genes Gclm, Gclc and Nqo1 prior to furosemide administration, and the expressions of these genes were increased further after furosemide administration.	Furosemide	125-135	glutamate-cysteine ligase, modifier subunit	Mus musculus	96-100
24813929-6	2014	The two genotypes of over-expressed Nrf2 mice had increased expression of the Nrf2 target genes Gclm, Gclc and Nqo1 prior to furosemide administration, and the expressions of these genes were increased further after furosemide administration.	Furosemide	216-226	nuclear factor, erythroid derived 2, like 2	Mus musculus	36-40
24813929-7	2014	Thus, our findings provide strong evidence that over-expression of Nrf2 in Keap1-KD and Keap1-HKO mice and the increases in mRNA of a number of genes involved in anti-oxidative stress, anti-inflammation, anti-ER stress and anti-apoptosis protect against furosemide-induced hepatotoxicity.	Furosemide	254-264	nuclear factor, erythroid derived 2, like 2	Mus musculus	67-71
24845404-4	2014	In this study, we found that lipopolysaccharide (LPS), an important component of bacterial endotoxin, when given in combination with kanamycin and furosemide, augmented the inflammatory response to hair cell injury and exacerbated hearing loss and hair cell injury.	Furosemide	147-157	toll-like receptor 4	Mus musculus	49-52
24940940-10	2014	In addition, our data suggested the severity of RIFLE classification and pathological injury of glomerular basement membrane was higher in large-dosage furosemide group (&gt;=120 mg/d) than in low-dosage group (&lt;120 mg/d).	Furosemide	152-162	leucine rich repeat and sterile alpha motif containing 1	Homo sapiens	48-53
25087413-2	2014	It was shown that the regular annual systematic spa and resort-based treatment with the strict compliance to the proposed balneotherapeutic modality and basal medicamental therapy enhances the effectiveness of rehabilitation of these patients, promotes the steady progress in the clinical and instrumental manifestations of decompensation, optimizes effects of ACE inhibitors and diuretic furosemide, improves exercise tolerance and quality of life.	Furosemide	389-399	surfactant protein A2	Homo sapiens	48-51
24526686-1	2014	The furosemide-sensitive Na(+)-K(+)-2Cl(-) cotransporter (NKCC2) is responsible for urine concentration and helps maintain systemic salt homeostasis.	Furosemide	4-14	solute carrier family 12 member 1	Homo sapiens	58-63
24772088-4	2014	Osmotic stress induced time-dependent activation of FAK as evidenced by phosphorylation at Tyr-397, and furosemide reduces FAK Tyr-397 phosphorylation in the rat renal medulla.	Furosemide	104-114	protein tyrosine kinase 2	Rattus norvegicus	123-126
23986517-10	2013	When furosemide (1.1 mg kg(-1) day(-1)) was coinfused with ANG II, no increase in plasma membrane Na pump activity was observed.	Furosemide	5-15	angiotensinogen	Rattus norvegicus	59-65
25995110-8	2015	These results suggest that the furosemide-induced H+ secretion is a consequence of a drop in intracellular Na+ concentration, increasing the driving force for NHE3.	Furosemide	31-41	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	159-163
25995110-9	2015	Intriguingly, in whole animal experiments, furosemide-induced urinary acidification and net acid excretion were markedly reduced by specific NHE3 inhibition.	Furosemide	43-53	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	141-145
25837675-7	2015	The MAP17-induced sensitivity to bortezomib is dependent on the oxidative status of the cells and the activity of Na(+)-coupled transporters because treatment with antioxidants or the inhibitor furosemide restores the cytoprotective activity induced by bortezomib.	Furosemide	194-204	PDZK1 interacting protein 1	Homo sapiens	4-9
26019342-3	2015	However, the widely used KCC2 inhibitor furosemide is nonselective with antiseizure efficacy in slices and in vivo, leading to a conflicting scheme of how KCC2 influences GABAergic control of neuronal synchronization.	Furosemide	40-50	solute carrier family 12, member 5	Mus musculus	25-29
26019342-3	2015	However, the widely used KCC2 inhibitor furosemide is nonselective with antiseizure efficacy in slices and in vivo, leading to a conflicting scheme of how KCC2 influences GABAergic control of neuronal synchronization.	Furosemide	40-50	solute carrier family 12, member 5	Mus musculus	155-159
25993027-7	2015	Renal hypoosmolality induced by furosemide (NKCC2 inhibitor) inhibited Prox1 expression and delayed maturation of the ascending limb of Henle"s loop.	Furosemide	32-42	solute carrier family 12, member 1	Mus musculus	44-49
25993027-7	2015	Renal hypoosmolality induced by furosemide (NKCC2 inhibitor) inhibited Prox1 expression and delayed maturation of the ascending limb of Henle"s loop.	Furosemide	32-42	prospero homeobox 1	Mus musculus	71-76
25834041-6	2015	Since NKCC2 is the molecular target of the loop diuretics bumetanide and furosemide, we asked about their effects on HNS function following disturbed water balance.	Furosemide	73-83	solute carrier family 12 member 1	Rattus norvegicus	6-11
24845846-6	2014	A slight increase in GPx and GR activities and GSH level was observed with propranolol and furosemide treatment alone, while the two drugs together caused a significant increase in GPx and GR activities (35% and 42%, respectively) and GSH content (35%) in ACHN cell lysates (p &lt; 0.05).	Furosemide	91-101	glutathione-disulfide reductase	Homo sapiens	29-31
24845846-6	2014	A slight increase in GPx and GR activities and GSH level was observed with propranolol and furosemide treatment alone, while the two drugs together caused a significant increase in GPx and GR activities (35% and 42%, respectively) and GSH content (35%) in ACHN cell lysates (p &lt; 0.05).	Furosemide	91-101	glutathione-disulfide reductase	Homo sapiens	189-191
24498157-7	2014	Furosemide (10(-4) M), an inhibitor of Na(+)-K(+)-2Cl(-) co-transporter, also inhibited the increased ISC response to CQ, whereas another Cl(-) channel inhibitor, CFTR(inh)-172(10(-5) M), had no effect.	Furosemide	0-10	CF transmembrane conductance regulator	Rattus norvegicus	163-167
24117047-8	2014	Consistent with these data, furosemide blocked individual CFTR Cl(-) channels with "very fast" speed and drug-induced blocking events overlapped brief channel closures, whereas piretanide inhibited individual channels with "intermediate" speed and drug-induced blocking events were distinct from channel closures.	Furosemide	28-38	CF transmembrane conductance regulator	Homo sapiens	58-62
23839288-7	2013	furosemide dose (slow diuretic response, SDR).	Furosemide	0-10	caveolae associated protein 2	Homo sapiens	41-44
23847084-5	2013	Microinjection of brain-derived neurotrophic factor (BDNF) into the NRM inhibited the KCC2 protein level in the NRM, and both BDNF administration and KCC2 inhibition by furosemide mimicked the pain-induced effects on EIPSC and excitability in MOR-expressing neurons.	Furosemide	169-179	brain-derived neurotrophic factor	Rattus norvegicus	18-51
23847084-5	2013	Microinjection of brain-derived neurotrophic factor (BDNF) into the NRM inhibited the KCC2 protein level in the NRM, and both BDNF administration and KCC2 inhibition by furosemide mimicked the pain-induced effects on EIPSC and excitability in MOR-expressing neurons.	Furosemide	169-179	brain-derived neurotrophic factor	Rattus norvegicus	53-57
23847084-5	2013	Microinjection of brain-derived neurotrophic factor (BDNF) into the NRM inhibited the KCC2 protein level in the NRM, and both BDNF administration and KCC2 inhibition by furosemide mimicked the pain-induced effects on EIPSC and excitability in MOR-expressing neurons.	Furosemide	169-179	brain-derived neurotrophic factor	Rattus norvegicus	126-130
23847084-5	2013	Microinjection of brain-derived neurotrophic factor (BDNF) into the NRM inhibited the KCC2 protein level in the NRM, and both BDNF administration and KCC2 inhibition by furosemide mimicked the pain-induced effects on EIPSC and excitability in MOR-expressing neurons.	Furosemide	169-179	solute carrier family 12 member 5	Rattus norvegicus	150-154
23847084-6	2013	Furthermore, inhibiting BDNF signaling by NRM infusion of tyrosine receptor kinase B-IgG or blocking KCC2 with furosemide prevented these pain effects in MOR-expressing neurons.	Furosemide	111-121	solute carrier family 12 member 5	Rattus norvegicus	101-105
23448699-11	2013	Cox model"s multivariate analysis showed that administration of furosemide and doxapram significantly increased the occurrence of severe hypokalaemia with relative risks of 4.9 (95% CI 1.9 to 12.5) and 8.2 (95% CI 3.1 to 21.7), respectively.	Furosemide	64-74	cytochrome c oxidase subunit 8A	Homo sapiens	0-3
25505556-6	2013	Furosemide acyl-glucuronidation was sigmoidal and best fitted to the Hill equation in hUGT1 mice and human liver microsomes, while it was fitted to the substrate inhibition equation in mouse liver microsomes.	Furosemide	0-10	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	86-91
25505556-7	2013	Kinetic parameters of furosemide glucuronidation were very similar between hUGT1 mice and human liver microsomes.	Furosemide	22-32	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	75-80
25505556-8	2013	The kinetics of S-naproxen acyl-glucuronidation and inhibitory effects of compounds on furosemide glucuronidation in hUGT1 liver microsomes were also slightly, but similar to those in human liver microsomes, rather than in wild-type mice.	Furosemide	87-97	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	117-122
23483451-1	2013	OBJECTIVES/HYPOTHESIS: To evaluate the ability of the Ad28.gfap.atoh1 to promote hair cell regeneration and hearing recovery in cochlea injured with kanamycin and furosemide.	Furosemide	163-173	atonal bHLH transcription factor 1	Mus musculus	64-69
23457060-6	2013	Furthermore, we have found that probenecid, furosemide, and diclofenac inhibit chlorothiazide transport by OAT1 and OAT3, of which the probenecide-mediated inhibition may be of clinical importance.	Furosemide	44-54	solute carrier family 22 member 6	Homo sapiens	107-111
23457060-6	2013	Furthermore, we have found that probenecid, furosemide, and diclofenac inhibit chlorothiazide transport by OAT1 and OAT3, of which the probenecide-mediated inhibition may be of clinical importance.	Furosemide	44-54	solute carrier family 22 member 8	Homo sapiens	116-120
23952288-8	2013	Plasma renin activity and plasma aldosterone were significantly lower after the administration of carperitide than after the administration of furosemide (P &lt; .05, respectively).	Furosemide	143-153	renin	Canis lupus familiaris	7-12
23986689-7	2013	Hypertonicity stimulates NKCC1, which, aided by beta-adrenergic stimulation of the Na(+),K(+)-ATPase, causes regulatory volume increase, furosemide-inhibited undershoot in [K(+)]e and perhaps facilitation of the termination of slow neuronal hyperpolarization (sAHP), with behavioral consequences.	Furosemide	137-147	solute carrier family 12 member 2	Homo sapiens	25-30
23565710-7	2013	On the other hand, pre-treatment with furosemide (a KCC2 inhibitor) suppressed the enhancing effects of zolpidem on morphine-induced hyperlocomotion.	Furosemide	38-48	solute carrier family 12 member 5	Homo sapiens	52-56
24695967-13	2013	Interestingly, Smad3/4 signaling was reduced by all compounds except furosemide, which even enhanced this profibrotic signaling.	Furosemide	69-79	SMAD family member 3	Homo sapiens	15-20
23483451-16	2013	CONCLUSIONS: Ad28.gfap.atoh1 promotes hair cell regeneration in cochlea ablated with kanamycin and furosemide resulting in moderate hearing recovery.	Furosemide	99-109	atonal bHLH transcription factor 1	Mus musculus	23-28
23438181-0	2013	Biophysical insight into furosemide binding to human serum albumin: a study to unveil its impaired albumin binding in uremia.	Furosemide	25-35	albumin	Homo sapiens	53-66
23269645-3	2013	Since furosemide attenuated the increase in TNF levels, we hypothesized that hypertonic NaCl intake increases renal TNF production by a pathway involving the Na(+)-K(+)-2Cl(-) cotransporter (NKCC2).	Furosemide	6-16	tumor necrosis factor	Mus musculus	44-47
23766851-3	2013	Graded activation of Nrf2 offered a Nrf2-dependent protection against the hepatotoxicity produced by carbon tetrachloride, acetaminophen, microcystin, phalloidin, furosemide, cadmium, and lithocholic acid, as evidenced by serum alanine aminotransferase (ALT) activities and by histopathology.	Furosemide	163-173	nuclear factor, erythroid derived 2, like 2	Mus musculus	21-25
22913624-5	2013	Animals were given a combined treatment of furosemide and a low dose of captopril (furo/cap), comprising a diuretic and an angiotensin-converting enzyme inhibitor, respectively, to elevate endogenous AngII levels in the brain.	Furosemide	43-53	angiotensinogen	Rattus norvegicus	200-205
23766851-3	2013	Graded activation of Nrf2 offered a Nrf2-dependent protection against the hepatotoxicity produced by carbon tetrachloride, acetaminophen, microcystin, phalloidin, furosemide, cadmium, and lithocholic acid, as evidenced by serum alanine aminotransferase (ALT) activities and by histopathology.	Furosemide	163-173	nuclear factor, erythroid derived 2, like 2	Mus musculus	36-40
22946656-6	2012	Exposure to caspase inhibitors, Fas-antagonistic antibody, DR4 antagonist, and furosemide (a blocker of Bax translocation) effectively abolished ar-turmerone-triggered apoptosis.	Furosemide	79-89	BCL2 associated X, apoptosis regulator	Homo sapiens	104-107
22997204-7	2012	MEASUREMENTS AND MAIN RESULTS: In the BNP-driven group, furosemide and acetazolamide were given more often and in higher doses than in the control group, resulting in a more negative median (interquartile range) fluid balance during weaning (-2,320 [-4,735, 738] vs. -180 [-2,556, 2,832] ml; P &lt; 0.0001).	Furosemide	56-66	natriuretic peptide B	Homo sapiens	38-41
26069797-0	2012	Increased expression of renal TRPM6 compensates for Mg(2+) wasting during furosemide treatment.	Furosemide	74-84	transient receptor potential cation channel, subfamily M, member 6	Mus musculus	30-35
26069797-1	2012	BACKGROUND: Furosemide is a loop diuretic, which blocks the Na(+), K(+), 2Cl(-) cotransporter (NKCC2) in the thick ascending limb of Henle (TAL).	Furosemide	12-22	solute carrier family 12, member 1	Mus musculus	95-100
26069797-1	2012	BACKGROUND: Furosemide is a loop diuretic, which blocks the Na(+), K(+), 2Cl(-) cotransporter (NKCC2) in the thick ascending limb of Henle (TAL).	Furosemide	12-22	talipes	Mus musculus	140-143
26069797-13	2012	CONCLUSIONS: During chronic furosemide treatment, enhanced active reabsorption of Mg(2+) via the epithelial channel TRPM6 in DCT compensates for the reduced reabsorption of Mg(2+) in TAL.	Furosemide	28-38	transient receptor potential cation channel, subfamily M, member 6	Mus musculus	116-121
26069797-13	2012	CONCLUSIONS: During chronic furosemide treatment, enhanced active reabsorption of Mg(2+) via the epithelial channel TRPM6 in DCT compensates for the reduced reabsorption of Mg(2+) in TAL.	Furosemide	28-38	talipes	Mus musculus	183-186
22846885-4	2012	Results showed that sodium depletion induced by Furo+low-Cap increased taste preference for hypertonic NaCl solution with amplified brain action of ANG II but without peripheral action, while Furosemide combined with a high dose of captopril can partially inhibit the formation of brain ANG II, with parallel decreased effects on salty taste changes.	Furosemide	48-53	angiotensinogen	Rattus norvegicus	148-154
22846885-4	2012	Results showed that sodium depletion induced by Furo+low-Cap increased taste preference for hypertonic NaCl solution with amplified brain action of ANG II but without peripheral action, while Furosemide combined with a high dose of captopril can partially inhibit the formation of brain ANG II, with parallel decreased effects on salty taste changes.	Furosemide	192-202	angiotensinogen	Rattus norvegicus	287-293
22846885-5	2012	And the resulting elevating forebrain ANG II may activate a variety of brain areas including SFO, PVN, SON and OVLT in sodium depleted rats injected with Furo+low-Cap, which underlines salty taste function and sodium intake behavioral changes.	Furosemide	154-159	angiotensinogen	Rattus norvegicus	38-44
22496496-9	2012	CONCLUSION: The IGF-I-mediated and PTH-independent increase in calcitriol synthesis in acromegaly is responsible for both absorptive hypercalciuria and increased fasting plasma calcium linked to enhanced distal tubular calcium reabsorption, as shown by the selectively diminished calciuric response to furosemide.	Furosemide	302-312	insulin like growth factor 1	Homo sapiens	16-21
22648948-1	2012	The oxidative stress-responsive kinase 1 (OSR1) is activated by WNK (with no K kinases) and in turn stimulates the thiazide-sensitive Na-Cl cotransporter (NCC) and the furosemide-sensitive Na-K-2Cl cotransporter (NKCC), thus contributing to transport and cell volume regulation.	Furosemide	168-178	odd-skipped related transcription factor 1	Mus musculus	42-46
22648948-13	2012	Na(+)/H(+) exchanger activity in osr(WT) DCs was increased by the NKCC1 inhibitor furosemide (100 nM) to values similar to those in osr(KI) DCs.	Furosemide	82-92	solute carrier family 12, member 2	Mus musculus	66-71
22791338-6	2012	Furosemide, an established stimulus for COX-2 induction, caused enhanced expression of both ANXA1 and COX-2 with maintained colocalization (99%).	Furosemide	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	40-45
22791338-6	2012	Furosemide, an established stimulus for COX-2 induction, caused enhanced expression of both ANXA1 and COX-2 with maintained colocalization (99%).	Furosemide	0-10	annexin A1	Rattus norvegicus	92-97
22791338-6	2012	Furosemide, an established stimulus for COX-2 induction, caused enhanced expression of both ANXA1 and COX-2 with maintained colocalization (99%).	Furosemide	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	102-107
22791335-8	2012	Furosemide-sensitive Na(+) reabsorption in cTAL was higher in KS-WNK1-knockout (KO) mice than in wild-type.	Furosemide	0-10	WNK lysine deficient protein kinase 1	Mus musculus	65-69
22873416-5	2012	PAL-treatment combines high levels of positive end-expiratory pressure, small volume resuscitation with hyperoncotic albumin, and fluid removal with furosemide (Lasix ) or ultrafiltration.	Furosemide	149-159	SHC binding and spindle associated 1	Homo sapiens	0-3
22873416-5	2012	PAL-treatment combines high levels of positive end-expiratory pressure, small volume resuscitation with hyperoncotic albumin, and fluid removal with furosemide (Lasix ) or ultrafiltration.	Furosemide	161-166	SHC binding and spindle associated 1	Homo sapiens	0-3
22751371-0	2012	Effect of albumin on diuretic response to furosemide in patients with hypoalbuminemia.	Furosemide	42-52	albumin	Homo sapiens	10-17
22612805-6	2012	In support of this hypothesis is an accumulation of data from a number of studies suggesting that furosemide and bumetanide mediate antiepileptic effects through their blockade of cell swelling, dependent on their antagonism of the glial Na+-K-2Cl cotransporter (NKCC1).	Furosemide	98-108	solute carrier family 12 member 2	Homo sapiens	263-268
21352352-6	2012	The results clearly demonstrate that FS produced toxic responses in the hepatocytes as evident from increased ALT/AST level, DNA damage, TUNEL positive cells and increased DNA fragmentation in mice in vivo.	Furosemide	37-39	glutamic pyruvic transaminase, soluble	Mus musculus	110-113
21352352-6	2012	The results clearly demonstrate that FS produced toxic responses in the hepatocytes as evident from increased ALT/AST level, DNA damage, TUNEL positive cells and increased DNA fragmentation in mice in vivo.	Furosemide	37-39	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	114-117
22496496-9	2012	CONCLUSION: The IGF-I-mediated and PTH-independent increase in calcitriol synthesis in acromegaly is responsible for both absorptive hypercalciuria and increased fasting plasma calcium linked to enhanced distal tubular calcium reabsorption, as shown by the selectively diminished calciuric response to furosemide.	Furosemide	302-312	parathyroid hormone	Homo sapiens	35-38
22441041-7	2012	We then measured KCC2 activity by monitoring both the rate and relative amount of furosemide-sensitive NH(4)(+) influx through the co-transporter using an intracellular pH-sensitive fluorescent indicator.	Furosemide	82-92	solute carrier family 12 member 5	Rattus norvegicus	17-21
22266263-10	2012	The physicochemical characterization of Furosemide:crospovidone SDs (1:1 and 1:2 w/w, respectively) generated by SAS revealed the presence of the drug amorphously dispersed in the 1:2 w/w sample at 100bar still remaining stable after 6months.	Furosemide	40-50	CUP2Q35	Homo sapiens	64-78
22343084-0	2012	Spectroscopic characterization of furosemide binding to human carbonic anhydrase II.	Furosemide	34-44	carbonic anhydrase 2	Homo sapiens	62-83
22343084-1	2012	This study reports the interaction between furosemide and human carbonic anhydrase II (hCA II) using fluorescence, UV-vis and circular dichroism (CD) spectroscopy.	Furosemide	43-53	carbonic anhydrase 2	Homo sapiens	64-85
22343084-1	2012	This study reports the interaction between furosemide and human carbonic anhydrase II (hCA II) using fluorescence, UV-vis and circular dichroism (CD) spectroscopy.	Furosemide	43-53	carbonic anhydrase 2	Homo sapiens	87-93
22343084-3	2012	The binding average distance between furosemide and hCA II was estimated on the basis of the theory of Forster energy transfer.	Furosemide	37-47	carbonic anhydrase 2	Homo sapiens	52-58
22343084-5	2012	Chemical modification of hCA II using N-bromosuccinimide indicated decrease of the number of accessible tryptophans in the presence of furosemide.	Furosemide	135-145	carbonic anhydrase 2	Homo sapiens	25-31
22133520-7	2012	With regard to brain Fos immunoreactivity, we observed that Furosemide-sodium depletion in the PM-Na group induced a higher number of activated cells in the subfornical organ, ventral subdivision of the paraventricular nucleus and vasopressinergic neurons of the supraoptic nucleus than in the PM-Ctrol animals.	Furosemide	60-70	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	21-24
22591021-1	2012	We wanted to test the hypothesis that treatment with amiloride or spironolactone reduced ambulatory (ABP) and central blood pressure (CBP) and that tubular transport via ENaCgamma and AQP2 was increased after furosemide treatment.	Furosemide	209-219	sodium channel epithelial 1 subunit gamma	Homo sapiens	170-179
22203737-8	2012	The PKC inhibitor calphostin C (1 mumol/L) or the PKCalpha/beta inhibitor Go6976 (1 mumol/L) decreased furosemide-sensitive O(2) consumption in both groups, achieving values that did not differ between sham and diabetic.	Furosemide	103-113	protein kinase C, alpha	Rattus norvegicus	50-58
22203737-11	2012	We conclude that NADPH oxidase and PKC (primarily PKCalpha) contribute to an increase in O(2) consumption by the mTAL during type 1 diabetes through effects on the ouabain-sensitive Na(+)-K(+)-ATPase and furosemide-sensitive Na(+)-K(+)-2Cl(-) cotransporter that are primarily responsible for active transport Na(+) reabsorption by this nephron segment.	Furosemide	204-214	protein kinase C, alpha	Rattus norvegicus	50-58
22081478-2	2012	Eight novel equimolar cocrystals of furosemide were obtained by liquid-assisted grinding with (i) caffeine, (ii) urea, (iii) p-aminobenzoic acid, (iv) acetamide, (v) nicotinamide, (vi) isonicotinamide, (vii) adenine, and (viii) cytosine.	Furosemide	36-46	cytochrome c oxidase subunit 8A	Homo sapiens	222-226
22591021-1	2012	We wanted to test the hypothesis that treatment with amiloride or spironolactone reduced ambulatory (ABP) and central blood pressure (CBP) and that tubular transport via ENaCgamma and AQP2 was increased after furosemide treatment.	Furosemide	209-219	aquaporin 2	Homo sapiens	184-188
22591021-4	2012	The increases in water and sodium absorption via AQP2 and ENaC after furosemide treatment most likely are compensatory phenomena to antagonize water and sodium depletion.	Furosemide	69-79	aquaporin 2	Homo sapiens	49-53
22120095-10	2011	However, furosemide also decreased serum potassium concentration and increased plasma arginine vasopressin concentrations and plasma renin activity.	Furosemide	9-19	renin	Canis lupus familiaris	133-138
21863227-9	2012	These differences were abolished by the administration of AM + BF (equivalent to the outflow from the TAL) and AM + BF + FUR (equivalent to the outflow from the proximal tubule), suggesting that the increase in NKCC2 expression was not functional.	Furosemide	121-124	solute carrier family 12 member 1	Rattus norvegicus	211-216
22080226-6	2012	A comparable reduction of SBP was observed in rats after MT-189, RT-93 or furosemide administration.	Furosemide	74-84	spermine binding protein	Rattus norvegicus	26-29
23235437-1	2012	BACKGROUND: The WNK-dependent STE20/SPS1-related proline/alanine-rich kinase (SPAK) regulates the renal thiazide sensitive NaCl cotransporter (NCC) and the renal furosemide sensitive Na+, K+, 2Cl- cotransporter (NKCC2) and thus participates in the regulation of renal salt excretion, extracellular fluid volume and blood pressure.	Furosemide	162-172	serine/threonine kinase 24	Mus musculus	30-35
23235437-1	2012	BACKGROUND: The WNK-dependent STE20/SPS1-related proline/alanine-rich kinase (SPAK) regulates the renal thiazide sensitive NaCl cotransporter (NCC) and the renal furosemide sensitive Na+, K+, 2Cl- cotransporter (NKCC2) and thus participates in the regulation of renal salt excretion, extracellular fluid volume and blood pressure.	Furosemide	162-172	serine/threonine kinase 39	Mus musculus	78-82
23235437-1	2012	BACKGROUND: The WNK-dependent STE20/SPS1-related proline/alanine-rich kinase (SPAK) regulates the renal thiazide sensitive NaCl cotransporter (NCC) and the renal furosemide sensitive Na+, K+, 2Cl- cotransporter (NKCC2) and thus participates in the regulation of renal salt excretion, extracellular fluid volume and blood pressure.	Furosemide	162-172	solute carrier family 12, member 3	Mus musculus	143-146
23235437-1	2012	BACKGROUND: The WNK-dependent STE20/SPS1-related proline/alanine-rich kinase (SPAK) regulates the renal thiazide sensitive NaCl cotransporter (NCC) and the renal furosemide sensitive Na+, K+, 2Cl- cotransporter (NKCC2) and thus participates in the regulation of renal salt excretion, extracellular fluid volume and blood pressure.	Furosemide	162-172	solute carrier family 12, member 1	Mus musculus	212-217
23548701-1	2012	BACKGROUND/AIMS: Since furosemide (FS) inhibits active Na(+) reabsorption by medullary thick ascending limb (mTAL) in the renal outer medulla, it may decrease its work during periods of low O2 supply to deep in the renal outer medulla.	Furosemide	23-33	talipes	Mus musculus	109-113
23548701-1	2012	BACKGROUND/AIMS: Since furosemide (FS) inhibits active Na(+) reabsorption by medullary thick ascending limb (mTAL) in the renal outer medulla, it may decrease its work during periods of low O2 supply to deep in the renal outer medulla.	Furosemide	35-37	talipes	Mus musculus	109-113
22236570-0	2012	GPR35 is a target of the loop diuretic drugs bumetanide and furosemide.	Furosemide	60-70	G protein-coupled receptor 35	Homo sapiens	0-5
22236570-1	2012	We report that the loop diuretic drugs bumetanide and furosemide used in the treatment of hypertension are GPR35 agonists.	Furosemide	54-64	G protein-coupled receptor 35	Homo sapiens	107-112
22139699-2	2011	The first objective was the evaluation of a possible role of intestinal P-gp in the kinetic absorption of a model drug: furosemide.	Furosemide	120-130	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	72-76
22139699-6	2011	The results indicated that verapamil at various drug concentrations (5-100 mug/mL) significantly decreased the B   A (2-3 fold) and increased the A   B (1.5-2 fold) permeability of furosemide, which showed that this drug could be a P-gp substrate.	Furosemide	181-191	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	232-236
21938673-4	2011	In addition, changes in HSP70 immunolocalization following the infusion of furosemide were investigated.	Furosemide	75-85	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	24-29
21938673-10	2011	However, furosemide infusion resulted in significantly reduced HSP70 immunolocalization in the IMCD and ATL.	Furosemide	9-19	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	63-68
21972418-6	2011	KSP-OSR1(-/-) mice exhibited impaired Na(+) reabsorption in the thick ascending loop on a low-Na(+) diet accompanied by remarkably decreased expression of p-NKCC2 and a blunted response to furosemide, an NKCC2 inhibitor.	Furosemide	189-199	odd-skipped related transcription factor 1	Mus musculus	0-8
21317676-16	2011	Logistic regression identified cyanosis, coadministration of furosemide, and baseline estimated creatinine clearance as independent risk factors for any degree of angiotensin-converting enzyme inhibitor-associated acute kidney injury (p &lt; .05).	Furosemide	61-71	angiotensin I converting enzyme	Homo sapiens	163-192
21317676-19	2011	The presence of cyanosis and coadministration of furosemide are independent risk factors for acute kidney injury in patients receiving angiotensin-converting enzyme inhibitor.	Furosemide	49-59	angiotensin I converting enzyme	Homo sapiens	135-164
21733846-4	2011	WNK1 and WNK4, members of the WNK (with no lysine [K]) kinase family, either directly or via the downstream SPAK/OSR1 Ste20-type kinases, regulate the furosemide-sensitive NKCC2 and the thiazide-sensitive NCC, kidney-specific CCCs.	Furosemide	151-161	WNK lysine deficient protein kinase 1	Homo sapiens	0-4
21733846-4	2011	WNK1 and WNK4, members of the WNK (with no lysine [K]) kinase family, either directly or via the downstream SPAK/OSR1 Ste20-type kinases, regulate the furosemide-sensitive NKCC2 and the thiazide-sensitive NCC, kidney-specific CCCs.	Furosemide	151-161	WNK lysine deficient protein kinase 4	Homo sapiens	9-13
21733846-4	2011	WNK1 and WNK4, members of the WNK (with no lysine [K]) kinase family, either directly or via the downstream SPAK/OSR1 Ste20-type kinases, regulate the furosemide-sensitive NKCC2 and the thiazide-sensitive NCC, kidney-specific CCCs.	Furosemide	151-161	serine/threonine kinase 39	Homo sapiens	108-112
21733846-4	2011	WNK1 and WNK4, members of the WNK (with no lysine [K]) kinase family, either directly or via the downstream SPAK/OSR1 Ste20-type kinases, regulate the furosemide-sensitive NKCC2 and the thiazide-sensitive NCC, kidney-specific CCCs.	Furosemide	151-161	odd-skipped related transcription factor 1	Homo sapiens	113-117
21733846-4	2011	WNK1 and WNK4, members of the WNK (with no lysine [K]) kinase family, either directly or via the downstream SPAK/OSR1 Ste20-type kinases, regulate the furosemide-sensitive NKCC2 and the thiazide-sensitive NCC, kidney-specific CCCs.	Furosemide	151-161	serine/threonine kinase 24	Homo sapiens	118-123
21733846-4	2011	WNK1 and WNK4, members of the WNK (with no lysine [K]) kinase family, either directly or via the downstream SPAK/OSR1 Ste20-type kinases, regulate the furosemide-sensitive NKCC2 and the thiazide-sensitive NCC, kidney-specific CCCs.	Furosemide	151-161	solute carrier family 12 member 1	Homo sapiens	172-177
21849545-6	2011	Moreover, furosemide and bumetanide, two inhibitors of sodium-coupled and/or potassium-coupled chloride movement strongly modified the phase shift, suggesting an involvement of two neuronal cotransporters, NKCC1 (Na-K-Cl) and KCC2 (K-Cl) in the genesis of the optical signal.	Furosemide	10-20	solute carrier family 12, member 2	Mus musculus	206-211
21849545-6	2011	Moreover, furosemide and bumetanide, two inhibitors of sodium-coupled and/or potassium-coupled chloride movement strongly modified the phase shift, suggesting an involvement of two neuronal cotransporters, NKCC1 (Na-K-Cl) and KCC2 (K-Cl) in the genesis of the optical signal.	Furosemide	10-20	solute carrier family 12, member 5	Mus musculus	226-230
21553016-5	2011	Moreover, the administration of furosemide in vivo decreased the blood pressure and increased the urine output and natriuresis in MHS rats demonstrating the actual involvement of NKCC2 activity in the pathogenesis of hypertension in this strain of rats.	Furosemide	32-42	solute carrier family 12 member 1	Rattus norvegicus	179-184
21177779-5	2011	Acute furosemide infusion increased urinary ET-1 excretion in anesthetized rats.	Furosemide	6-16	endothelin 1	Rattus norvegicus	44-48
21414853-9	2011	All 3 patients received intravenous treatment with serum, furosemide and corticoids and in one case with subcutaneous calcitonine as well.	Furosemide	58-68	paired box 5	Homo sapiens	0-5
21373963-0	2011	Water flux through human aquaporin 1: inhibition by intracellular furosemide and maximal response with high osmotic gradients.	Furosemide	66-76	aquaporin 1 (Colton blood group)	Homo sapiens	25-36
21373963-3	2011	In this way, the specific intracellular inhibition of hAQP1 by the diuretic drug furosemide was demonstrated.	Furosemide	81-91	aquaporin 1 (Colton blood group)	Homo sapiens	54-59
21118399-2	2011	Astrocytic swelling also occurs following brain trauma or ischemia, together with an increase in extracellular K(+) ([K(+)](o)), stimulating a bumetanide/furosemide/ethacrynic acid-inhibitable cotransporter, NKCC1, that accumulates Na(+) and K(+) together with 2 Cl(-) and osmotically obliged water.	Furosemide	154-164	solute carrier family 12, member 2	Mus musculus	208-213
21616283-10	2011	After reinitiation of furosemide, both urinary KIM-1 and NAG concentrations returned to baseline (both p &lt; 0.05), but NGAL values were unaffected.	Furosemide	22-32	hepatitis A virus cellular receptor 1	Homo sapiens	47-52
21616283-10	2011	After reinitiation of furosemide, both urinary KIM-1 and NAG concentrations returned to baseline (both p &lt; 0.05), but NGAL values were unaffected.	Furosemide	22-32	O-GlcNAcase	Homo sapiens	57-60
21325280-2	2011	To investigate how these changes are transmitted to the hormone-binding site, we developed a sensitive assay using a synthesized thyroxine fluorophore and solved the crystal structures of reactive loop cleaved TBG together with its complexes with thyroxine, the thyroxine fluorophores, furosemide, and mefenamic acid.	Furosemide	286-296	serpin family A member 7	Homo sapiens	210-213
21414921-5	2011	Moreover, pretreatment with furosemide, a blocker of Bax translocation to mitochondria, significantly protected rat and mouse oligodendrocytes from AMPA- and kainate-induced damage; in contrast, bongkrekic acid, a blocker of the mitochondrial permeability transition pore, had no effect.	Furosemide	28-38	BCL2 associated X, apoptosis regulator	Rattus norvegicus	53-56
19729213-10	2010	Sex, left cardiac work index, stroke index, hemoglobin, renal failure and discharge furosemide and lisinopril doses were associated to BNP only in univariate analysis.	Furosemide	84-94	natriuretic peptide B	Homo sapiens	135-138
20810575-7	2010	This study revealed the following characteristics of these disorders: 1) subjects with CLCNKB mutations showed one or more biochemical features of Gitelman syndrome (including hypomagnesemia, hypocalciuria, and fractional chloride excretion insensitivity to thiazide administration); and 2) subjects with KCNJ1 mutations appeared to show normal fractional chloride excretion sensitivity to furosemide and thiazide administration.	Furosemide	390-400	chloride voltage-gated channel Kb	Homo sapiens	87-93
21893990-2	2011	It is second only to the collecting duct as a source of renal endothelin (ET)-1, which inhibits NaCl reabsorption in the thick ascending limb by reducing NaCl entry into the cell via the furosemide-sensitive Na(+)/K(+)/2 Cl(-) cotransporter.	Furosemide	187-197	endothelin 1	Homo sapiens	62-79
21112289-7	2010	The furosemide or DIOA (dihydroindenyl-oxy-alkanoic acid)-sensitive water flux was much larger than expected when water passively followed the KCC1-mediated ion flow.	Furosemide	4-14	solute carrier family 12 member 4	Homo sapiens	143-147
20810651-9	2010	Furthermore, loop diuretics, such as furosemide and bumetanide, substantially interacted with hNPT4.	Furosemide	37-47	solute carrier family 17 member 3	Homo sapiens	94-99
20813865-7	2010	We observed a blunted response to thiazide but normal response to furosemide in SPAK(-/-) mice.	Furosemide	66-76	serine/threonine kinase 39	Mus musculus	80-84
20516068-9	2010	Dose-response curves of wild-type and chimeric KCCs revealed that the LEL contributes to the different sensitivity to loop diuretics; a KCC2 chimera containing the KCC4 LEL displayed an IC(50) of 396.5 mum for furosemide, which was closer to KCC4 (548.8 mum) than to KCC2 (184.4 mum).	Furosemide	210-220	solute carrier family 12 member 5	Homo sapiens	136-140
20660105-8	2010	Likewise, cinacalcet decreased furosemide-stimulated renin from 30.6 +- 2.3 to 21.3 +- 2.3 ng ANG I ml(-1) h(-1) (P &lt; 0.001).	Furosemide	31-41	renin	Rattus norvegicus	53-58
20516068-9	2010	Dose-response curves of wild-type and chimeric KCCs revealed that the LEL contributes to the different sensitivity to loop diuretics; a KCC2 chimera containing the KCC4 LEL displayed an IC(50) of 396.5 mum for furosemide, which was closer to KCC4 (548.8 mum) than to KCC2 (184.4 mum).	Furosemide	210-220	solute carrier family 12 member 7	Homo sapiens	164-168
20413337-12	2010	CONCLUSION: Furosemide is physically compatible with bicarbonate solution, heparin, insulin, morphine and nitroglycerin and incompatible with amiodarone, cisatracurium, haloperidol, midazolam and urapidil.	Furosemide	12-22	insulin	Homo sapiens	84-91
20146722-9	2010	All NKCC2 isoforms were more efficiently inhibited by bumetanide than by furosemide.	Furosemide	73-83	solute carrier family 12 member 1	Homo sapiens	4-9
20410470-5	2010	Ussing chamber experiments demonstrated that the NKCC inhibitors (bumetanide and furosemide) were ineffective at blocking the cotransporter under basal conditions, as well as under pharmacologically stimulated Cl(-)-secreting conditions (forskolin and chlorzoxazone application).	Furosemide	81-91	solute carrier family 12 member 1 L homeolog	Xenopus laevis	49-53
20219947-8	2010	In vivo, osmoresponsiveness of Cln3 was demonstrated by reduction of medullary Cln3 transcript abundance after furosemide administration.	Furosemide	111-121	ceroid lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-Vogt disease)	Mus musculus	31-35
20308015-0	2010	Influence of myristic acid on furosemide binding to bovine serum albumin.	Furosemide	30-40	albumin	Homo sapiens	59-72
20308015-1	2010	Comparison with furosemide-human serum albumin complex.	Furosemide	16-26	albumin	Homo sapiens	33-46
20308015-2	2010	Fluorescence studies on furosemide (FUR) binding to bovine serum albumin (BSA) showed the existence of three or four binding sites in the tertiary structure of the protein.	Furosemide	24-34	albumin	Homo sapiens	59-72
20308015-2	2010	Fluorescence studies on furosemide (FUR) binding to bovine serum albumin (BSA) showed the existence of three or four binding sites in the tertiary structure of the protein.	Furosemide	36-39	albumin	Homo sapiens	59-72
19835936-10	2010	Interestingly, egr-1 mRNA levels were significantly higher only in the furosemide-treated group compared with controls.	Furosemide	71-81	early growth response 1	Rattus norvegicus	15-20
20597365-4	2010	These data for the first time show that furosemide not only decreases sodium reabsorption, but also blocks some componentin molecular mechanism of vasopressin-dependent increase of the osmotic permeability of water.	Furosemide	40-50	arginine vasopressin	Rattus norvegicus	147-158
20181798-10	2010	Ang II also increased type-1 Ang II receptor-mediated BDNF expression in vivo in furosemide-treated rats.	Furosemide	81-91	angiotensinogen	Rattus norvegicus	0-6
20181798-10	2010	Ang II also increased type-1 Ang II receptor-mediated BDNF expression in vivo in furosemide-treated rats.	Furosemide	81-91	angiotensinogen	Homo sapiens	29-35
20181798-10	2010	Ang II also increased type-1 Ang II receptor-mediated BDNF expression in vivo in furosemide-treated rats.	Furosemide	81-91	brain-derived neurotrophic factor	Rattus norvegicus	54-58
23960725-3	2010	This study was done due to the great disagreement between what is published in the literature regarding the influence of P-gp on furosemide and at the same time due to the importance of this drug in the treatment of different conditions as described above.	Furosemide	129-139	ATP binding cassette subfamily B member 1	Homo sapiens	121-125
23960725-5	2010	METHODS: The study utilized the everted intestinal sacs technique to investigate both the effect of the efflux transporter (P-gp) on furosemide absorption and also the effect of the chosen excipients.	Furosemide	133-143	ATP binding cassette subfamily B member 1	Homo sapiens	124-128
23960725-6	2010	RESULTS: The absorption of furosemide was significantly influenced by the P-gp as confirmed by the everted vis the non-everted sacs together with the verapamil study in which the transport of furosemide was inhibited by verapamil.	Furosemide	27-37	ATP binding cassette subfamily B member 1	Homo sapiens	74-78
23960725-6	2010	RESULTS: The absorption of furosemide was significantly influenced by the P-gp as confirmed by the everted vis the non-everted sacs together with the verapamil study in which the transport of furosemide was inhibited by verapamil.	Furosemide	192-202	ATP binding cassette subfamily B member 1	Homo sapiens	74-78
23960725-8	2010	CONCLUSIONS: P-glycoprotein and some of the used excipients in the formulation play a very important role in the transport of furosemide and other drugs.	Furosemide	126-136	ATP binding cassette subfamily B member 1	Homo sapiens	13-27
20035777-1	2010	We investigated if a history of FURO/CAP, a protocol that increases brain angiotensin II (ANG II), sensitizes or enhances sodium intake.	Furosemide	32-36	angiotensinogen	Homo sapiens	74-88
20035777-1	2010	We investigated if a history of FURO/CAP, a protocol that increases brain angiotensin II (ANG II), sensitizes or enhances sodium intake.	Furosemide	32-36	angiotensinogen	Homo sapiens	90-96
20035777-10	2010	The results suggest that a history of FURO/CAP enhances stimulated and spontaneous sodium intake, as well as water deprivation-induced sodium appetite, and reinforce the role of ANG II as a peptide that mediates long-term effects on behavior.	Furosemide	38-42	angiotensinogen	Homo sapiens	178-184
19789943-16	2010	Renal cortical Cox-2 protein expressions due to furosemide and rofecoxib with or without furosemide were similar and significantly increased compared with controls.	Furosemide	48-58	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	15-20
19789943-16	2010	Renal cortical Cox-2 protein expressions due to furosemide and rofecoxib with or without furosemide were similar and significantly increased compared with controls.	Furosemide	89-99	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	15-20
20234144-10	2010	Compared with the control group, serum creatinine and cystatin C levels and fractional excretion of sodium were significantly increased in the furosemide group for 24-36 h after indomethacin therapy (p &lt; 0.01).	Furosemide	143-153	cystatin C	Homo sapiens	54-64
19709838-0	2010	Alterations of furosemide binding to serum albumin induced by increased level of fatty acid.	Furosemide	15-25	albumin	Homo sapiens	43-50
19709838-1	2010	Localization of high and low affinity binding sites of furosemide in human serum albumin (HSA) as well as the influence of myristic acid on the drug binding to the albumin using fluorescence quenching method was investigated.	Furosemide	55-65	albumin	Homo sapiens	81-88
19709838-4	2010	It was concluded that association of myristic acid in its low affinity binding sites which corresponds to elevated fatty acid level in vivo, significantly decreases albumin affinity towards furosemide.	Furosemide	190-200	albumin	Homo sapiens	165-172
19428648-4	2009	The impairment of LTP maintenance was significantly reversed by picrotoxinin, a specific GABA(A) receptor-chloride channel blocker and furosemide, a K+-Cl- cotransporter 2 (KCC2) blocker, respectively.	Furosemide	135-145	solute carrier family 12 member 5	Rattus norvegicus	149-171
19919977-0	2009	Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.	Furosemide	21-31	urocortin-2	Ovis aries	0-11
19919977-0	2009	Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.	Furosemide	21-31	renin	Ovis aries	54-59
19919977-4	2009	Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide&gt;Ucn2), urine sodium (furosemide&gt;Ucn2), potassium (furosemide&gt;Ucn2), and creatinine excretion (Ucn2&gt;furosemide) and creatinine clearance (Ucn2&gt;furosemide).	Furosemide	55-65	urocortin-2	Ovis aries	133-137
19919977-4	2009	Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide&gt;Ucn2), urine sodium (furosemide&gt;Ucn2), potassium (furosemide&gt;Ucn2), and creatinine excretion (Ucn2&gt;furosemide) and creatinine clearance (Ucn2&gt;furosemide).	Furosemide	55-65	urocortin-2	Ovis aries	133-137
19919977-4	2009	Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide&gt;Ucn2), urine sodium (furosemide&gt;Ucn2), potassium (furosemide&gt;Ucn2), and creatinine excretion (Ucn2&gt;furosemide) and creatinine clearance (Ucn2&gt;furosemide).	Furosemide	55-65	urocortin-2	Ovis aries	133-137
19919977-4	2009	Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide&gt;Ucn2), urine sodium (furosemide&gt;Ucn2), potassium (furosemide&gt;Ucn2), and creatinine excretion (Ucn2&gt;furosemide) and creatinine clearance (Ucn2&gt;furosemide).	Furosemide	55-65	urocortin-2	Ovis aries	133-137
19919977-4	2009	Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide&gt;Ucn2), urine sodium (furosemide&gt;Ucn2), potassium (furosemide&gt;Ucn2), and creatinine excretion (Ucn2&gt;furosemide) and creatinine clearance (Ucn2&gt;furosemide).	Furosemide	55-65	urocortin-2	Ovis aries	133-137
19919977-4	2009	Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide&gt;Ucn2), urine sodium (furosemide&gt;Ucn2), potassium (furosemide&gt;Ucn2), and creatinine excretion (Ucn2&gt;furosemide) and creatinine clearance (Ucn2&gt;furosemide).	Furosemide	119-129	urocortin-2	Ovis aries	46-50
19919977-4	2009	Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide&gt;Ucn2), urine sodium (furosemide&gt;Ucn2), potassium (furosemide&gt;Ucn2), and creatinine excretion (Ucn2&gt;furosemide) and creatinine clearance (Ucn2&gt;furosemide).	Furosemide	119-129	urocortin-2	Ovis aries	46-50
19919977-4	2009	Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide&gt;Ucn2), urine sodium (furosemide&gt;Ucn2), potassium (furosemide&gt;Ucn2), and creatinine excretion (Ucn2&gt;furosemide) and creatinine clearance (Ucn2&gt;furosemide).	Furosemide	119-129	urocortin-2	Ovis aries	46-50
19919977-4	2009	Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide&gt;Ucn2), urine sodium (furosemide&gt;Ucn2), potassium (furosemide&gt;Ucn2), and creatinine excretion (Ucn2&gt;furosemide) and creatinine clearance (Ucn2&gt;furosemide).	Furosemide	119-129	urocortin-2	Ovis aries	46-50
19919977-4	2009	Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide&gt;Ucn2), urine sodium (furosemide&gt;Ucn2), potassium (furosemide&gt;Ucn2), and creatinine excretion (Ucn2&gt;furosemide) and creatinine clearance (Ucn2&gt;furosemide).	Furosemide	119-129	urocortin-2	Ovis aries	46-50
19919977-5	2009	Compared with furosemide treatment alone, Ucn2+furosemide produced a further diuresis (P&lt;0.05), natriuresis (P&lt;0.05), and a sustained increase in creatinine excretion (P&lt;0.05) and clearance (P&lt;0.05), without additional potassium elimination.	Furosemide	14-24	urocortin-2	Ovis aries	42-46
19919977-7	2009	In contrast to the increase in plasma renin activity elicited by furosemide alone, Ucn2 and Ucn2+furosemide markedly reduced plasma renin activity.	Furosemide	65-75	renin	Ovis aries	38-43
19919977-7	2009	In contrast to the increase in plasma renin activity elicited by furosemide alone, Ucn2 and Ucn2+furosemide markedly reduced plasma renin activity.	Furosemide	97-107	renin	Ovis aries	132-137
19919977-9	2009	CONCLUSIONS: Ucn2 cotreatment with furosemide enhanced hemodynamic and renal function and diuretic responsiveness (without additional potassium depletion) in experimental heart failure.	Furosemide	35-45	urocortin-2	Ovis aries	13-17
19919977-10	2009	Furthermore, Ucn2 reversed furosemide-induced increases in plasma renin activity and induced greater decreases in plasma aldosterone and vasopressin.	Furosemide	27-37	urocortin-2	Ovis aries	13-17
19919977-10	2009	Furthermore, Ucn2 reversed furosemide-induced increases in plasma renin activity and induced greater decreases in plasma aldosterone and vasopressin.	Furosemide	27-37	renin	Ovis aries	66-71
19428648-4	2009	The impairment of LTP maintenance was significantly reversed by picrotoxinin, a specific GABA(A) receptor-chloride channel blocker and furosemide, a K+-Cl- cotransporter 2 (KCC2) blocker, respectively.	Furosemide	135-145	solute carrier family 12 member 5	Rattus norvegicus	173-177
19126296-0	2009	Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism.	Furosemide	90-100	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	11-26
19052532-8	2009	As expected, the expression of TonEBP target genes in the renal medulla also decreased in response to furosemide.	Furosemide	102-112	nuclear factor of activated T-cells 5	Rattus norvegicus	31-37
19075089-2	2009	We analyzed the degree of cross-linking and the expression of the enzyme lysyl oxidase, which regulates cross-linking, in the myocardium of patients with chronic heart failure at baseline and after 8 months of treatment with either torasemide or furosemide in addition to their standard heart failure therapy.	Furosemide	246-256	lysyl oxidase	Homo sapiens	73-86
19675228-3	2009	Functional analysis indicates that, like mammalian KCCs, C. elegans KCC-2 transports chloride, is activated by hypotonic conditions, and is inhibited by the loop diuretic furosemide.	Furosemide	171-181	K+/Cl- Cotransporter	Caenorhabditis elegans	68-73
19340543-7	2009	Furosemide- and low Cl(-)-induced NO generation was completely inhibited by 50 microM 7-nitroindasole (7-NI), a nNOS inhibitor.	Furosemide	0-10	nitric oxide synthase 1, neuronal	Mus musculus	112-116
19119014-3	2009	Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	Furosemide	160-170	carbonic anhydrase 2	Homo sapiens	107-112
19119014-3	2009	Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	Furosemide	160-170	carbonic anhydrase 2	Homo sapiens	206-211
19119014-5	2009	Examining the four X-ray crystal structures of their CA II adducts, we observed several (2-3) active site water molecules interacting with the chlorthalidone, trichloromethiazide, and furosemide scaffolds which may be responsible for this important difference of activity.	Furosemide	184-194	carbonic anhydrase 2	Homo sapiens	53-58
18843255-2	2009	Here we found that mRNA expression by the PGE(2)-activated G-protein-coupled receptors, EP3 and EP4 in the renal medulla was decreased by furosemide treatment, a procedure that reduces medullary hypertonicity.	Furosemide	138-148	prostaglandin E receptor 3	Homo sapiens	88-91
18843255-2	2009	Here we found that mRNA expression by the PGE(2)-activated G-protein-coupled receptors, EP3 and EP4 in the renal medulla was decreased by furosemide treatment, a procedure that reduces medullary hypertonicity.	Furosemide	138-148	prostaglandin E receptor 4	Homo sapiens	96-99
19126296-5	2009	After incubation of furosemide with baculovirus-infected insect cells expressing CYP2C11, 2E1, 3A1 or 3A2, furosemide was metabolized via CYP2C11, 2E1, 3A1 and 3A2.	Furosemide	20-30	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	81-88
19126296-5	2009	After incubation of furosemide with baculovirus-infected insect cells expressing CYP2C11, 2E1, 3A1 or 3A2, furosemide was metabolized via CYP2C11, 2E1, 3A1 and 3A2.	Furosemide	20-30	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	138-145
19126296-5	2009	After incubation of furosemide with baculovirus-infected insect cells expressing CYP2C11, 2E1, 3A1 or 3A2, furosemide was metabolized via CYP2C11, 2E1, 3A1 and 3A2.	Furosemide	107-117	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	81-88
19126296-5	2009	After incubation of furosemide with baculovirus-infected insect cells expressing CYP2C11, 2E1, 3A1 or 3A2, furosemide was metabolized via CYP2C11, 2E1, 3A1 and 3A2.	Furosemide	107-117	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	138-145
19126296-6	2009	CONCLUSIONS: These findings could help explain possible pharmacokinetic changes of furosemide in various rat disease models (where CYP2C11, 2E1, 3A1 and/or CYP3A2 are altered) and drug-drug interactions between furosemide and other drugs (mainly metabolized via CYP2C11, 2E1, 3A1 and/or 3A2).	Furosemide	83-93	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	131-138
19126296-6	2009	CONCLUSIONS: These findings could help explain possible pharmacokinetic changes of furosemide in various rat disease models (where CYP2C11, 2E1, 3A1 and/or CYP3A2 are altered) and drug-drug interactions between furosemide and other drugs (mainly metabolized via CYP2C11, 2E1, 3A1 and/or 3A2).	Furosemide	83-93	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	156-162
19126296-6	2009	CONCLUSIONS: These findings could help explain possible pharmacokinetic changes of furosemide in various rat disease models (where CYP2C11, 2E1, 3A1 and/or CYP3A2 are altered) and drug-drug interactions between furosemide and other drugs (mainly metabolized via CYP2C11, 2E1, 3A1 and/or 3A2).	Furosemide	83-93	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	262-269
19007810-11	2009	The Gd3+ action was blocked by furosemide, a blocker of both KCC and Na+-K+-Cl- co-transporter (NKCC), but not bumetanide, a specific blocker of NKCC.	Furosemide	31-41	GRDX	Homo sapiens	4-7
18546202-2	2008	The chloride channel inhibitor furosemide prevented the intracellular acidification, the translocation of Bax and the cell death.	Furosemide	31-41	BCL2 associated X, apoptosis regulator	Homo sapiens	106-109
18724382-9	2008	CONCLUSIONS AND IMPLICATIONS: These data suggest that inhibition of MRP4-mediated urate efflux by furosemide and thiazide diuretics could have an important function in their hyperuricaemic mechanisms.	Furosemide	98-108	ATP binding cassette subfamily C member 4	Homo sapiens	68-72
19001187-5	2008	Ang II-dependent hypertension increased furosemide-sensitive oxygen consumption (26.2+/-1.0% versus 36.6+/-1.2% of total oxygen consumption; P&lt;0.01).	Furosemide	40-50	angiotensinogen	Rattus norvegicus	0-6
19001187-11	2008	Unilateral renal infusion of the PKCalpha inhibitor Go6976 reduced furosemide-sensitive oxygen consumption (37.4+/-1.5% versus 25.1+/-1.0% of total oxygen consumption; P&lt;0.01) in hypertensive rats.	Furosemide	67-77	protein kinase C, alpha	Rattus norvegicus	33-41
18840481-7	2008	The E(Cl)-sustained was blocked by furosemide, a blocker of both KCC2 and NKCC1, but not bumetanide, a blocker of NKCC1.	Furosemide	35-45	solute carrier family 12 member 5	Homo sapiens	65-69
18840481-7	2008	The E(Cl)-sustained was blocked by furosemide, a blocker of both KCC2 and NKCC1, but not bumetanide, a blocker of NKCC1.	Furosemide	35-45	solute carrier family 12 member 2	Homo sapiens	74-79
18753266-5	2008	Activation of endogenous ANG II production by sodium depletion (10 days low-sodium diet followed by furosemide, 1 mg sc) enhanced NaCl intake in NSE-AT(1A) mice compared with wild types.	Furosemide	100-110	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	25-31
18759624-6	2008	Bumetanide, a furosemide-related diuretic already used to treat volume overload in neonates, is a specific inhibitor of NKCC1 at low doses, can switch the GABA equilibrium potential of immature neurons from depolarizing to hyperpolarizing, and has recently been shown to inhibit epileptic activity in vitro and in vivo in animal models of neonatal seizures.	Furosemide	14-24	solute carrier family 12 member 2	Homo sapiens	120-125
18385266-6	2008	Furosemide-induced increments in the fractional excretion rate of Na(+) and K(+) and absolute excretion of Na(+) and K(+) were significantly blunted in Romk(-/-) mice, consistent with a major salt transport defect in the TAL.	Furosemide	0-10	potassium inwardly-rectifying channel, subfamily J, member 1	Mus musculus	152-156
18385266-6	2008	Furosemide-induced increments in the fractional excretion rate of Na(+) and K(+) and absolute excretion of Na(+) and K(+) were significantly blunted in Romk(-/-) mice, consistent with a major salt transport defect in the TAL.	Furosemide	0-10	talipes	Mus musculus	221-224